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Introduction: High risk-human papillomavirus (HR-HPV) is a well-established 
aetiological factor in a subset of oropharyngeal squamous cell carcinoma (OPSCC) that 
shows distinct biological and clinical behaviour when compared to HPV-negative 
OPSCC. HPV-positive OPSCC patients have improved responses to oncological 
treatment and better overall survival in comparison to HPV-negative OPSCC patients. 
The role of the tumour microenvironment (TME) in tumour cell promotion and metastasis 
has been studied intensively in the last decades, and it is thought to play a crucial role 
in HPV-negative OPSCC progression. In oral squamous cell carcinoma (OSCC), cancer-
associated fibroblasts (CAFs) phenotypes have been characterised thoroughly in our lab 
and we have reported, with others, the critical function of CAFs in OSCC progression. 
CAF phenotypes and their role in OPSCC, and the influence of HPV on this, have not 
been investigated before.  
 
Objective: To investigate the presence and clinical significance of CAFs in OPSCC and 
explore novel candidates in tumour-fibroblast crosstalk. 
 
Results: A retrospective cohort of primary OPSCC presented in tissue microarrays 
(n=143) was subjected to HPV 16 and 18 RNAScope assay and p16 IHC to determine 
the prevalence of HPV-associated OPSCC. ɑ-SMA IHC was performed for CAF 
detection. Although ɑ-SMA expression was observed in both OPSCC subtypes (p>0.05), 
it provided further survival stratification in the HPV-positive group (n= 87) with significant 
prognostic value for the poor prognosis (Log-Rank p=0.02).  
  
To investigate the functional role of CAFs in HPV-positive and HPV-negative OPSCC 
TME, we had first to establish a strong framework of understanding in OPSCC fibroblast 
phenotypes. Using 3 normal tonsillar fibroblasts cultures (NTFs), myofibroblastic and 
senescent in vitro models were established and characterised; moreover, two OPSCC-
derived CAF cultures, originating from HPV-positive tumours, were established and 
characterised. The comparison between OPSCC CAFs models and previous data from 
previously established models derived from oral fibroblasts revealed no differences in 
the developed phenotypes in responses to TGF-β1 and H2O2 stimuli (which in oral 
fibroblasts induce myofibroblast differentiation and senescence, respectively), 
suggesting that the biological differences in OPSCC subtypes are mainly attributed to 
cancer cells and their capacity to modulate the underlying microenvironment. 
III 
 
With the purpose to test this hypothesis, cytokine expression profiling was performed on 
in vitro co-culture 2D models to identify novel candidates in the crosstalk between 
OPSCC tumour cells and fibroblasts. Osteopontin (OPN) was identified among other 
factors as a novel secreted factor, particularly with HPV-negative OPSCC cell line 
(SCC89), but not with HPV-positive cell line (SCC2). Using interactive co-culture 2D 
models provided further validation regarding OPN expression and revealed an 
upregulation in IL-6 in the associated fibroblasts in the co-cultured model. 
 
The preliminary investigation of OPN effect on NTFs showed a potential alteration in NTF 
phenotype. Targeting CD44v6 attenuated the production of Interleukin-6 (IL-6) in 
recombinant OPN-induced NTFs. However, blocking of CD44v6 on NTF before the 
incubation with OPSCC cell line conditioned media revealed a variable degree of IL-6 
reduction. The initial assessment of OPN effect on OPSCC cell lines demonstrated 
activation of CD44 receptor in response to recombinant OPN treatment that was more 
evident in HPV-negative cell lines. 
  
Assessment of OPN expression on the study cohort was limited to IHC; this indicated 
OPN as an independent prognostic biomarker in OPSCC associated positively with 
favourable survival at univariate and multivariate regression models (HR= 0.37; 95% CI: 
0.17-0.79, p-value = 0.01) and (HR= 0.44; 95% CI: 0.20-0.93, p-value = 0.03) 
respectively. 
 
Conclusion: The isolation and characterisation of OPSCC fibroblasts described provide 
novel insights into the role of CAFs in OPSCC mediated by OPSCC cancer cell:CAF 
crosstalk. Moreover, it is proposed that ɑ-SMA has the potential as a prognostic 
biomarker for HPV-positive OPSCC stratification. The positive correlation between OPN 
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1. Literature Review  
1.1 Oropharyngeal squamous cell carcinoma  
The oropharynx (OP) is the middle part of the pharynx that extends from the mobile soft 
palate superiorly to the upper border of the epiglottis inferiorly.  Anteriorly, it is bordered 
by the base of the tongue and laterally by the tonsillar pillars with palatine tonsils and 
lateral pharyngeal walls. The back wall of the pharynx represents the posterior boundary 
of the oropharynx (Logan, 2016) (Figure 1.1). Oropharyngeal squamous cell carcinoma 
(OPSCC) is one of the head and neck cancers (HNC) that has been studied intensively 
in the literature, coinciding with marked increases in incidence over the last three 
decades. The traditional HNC risk factors (tobacco use and alcohol drinking), in addition 
to HPV oncogenic infection, are considered the main risk factors for OPSCC 
development. Diversity in risk factor distribution among countries, besides the 
demographic disparities, reflect the discrepancies in OPSCC trends worldwide, making 
the understanding of OPSCC epidemiology a complex issue. However, generally, HPV-
positive OPSCC displays distinct clinical and molecular profiles from its HPV-negative 
counterpart, in addition to superior prognosis. This advantage offers the possibility of 
reducing treatment intensity in HPV-positive OPSCC populations to improve patients’ 










Figure 1.1: The anatomy of the oropharynx. Parts of the pharynx (left). A detailed illustration 
of the oropharynx (Right). The illustration is modified from (Oropharynx: Introduction, 2021) and 
(Parts of the throat (pharynx), 2021). 
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1.1.1 OPSCC Risk factors 
Tobacco and alcohol consumption are known as the traditional primary causes for the 
development of HNC and they are responsible for approximately 80% of upper aero-
digestive tract cancers (Schiffman, Clifford and Buonaguro, 2009). Cigarette smoking is 
a common form of tobacco consumption. It comprises a complex mixture of more than 
500 carcinogenic and mutagenic substances, including polycyclic aromatic 
hydrocarbons, N-nitrosamines, formaldehyde, and a variety of free radicals 
(Schlotzhauer and Chortyk, 1987; Zhang et al., 2003). The synchronised consumption 
of alcohol and tobacco further potentiates the risk of cancer developing (Kreimer et al., 
2005), however, the mechanism of pathogenicity of alcohol in the development of cancer 
is still unclear. 
In the literature, the presence of a significant proportion of OPSCC patients who are non-
smokers and non-drinkers suggests different aetiological factors. Since the 1970s, when 
the aetiological role of HR-HPV was initially proposed, a large number of reports have 
offered supportive evidence regarding the significant association between OPSCC and 
HPV oncogenic infection. In 2009, the International Agency for Research on Cancer 
(IARC) acknowledged HPV 16 as a causative agent in OPSCC (Bouvard et al., 2009), 
then the categories of HPV-positive or HPV-negative tumours were formally introduced 
in the World Health Organization 2017 classification of HNC (El-Naggar et al., 2017). 
HPV-associated OPSCC is described as a sexually acquired disease, with a most likely 
genital-oral route of infection (D’Souza et al., 2007a; Heck et al., 2010; Gillison et al., 
2015).  High-risk HPV genotypes have been detected in OPSCC, mainly HPV 16 
genotypes, that were reported at a higher percentage of detection in HPV-positive 
OPSCC (>85%) (Kreimer et al., 2005; Schache et al., 2011; Craig et al., 2020; Zamani 
et al., 2020). Changes in sexual behaviour were believed to be the primary risk factors 
in developing HPV-positive OPSCC (Rettig, Kiess and Fakhry, 2014). Earlier age at 
sexual debut, a higher number of lifetime oral and genital sexual partners (greater than 
8-10), women with HPV-positive cervical lesions and their partners and an increase in 
oral sex practices (>6-4 oral sexual partners), all these are considered risk factors in 







OPSCC has been highly debated over the last two decades. In 2018, the epidemiological 
data presented 140,000 new cases of OPSCC in addition to 50,000 deaths worldwide. 
The burden attributed to HPV-associated OPSCC was estimated to be a third of all 
OPSCC cases (42,000 cases) (Bray, Ferlay and Soerjomataram, 2018; Martel et al., 
2020). However, this proportion may not portray the realistic picture of HPV driven 
OPSCC incidence in the epidemic areas. There is a great discrepancy in the distribution 
of HPV-related OPSCC around the world, with a high increase in incidence being most 
observed in North America, Europe, and Australia (Martel et al., 2017). The alarming 
increase in OPSCC in epidemic countries was believed to be linked to an HPV oncogenic 
infection that was reported as being responsible for around 70% of all OPSCC. However, 
due to the inconsistency in HPV detection methods between the reports, the range in 
this percentage was between 18% and 65%, as presented in a recent systematic review 
assessing HPV prevalence in Europe (Stjernstrøm et al., 2019). 
.  
Although the early evidence from western countries showed an evident increase in HPV-
associated OPSCC compared to non-HPV OPSCC  in the period between 1988-2011 
(Schache et al., 2011; Gillison et al., 2015; Schache et al., 2016), the following data in 
the period between 2002-2015 showed a levelling out of HPV incidence that was 
accompanied by a comparable increase in non-HPV related OPSCC, suggesting the 
possible contribution of another aetiological factor to the growing OPSCC incidence 
(Schache et al., 2016). This observation was based on the largest nationwide study 
(n=1710) recruited from 11 centres around the UK (Schache et al., 2016). However, in a 
recent comparable large population-based study (n= 2169) from Eastern Denmark that 
covered a consecutive 18-year span (2000-2017), there was an increase in OPSCC 
incidence per 100,000 from 1.8 in 2000 to 5.1 in 2017, with a trend break around 2008. 
Intriguingly, oncogenic HPV infection was the main contributor to the total OPSCC figure. 
The incidence of HPV-positive OPSCC was increased by 3-fold compared with a 2-fold 
increase in HPV-negative OPSCC (Zamani et al., 2020). It is worth mentioning here that 
in 2020, Denmark recorded the highest OPSCC incidence in Europe according to the 
European Cancer Information System (2021). 
 
The promising effect of the HR-HPV vaccination programme could potentially prevent 
HPV-related cancer; however, changes in the incidence due to the vaccination are not 




1.1.3 OPSCC Patient profile 
HPV-positive HNSCC possesses unique demographic characteristics with features that 
are distinct from the classic population of HNC patients. HPV-positive OPSCC patients 
tend to be overwhelmingly male, mostly Caucasian, within the middle age group (less 
than 60 years) (Gillison et al., 2015; Schache et al., 2016; Zamani et al., 2020; Sheth et 
al., 2021). However, recent studies reported an expansion of the age group up to more 
than 70 years (Zumsteg et al., 2016, Melina et al., 2018, Rettig et al., 2018 a, Rettig et 
al., 2018 b). The favourable prognosis is a characteristic in HPV-positive OPSCC white 
patients, whereas evidence has suggested that racial disparities have a lower survival 
effect (Schrank et al., 2012; Sheth et al., 2021)  
In the USA, compared to HPV-negative OPSCC patients, HPV-positive OPSCC patients 
are unlikely to have a history of tobacco and alcohol. In the majority of OPSCC, HPV-
positive OPSCC consists of about 30% non-smokers, while in the HPV-negative group, 
the percentage of non-smokers is less than 5% (Hong et al., 2013). The site distribution 
of HPV-positive OPSCC shows it is more common in tonsil and base of tongue subsites 
and less common in the soft palate and uvula (Bishop, 2015). This association between 
the virus and these anatomical subsites is unexplained but may be related to the 
anatomical structure of the tonsillar mucosa including deep invagination and a reticulated 
epithelium structure, which might offer virus capture and maintenance sites and promote 
its access to basal cells (Chu et al., 2013).  
Histologically, HPV-positive OPSCC displays a distinct pattern from conventional 
OPSCC. In HPV-unrelated lesions, the origin of tumour epithelium is the lining epithelium 
and often shows squamous differentiation in the form of squamous pearls (keratinization) 
and abundance of keratinizing cytoplasm attributing for the “pink” appearance of the 
tumour at low-power. Unlike conventional OPSCC, HPV-positive OPSCC arises from the 
specialised lympho-epithelium of the tonsillar crypts and the tumour lacking keratin 
formation. The general appearance of HPV-related OPSCC is characteristically “blue”, 
which might be attributed to the high nuclear-cytoplasmic ratios, and numerous tumour-
associated lymphocytes (Bishop, 2015). Initially, HPV-positive OPSCC was described 
as “a non-keratinized, poorly differentiated basaloid tumour” (Gillison et al., 2000); 
however, after further histopathological analysis, these terms have been modified and 
used more specifically. Although most HPV-positive OPSCCs demonstrate some 
basaloid features, they usually are not aggressive tumours. Using the “basaloid” term 
may not precisely reflect that fact; furthermore, most HPV related OPSCCs do not exhibit 
the basaloid SCC criteria that were set out initially by Wain et al. (1986). According to 
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the classical SCC grading system, most HPV-positive OPSCCs have been graded as 
poorly differentiated, and that description might be attributed to the origin of the tumour 
cells which resemble the tonsillar crypt epithelium rather than tumour behaviour; 
particularly, this subtype of OPSCC possesses a better prognosis and response to the 
treatment (Bishop, 2015). From this point, some authors have suggested to regard HPV-
positive OPSCC as well-differentiated (Westra, 2012), whereas others have agreed not 
to assign a histologic grade to HPVSCC (Lewis, Chernock and Chernock, 2014). In the 
4th edition of the WHO head and neck tumour classification, the histologic grading of 
HPV-positive OPSCCs has been discouraged until appropriate histologic correlates are 
established (El-Naggar et al., 2017). 
HPV-positive OPSCC patients usually present with small primary tumours that are 
associated with more advanced nodal disease (O’Sullivan et al., 2012). Nodal disease 
may be present as a cystic lesion as a consequence of tumour necrosis, which is 
sometimes misdiagnosed clinically and histologically as a branchial cleft cyst, especially 
if the primary tumour is asymptomatic (Corey and Hudgins, 2012; Pickard et al., 2012). 
Compared with HPV-negative OPSCC at the same advanced tumour stage, HPV 
patients demonstrate better clinical outcomes. Based on these features, HPV-positive 
OPSCC has been categorised as a separate entity from non-HPV related OPSCC, with 
a distinct staging system, in the last TNM edition of the American Joint Commission on 
Cancer (AJCC/UICC 8).   
HPV-related OPSCCs have been reported with an unusual pattern and timing of 
metastases. HPV-OPSCC has a higher tendency to disseminate to distant sites rather 
than the head and neck region. Secondary non-keratinized SCC has been reported in 
bones such as vertebrae, humerus and multiple organs such as skin, lung, liver, 
pancreas (Mü et al., 2012). Additionally, in HPV-positive patients, these metastases 
might appear after 2 years from the initial treatment, whereas patients with HPV-negative 
OPSCC typically presented with metastases within 2 years (O’Sullivan et al., 2013). 
 
1.1.4 De-escalation of therapy in HPV-positive OPSCC 
Currently, strategies in OPSCC management are determined by conclusive decisions in 
multidisciplinary meetings depending on presented data regarding the histopathological 
features, tumour stage, general patient health, and fitness. At the early stage, surgery or 
radiotherapy are the available options, however, in more advanced stage disease with 
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lymph node metastases, surgery combined with postoperative radiotherapy or 
chemoradiotherapy are the treatment options. Cytotoxic chemotherapy and targeted 
drugs such as Methotrexate, 5-fluorouracil, Bleomycin, Cisplatin, Cetuximab, and 
Nivolumab have been used accompanied by radiotherapy. Unfortunately, despite 
different treatment modalities and approaches, the five-year survival rate for HNSCC has 
not shown an improvement over the past few decades. At the same time, the majority of 
patients who are completely cured still suffer from late side-effects resulting in non-
cancer morbidity and even mortality in a small proportion. 
The emergence of an HPV-associated OPSCC subtype with better survival rates has 
encouraged clinicians to explore modifying non-surgical therapy according to the viral 
status with the aim to decrease acute and long-term treatment morbidity and mortality, 
and at the same time maintain survival (Sturgis and Ang, 2011). This would involve de-
intensification of treatment protocols using less invasive surgical procedures, such as 
organ preservation by transoral robotic surgery or transoral laser microsurgery; also, de-
intensifying radiation therapy dosage and using targeted molecular agents or 
immunotherapy as an alternative for chemotherapy (Budu et al., 2019). However, Initial 















1.2 Human papillomavirus 
Human papillomaviruses belong to the Papillomaviridae family which are characterised 
by a non-enveloped DNA genome and high affinity to the cutaneous and mucocutaneous 
epithelium (Burk et al., 2011). HPV subtypes can cause a wide range of diseases from 
benign lesions such as benign condylomas to invasive tumours involving different 
organs. However, HPV’s affinity to mucosal squamous epithelia varies depending on the 
histological features of different body organs; for instance, the squamocolumnar junction 
zone in the cervix has shown to be a highly susceptible location for HPV infection (Herfs 
et al., 2012).  
 
1.2.1 HPV Structure 
The virus genome size is approximately 8 kb, while the size of the virion (infective form) 
is around ∼55 nm in diameter (Zheng and Baker, 2006). All papillomaviruses consist of 
a circular double-stranded, non-enveloped DNA genome which is divided into three 
major regions separated by two polyadenylation sites. The “Early region” occupies over 
50% of the virus genome and encodes six genes including E1, E2, E4, E5, E6 and E7. 
This part is responsible for virus replication and cellular transformation. The “Late region” 
encodes the L1 and L2 capsid proteins which are responsible for virion self-assembly 
and release. The third region is the “Upstream Regulatory Region” (URR), also known 
as “Long Control Region” (LCR), which includes transcription factor-binding sites and 






Figure 1.2: HPV16 genome organisation. Illustration showing the position of the three major 
regions of the HPV genome: (E) early genes, (L) late genes, and (LCR) long control region. The 
illustration was created using PowerPoint software, adapted from Berg and Archambault (2010). 
 
1.2.2 HPV Classification 
The HPV genotype classification scheme has proven its efficiency in different 
applications such as in basic research, clinical evaluation, epidemiological studies and 
vaccine generation (Bzhalava, Eklund and Dillner, 2015). The given number in the HPV 
genotype name is dependent on the nucleotide sequence in the open reading frame 
(PRF) which encodes the capsid protein L1. According to the similarity within the L1 part 
of the genome, HPV has been categorised into major five genera: α-papillomavirus, β-
papillomavirus, γ-papillomavirus, mu-papillomavirus, and nu-papillomavirus among the 
65 genotypes under the α-papillomavirus category, a limited set of viruses are linked to 
precursor and cancer development (Bernard et al., 2010).  
According to epidemiological data on cervical cancer aetiology, HPV has been classified 
based on the oncogenic capability into two groups: high risk and low-risk. However, in 
head and neck squamous cell carcinoma (HNSCC), an HPV low-risk group also was 
detected. HPV 11 and HPV 6 were reported in association with squamous cell carcinoma 
(SCC) of the larynx and giant condyloma acuminatum (D’Souza et al., 2007; Osei-Sarfo 
et al., 2013). 
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HPV-16 is the most common type associated with SCC in the cervical and head and 
neck region. Over 80% of OPSCC is associated with HPV-16, while this percentage is 
lower in cervical cancer (60%) (Gillison et al., 2008; Sanjose et al., 2010). HPV-16 
genotype was correlated with a better prognosis compared to HPV-18 in cervical cancer 
and OPSCC (Kónya et al., 1995; Thibaudeau et al., 2013; Mazul et al., 2016).  
Besides the heterogeneity in virus virulence among HPV genotypes, lineages and sub-
lineages originated from the same genotypes exhibit distinct phenotypic profiles. 
Differences between lineages were observed in their ability to induce the tumour; for 
instance, HPV 31 A and B lineages have a higher risk than lineage C in developing 
cervical intraepithelial neoplasia grades 2 and 3 (Xi et al., 2014). Moreover, some 
lineages appeared with characteristic geographic dispersion, with HPV58 sub-lineage 
A3 being highly detected in East Asia compared to other HPV58 variants and associated 
with 7-9 fold higher in cervical cancer development (Chan et al., 2011). These data 
suggest further investigations on HPV genomes and variants classification that might 
provide a new basis for the preventative/therapeutic interventions of HPV infection and 
epidemiology studies.  
 
1.2.3 Pathogenesis of HPV related cancer 
The full mechanism of HPV gene regulation within the differentiated keratinocyte is still 
unclear. According to the observations in cervical cancer, there is a general agreement 
that the non-structural proteins which include E1, E2, E4, E5, E6 and E7 are expressed 
in the basal cell layer and intermediately differentiated keratinocytes, whereas the two-
structural viral capsid proteins that include L1 and L2 are expressed at more superficial 
layers in keratinocytes undergoing terminal differentiation (Longworth and Laimins, 
2004). Thus, HPV oncoprotein expression is proportional to their function during the virus 
life cycle: E1 and E2 contribute to HPV DNA replication and the regulation of the process 
of early transcription; E5 increases the proliferative capacity of keratinocytes; E6 and E7 
maintain the differentiating keratinocyte in a state that allows viral genome amplification 
and consequent late gene expression; and E4 associates with cytokeratin filament 




Figure 1.3: The HPV productive life cycle. Uninfected epithelium (left) and HPV infected 
epithelium (right). The HPV life cycle is dependent on epithelial differentiation and coincident with 
virus protein expression. Expression of HPV proteins within the stratified epithelium is correlated 
with their function in infection establishment and virion production. The infection starts by virion 
penetrating the basal layer and is maintained at low copy numbers until cells start to differentiate 
to increase the expression of early proteins (E1, E2). By entering the differentiating cells into the 
active cell cycle, the viral genome starts to amplify, making a high copy number coincident with 
E6/E7 expression. At higher layers, L1, L2 and E4 start to be expressed at a high level to enable 
virion assembly and egress. Finally, on reaching the superficial layers of epithelium, virion 
particles are released. The illustration was created using PowerPoint software, adapted from Mac 
and Moody (2020). 
 
E6 and E7, which are known as HPV viral oncogenes, are characterised by their 
pleiotropic functions in overlapped pathways, resulting eventually in cell immortalisation, 
genetic instability alongside virion production (Yim and Park, 2005). E6 protein acts on 
p53 protein through ubiquitin ligase E6-associated protein (E6AP), leading to p53 
ubiquitin changes and proteasomal degradation of p53 (Huibregtse, Scheffner and 
Howley, 1991). p53 is known as the “guardian of the genome” due to its regulatory effect 
on cell cycle arresting and apoptosis formation as a response to cellular stress or DNA 
damage, while loss of p53 check-point leads to uncontrolled cell cycle progression 
(Huibregtse, Scheffner and Howley, 1991). 
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Similarly, E7 protein elicits its action through Rb/E2F inactivation which results in cell 
cycle promotion and reciprocal p16 overexpression. p16 protein is a cell cycle inhibitor 
that controls the G1-S phase transition of the cell cycle by inhibiting phosphorylation of 
retinoblastoma protein (pRb)/E2F complex leading to E2F release and subsequently cell 
cycle activation (Bova et al., 2001). This pathway is regulated by E2F re-binding to Rb. 
E7-pRb/E2F complex interaction results in an independent release of E2F which results 
in loss of the p16 feedback loop (Figure 1.4). The high affinity of E6 and E7 protein to 
bind p53 and Rb is a feature of high-risk HPV rather than low-risk genotypes (Jones and 
Münger, 1996), however, the correlation between p16 pattern of expression in OPSCC 
and low-risk HPVs has not been studied thoroughly yet. 
 
 
Figure 1.4: Dysregulation of cell cycle proteins mediated by HPV oncoproteins. E6 and E7 
viral oncogenes target P53 and pRb, respectively, and cause irreversible degradation and 
inactivation. The abrogation of cell cycle regulators (p53 and pRb) leads eventually to genetic 
instability which contributes to the development of cancer. The illustration was created using 




The pathogenesis of HPV-associated cervical lesions is well documented in the 
literature, whereas in OPSCC, the precise mechanism of HPV pathogenesis still is 
unclear. Although there is some evidence suggesting the same mechanism in OPSCC, 
including detection of E6 and E7 oncogenes within the tumour, p16 biomarker 
overexpression, and lack of p53 somatic mutations (El-Naggar & Westra 2012; Mork et 
al. 2001), the comparison of HPV pathogenesis between cervical cancer and OPSCC 
reflects discrepancies in several aspects that might suggest a different unexplained 
mechanism in OPSCC. Cervical cancer is developed over a sequential progression 
process from low premalignant phase to high-grade intraepithelial neoplasias. However, 
in OPSCC, the vast majority of lesions present primarily at an advanced neoplastic stage 
and the concept of in situ carcinoma or precancerous has not been identified in OPSCC, 
which may be due to the histological nature of lymphoid tissue (Westra, 2012). Moreover, 
in vitro observations reported a transition from HPV-genome as extrachromosomal 
episomes into a genome integrated form in higher grade dysplastic epithelium. This 
feature is a characteristic of cervical lesions, while it is found to be less frequent in 
OPSCC. Non-integrated HPV episomes are the predominant form in OPSCC (Pett et al., 
2004; Gao et al., 2014; Olthof et al., 2014; Morgan, Dinardo and Windle, 2017). HPV 
productive mechanism through the stratified squamous epithelium is understood and 
documented in the cervical and oral mucosa (Griffin et al., 2015; Hendawi et al., 2020), 
however, it is not known if the virus establishes a productive infection in the ‘unsorted’ 
keratinocytes of the tonsil crypt. 
 
1.2.4 Methods of HPV detection 
The basic clinical requirement of HPV testing is the detection of HPV-relevant infection 
within the lesion. Identification of HR-HPV E6/E7 mRNA is strong evidence of 
transcriptionally active infection (Smeets et al., 2007).  E6/E7 mRNA (qRT-PCR) for HR-
HPV has been suggested as a gold standard test in fresh-frozen tissue (Gillison et al. 
2000), however, in practice, implementation of this technique in routine clinical settings 
is challenging; the test sensitivity depends mainly on the integrity of RNA in a fresh tissue 
sample that could deteriorate during the fixation process in FFPE material (Schache et 
al., 2011). Different strategies have been investigated concerning HPV detection in 
HNSCC, including HPV DNA, HPV RNA, HPV oncoproteins, HPV-related cellular 
proteins, and HPV antibodies. Meanwhile, the target is to achieve a reliable, accurate 
method that can be applied with less cost in the clinical setting (Westra, 2014). 
14 
 
1.2.4.1 p16 IHC - The surrogate biomarker 
Klussmann et al. (2003) were the first to suggest p16 IHC expression as a surrogate for 
HPV infection. Years later, Lassen et al. (2009) correlated p16 IHC expression with the 
survival in OPSCC as part of the Danish Head and Neck Cancer Group (DAHANCA) 5 
Trial. Overexpression of p16 IHC has been used widely in clinical settings as a surrogate 
biomarker for HPV associated lesions in cervical and head and neck lesions. p16 
abundance in tissue is believed to be attributed to cell cycle protein dysregulation 
mediated by E7 expression (McLaughlin-Drubin, Crum and Münger, 2011). Due to its 
acceptable sensitivity, high prognostic value and cost-effectiveness, p16 has been 
utilised by the majority as a first-line test for HPV in OPSCC. In 2017, the eighth edition 
of the staging manual of AJCC proposed p16 as the key test for OPSCC stratification 
into p16-positive and p16-negative OPSCC sub-entities. The classification was based 
on compelling evidence supporting p16 as highly predictive. In the same year, the 
College of American Pathologists (CAP) issued the recent update on HPV detection 
guidelines that recommended p16 IHC testing in OPSCC, with emphasis on using >70% 
p16 tissue positivity as a threshold. Adding a specific test is also suggested in areas with 
low HPV prevalence (Lewis, 2020).  
These guidelines were accompanied by ongoing evidence highlighting the shortcomings 
of p16 regarding specificity and emphasising the necessity of adopting algorithm-based 
two-test protocols in HPV testing (Schache et al., 2011). Although p16 is considered a 
strong independent prognostic biomarker in OPSCC, it has low specificity (82%) against 
the gold standard test. False-positive p16 expression has been detected in the normal 
structure of pharyngeal mucosa and in various tumours independent of HPV which might 
be due to other mechanisms involved in pRb inactivation such as gene deletions, point 
mutations or epigenetic modifications (Witkiewicz et al., 2011). p16’s relatively low 
specificity is responsible for a percentage of non-HPV related patients (5%-20%) who 
demonstrated worse outcomes compared to the HPV-negative group. Another pitfall in 
considering p16 IHC for testing is the ambiguity regarding the positivity threshold of the 
test; >70% tissue strong positivity is generally defined as the cut-off and that was 
stressed within CAP guidelines, however, partial staining of 50–70% revealed a number 





1.2.4.2 Two-step Algorithms 
With the purpose to enhance the low specificity of p16 IHC, an HPV-specific test was 
suggested to be included, establishing two step-wise algorithms. Smeets et al. (2007) 
were the first to propose and test this concept. p16 IHC and (Gp)5+/6+ Polymerisation 
chain reaction (PCR) algorithm revealed superior performance with 100% sensitivity and 
specificity compared with the gold standard test, however, it is worth mentioning that the 
PCR primers were designed to cover the HPV16 genotype only, and the analysis was 
limited to 48 cases of HNSCC. In a larger cohort of OPSCC (n=108), Schache et al. 
(2011) reported acceptable diagnostic and prognostic performance for p16 IHC / DNA 
qPCR algorithm compared with the reference test (97% sensitivity and 94% specificity, 
overall survival p=0.002). The qRT-PCR primers in this study cover HPV 16, 18 and 33 
genotypes.  p16 IHC / HR HPV in situ hybridization (ISH) combination displayed 
relatively low specificity that affected the prognostic performance of the algorithm 
(p=0.02). DNA ISH covers 12 genotypes of high-risk HPV.  
Schache et al., among others, emphasised that HPV DNA PCR or HPV DNA ISH should 
not be used alone. Although the PCR technique is known for its high sensitivity in 
simplifying detection of low copy numbers of viruses, the risks of contamination and 
detection of latent or transit HPV infection increase the false positive risk (Robinson et 
al. 2012; Venuti and Paolini 2012; Westra, 2014). DNA ISH is preferable to qRT-PCR 
since it is applicable for formalin-fixed and paraffin-embedded material (FFPE). It 
provides clinical significance as it permits direct visualisation of HPV DNA signals within 
the section (Moutasim, Robinson, and Thavaraj 2015). However, DNA ISH is considered 
less sensitive for low copy number infection. Increasing the number of signal 
amplification steps improved DNA ISH sensitivity, although that was on account of 
background clarity (Huang et al., 1998). Advances in using automated systems have 
made DNA ISH a convenient procedure for sample processing in most pathology 
laboratories. In the UK, currently, HPV DNA ISH is the second line test for all p16-positive 
OPSCCs to confirm HPV status and is recommended by the National Institute for Health 







1.2.4.3 RNAScope assay 
HPV RNA testing has been demonstrated as a more reliable approach. Detecting the 
transcriptionally active mRNA within the tumour relieves any doubt regarding the viral 
contamination or thoughts of transient non-related infection (Mirghani et al., 2016; 
Plebani et al., 2018). Nevertheless, the standing challenge is the feasibility of 
implementing this approach in FFPE tissue material. While RNA PCR offers excellent 
sensitivity, the technical hurdles were enough to exclude the test from clinical settings 
(Amin et al., 2017).  
In the last decade, the investments of Advanced Cell Diagnostics (ACDbio, CA, USA) in 
RNA-ISH introduced RNAScope assay as a promising alternative in FFPE material. The 
technique is based on a unique “Z-shaped” complementary probe to E6 and E7 mRNA 
nucleotides that offers superior advantages; the lower arm of the probe provides high 
sensitivity and mRNA identification, and the upper arm amplifies the signals specifically 
within a clear background which makes results interpretation an easy forward step. 
Visualisation of in-situ E6/E7 mRNA chromogenic signals definite evidence on the viral 
involvement in lesions development. 
RNAScope diagnostic performance against the reference test (E6 E7 mRNA qRT-PCR) 
was evaluated firstly by Schache et al. (2013), followed by Mirghani et al. (2015). The 
test revealed high sensitivity (97% and 93%) and specificity (93% and 94%, respectively) 
with respect to the difference in HPV probes number between the two studies (7 and 18, 
respectively). Although RNAScope demonstrated excellent prognostic performance, an 
unproven issue remains in the literature regarding whether it is superior to p16 or at least 
at an equivalent level. A few studies reported a comparison between RNAScope and 
p16 prognostic values (Ukpo et al., 2011, Schache et al. 2013, Craig et al., 2020). At 
univariate analysis, RNAScope displayed an equivalent prognostic value to p16, 
although in multivariate analysis the comparison between them was ambiguous. While 
p16 showed a stronger prognostic value in the Upko et al. report, p16’s strength was 
reported as equivalent in the Craig et al. report with respect to the difference in HPV 
probes (Table 1.1).   
Different methods have been suggested recently to enhance p16’s diagnostic 
performance, such as using digital droplet PCR (Marques et al., 2021) and combining 
p16 IHC with p53 assessment (p16/p53 IHC) (Benzerdjeb et al., 2021). Utilising digital 
imaging for the detection of HPV histological features in the H&E sections also was 
proposed as a promising approach in HPV-detection (Klein et al., 2021). 
17 
 
Table 1.1: List of studies concerning RNAscope diagnostic and prognostic performance in OPSCC. 
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1.3 Tumour microenvironment 
Although the components of the TME may vary depending on the type and location of 
the tumour, thus making each tumour unique, TME generally comprises two major 
components (Gkretsi et al., 2015). First, the extracellular matrix (ECM) consists of a 
basement membrane and an interstitial matrix that contains and maintains various 
soluble molecules including chemokines, matrix metalloproteinases, protease inhibitors, 
and growth factors, among others. The significance of ECM in tumours is presented in 
the anchorage and facilitating cancer cells migration (Alphonso and Alahari, 2009). The 
second important component in TME is the cellular part. Various cell types are integrated 
into ECM and present significant participation in tumorigenicity. Fibroblasts are the main 
cellular component, in addition to other cell types such as cells of the immune system, 
pericytes, endothelial cells, adipocytes and mesenchymal stem cells. Communication 
between tumour cells and surrounding stroma is constantly maintained through a 
complex and dynamic network of factors including cytokines, chemokines, exosomes, 
growth factors, among others, that contribute to tumour progression and survival (Joyce 
and Pollard, 2009) (Figure 1.5). 
Fibroblasts are a heterogeneous population of spindle-shaped cells of mesenchymal 
origin that are characterised by varying degrees of contractility, ranging from quiescent 
fibroblast at homoeostasis to myofibroblast in acute inflammation and wound healing 
(McAnulty, 2007). In tumour stroma, the associated fibroblasts showed active phenotype 





Figure 1.5: Tumour microenvironment components. The diagram illustrates the wide variety 
of cells within TME. The illustration was created using PowerPoint software, adapted from Foster 
et al. (2018). 
 
1.3.1 Quiescent fibroblasts  
Quiescent fibroblasts or resting fibroblasts are non-dividing, low metabolic fibroblasts 
that are scattered within the stromal tissue as single cells (Kristensen and Petersen, 
1988). They are located proximal to the basement membrane, but without direct contact 
to the epithelial compartment or the basement membrane (Tschumperlin, 2013). They 
perform a crucial function in defining the differentiation status of the overlying epithelium 
through the production of signalling factors, and the secretion and organisation of matrix 
proteins, such as collagen and elastin at the minimum rate (Kalluri, 2016). 
In general, they are defined as fibroblasts that do not express activated fibroblasts 
markers such as α-smooth muscle actin (α-SMA) and fibroblast activation protein (FAP) 
while expressing tissue mesenchymal markers including vimentin, Cluster 
of Differentiation (CD39), and fibroblast specific protein-1 (FSP-1) (Kalluri, 2016; Agorku 
et al., 2019). However, there is a lack of data concerning the quiescent fibroblasts in the 
literature, which may be attributed to the inability to achieve fibroblast cultures with 
definite ‘resting’ status in vitro. Culturing fibroblasts in plastic flasks reminiscent of a 
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stiffened, fibrotic ECM can at least induce partial fibroblast phenotype (proto-
myofibroblast) activation (F. Liu et al., 2015). 
 
1.3.2 Myofibroblasts 
Myofibroblasts have a specialised phenotype that is generated during wound healing 
and in different fibro-contractive diseases (Serini and Gabbiani, 1999). It is a hybrid 
differentiated type that displays combined features between fibroblast and smooth 
muscle cells; they are able to produce intense matrix consisting of extracellular matrix 
proteins, proteases, growth factors, and cytokines resembling fibroblast, besides their 
ability to form well-developed microfilament (Gabbiani, Ryan and Majno, 1971; 
Frangogiannis, Michael and Entman, 2000). The key function of the myofibroblasts in 
active stroma is demonstrated in the enhanced collagen formation and production of 
ECM modulators and growth factors (Madar, Goldstein and Rotter, 2013). However, 
myofibroblasts are not simply limited to this function; they also communicate with other 
cell types via a plethora of secreted factors (Arina et al., 2016). In wound healing, 
fibroblasts are involved as a part of a dynamic process with other cell types including 
platelets, epithelial, endothelial, and immune cells to re-establish the normal tissue 
homoeostatic status and architecture. This process is mediated via a continuous 
sequence of signals including growth factors and cytokines.  
 
1.3.3 Cancer-associated fibroblasts 
These are among the most fundamental components of TME. In general, they are 
described as fibroblasts located within or approximate to the tumour (Kanzaki and 
Pietras, 2020). Fibroblasts within the TME acquire an active phenotype similar to the 
myofibroblasts in wound healing and acute inflammation and are known as CAFs. 
However, they have the ability to secrete vital factors contributing to tumour cells 
proliferation, differentiation, and migration. This might explain the correlation between 
the abundant presence of myofibroblasts and local disease recurrence and poor 






1.3.3.1 Original heterogeneity of CAFs 
During tumour growth, the number of CAFs increases within the tumour stroma. Normal 
resident fibroblasts are considered the most immediate pool of cells to be recruited at 
tumour sites (Ishii, Ochiai and Neri, 2016). However, although laboratory studies support 
the idea that the initial functional role of fibroblasts is to suppress the early lesions 
(Özdemir et al., 2014; Rhim et al., 2014), validation of this hypothesis on tissue is not 
feasible due to the difficulty of longitudinal sampling of the same lesion (Sahai et al., 
2020). Other local sources from non-fibroblastic lineage have also been described as 
possible progenitors of CAFs, including adipocytes, pericytes, smooth muscle cells, 
epithelial cells, and endothelial cells (Alt et al., 2010; Dulauroy et al., 2012; Fischer et al., 
2015). Bone-marrow derived mesenchymal stem cells also have been reported as a 
source of CAFs in various tumour types (Jung et al., 2013; Zhu et al., 2014) (Figure 1.6). 
 
 
Figure 1.6.: CAF sources in the TME. CAFs are derived from different cell populations. CAF 
precursors undergo a series of molecular events that lead eventually to phenotype transformation. 
Epithelial cells undergo Epithelial to Mesenchymal transition (EMT), and Endothelial cells are 
transformed through Endothelial to Mesenchymal transition (EndMT). Normal resident fibroblasts 
become CAFs through the activation pathway and mesenchymal stem cells through the 
recruitment and activation process. Other cells like pericytes, adipocytes and smooth muscle cells 
undergo a transdifferentiation mechanism. The illustration was created using PowerPoint 
software, adapted from Liu et al. (2019). 
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1.3.3.2 CAFs generation in TME 
Compelling evidence has demonstrated that fibroblast activation is a critical step in 
tumour growth and progression. Reciprocal epithelial-mesenchymal interaction has been 
described as a fundamental process that modulates fibroblasts phenotype to 
myofibroblast phenotype which in turn modulates cancer cells progression. This 
interaction occurs through the direct cell to cell interaction in addition to the effect of 
secretions in the form of cytokines, exosomes, growth factors or through secretion of 
ECM molecules (Mukaratirwa et al., 2005; Powell et al., 2005; Camussi et al., 2010; 
Wang, Su and Amoah, 2020).  
 
Tumour cell and fibroblast interactions have been investigated in OSCC using in vitro 
and in vivo models (Lewis et al., 2004; Vered et al., 2007; Kellermann et al., 2008). The 
evidence revealed further validation of tumour cells’ ability to induce differentiation in 
normal fibroblasts through the TGF-β1 pathway, also demonstrating the effect of a 
significant increase in tumour cell growth and invasion into a Matrigel matrix when they 
were treated with myofibroblast conditioned media (Lewis et al., 2004). Using 
experimental animal models also provides evidence indicating the role of malignant 
epithelial cells in presence of myofibroblasts in oral cancer patients compared to the 
hyperplastic and dysplastic epithelium (Vered et al., 2007). TGF-β is the main cytokine 
inducing the myofibroblastic phenotype that is tightly regulated by integrins (Löhr et al., 
2001; Hassona et al., 2013; Khan and Marshall, 2016). Its action is mediated through a 
signalling pathway via interaction with an intracellular receptor-regulated effector 
(SMAD2 / SMAD3) and (SMAD4) (Massagué, 2012). Once fibroblasts are activated, they 
form stress fibers (proto-myofibroblasts) which generate mechanical tension in the 
extracellular matrix resulting in uncontrolled TGF-β1 activation (Wipff et al., 2007). 
Further production of TGF-β1 leads to myofibroblast trans-differentiation that, 
consequently, increases the stromal stiffness (Khan and Marshall, 2016).  
 
Reports from our lab described successfully establishing a myofibroblastic CAF model 
derived from normal oral fibroblasts (NOFs) using TGF-β1 and highlighted the 
significance of miRNA upregulation in CAF transdifferentiation (Abidin, 2017; Melling et 
al., 2018). Moreover, the functional role of oral-derived CAFs in bone invasion was 
studied thoroughly (Elmusrati et al., 2017; Elmusrati, 2020). However, the response of 




Other factors that promote CAF activation include inflammatory modulators that can 
promote CAF activation, such as interleukin-1 through NF-κB signal transducer (Erez et 
al., 2009; Mughees et al., 2021). Changes in ECM physical properties are also capable 
of triggering CAFs (Avery et al., 2018).  Additionally, genomic stresses can provoke 
alteration in the fibroblast phenotype. Double-stranded DNA breaks can induce TGFβ 
family activity and upregulate IL-6 production (Fordyce et al., 2012). In some conditions, 
these factors transdifferentiate fibroblasts into senescent CAF phenotypes (Demaria et 
al., 2017). Tumour-derived Osteopontin was linked to fibroblasts activation in HNC (Qin 
et al., 2018).  The functions which it plays in promoting a tumour-permissive TME are yet 
to be fully elicited in OPSCC. Osteopontin (OPN) shall be discussed in detail in the next 
section 1.4. 
 
1.3.3.3 Phenotypic heterogeneity of CAFs 
The diversity of CAFs’ origin is believed to be reflected in the heterogeneity of CAF 
biomarkers and functionality in TME (Kidd et al., 2012; Prime et al., 2017). Mounting 
evidence based on the molecular analysis and single-cell RNA-sequencing data 
described CAFs as a heterogeneous population of cells, with different biomarkers 
expression and functions. In a recent RNA-sequence analysis on HNSCC (n=18), 
fibroblasts were categorised into 4 populations: resting fibroblasts, myofibroblasts, 
CAF1, and CAF2. While CAF1 expressed mesenchymal biomarkers and ECM proteins, 
CAF2 subtype expressed immediate-early response genes such as JUN, FOS, besides 
ligands and receptors such as Keratinocyte growth factor 7 (FGF7) and, TGF-β receptor 
(Puram et al., 2018). Similar reports on CAFs RNA-sequencing emphasise the concept 
of CAFs’ heterogeneity in other tumours including non-small cell lung cancer 
(Lambrechts et al., 2018), colorectal carcinoma (Li et al., 2017), and breast cancer 
(Bartoschek et al., 2018). However, despite the wide variety between CAFs subtypes 
among distinct cancer types, CAFs were shown to share similar gene signatures and 
molecular functions. In recent work on CAFs RNA-sequencing from three different 
tumours (HNSCC, lung cancer and melanoma), six pan-CAF subtypes were observed 
including normal fibroblasts, proliferative CAF like fibroblasts, myofibroblasts, two 
inflammatory fibroblasts and desmoplastic fibroblasts. CAF phenotypes analysis has 
identified the prognostic utility of signature genes for these CAF subsets, providing new 
insights into how cancers residing in specific tissue types may benefit from CAF subtype 




α-SMA expression is a widely accepted biomarker for CAF detection, although its 
expression has been observed also in pericytes, endothelial cells in addition to muscle 
fibers (Hinz et al., 2007; Eyden et al., 2009). Moreover, CAFs with no α-SMA expression 
have also been reported (Mellone et al., 2016; Patel et al., 2018). In vitro, CAF culture 
isolation is performed by excluding contamination by other lineages such as epithelial 
cells, endothelial cells, and macrophages; in addition to confirming fibroblasts’ identity 
using a number of biomarkers (Table 1.2). Asporin (Maris et al., 2015) and collagen 11-
α1 (COL11A1) (Galván et al., 2014) were reported as markers that expressed specifically 
with CAFs in vitro in studies on breast tumour and colon adenocarcinoma, respectively; 
nevertheless, further validation is required to assess the clinical significance as a 
prognostic biomarker in tissue. 
 




CAF subtype heterogeneity was also evident based on the traditional molecular 
biomarker expression. In pancreatic ductal adenocarcinoma, CAF populations have 
been categorised according to α-SMA expression into α-SMAhigh and α-SMAlow. The latter 
population has shown to be more tumour-promoting by producing chemokines and 
cytokines, while the former demonstrated high capability in ECM deposition (Öhlund et 
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al., 2017). Moreover, based on analysing the expression of fibroblast markers including 
αSMA, FAP, FSP1, PDGFRβ, caveolin1 and β1/CD29, Givel et al. (2018) identified four 
subsets of CAFs in ovarian cancer with distinct functional roles. The role of CAFsα-SMA 
was described as enhancing tumour proliferation, immunosuppression, besides 
impeding drug delivery, while CAFsFSP1 and CAFsFAP were linked to tumour metastasis 
and immune evasion (Han, Liu and Yin, 2020). To the best of our knowledge, CAFs have 
not previously been extracted and assessed from OPSCC. We highlight this aspect as a 
gap in the literature that warrants further investigation. Identification of CAFs subtypes 
and their functional role in OPSCC may reveal a target therapeutic approach.  
 
 
1.3.3.4 Clinical significance of CAF detection in tissue 
Although myofibroblasts shared similar features in inflammation/repair and tumours, 
there is a crucial difference in the established reactive stroma. In the former, the 
functional role of myofibroblasts is constitutively activated and then terminated when the 
tissue has repaired, either by a reversion to a normal phenotype or undergoing apoptosis 
(Desmouliere et al., 1995; Shiga et al., 2015). However, CAFs in tumour stroma undergo 
irreversible activation via signalling pathways mediated by many tumour-derived factors 
and autocrine loops (Augsten, 2014; Costa, Scholer-Dahirel and Mechta-Grigoriou, 
2014); therefore, the tumour stroma fails to abate the fibrotic response, which leads to 
further matrix deposition and disorganisation and tissue desmoplasia. The abundance of 
CAFs in tumours is described to be strongly associated with a worse prognosis in distinct 
tumour types (Galbo, Zang and Zheng, 2021). In desmoplastic tumours such as breast 
and pancreatic cancers, CAFs form up to 80% of the tumour mass; conversely, a low 
percentage has been found in kidney and brain tumours (Öhlund, Elyada and Tuveson, 
2014; Gascard and Tlsty, 2016). CAFs were observed in approximately 60% of OSCC 
(Kellermann et al., 2008). Tumours with a high percentage of CAFs (>50%) within the 
stroma are correlated with poor survival (Gascard and Tlsty, 2016). That is thought to be 
attributed to the generated mechanical forces which in turn activate further CAFs’ 
precursors. Moreover, the dense desmoplastic tumour creates hypoxia within the tissue 
that has its drawback effects on treatment response, and angiogenesis promotion 
(Semenza, 2000; Jain, Martin and Stylianopoulos, 2014). 
 
In OSCC, Kellermann et al. (2007) reported the first evidence for the importance of 
myofibroblasts’ presence as a prognostic factor in OSCC patients’ mortality. Among 72 
samples of invasive tumour front in tongue SCC, 71% showed a high abundance of 
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myofibroblasts. This high proportion also demonstrated a significant correlation with 
lymph node stage and shorter overall survival. The same correlation also was reported 
in a larger OSCC cohort study by Marsh et al. (2011) where ɑ-SMA IHC expression 
demonstrated the highest hazard ratio (HR) = 3.06 (95% CI 1.65–5.66) among the other 
significant prognostic features (surgical margins, metastatic disease, and pattern of 
invasion). In a recent meta-analysis that investigated CAF expression in OSCC tissue, 
high levels of CAF revealed a strong correlation with poor prognosis, disease-specific 
survival (DFS) HR = 3.32 (95% CI: 2.09‐5.26, p < .00001) and overall survival (OS) (HR: 
2.16, 95% CI: 1.60‐2.92, p < .00001) (Dourado et al., 2018). Furthermore, in the majority 
of included studies in the previously mentioned meta-analysis, high CAF detection was 
associated with advanced clinical parameters such as advanced disease stage, high 
tumour grade, recurrence, and extranodal metastatic spread. However, there is no 
consistency among the reports in defining the CAF detection threshold in the tissue; 
while the majority look for the amount/percentage of CAF within the stroma (Kellermann 
et al., 2007, 2008; Marsh et al., 2011), others consider the α-SMA intensity as another 
significant criterion in the scoring scheme (Oguejiofor, 2016). 
 
In OPSCC, the presence of CAFs and their clinical significance has not been investigated 
thoroughly. It is thought that CAF distribution in HNSCC is correlated with the anatomical 
sites; while tumours localised to palatine tonsils present more often with ɑ-SMA positive-
CAFs, on the other hand, oral cavity, pharyngeal wall, and soft palate are more likely to 
demonstrate ɑ-SMA-negative CAFs (Valach et al., 2012). Concerning HPV-positive 
OPSCC, CAFs were reported as being a common feature associated with HPV-driven 
tumours (Rahrotaban et al., 2019). The limited available data on CAFs’ clinical 
significance in OPSCC tissue revealed no correlation with overall survival (Oguejiofor, 
2016). However, reports from our lab demonstrated a difference in normal fibroblasts’ 
early response to conditioned media from HPV-negative OPSCC cell lines, but not from 
HPV-positive cell lines (Bolt et al., 2018; Peacock et al., 2018; Al-Sahaf et al., 2019), 
which may indicate a difference in stroma reactivity in OPSCC subtypes. From the 
above, ɑ-SMA positive-CAFs’ abundance among OPSCC subtypes is an interesting area 
within the literature that requires further investigations in terms of its relation to the 
survival, nature of the behaviour, and anatomical site. These findings might suggest ɑ-





1.3.4 Senescent CAFs  
Senescence is another feature of CAFs within the solid tumour stroma. Senescent CAFs 
characteristically demonstrate the status of proliferation arrest associated with the active 
production of a plethora of pro-inflammatory mediators including cytokines, chemokines, 
in addition to metabolites, growth factors and other factors. Collectively, active CAFs 
secretome called the senescence-associated secretory phenotype (SASP), is known for 
its established role in creating a permissive TME that supports tumour cells’ proliferation 
and spread (Coppé et al., 2008, 2010).  
The senescent CAFs phenotype is developed as a consequence of persistent DNA 
damage that might be caused by internal insults including oxidative stress (Campisi and 
Fagagna, 2007), or external inducers such as cigarette smoke, irradiation, and 
chemotherapy (e.g., Cisplatin) (Coppé et al., 2008). CXCL1 also demonstrated the ability 
to induce senescence in normal oral fibroblasts through an autocrine mechanism (Kim 
et al., 2018). The senescent CAFs phenotype exhibits several changes in gene 
expression, the majority of which are related to permanent growth arrest (p53/p21 or/and 
p16/pRb pathways). It is also characterised by the secretion of more active secretome 
(SASP) (Campisi and Fagagna 2007; Hassona et al. 2013; Laberge et al., 2015) that 
generates pro-inflammatory and pro-metastatic factors, providing supportive media for 
further tumour progression (Kabir et al., 2016; Prime et al. 2017). Mellone et al. (2012) 
have introduced a successful in vitro induction model of oral fibroblast senescence, 
which has been performed by exposing the fibroblasts to DNA damaging agents (H2O2 
and Cisplatin). The senescent fibroblasts conditioned media analysis demonstrated 
more active SASP compared to the control, besides the ability to promote cancer cells 
proliferation and invasion.  
To date, the molecular mechanisms underlying SASP generation remain poorly 
understood. The role of COX-2/miRNA-335/PTEN signalling cascade has been 
demonstrated from our lab as a novel modulator for the inflammasome in senescent 
fibroblasts in HNSCC (Kabir et al., 2016); moreover, in senescent skin fibroblasts 
miRNA-146a/b has been demonstrated as a supportive factor in excessive IL-6 and IL-
8 secretion via IL-1α depending on the manner of skin fibroblasts senescence (Bhaumik 
et al., 2009). The senescence-associated β-galactosidase (SA-βgal) is the most specific 
senescent cell marker (Dimri et al., 1995). It is thought to be derived from lysosomal 
biogenesis, a mechanism which frequently occurs in senescent cells (Lee et al., 2006); 
however, SA-βgal expression could be induced by cellular stress in prolonged 
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confluence culture (Campisi and Fagagna, 2007). Lack of DNA replication markers 
including proliferating cell nuclear antigen (PCNA) and Ki-67 are suggested as other 
senescence markers; nevertheless, they cannot distinguish between quiescent and 
senescent cells (Campisi and Fagagna, 2007). p16 expression is utilised by some 
authors to identify the senescent cells as it is considered an important regulator in this 
process (Krishnamurthy et al., 2004). It is worth mentioning here that not all senescent 
cells engage the p16-pRb pathway, and the possibility of other pathways has been 
suggested (Shelton et al., 1999; Olsen et al., 2002), which might explain the lack of p16 
expression in some senescent cells (Beausejour et al., 2003).  
The clinical significance of senescent CAFs is presented in high inflammatory secretome 
(SASP) that has been implicated in transcriptional regulatory mechanisms (Krtolica, 
Parrinello, Lockett, P. Y. Desprez, et al., 2001). Although there is an overlap between 
the senescent CAF and myofibroblastic CAF secretome, as represented in a high 
amount of IL-6 production (Mellone et al., 2016), the non-proliferative status of senescent 
CAFs suggests less effect in developing desmoplastic tumours (Parrinello et al., 2005). 
The exact identity of myofibroblastic CAFs and senescent CAFs phenotypes is 
controversial; while some authors consider them as stages in a unified pathway, as they 
share common functions and are mediated by similar signalling pathways (Prime et al., 
2017), there is another view which considers CAFs as a “dynamic state” in the fibroblast 
lifecycle that is present in the tumour vicinity and promotes its progression (Madar, 
Goldstein and Rotter, 2013). To date, the biological behaviour of these phenotypes and 
their impacts on OPSCC have not yet been investigated.  












1.4 Osteopontin (OPN)  
OPN is a phosphorylated glycoprotein that was first identified in 1979 as a secreted 
phosphoprotein in mamillary transformed cell lines (Senger, Wirth and Hynes, 1979). In 
1985, OPN was detected in osteoblasts (Franzen and Heinegard, 1985). Osteopontin is 
a combined word of “osteo = bone” and “pontin = binding”, which typically describes its 
function in linking bone cells to the bone extracellular matrix. OPN is also known as Bone 
Sialoprotein 1 (BSP1) and Early T-lymphocyte Activation 1 (ETA1) protein. At present, 
OPN has been included as a member of the Small Integrin-Binding Ligand N-linked 
Glycoprotein (SIBLING) family, as they share several structural and functional properties 
(Fisher et al., 2001). OPN is predominantly expressed in osteoclasts, osteoblasts, in 
addition to its expression in skeletal smooth muscle cells, neural cells, endothelial cells 
and immune cells. OPN was established as a protumorigenic and premetastatic factor in 
malignant cells in various cancer types including oral cancer, breast cancer, kidney 
cancer, pulmonary cancer, colon cancer and hepatic carcinoma (Senger, Wirth and 
Hynes, 1979; O’Brien et al., 1994; Malyankar et al., 1997; Abdel-Hafiz et al., 2018; Assidi 
et al., 2019; Maleš et al., 2021).  
OPN is a pleiotropic factor that involves several physiologic and pathologic processes 
such as bone remodelling, wound healing, immunity regulation, and cancer progression. 
The multifunctionality of OPN is attributed to the presence of different isoforms and 
variants that undergo further posttranslational modifications such as phosphorylation, 
sulfation, glycosylation, and proteolytic cleavage (Qin, Baba, and Butler, 2004). Despite 
OPN’s heterogeneity, it is assessed and reported by the majority as a standard molecule 
(OPN), although a few studies reported a distinction in biological function between OPN 
variants. 
 
1.4.1 The molecular structure of OPN 
OPN is encoded by the human gene secreted phosphoprotein 1 which is located on 
chromosome 4, locus 4q13.22. OPN gene carries seven exons which are responsible 
for OPN isoforms generation (Young et al., 1990). SPP1 gene undergoes alternative 
splicing that results in the formation of five transcript variants encoding five different 
isoforms for OPN protein (Figure 1.7). OPN-a is the full-length isoform of OPN gene that 
is translated to full protein amino acid sequence (314 AA) (Christensen, Petersen and 
Sørensen, 2008). It is considered as the canonical reference sequence for OPN, while 
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the rest of the isoforms, OPN-b and OPN-c, were compared against OPN-a sequence; 
however, much is still unknown regarding OPN-d and OPN-e isoforms and whether they 
are translated to protein or not (Moorman et al., 2020). OPN isoforms all share the feature 
of being secreted forms of OPN (sOPN) that are produced and delivered extracellularly 
(Castello et al., 2017) (Table 1.3). According to the limited available reports, sOPN 
isoforms appear to be tumour specific with different biological effects. OPN-a is highly 
expressed in pulmonary tumours and papillary thyroid carcinoma and acts as a bone 
metastatic factor and invasion modulator, respectively (Ferreira et al., 2016; Hao et al., 
2017). OPN-c was detected in prostate tumour and its expression was correlated with 
the degrees of cell transformation from benign to an invasive tumour (Tilli et al., 2012). 
In breast tumours, OPN-c overexpression was correlated with tumour grade and worse 
outcome, suggesting a prognostic role for OPN biomarker (Mirza et al., 2008), while in 
ovarian cancer it gained further clinical significance through its association with platinum-
resistant therapy that suggested OPN as a prognostic and predictive tool in ovarian 
cancer (Dion et al., 2020).  
 
 
Figure 1.7: Human OPN gene and OPN isoform transcripts. SPP1 locus (red rectangle) on 
chromosome 4. SPP1 genes have seven exons that encode three alternative spliced isoforms, 
OPN-a. OPN-b and OPN-c. The illustration was created using PowerPoint software, adapted from 




Table 1.3: The molecular structure of sOPN isoforms. 
*sOPN, secreted OPN, AA= Amino acid. 
 
1.4.2 Secreted OPN and Intracellular OPN 
Although OPN has been studied intensively and identified as an extracellular protein, few 
reports have precisely differentiated between the OPN isoforms. Otherwise, unless 
specifically noted, previous studies have been concerned with the sOPN form. The 
intracellular form of OPN (iOPN) was identified initially by Zohar et al. (1997) in rat 
calvarial cells. Years later, Shinohara et al. (2008) described iOPN as an alternative 
translation for OPN mRNA that demonstrated a distinct biological function in dendritic 
cells. iOPN was described as a short non-secreted form of OPN that is lacking the signal 
sequence due to the initiation of OPN mRNA translation from the downstream 
noncanonical start codon. This leads to the missing of the first 16 AAs which acts as a 
membrane localisation signal peptide (Shinohara et al., 2008) (Figure 1.8). Further work 
from the same group indicated that iOPN and sOPN may differentially control the nature 
of immune responses (Inoue and Shinohara, 2011). At the cellular level, iOPN is thought 
to be accumulated in the peri-membranous zone, retained inside the nuclear zone, and 
distributed in the cytoplasm, whereas sOPN is localised at the perinuclear zone (Castello 
et al., 2017). Expression of OPN form (sOPN and iOPN) has been shown to depend on 
the cell type, which suggests that cell-type-specific factors might regulate the alternative 




Figure 1.8: OPN mRNA translation. OPN mRNA has two translation sites: the canonical AUG 
translation initiation site (left) and an alternative translation initiation site (right). Translation from 
the canonical initiation site results in the formation of the full length of OPN peptides (sOPN), 
including a signal sequence that is targeted to secretory vesicles. Translation from the alternative 
initiation site leads to a short peptide (iOPN) that lacks a signal sequence and accumulates 
intracellularly. The illustration was created using PowerPoint software, adapted from Cantor and 
Shinohara (2009). 
The differences between iOPN and sOPN were described in a few reports concerning 
the biological effects of OPN on immunity. Innate immune cells such as dendritic cells 
and macrophages appeared to have more iOPN stored in the cytoplasm than the 
produced OPN (sOPN), while the lymphocytes produced a higher proportion of sOPN 
compared by iOPN (more than 50-fold) (Shinohara et al., 2008). Immune cells-derived 
sOPN has shown to be implicated in adaptive immunity by promoting immune cell 
proliferation, migration, and cytokine production (Clemente et al., 2016), whereas iOPN 
acts as an adaptor molecule in signalling pathways downstream of innate immune 
receptors (Inoue and Shinohara, 2011), in addition to its crucial role in the natural killer 
cells (NK) expansion and survival (Leavenworth et al., 2015). These observations 
suggested different functional roles for iOPN and sOPN in the innate and adaptive 
responses, respectively (Cantor and Shinohara, 2009).  
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1.4.3 Expression regulatory factors and signal mediators 
OPN expression is regulated by several transcription factors such as Myb proto-
oncogene protein (c-Myb) (Schultz et al., 2009) and Erythroblast transformation-specific -
related gene (ERG) (Flajollet et al., 2011).  Moreover, a number of potential regulatory 
sequences have been described in SPP1 promoter such as vitamin-D-responsive 
(VDR)-like motifs (nucleotides −1892 to −1878 and −698 to −684), and an Ets-1 motif 
(nucleotides −47 to −39) (Safran, Butler and Farach-Carson, 1998; Tang et al., 2008). 
Mechanical stress and inflammatory mediators such as TNFα, IL-6, TGFβ and IL-17a 
also were reported as an inducer for OPN (Liu et al., 2015). 
CD44 and integrin receptors are the binding partners of OPN. CD44 is a surface 
glycoprotein expressed in a wide variety of cells including malignant epithelial cells and 
CAFs (Kinugasa, Matsui and Takakura, 2014; Ludwig et al., 2019). OPN/CD44 
interaction mediates cell-matrix or cell-cell interactions. It plays functional activities in the 
regulation of invasion, angiogenesis, and metastasis (Senbanjo and Chellaiah, 2017), in 
addition to cellular adhesion, lymphocyte activation, chemotaxis of macrophages 
(Schimizu et al., 1989; Zhu et al., 2004). Three integrin-binding domains were identified 
for OPN isoforms: RGD domain, OPN-R domain, and N-terminal thrombin cleavage 
fragment (Wai and Kuo, 2008). Each domain is associated with specific integrin isoforms 
as illustrated in Figure 1.9 OPN/integrin interaction contributes to the activation of several 
signal transduction pathways such as STAT-3, ERK1/2, PI3K/Akt/mTOR and NF-κB that 
are involved in immune cell regulation, cell adhesion, tumour metastasis and survival 





Figure 1.9: Human OPN protein. A translated full-length OPN isoform (OPN-a). The receptor-
interacting domains are illustrated in red. The respective receptors are illustrated in blue. The 
illustration was created using PowerPoint, adapted, and modified from Mooreman et al. (2020). 
 
1.4.4 OPN in Cancer  
As has been mentioned above, OPN overexpression has been detected in several 
tumour types. Its expression has been linked to the aggressiveness of the tumour and 
worse clinical outcomes and that might be attributed to its active participation in several 
oncogenic pathways such as PI3K/Akt/mTOR and JAK2/STAT3 signalling pathways 
(Guertin and Sabatini, 2007; Behera et al., 2010). In HNSCC, OPN overexpression was 
linked to tumour progression, metastasis, and cancer therapy resistance (cetuximab and 
cisplatin) (Luo et al., 2015; Liu et al., 2020). Compelling evidence indicated that high 
OPN plasma level is correlated positively with neck lymph nodes (Maleš et al., 2021). 
Comparisons between metastatic nasopharyngeal carcinoma and its non-metastasised 
counterpart showed a discrepancy in plasma OPN level, the level being higher in the 
former (Hui et al., 2008); moreover, a high OPN level was associated with lymph node 
metastasis (Celetti et al., 2005; Wong et al., 2005). In laryngeal squamous cell 
carcinoma, OPN demonstrated a pro-invasive effect in vitro and its expression was 
correlated with the lymph nodes’ involvement and low survival (Celetti et al., 2005). In 
OSCC, overexpression of OPN in tissue and body fluids was associated with advanced 
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tumour stage, high lymph nodes status, therapy resistance and development of 
recurrence (Table 1.4). Based on this evidence, OPN was suggested as a prognostic 
and predictive biomarker in OSCC. Notably, these observations were built on OPN 
overexpression in tumour cells only within the tissue, however, the Avirović et al. (2013) 
study revealed a difference in the clinical significance of OPN expression in cancer cells 
and tumour stroma; only high tumour-OPN IHC expression was correlated positively with 
advanced clinical parameters and outcome, while that was not evident with stroma-OPN 
expression. The study finding suggests that tumour-derived OPN may have a different 
function compared with stromal OPN and probably only the tumour derivation has 
independent prognostic value in OSCC (Avirović et al., 2013).  
In OPSCC, the clinical significance of OPN expression has not been assessed until now. 
Small numbers of OPSCC patients have been included in a few studies investigating 
OPN’s effect in HNSCC (Overgaard et al., 2005; Maleš et al., 2021). Meanwhile, OPN 
assessment in OPSCC tissues requires a comprehensive evaluation for OPN expression 




















*FFPE= formalin-fixed paraffin-embedded. IHC= immunohistochemistry. ELISA= Enzyme linked immunoassay. 




1.4.4.1 Effect of tumour-derived OPN on TME  
Tumour-derived OPN has a supportive role for tumour cells by contributing to 
establishing an active microenvironment and promoting metastasis. Tumour-derived 
OPN has shown the ability to underpin CAFs’ presence in TME and to do that by 
reprogramming normal resident fibroblasts as reported in breast cancer. OPN-derived 
CAFs demonstrated mimics of molecular and functional profiles similar to the 
myofibroblastic CAF phenotype (Sharon et al., 2015; Prasanna et al., 2021). 
Mesenchymal stem cells are considered one of the alternative sources of CAFs in TME. 
Tumour-derived OPN was described as a mediator for mesenchymal stem cells’ 
transformation into CAFs in breast cancer. This process was demonstrated by OPN-
integrin interaction, which in turn activated the transcription factor myeloid-zinc finger 1 
(MZF1). The latter has been found to have a promoting effect on TGF-β1 production 
(Weber et al., 2015). Inhibition of OPN-integrin binding using aptamer abolished the 
MSC-CAF transformation process (Weber et al., 2015).  
Further evidence for the supportive role of OPN in metastasis is presented in the ability 
of the systemic sOPN to instigate indolent disseminated tumour cells to form a 
premetastatic niche. This function was supported by the ability of sOPN to activate and 
mobilise bone marrow-derived cells into distant metastatic cells, which subsequently 
results in the outgrowth of the distant metastases (McAllister et al., 2008). The growing 
evidence supports the hypothesis that tumour-derived sOPN and iOPN have a 
complementary role in the tumour metastasis process. sOPN promotes EMT in the 
primary non-invasive tumour to establish early metastatic dissemination (Thiery, 2002; 
Thiery et al., 2009). On the other hand, iOPN function appeared at later stages of 
metastasis by inducing MET in the disseminated cancer cells to facilitate metastatic 
colonisation (Zohar et al., 2000; Junaid et al., 2007; Jia et al., 2016). 
OPN enhances tumour progression through the recruitment of macrophages and 
suppression of T cell response. Tumour-derived OPN showed the ability to attract 
macrophages to a tumour site by promoting chemotaxis. The presence of a high number 
of tumour-associated macrophages was linked to tumour stage and poor disease 
outcome (Qian and Pollard, 2010). The functional role of the macrophage in TME was 
implicated in tumour formation and progression (Liguori et al., 2011; Shih et al., 2014); 
moreover, OPN had an immunosuppressive influence on macrophages by inducing M2 
polarisation and regulating Programmed death-ligand 1 (PD-L1) expression, which 
further contributes to cancer immunosuppression. OPN also appears to act as an 
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immune checkpoint that inhibits T cell activity in the tumour environment (Klement et al., 
2018).  
1.4.4.2 Effect of stromal-derived OPN on tumour cells 
OPN was also detected in cells within TME with a distinct biological effect on tumour 
cells.  iOPN expression in NK cells demonstrated anti-tumour function through its ability 
in NK activation and inhibition of apoptosis. This process maintains NK activity by 
reaching the full maturation and lytic function. This observation was evident in vivo using 
Rag−/− γC−/− mice co-injected with melanoma cells and NK cells expressing iOPN only. 
Compared with the control that had been co-injected with tumour cells and NK lacking 
iOPN, the former had a significant increase in NK number and less metastatic 
dissemination (Leavenworth et al., 2015). In keeping with this report, Danzaki et al. 
(2016) described the functional role of stromal-derived OPN in enhancing NK 
infiltration in vivo using a transgenic adenocarcinoma of mouse prostate model. 
However, antitumorigenic functions of OPN appeared to give a tumour-specific 
response. Using B16 melanoma tumours, OPN did not show OPN-mediated cell 
recruitment (Danzaki et al., 2016).  
To the contrary, OPN produced by senescent fibroblasts showed tumour-supportive 
effects. Accumulating evidence in the literature supports the fact that senescent 
fibroblasts have an important role in tumour development/formation in ageing tissues 
(Krtolica, Parrinello, Lockett, P. Desprez, et al., 2001; Krtolica and Campisi, 2002). OPN 
driven by senescent fibroblasts has been shown as a necessary factor of preneoplastic 
cell growth in vitro and in vivo. Targeting OPN also blocked the senescent fibroblasts’ 
ability to promote keratinocytes’ growth (Pazolli et al., 2009).  
From the above, the functional effects of OPN indicate its importance as a mediator in 
tumour-stroma interaction. Tumour-derived or stromal-derived OPN was reported with a 
supportive function in tumour cells’ progression and metastasis. However, some 
evidence revealed a suppressive role of OPN tumour progression; particularly, an in vivo 
model for SCC in OPN-deficient mice showed development in tumour growth and higher 
metastatic dissemination (Crawford, Matrisian and Liaw, 1998). Moreover, OPN deficient 
macrophages displayed improper anti-tumour activity (Bourassa, Monaghan and Rittling, 
2004) which indicates OPN either inhibits or promotes leukocyte functions. This may 
indicate a presence of balance between the OPN effect on the tumour that determines 
whether the overall effect of the immune response will be tumour promoting or tumour 
inhibiting (Terabe and Berzofsky, 2007). 
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1.5 Hypothesis and aims 
 
Hypothesis:  
The poor clinical outcomes of HPV-negative OPSCC are believed to be attributed to the 
activated underlying microenvironment. Tumour microenvironment plays a crucial role in 
tumour growth and behaviour. Previous research from our lab demonstrated a 
remarkable response of normal fibroblast to HPV-negative OPSCC cell lines conditioned 
media, but not with HPV-positive counterpart.  
 
These observations inspire us to test this hypothesis: that the abundance and activity of 
CAFs correlate with poor clinical outcomes in OPSCC owing to their ability to modulate 
cancer cell behaviour, and that will differ between HPV-negative and HPV-positive 
tumours.  
 
Research aim:  
To investigate the presence and clinical significance of CAFs in OPSCC and explore 




• To determine the status of biologically relevant HPV infection in an established 
OPSCC cohort. Explore ɑ-SMA expression in OPSCC subtypes and assess its 
prognostic value. 
 
• To establish in vitro models of myofibroblastic-CAF and senescent-CAF models 
using NTFs, and isolate and characterise OPSCC CAF primary cultures.  
 
• To explore the secretome mediated crosstalk between tonsil derived fibroblasts 
and HPV-positive and HPV-negative OPSCC subtypes and provide further 





























2.1. Cell Culture 
2.1.1 Cell lines 
Two OPSCC HPV negative cell lines (UPCI:SCC 089 and UPCI:SCC 072) and two 
HPV16 positive cell lines (Hypopharynx UD:SCC 2 and UPCI:SCC 090) were kindly 
provided by Dr Suzanne Gollin (University of Pittsburgh) following the university 
guidelines for the material transfer agreement. Table 2.1 summarises the relevant 
information linked to each cell line, as reported in the literature (Virgilio et al., 1996; 
Camille, 2004; Ferris et al., 2005; White et al., 2007; Wald et al., 2011). HPV status of 
the provided cell lines was confirmed by the HPV Cytology Screening Unit (Royal 
Hallamshire Hospital) (Appendix A.1). 
Cell lines are a commonly used tool in the investigation of response to treatment and 
assessment of the drivers of carcinogenesis. However, they do not have the complexity 
of the tissues, thus there is limitation as to how representative they are. When 
considering cell lines as a potential model of HPV- positive OPSCC, there is a necessary 
reliance on cell lines that are indeed reported to be HPV-positive, yet they do not 
necessarily derive from the same anatomical subsite of the head and neck. The majority 
of in vitro studies on HPV-positive HNSCC cell lines use a limited number of established 
cell lines that are commercially available (Greaney-Davies et al., 2020). These cell lines 
have disparate aetiologies: they have been isolated from both oral and oropharyngeal 
anatomical subsites and from individuals with a history of cigarette and alcohol use, yet 
they still represent the most readily available model for the study of HPV-positive HNC, 
OP or otherwise. Complexity of experiments in this thesis leads to the decision to use 
one cell line from each entities, but then to validate in another pair of HPV-positive and 
HPV-negative cells lines. Conclusions based solely on a single cell culture of each type 











Table 2.1: Summary of used cell lines relevant information. 
Cell line Nature P53 
status 
11q13 Age Gender Smoker Drinker 
UPCI:SCC 089 New 
primary 
- Amplified 58 M Y Y 




Amplified 61 F y y 
UPCI:SCC090 Recurrence Wild 
type 
Not 46 M Y Y 
UD-SCC2 - Wild 
type 
Not - M Y Y 
 
Cells were cultured using basal media consisting of Dulbecco's modified Eagle's media 
(DMEM) (Gibco, Life Technology), supplemented with 10% Foetal bovine serum (FBS) 
(Sigma-Aldrich, UK) owing to its high content of embryonic growth promoting factors 
which support cells growth. 2mM L-Glutamine also was added as an alternative energy 
source for rapidly dividing cells. 50 IU/50 µg ml-1 Penicillin-Streptomycin (Sigma-Aldrich, 
UK) also was added to control bacterial contamination. Cells were maintained in the 
incubator with 5–7% CO2 - the recommended CO2 tension concentration to obtain the 
appropriate pH level of the media.  
2.1.2 Normal tonsillar fibroblasts  
Human primary normal tonsillar fibroblasts (NTF322, NTF6 and NTF10) were provided 
by Dr Helen Colley, University of Sheffield (IRAS number 09/H1308/66). Table 2.2 
summarised the relevant information. Cells were cultured using the same mentioned cell 
lines’ growth media unless otherwise stated when the serum is omitted from the growth 










2.1.3 Tonsillar cancer-associated fibroblasts  
Human primary tonsillar cancer-associated fibroblasts (CAF1 and CAF2) were isolated 
from biopsies taken during a tonsillectomy surgical procedure, (as part of initial cancer 
treatment), at the Royal Hallamshire Hospital, Sheffield Teaching Hospitals NHS 
Foundation Trust with informed consent: IRAS 13/NS/0120. Both CAF1 and CAF2 were 
isolated from HPV-positive tumours. Table 2.3 summaries the available relevant 
information. 
 
Table 2.3: Summary of clinical information of tumour from which cancer 
fibroblasts were isolated. 
Primary culture Gender Age (Y) Site  Stage p16-status 
CAF1 Male 61 L. Tonsil T2N1 Positive 
CAF2 Male 80 R. Tonsil T2 N3b Positive 
 
2.1.3.1 CAF isolation: 
We followed a common method in cell isolation from primary tissue utilising the 
enzymatic disaggregation effect of collagenase. Fragments of human tonsil tissue were 
received in transport media (DMEM supplemented with 100 IU/ml penicillin, 100 μg/ml 
Primary culture Gender Age (Y) Site 
NTF6 Female 29 Tonsil 
NTF10 Female 19 Tonsil 
NTF322 Female 21 Tonsil 
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streptomycin and 0.625 μg/ml amphotericin B). CAFs were isolated from the tissue by 
fine mincing of the tissue in a 9 cm dish in the transport media, then all the tissue pieces 
were transferred to a 15 ml falcon tube and centrifuged at 1400 rpm for 10 mins. The 
supernatant was pipetted carefully, and tissue resuspended in growth media followed by 
spinning at 1400 rpm for 10 mins. The supernatant was then discarded, and the 
precipitated tissue was washed with PBS followed by a further spin and elimination of 
the supernatant. 3 ml of 0.5% (w/v) collagenase (Sigma Aldrich, UK) was added to the 
precipitated tissue in a 15 ml falcon tube and incubated overnight at 37°C. The next day, 
the tube was centrifuged at 1400 rpm for 10 mins, and the supernatant was pipetted 
carefully, while the precipitated tissue was resuspended in growth media. The mixture 
was transferred to a T25cm2 flask and incubated for 7 days at 37°C in a humidified 
incubator with 5% CO2 and the media was replaced carefully every 2 days. Seeding 
stock and working stock were generated (section 2.1.5). Cells were expanded as needed 
(section 2.1.6).  
2.1.4 Routine maintenance of cells 
OPSCC cancer cell lines’ working passages were up to 15 passages starting from the 
earliest available passage. Primary tonsillar fibroblasts were cultured up to passage 7. 
Growth media change was undertaken every 2 days for OPSCC cell lines and every 5 
days for primary tonsillar fibroblast cultures. Cells were cultured in T75cm2 flasks up to 
approximately 70% confluence. At this time point, cells were still actively dividing (Log 
phase). Late log phase is the appropriate time to passage cells, before reaching Plateau 
(Stationary) Phase, where cell growth slows down due to overcrowding and cellular 





Figure 2.1: Growth phases of cultured cells.  The semi-logarithmic plot shows the cell 
density versus the time spent in culture.  Lag phase, the first phase of growth after cell 
accommodation in the new culture. The log phase, the period when the cells proliferate 
exponentially and consume the nutrients in the growth medium. Stationary phase, the 
stage where cells’ proliferation is greatly reduced or ceases entirely. Decline phase, a 
reduction in the number of viable cells death as a natural progression of the cellular cycle. 
The late Lag phase is the ideal sub-culturing time. 
 
To detach the adherent cells from the flask/plate for the sub-culturing step, (TE) Trypsin/ 
Ethylenediaminetetraacetic acid (EDTA) (Sigma-Aldrich, UK) was used.  Cells were 
washed twice with PBS and incubated with 3 ml of TE for 5 minutes at 37ºC. TE was 
then neutralized using 10% v/v serum-containing media followed by centrifuging at 1000 
rpm for 5 minutes. The supernatant was discarded, and the cell pellet was re-suspended 
in growth media and seeded at the desired concentration.  
  
Mycoplasma test was performed routinely by the Core facility service using Mycoplasma 
Detection Kit (Cat. No. 13100-01, Southern biotech). The kit incorporates polymerase 
chain reaction (PCR) to amplify the conserved 16S ribosomal RNA coding region within 








2.1.5 Cell freezing  
A cryoprotectant is added to the freezing medium to avoid the risk of ice crystal formation 
which can cause cellular damage during the freezing process. Dimethyl sulphoxide 
(DMSO) was selected for the best osmotic features upon the cell suspension thawing. 
For stock preparation, cells were resuspended in 100% FBS and placed in well-labelled 
cryotubes (Greiner Bio-one, UK) at density 1 x106 cells for cell lines and 15 x104 cells for 
fibroblasts in 1 ml FBS. 10% DMSO diluted in FBS (Sigma-Aldrich, UK) was added to 
the cryotubes then placed in a cryo-cooler (Mr Frosty) filled with isopropanol to allow 
slow freezing of the cells. The cryo-cooler was stored immediately at - 80ºC for 24 h, 
then cryotubes were moved into liquid nitrogen for longer storage. 
 
2.1.6 Cell resurrection  
After retrieving the cryotube from the liquid nitrogen, it was thawed by hand for a few 
minutes. Cell suspension was added to 10 ml of pre-warmed media in a 15 ml falcon 
tube then centrifuged at 1000 rpm for 5 minutes. The supernatant was discarded, and 
the cell pellet was re-suspended in 10 ml of growth media and seeded in a T75 cm2 flask 
at the required concentration. The flask kept at 37ºC in a humidified incubator with 5% 
CO2. The next day, cells were checked and incubated with fresh growth media. 
 
2.1.7 Counting Cells 
The haemocytometer and cover-slip (Baxter Scientific) were cleaned with alcohol and 
left to dry at RT. 10 µl of 0.4% trypan blue dye (Life Technologies, UK) was added to 10 
µl cell suspension and mixed by pipetting up and down. Trypan Blue dye was added to 
identify the percentage of viable cells present in the cell suspension. The mixture was 
incubated for not more than 1 min at room temperature (RT), to avoid false-positive 
results in counting of non-vital cells. The coverslip was fixed in position on the 
haemocytometer, and 10 µl of the trypan blue/cell mixture was pipetted at the slide notch. 





Figure 2.2: Haemocytometer slide. 
Cells were counted (blue-stained and unstained cells) in all large squares at the corners 
of the haemocytometer and the average was obtained by dividing the total cells number 
by 4.  Final cell count estimation = the average X suspension dilution factor X 104. 
The proportion of viable cells was determined by dividing the number of unstained cells 
by the number of total cells then multiplying by 100. Culture viability of more than 90% is 
considered appropriate to continue the culturing work. 
 
2.1.8 Fibroblast stimulation using rh-TGF-β1 
To characterise the response of NTFs to TGF-β1 stimulation and establish active 
myofibroblastic phenotype, cells were incubated with rh-TGF-β1, the master cytokine in 
fibroblast differentiation and the activation of cancer stroma (Postlethwaite et al., 1987; 
Caja et al., 2018).  
The activation protocol is based on previous work from our lab on oral fibroblasts (Melling 
et al., 2018). NTF322, NTF10, and NTF6, cells were incubated with TGF-β1 (R&D 
Systems, USA) at 24 h or 48 h or 72 h, at a concentration of 5 ng/ml. Cells were plated 
into 6-well plate (Greiner Bio-one, UK) at a density of 1.5 x 105   per well with 2 ml of 
growth media and incubated overnight at 37°C in a humidified incubator with 5% CO2. 
The next day, the media was aspirated, and cells were washed with PBS x2 and serum-
starved overnight using DMEM serum-free media. On the third day, 1 ml of DMEM 
serum-free medium containing 5 ng/ml rh-TGF-β1 was added to each well. The 
experimental control wells were incubated with 1 ml serum-free medium. Plates were 
incubated for 24 h, 48 h or 72 h in a humidified incubator. At the end of the experiment, 
cells were pelleted for downstream RNA/protein analysis and the media was aspirated, 
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centrifuged, and the supernatant was stored at -20°C. The experiment was performed in 
three biological repeats. 
 
2.1.9 Tonsillar fibroblast stimulation using rh-OPN 
To explore the correlation between OPN and IL6 expression in OPSCC tumour cells/ 
fibroblasts crosstalk, NTF322, NTF10 and CAF2 were incubated with 180 ng/ml rh-OPN 
(R&D Systems, USA) for 48 h then IL-6 expression/production was assessed. The 
activation protocol is based on previous work (Bramwell et al., 2006; Weber et al., 2015). 
Fibroblasts were cultured in a T75 cm2 flask in growth media up to 70% confluence. Cells 
were washed with PBS x3 and serum-starved overnight. On the third day, cells were 
incubated with 10 ml of serum-free medium containing 180 ng/ml of rh-OPN for 48h at 
37°C in a humidified incubator with 5% CO2. The experimental control was incubated 
with 10 ml serum-free media only in the same conditions.  At the end of the experiment, 
the media were aspirated, centrifuged, and stored at -20°C for IL-6 ELISA analysis. Cells 
were harvested and counted to normalise ELISA analysis results then cells were 
collected for further IL-6 gene evaluation. The experiment was performed in triplicate. 
 
2.1.10  Collagen gel contraction assay  
Myofibroblastic phenotype is characterised by the capability to form potent actin stress 
fibres through a well-developed contractile apparatus. Collagen gel contraction assay is 
commonly used in the field of mechanobiology to investigate cell-induced contraction of 
extracellular in wound healing and inflammation. We utilised this technique as a 
parameter to quantify the degree of NTF contractility by measuring the reduction in NTF 
gel diameter after TGF-β1 or OPN treatment. 
Following the protocol of the collagen gel contraction kit (Cell Bio-Lab Inc, CBA-201), 
NTFs were harvested and resuspended in growth medium at 2 x 104 cells/ml.  A collagen 
lattice was prepared by mixing 2 parts of cell suspension and 8 parts of cold collagen gel 
working solution. From this mixture, 0.5 mL was pipetted in a well in a 24-well plate and 
incubated for an hour at 37ºC. After collagen polymerization, 1.0 ml of growth medium 
was added on the top of the collagen gel lattice and the plate incubated for 24 h at 37ºC 
in a humidified incubator with 5% CO2. The next day, the cells were serum-starved for a 
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further 24 h, then were treated with 5 ng/ml TGF-β1 or 180 ng/ml OPN before releasing 
the stressed gel matrix from the plate using a sterile spatula. The gels were then 
incubated for 72 h in the TGF-β1 stimulation experiment or 48 h in the OPN stimulation 
experiment. Photographs of the gel disc were taken at 24 h, 48 h and 72 h. The 
contractility of the gels was then calculated by measuring the distance between the 
collage disc border and the plate well using ImageJ. The experiment was performed in 
triplicate. 
2.1.11 Fibroblast senescence induction 
Senescence typically occurs in response to damaging stimuli, such as DNA damage 
(DNA damage-induced senescence), oxidative stress or replicative exhaustion. Cells 
were treated with Hydrogen peroxide (H2O2) which provokes oxidative stress-induced 
premature senescence. This experimental protocol is based on previous similar work on 
oral fibroblasts (Kabir et al., 2016) using the optimal dose of H2O2 (500 µM) that caused 
a gradual reduction in the rate of cell proliferation overtime points with minimum 
cytotoxicity.  
Early-passage NTF322, NTF6 and NTF10 cells were grown in 75cm2
 
flasks up to 70% 
confluence. Cells were then washed with PBS x2 and incubated with 500µM of H2O2 
(Sigma-Aldrich, UK) in serum-free media for 2h at 37°C in a humidified incubator with 
5% CO2. The negative control cells were incubated with serum-free media alone for 2h, 
at the same incubation conditions.  After that, cells were washed with PBS x3 and 
incubated with growth media for 15 days. Cells were split on day 8. At the end of the 
experiment, the media were collected, centrifuged at 3000 rpm for 5 min and stored at -
20°C. Cells were counted and the culture viability percentage was recorded. 4 x 104 cells 
were seeded in a 12-well plate, prepared for Senescence-Associated β-galactosidase 
Assay (SA-β-gal) staining (section 2.1.12). The rest of the suspension was centrifuged, 
and the formed pellet was collected and stored at -80°C for further analysis. The 
experiment was performed in triplicate.  
2.1.12 Senescence-Associated β-galactosidase Staining Assay  
The SA-β-gal assay is a cytochemical assay used for the detection of senescent cells 
based on an increased level of lysosomal β-galactosidase activity. Under normal 
conditions, the lysosomal β-galactosidase activity can be detected at pH4 using the 
chromogenic stain 5-bromo-4-chloro-3-indolyl-β-d-galactopyranoside (X gal). In 
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senescent cells, the lysosomes produce a high level of β-galactosidase that can be 
detected at pH 6 (Kurz et al., 2000).  
SA-β-gal activity was assessed using a Senescence Detection Kit (ab65351; Abcam, 
Cambridge, UK) following the manufacturer's instructions. 40,000 cells were seeded in 
12 well-plates and left to adhere overnight. The next day, cells were washed twice with 
PBS and incubated with 500 µL fixative reagent for 20 min at RT, followed by a wash 
with PBS x2. 500µL of total solution mixture (Table 2.4) was added to each well, then 
the plate was kept overnight in the incubator after wrapping with aluminium foil and 
sealed in a plastic bag to prevent pH changes during the incubation. The next day, SA-
βgal staining was observed at 20X magnification using an inverted microscope 
(Olympus; CKX41). The percentage of stained cells was calculated using ImageJ 1.45s 
software. 
Table 2.4:  SA-β-gal stain recipe per well. 
 
 
2.1.13 Cell growth kinetics of CAFs   
To assess and compare the proliferation rate of the CAFs cultures, CAF1 and CAF2 
were seeded at a density of 5,000 cell/ml in a 6 well-plate with 2ml growth media. At two-
day intervals, cells from one well of the 6 well-plate were detached and counted giving 
the total count/mL of cells. The experiment was repeated 3 times allowing calculation of 
mean and standard deviation. A graph was plotted of cells per ml at each time point, 
namely 1, 2, 3, 4, 5, and 6 days. The experiment was performed in triplicate.  
 
2.1.14 Cancer cell line induction with IL-6 
To test the ability of IL-6 to induce OPN production in OPSCC cells, the OPSCC cell lines 
were incubated with rIL-6 (Catalogue 200-06, Peprotech, UK) for 48h. We started with a 
dose of 15ng/ml rIL-6, as this has been shown to be sufficient for induction in previously 
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reported optimising work on the tumour cells (Chen et al., 2018). SCC89, SCC72 and 
SCC2 were cultured in a T75cm2 flask in growth media up to 70% confluence. Cells were 
washed with PBS x3 and serum-starved overnight. Next day, cells were incubated with 
serum-free media supplemented with 15ng/ml of rh-IL6 (PeproTech, USA. Catalogue 
200-06) for 48h at 37°C in a humidified incubator with 5% CO2. The experimental control 
was incubated with 10 ml serum-free media only in the same conditions. Thp-1 
monocytes were included as a positive control (Uchibori et al., 2017). Thp-1 cells were 
provided kindly by Dr Emilia Barker. At the end of the experiment, the media was 
aspirated, centrifuged, and stored at -20°C for OPN ELISA analysis. Cells were 
harvested and counted to normalise ELISA analysis results then cells were collected for 
further OPN gene evaluation. The experiment was performed in triplicate.  
 
2.1.15 CD44v6 blocking in NTFs 
NTF322 and NTF10 were cultured in T75 cm2 flask with growth media up to ~70% 
confluence. Cells were incubated for 1h with serum-free media supplemented with 
5µg/ml of CD44var (v6) Monoclonal Antibody (VFF-18) supplied by eBioscience™ 
(Catalogue: BMS125). The experimental control was incubated with serum-free media 
only. 6.5 ml of cell lines conditioned media (SCC89, SCC72 and SCC2) (prepared in 
section 2.1.1) was thawed in the water bath and supplemented with 1.5ml of fresh growth 
media. After 1 h of CD44 blocking, rOPN or cell line CM was added to NTFs and 
incubated for 24 h at 37°C in a humidified incubator with CO2. The next day, media were 
collected, centrifuged, and stored at -20°C immediately. Fibroblasts were harvested, 
counted and collected as a pellet for further gene analysis. 
2.2 Protein analysis 
2.2.1 Cytokine analysis 
Cell-cell communication between tumour cells and cells in the microenvironment plays 
an important role in cancer initiation, promotion, and progression (Lorusso and Rüegg, 
2008). CAFs have functional or regulatory roles in HNSCC carcinogenesis and 
malignancy such as metastasis, proliferation, and angiogenesis through the cytokine 
signals facilitating autocrine and paracrine interactions between tumour cells and cells in 
the microenvironment (Orimo and Weinberg, 2006).  
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To understand the nature of this communication in OPSCC and investigate differences 
between HPV positive and HPV negative subtypes, an in vitro co-culture system was 
used in which these cellular interactions in OPSCC can be examined. Different 
approaches to the study of cell-cell communication in co-culture systems have been used 
in the literature depending on the hypothesis of interest (Bogdanowicz and Lu, 2013) 
(Table 2.5). The objectives of this study were to identify secreted cytokines in 
tumour/fibroblast cells crosstalk and explore the source of these secretory cytokines. 
For cytokine screening, we collected fibroblast conditioned media after incubation with 
the relevant OPSCC cell line media for 24 h, then subjected these media to cytokine 
array analysis. To validate the array findings and explore the source of the cytokine 
production, we used an indirect co-culture system (Transwell) taking advantage of cell 
culture separation with a porous membrane which permitted fluid movement between 
the co-cultivated cell populations while they were kept separated. In these experiments, 
all collected media was stored at −20°C in small aliquots to avoid a freeze-thaw cycle. 















            Table. 2.5: Comparison between co-culture methods. 
 
2.2.1.1 Collection of cell line conditioned media for fibroblast activation 
HPV negative cell lines (SCC89) and HPV positive cell lines (SCC2) were cultured in 
T75 cm2 flasks using growth media (section 2.1) until ~85% confluency. Cells were 
washed twice in PBS, then incubated for 24h in 7 ml of growth media. The next day, the 
(conditioned) media was collected and centrifuged for 5 minutes at 3,000 rpm. 6.5 ml of 
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the supernatant was aspirated carefully and stored immediately at -20°C. Cells were 
trypsinised and counted to record the number of cells that contributed to each ml of 
conditioned media, 3 ±1 million cell/ml was the target. 
2.2.1.2  Fibroblast stimulation with cell line conditioned media – Passive 
coculture 
NTF322, NTF10, CAF1 or CAF2 cells were cultured in T75 cm2 flasks with growth media 
up to ~70% confluence (as fibroblasts will be incubated for a further 48 h, enough space 
is required between cells to avoid cellular stress). Conditioned media (section 2.1.1) from 
the HPV negative cell line (SCC89) and HPV positive cell line (SCC2) were thawed in 
the water bath. Fibroblasts were washed three times with PBS, then 6.5 ml of HPV 
positive or HPV negative cell line conditioned media was added to fibroblasts and 
incubated for 24 h at 37°C in a humidified incubator with CO2. The experimental control 
cells were incubated with fresh growth media and incubated at the same condition. The 
next day, media were collected (Media1), centrifuged, and immediately stored at -20°C. 
Fibroblasts were washed with PBS x3 and incubated with 6.5 ml of fresh serum-free 
media for a further 24 h. After that, media were collected (Media2), centrifuged, and 
stored at -20°C immediately. Fibroblasts were harvested and counted to allow for 
normalisation of the ELISA results (Figure 2.3). 
 
Figure 2.3: Illustration for conditioned media procedure. A. cell line conditioned media 
collection. B. Stimulation of fibroblast by cell line media and collection of the stimulated fibroblasts 
media. C. incubation of fibroblast with normal media to get media2. 
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2.2.1.3 Cytokine arrays  
Multiplex arrays are an antibody-pair-based assay for screening and comparing 
expression levels of up to hundreds of cytokines in a single assay. By comparing cytokine 
arrays with other methods for cytokine screening, such as Mass Spectrometry and 
Cytometric Bead Array, cytokine arrays are simpler, use standard lab equipment, and 
are relatively cost-effective. However, a cytokine array is a semi-quantitative method that 
requires further quantitative analysis using for example an ELISA assay for validation.  
The technology is based on the specific binding ability between captured antibody 
spotted in duplicate on nitrocellulose membranes and target cytokine that can be applied 
in different forms such as cell culture supernatant, cell lysate, serum, or plasma samples. 
Detection and visualisation of cytokine-capture antibody complex are obtained by 
incubating the membrane with streptavidin-Horseradish Peroxidase and 
chemiluminescent detection reagents. The signals are presented in the semi-quantitative 
form in proportion to the amount of cytokine bound.  
The Proteome Profiler Human XL Oncology Array kit (Catalogue number ARY026) 
was purchased from R&D Systems, Inc., Minneapolis, US. The arrays are designed to 
provide a relative expression of 84 human cancer-related proteins (Figure 2.4) the full 
names of included factors are listed in Appendix A.2. The protocol was followed 
according to the manufacturer’s instructions throughout the experimentation. Developed 
films were then scanned at high resolution and analysed using Image Studio software 
(Version 5.2; LI-COR, Inc, USA). Densitometry data were then normalised to the positive 
control spot (reference spots).  
 
Figure 2.4: The Proteome Profiler Human XL Oncology Array map (Catalogue number 
ARY026, R&D Systems, UK). 
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2.2.1.4 Indirect interactive co-culture (Transwell) 
In this experiment, we followed a modified protocol of the transwell co-culture method, 
based on a previous report (Aiuti et al., 1998). 3x105 Cancer cells were seeded in 1.5ml 
of growth media on cell culture inserts (Life Sciences, USA) containing a 0.45μm plastic 
membrane filter and placed on a 6-well plate filled with 2.6 ml of growth media. Cells 
were allowed to adhere overnight at 37°C in a humidified incubator with 5% CO2. The 
filters were conditioned before cell seeding to enhance the cellular adhesion by 
preincubation for a minimum of 1 hr at 37°C. 50,000 cells of NTF 3, NTF 10, CAF1 or 
CAF2 were plated in 6-well plate in 2 ml growth media and incubated for 24 h The 
experimental controls were plated in the same way with omitting the fibroblasts or cancer 
cells. The next day, the media change was undertaken, 1.5 ml fresh growth media was 
added to the inserts and 2.6 fresh growth media was added to the fibroblasts in 6-well 
plate, then the cell culture inserts were inserted into the wells carefully to avoid air bubble 
formation (Figure 2.5). The co-culture system was maintained for 48 h at 37°C in a 
humidified incubator with 5% CO2.  At the end of the experiment, the media were 
aspirated and centrifuged at 3000 rpm for 5 min and stored immediately at 20°C. Cancer 
cells and fibroblasts were detached from the culture system, counted and stored 
separately as pellets at -80°C. 
 
 





2.2.2 ELISA analysis 
The indirect ELISA detection method was utilised in this study where the captured 
antigen (the target) has been coated on a plate surface and then complexed with an 
antibody that is linked to a reporter enzyme (horseradish peroxidase). Detection of 
cytokine-captured antibody complex is achieved by measuring the activity of the reporter 
enzyme via incubation with the appropriate substrate to produce measurable signals. 
Secreted IL-6, and CCL2 were quantified using the BD OptEIA™ sets for human IL-6 
and CCL2 detection (BD Biosciences, San Jose, US). OPN was quantified using the 
DuoSet Elisa set (R&D Systems, Minneapolis, US). For IL-6 and CCL2 analysis, 
conditioned media was diluted 1:100, whereas in OPN conditioned media was used 
without dilution. The calculated values were adjusted to the respective dilution factors. 
Delta Soft Microplate Analysis Software (MTX Lab system, USA) was used for ELISA 
data analysis. The corrected wavelength was used to plot the standard curve in (Log-
Log) regression. The standard curve equation was used to determine the target protein 
concentration (pg/ml). The concentration of secreted target protein was normalised 
according to the cell number at 10,000 cell/ml. 
 
2.2.3 SDS-PAGE  
SDS-PAGE was used to separate and identify target proteins. The protein mixture is 
separated on a polyacrylamide gel matrix based on molecular weight. The negatively 
charged proteins migrate depending on their size down the gel towards the positively 
charged electrode when a voltage is applied. However, this technique provides a semi-
quantitative result compared to other relative protein levels.  
2.2.3.1 Protein extraction and quantification:  
Radioimmunoprecipitation assay buffer (RIPA buffer, Sigma-Aldrich, UK) was used 
to lyse cells and solubilise proteins. One tablet of complete mini-EDTA free protease 
inhibitor cocktail and one tablet of phosphatase inhibitors were added to 10 ml RIPA to 
ensure protein stability. The cell pellet was removed from - 80 °C storage and kept in an 
ice box. 150-300 ml lysis buffer was added to the cell pellet and gently pipetted up and 
down to mix thoroughly and kept in the ice for 30 min followed by cooling centrifugation 
for 20 min at 13,300 rpm to avoid protein denaturing. The supernatant (soluble protein) 
was then aspirated and stored at -20°C, and the formed pellet was discarded. Protein 
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was quantified using the bicinchoninic acid assay (BCA) (Fisher-Scientific, UK) following 
the manufacturer's protocol. A POLAR-star Galaxy spectrophotometer was used for 
plate reading. 
 
2.2.3.2 Separation by size 
The percentage of acrylamide gel to use was determined according to the target protein 
molecular weight. Table 2.6. illustrates the recipe of used Acrylamide gel to make 1.5 
mm gel thickness. 
Table 2.6: acrylamide gels’ recipe 
 
 
Total protein lysate (20-30 μg) was mixed with 5x SDS lysis buffer (1:5) then heated for 
5 min at 95°C in a heat block. This step aimed to denature the higher-order structure, 
which ensures that the negative charge of amino acids is not neutralized, enabling the 
protein to move in an electric field. The gel was placed into the XCell SureLock Mini Cell 
electrophoresis system (Invitrogen Ltd, UK) following the manufacturer’s instructions and 
filled with 1x SDS running buffer. A pre-stained protein ladder (Ez run protein ladder) and 






2.2.3.3 Transfer to a solid support 
Protein in the gel was transferred into nitrocellulose membrane or polyvinylidene 
difluoride (PVDF) membrane using the Trans-Blot® TurboTM Transfer System (Bio-Rad, 
UK). PVDF offers a higher protein binding capacity which allows it to detect lowly 
expressed proteins at a cost of higher background noise. More attention is required 
during the washing steps to minimise the dark background. Membrane was then stained 
with a Ponceau solution (Sigma- Aldrich, UK) to check for even protein transfer followed 
by washing dH2O.  
2.2.3.4 Marking the target protein 
The immunodetection step started by membrane blocking with 5% (w/v) milk (Marvel, 
UK) in TBS-T (Tris-buffered saline 10mM, containing 0.5% Tween (v/v)) for 1 hour at 
room temperature. The membrane was then incubated overnight at 4°C on a rocking 
platform with the primary antibody at the recommended concentration (Table 2.7) in 5% 
TBS-T milk. 
Table 2.7: List of used primary antibodies in immunoblotting. 
Primary antibody Working 
concentration 
Catalogue No – Supplier 
Anti-α-SMA 1:1000 A5228 - Sigma-Aldrich, UK 
Anti-p16 1:1000 108349 – Abcam, Cambridge, UK 
Anti-p21 1:1000 MAB1047 – R&D Systems, US 
Anti-phosphorylated p38 1:1000 Ab4822 – Abcam, UK 
Anti p38 1:500 Ab27986 – Abcam, UK 
Anti-CD44 1:1000 15675-1-AP – Proteintech, UK 
Anti-β-actin 1:3000 A1978 – Sigma-Aldrich, UK 
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The next day, the membrane was washed x3 for 5 min with TBS-T and then was 
incubated with the secondary antibody (Table 2.8) in 5% TBS-T milk for 1hr at room 
temperature on a rocking platform. 
 
Table 2.8: List of used secondary antibodies in immunoblotting. 
 
The membrane was then washed twice for 10 min with TBS-T and once with TBS for 5 
min. Membrane was developed with enhanced chemiluminescence (ECL), Pierce ECL 
western blotting substrate (Thermo-Fisher, USA), according to the manufacturer’s 
instructions, then the membrane was scanned with a digital scan. Image Studio Software 
(LI-COR Biosciences, US) was used for densitometry analysis of the bands and the 
intensity of each band was expressed normalized to the corresponding internal control 
(β-actin). When needed, membranes were stripped of bound antibodies using 10 ml of 
stripping buffer (Sigma-Aldrich, UK) for 30 minutes at room temperature on a rocking 
platform and then washed with TBS.  
 
2.2.4 Immunofluorescence staining 
Immunofluorescence staining was performed to detect and localise the antigens in 
cellular contexts (α-SMA, FAP-α, FSP-1), also, to determine the activation states of 
CD44 in OPN-treated OPSCC cell lines.   
8-well slide chamber (Starstedt, GER) was used to culture the cells for 
immunofluorescence analysis. 20,000 cells were seeded in each chamber with 800 μL 
of growth media. Chambers were covered with a lid and incubated for 24 h at 37°C in a 
humidified incubator with 5% CO2. After treatment with TGF-β1 or OPN, cells were fixed 
using the recommended reagent according to the manufacturer’s instructions (Table 
2.10). This was followed by another incubation with the permeabilisation reagent if 
needed (Table 2.11). After that, cells were blocked by the appropriate blocking (Table 
2.9) on a shaker for 15 mins. 200 μL of the diluted primary antibody was added, including 
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in the experiment negative control and incubated for 1.5h. Cells were then washed twice 
with PBS and incubated with the secondary antibody for 1h (if a non-conjugated 
antibody). The antibody control chamber was incubated with 200 μL of secondary 
antibody only. After that, the chambers were washed x3 with PBS and mounted with a 
coverslip containing a drop of Prolong diamond antifade mountant (DAPI, thermo fisher 
P36966). The slide was placed in a slide box at 4°C for 24h. Images have been taken 
used Ziess Axioplan 2 fluorescence light microscope (Carl Zeiss, UK), staining intensity 
has been quantified using Image J software quantifying the green colour only in fields 
with equal cells number. 
Table 2.9: Summary of the essential information for the used antibodies in 
immunofluorescent staining. 
Protocol  α-SMA FAP-α, FSP-1 CD44 
Fixation 100% Methanol 
for 15 min 
4 % formaldehyde 
for 10 minutes 
100% Methanol 
for 15 min 
100% Methanol 
for 15 min 
Permeabilization 4mM Sodium 
deoxycholate for 




Not required. 4mM Sodium 
deoxycholate for 




(2.5% BSA in 
PBS) 15 min 
5 % normal goat 
serum/PBS. 15 
min 
10% goat serum 
in PBS. 15 min 
10% goat serum 






























Not required  1:1000, goat anti 
rabbit. 1h at 37°C 
1:1000, goat 
anti rabbit. 1h at 
37°C 
1:1000, goat anti 




2.3 Molecular analysis 
2.3.1 RNA extraction and reverse transcription 
Total RNA was extracted using the Isolate II RNA Mini Kit (Bioline, UK) following the 
manufacturer’s instructions. RNA was quantified using a Nanodrop spectrophotometer. 
The purity of extracted RNA was determined by 260/280 ratio. 400ng of extracted RNA 
was reverse transcribed using a High-Capacity cDNA reverse transcription Kit (Applied 
Biosystems, USA) following manufacturer ś protocol using Peltier Thermal cycler (MJ 
Research, UK). The thermal cycler was set to run at 25°C for 10 min, followed by 2 h at 
37°C, and finally at 85°C for 5 min. cDNA was then stored at -20˚C. 
2.3.2 Quantitative PCR (qRT-PCR) 
Gene expression was quantified by a Rotor-gene qRT- PCR cycler (Qiagen, UK) using 
SYBR green chemistry or TaqMan chemistry. The quantification result was calculated 
using delta CT values normalized to the cellular reference gene beta2-microglobulin 
(β2m). All reactions were performed in a total volume of 10 µl, loading 500-120 ng of 
cDNA. The standard thermal cycle consisted of 95ºC for 10 sec, 60ºC for 15 sec and 72 
ºC for 20 sec. Table 2.10 outlines the probes used in this project. 
Table 2.10: List of the used qRT-PCR primers and probes in the study
 
SYBR Green primers 
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Table 2.10 B: List of the used qRT-PCR probe in the study 
TaqMan chemistry probe 
Name  Hs number Supplier 
HAL-DR 00219575 Thermo Fisher scientific, UK 
CD31 10652790 Thermo Fisher scientific, UK 
FAP-α 00159849 Thermo Fisher scientific, UK 
PDGFRα 
00183486 
Thermo Fisher scientific, UK 
IL-6 00985639 Thermo Fisher scientific, UK 
CDKN1A 
(P21) 
00355782 Thermo Fisher scientific, UK 
CDKN2A 
(P16) 
00923894 Thermo Fisher scientific, UK 
SPP1 (OPN) 00960942 Thermo Fisher scientific, UK 
β2m 
4325797 Thermo Fisher scientific, UK 
 







2.4 Tissue microarrays 
We constructed TMAs to validate the expression of some of the HNSCC biomarkers on 
OPSCC tissue samples. The TMA technique has been used widely in cancer research 
in clinical outcome analysis, and validation of tumour biomarkers. It allows high-
throughput molecular profiling to the tissue sections (Hoos and Cordon-Cardo, 2001), 
and provides rapid visualisation and analysis of molecular targets in hundreds/thousands 
of tissue samples at a time, either the DNA, RNA or protein level. The speed of molecular 
analyses is increased by more than 100-fold when compared with conventional 
techniques (Kallioniemi et al., 2001). Additionally, the simultaneous processing of tissue 
material in arrays provides high reproducibility as well as the reliability of the score 
interpretation (Radhakrishnan et al., 2007). The validation of TMAs results has been 
assessed and compared previously with the whole section results, no significant 
differences between the two methods have been observed (Hoos and Cordon-Cardo, 
2001). The major limitation is the small tissue volume may not be representative of the 
entire sample. To overcome this point, 3 cores from each sample were selected 
purposely including stroma and tumour cells, so they were similar and representative of 
the tumour in areas of interest in the main diagnostic slide. TMA construction can be a 
time-consuming method especially in the preparatory step of marking the tissue area, 
however, this time is worth using multiple replicates in array construction as this will be 
time and effort efficient at the staining assessment stage. 
 
Two retrospective pre-treated primary cohorts of OPSCC patients have been employed 
in this project: Cohort of 96 cases associated with all relevant clinical information was 
shared kindly by Dr Hisham Mehanna - University of Birmingham. The material formed 
part of the PREDICTR-OPC study cohort. The clinical material was provided as 10 
unstained TMA slides. A material transfer between the two universities was approved 
under the project ethical number 12/Lo/2018.  
 
Cohort of 72 cases associated with all relevant clinical information, original diagnostic 
biopsy blocks, and respective slides were retrieved from Sheffield Teaching Hospitals 
pathology reporting database in the period between 2002-2012 (also authorised under 






2.4.1 Array design and construction: 
Relevant haematoxylin-stained tissue sections of the corresponding FFPE donor blocks 
were histologically reviewed by KDH & NBH. Tumour representative areas (including 
epithelium and stroma) subsequently were marked, using a microscope mounted 
biomarker. By counting the number of marked cores, the TMA maps were designed 
(Appendix A.4): 
3 TMAs blocks were designed to cover all cohort cases; each recipient TMA block was 
designed to include 70 cores. Triplicate 1.0 mm cores from each donor block were 
included in the TMA design (whenever possible). Controls cores account for 28.5% of 
TMA cores in each TMAs block, including controls in the same OPSCC slide which helps 
in ensuring the specificity and sensitivity of used biomarkers. Controls were located at 
template borders to minimise the risk of losing OPSCC cores. Positive control tissues 
include lymph node (LN), submandibular salivary gland (Sub SG), tonsillar tissue, 
granulation tissue, and normal mucosa (N moucsa).  Additionally, 3 orientation cores 
were added to the template to allow easy slide orientation. TMAs were constructed 
manually with high precision and according to the manufacturer's instructions (Parsons 
and Grabsch, 2009) using MTA-1 Beecher manual instrument (Sun Prairie, USA). Blocks 
were then incubated at 37° C for 30 minutes in an upside-down position facing a glass 
slide for block tempering and to get all cores at the same horizontal level. Sequential 
FFPE sections (4μm thickness) were cut from TMAs blocks and placed on coated super-
adhesive slides (Thermo Fisher Scientific). Slides dried at RT for 24 h and then stored in 
a slides box at 4 °C. Slide baking was postponed until 1 hr before the staining procedure. 
Slide baking was done by incubation in the lab oven at 50°C for one hour, then drying at 
RT for 30 min.  
 
2.4.2 RNAScope assay  
RNAScope is a novel nucleic acid in situ hybridization (ISH) technology that provides 
high specificity detection for single-RNA molecules within the context of complex tissue 
microenvironments. The principle of this technology relies on a unique probe design that 
provides simultaneous signal amplification and suppresses background noise. 
RNAScope is quite similar to IHC in terms of tissue deparaffinization, rehydration, 
blocking endogenous peroxidase activity, and antigen retrieval, however, the target in 
IHC is to detect and amplify the interested protein signals, whereas in RNAScope the 
target is mRNA molecules within the intact cell. In this study, we utilised this technique 
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to detect HPV-16, HPV-18 and IL-6 mRNA using hybridisation targeting probes followed 
by several highly specific amplification steps using HybEZ oven (Advanced Cell 
Diagnostics (ACD), CA, USA). 
 
RNAScope assay reagents 
The assay was provided by Advanced Cell Diagnostics (ACD), CA, USA. Reagents in 
ISH and their preparation are listed in (Table 2.11). 
 








The humidity tray was loaded with fresh wet humidifying paper and inserted in place into 
the HybEZ oven (Advanced Cell Diagnostics, USA). The oven was warmed to 40°C for 
30 minutes in advance. Deparaffinization and rehydration of the slides were performed 
by immersing the sections twice in Xylene, for 5 minutes followed by 2 immersions in 
fresh 100% Ethanol for 1 minute, then a hydrophobic barrier was drawn around each 
section with IMMEDGE hydrophobic barrier pen, to ensure proper coverage to the whole 
TMAs cores, slides were placed on absorbent paper and allowed to dry for 5 minutes at 
RT. Pre-treat 1 was added to cover the whole cores and incubated for 10 minutes at RT 
followed by brief washing in dH2O. Slides were then submerged carefully, using plastic 
forceps, in boiling ‘pre-treat 2’ for 15 minutes, and left to cool down in dH2O. Pre-treat 3 
was added to the slides and incubated in the HybEZ oven at 40°C, for 30 minutes, 
followed by two washes in dH2O. The hybridisation probe was pre-warmed in an 
incubator at 37°C, to dissolve any precipitations before use. The target hybrids probe 
was added and incubated for 2 hours in the HybEZ oven at 40°C, followed by two washes 
in wash buffer for 2 minutes. According to the manufacturer's instructions, sequential 
signal amplification steps were carried out using RNAScope 2.5 HD Detection Reagents 
BROWN (Table 2.12). Signal Detection was obtained by incubating the slides for 10 
minutes with DAB Mixture (1:1 Brown-A & Brown-B, amplification kit) then slides were 
immersed in a water bath to stop the colour reaction. Counterstaining was performed 
using Leica ST4020 Stainer, and the glass coverslips were mounted using DPX 
mounting media. 
 





2.4.2.1 RNAScope scoring criteria 
All the stained slides were scored independently by KDH and NH, then the final scores 
were recorded with an agreement between the two parties. For each case, all relevant 
cores were analysed and the highest score among the cores was selected. Scoring 
criteria in HPV-16 RNAScope assay was according to the manufacturer's instructions. 
We considered score (0) as a negative result whereas scores (1-4) as positive HPV 
results (Table 2.13). 
 
Table 2.13: HPV RNAScope scoring criteria 
 
 
IL-6 RNAScope scoring criteria: 
The expression of IL-6 signals has been evaluated and scored for OPSCC stroma 
according to modified scoring scheme from Yu et al., (2015) work in their scoring 
scheme, IL-6 expression has been classified to 4 levels according to the number of 
positive cells: 0, no cells. 1, areas with 5-10 positive cells per 20x field. 2, areas with 11-
25 positive cells per 20x field. 3, areas with 26-50 positive cells per 20x. 4, areas of more 
than 50 positive cells per 20x field. 
We grouped those 4 levels into 2 groups: group 1 “Low IL-6” (≥26 positive cells) and 






2.4.3 Immunohistochemistry analysis (IHC) 
A standard two-step IHC staining procedure was followed to detect the expression of 
p16, ɑ-SMA, and OPN biomarkers using the streptavidin‐biotin-peroxidase complex. 
Primary antibodies, the appropriate secondary antibody, blocking serum and control are 
summarised in Table 2.14.  
 
Table 2.14: Summary of the essential information in IHC procedure. 










Anti-p16 P16 IHC staining has been carried out by the Royal Hallamshire Hospital 
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IHC reagents in IHC analysis and their preparations are listed in (Table 2.15) 
Table 2.15: IHC reagents. 
  
IHC Protocol 
Tissue deparaffinization and rehydration was performed by immersing the sections twice 
in Xylene for 5 minutes each followed by another immersion in absolute Ethanol, twice 
for 5 minutes in each. The endogenous peroxidase activity was quenched using 3% 
methanolic hydrogen peroxide for 20 minutes to minimise background staining, followed 
by a brief wash in PBS. Antigen retrieval was conducted according to the 
recommendation of the manufacturer of the relevant primary antibody (Table1.2). A 
hydrophobic barrier was drawn around each slide using IMMEDGE TM hydrophobic 
barrier pen to ensure proper coverage of the whole TMA cores. 100% normal serum was 
used as a blocking serum to prevent the non-specific staining, slides were incubated for 
30 minutes at RT in humidity. After that, the blocking serum was discarded, and slides 
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were further incubated with a sufficient volume of primary antibody diluted in serum in a 
humidity chamber overnight at 4°C. The next morning, slides were washed 2X with PBS 
for 5 minutes, followed by incubation with the secondary antibody for 30 minutes at RT 
(The secondary antibody is conjugated to biotin which has a strong affinity to ABC 
solution, the latter works as an amplifier to the antigen signals and aids in antigens 
visualisation). After the incubation, the slides were washed x2 with PBS for 5 minutes 
each and covered with ABC solution for a further 30 minutes at RT, followed by x2 wash 
in PBS, for 5 minutes. DAB Peroxidase Substrate was used for colour development for 
8-10 minutes then slides immersed immediately in dH2O to stop the colour reaction. 
Haematoxylin counterstaining was performed using an automated linear staining 
machine (Shandon). Glass coverslips were mounted with DPX mountant (Thermo Fisher 
Scientific).  
 
2.4.3.1 IHC scoring criteria 
All biomarkers have been scored semi-quantitatively by KH and NH, then the final score 
was agreed by the two parties. The highest score among the 3 TMA cores was chosen: 
 
p16 IHC biomarker: 
TMAs slides were scored using Histo-score (H-score). H-score is the sum of individual 
stain intensity level seen in the field giving more relative weight to higher-intensity 
staining in each tumour core. For each core, the staining intensity (0, 1+, 2+, or 3+) is 
determined then the percentage of cells at each staining intensity level is recorded, then 
H-score is calculated using the following formula: [1 × (% cells 1+) + 2 × (% cells 2+) + 
3 × (% cells 3+)]. H-score results range from 0 to 300. 
 
ɑ-SMA biomarker: 
ɑ-SMA immunopositivity was scored to “Low” and “High” based on positive staining 
amount, followed by Kellermann et al., (2008) criteria. “Low” indicated a patchy/focal 
expression less than 50% of the stroma, while High referred to a diffuse expression 







The expression of OPN was scored in tumour cells only. OPN IHC score was based on 
the assessment of OPN stain intensity in the tumour cells: (0=absence, 1=weak, 
2=moderate, 3=strong) multiply by the score of stained percentage of epithelium 
thickness (0=<5%, 1=<25%, 2=<50%, 3=<75, 4=75-100%). The scoring scale range 
from 0-12. 
The extent of the OPN staining (E) within tumour cells (percentage of positive cells 
concerning the total number of epithelial cells) was scored from 0-4, 0 = 0% positive 
cells, 1 ≤ 25% positive cells, 2 = 26%–50% positive cells, 3 ≥ 50% positive cell, 4 100% 
positive cells. OPN final score is corresponding to the yield of (I * E), with the maximum 
score being 12. 
 
2.4.4 Imaging  
All histological images for H&E, ISH, and IHC slides were obtained using Cell-D^ 














Chapter 3: TMA-based clinical validation of molecular 





















High-risk HPV infection is a well-established risk factor for developing OPSCC, in 
addition to traditional OPSCC risk factors, including tobacco use and alcohol 
consumption. However, HPV-driven OPSCC is a distinct entity with a characteristic 
molecular and clinical profile. The differences between both OPSCC subtypes are 
evident in the clinical epidemiological figures which report an alarming increase in the 
incidence of HPV-associated OPSCC over the last few decades. OPSCC incidence was 
expected to increase further in England by 239% in the period between 2011 to 2025, at 
that time point, OPSCC would compose 35% of all HNC (Louie, Mehanna and Sasieni, 
2015). The differences in OPSCC subtypes are also demonstrated in the clinical patient 
profile. HPV-positive patients tend to be male, younger in age, with no history of chronic 
smoking and drinking habits. Most importantly, HPV-positive OPSCCs display better 
clinical outcome than their non-HPV related counterparts regardless of the treatment 
modalities (Lindquist et al., 2007, Lassen et al., 2009, Ang et al., 2010). Based on these 
clinical differences, there was a key change regarding HPV-positive OPSCC in the 8th 
edition of the UICC TNM classification (Union for International Cancer Control), which 
considers HPV-associated OPSCC a separate entity, based on p16 expression.  
In this context, determining HPV status in OPSCC has become a mandatory requirement 
in routine practice, based on p16 IHC as a first-line test. Although this technique is 
considered sensitive, cost-effective, and feasible to apply, it is subject to the limitations 
of IHC evaluation, with a lack of standardised scoring criteria and an agreement on a 
definite single threshold. Intense nuclear and cytoplasmic expression in >70% of tumour 
cells has been adopted by the majority; however, others demonstrated >50% positivity 
threshold with better specificity. An H-score based scheme was also proposed for p16 
scoring which still awaits extensive clinical validation (Jordan et al., 2012). 
Given the superior prognosis of HPV-driven OPSCC, currently, there is wide interest in 
treatment de-escalation programmes, seeking to reduce treatment morbidity whilst 
maintaining favourable survival features. Several ongoing trials are considering de-
intensifying chemotherapy or radiotherapy and/or applying targeted therapy or 
immunotherapy as alternative approaches (Howard et al., 2018, Beaty et al., 2019, Jones 
et al., 2020). However, the criteria of patient selection based on HPV-status only could 
be too simplistic, raising the concern of establishing additional adequate parameters for 
HPV-positive OPSCC stratification based on molecular biomarkers.  
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The crucial role of tumour microenvironment (TME) in cancer progression is a promising 
approach in cancer research generally. CAFs are the most prominent TME component 
in solid tumours which have been suggested to have profound influences on tumour 
behaviour. CAFs have shown the capability to enhance tumour growth, local invasion 
and metastasis and were, characteristically, known by the expression of ɑ-SMA (Attieh 
and Vignjevic, 2016, LeBleu and Kalluri, 2018). Given the established functional features 
of CAFs, they have become increasingly accepted as prognostic biomarker. CAFs have 
been correlated with poor clinical outcome in several tumours (Chen et al., 2017, Cong 
et al., 2020, Zhan et al., 2020). In OSCC, Marsh et al. (2011) linked the high presence 
of CAFs in OSCC stroma with worse prognosis compared to OSCC with fewer CAFs 
detected, introducing ɑ-SMA IHC as an independent and effective mortality predictor. 
Although well-established for OSCC, CAFs’ prognostic role in OPSCC has not been 
investigated thoroughly in the literature. In previous work from our lab, Bolt et al. (2018) 
reported a significant difference in HPV-positive and HPV-negative OPSCC cell lines’ 
interaction with stromal fibroblasts in 2D and 3D models. HPV-negative cell lines showed 
the ability to promote normal fibroblast production of a supportive secretome able to 
enhance cancer cell migration and invasion. These interesting observations underpin the 












3.2. Aims  
● Determine the status of biologically relevant HPV infection in an established 
OPSCC cohort and compare its demographic characteristics with non-HPV 
related OPSCC. 
 
● Determine the p16 H-score threshold in OPSCC and evaluate its diagnostic and 
prognostic performance in OPSCC. 
 
● Explore and compare ɑ-SMA presence in OPSCC subtypes and assess its 
prognostic value. 
 
3.3. Experimental approach and statistical analysis 
● The main study cohort was established from two small cohorts: Cohort 1 was 
collected from cases treated between 1996-2004 in Birmingham and Oxford, as 
part of the Predictr study. Cohort 2 was collected from cases treated between 
2002-2012 at Sheffield Teaching Hospitals NHS Trust. 
 
● Tissue microarrays were constructed, then subjected to RNAScope assay to 
detect HPV 16/18 mRNAs. The whole cohort was divided into two sub-groups 
according to HPV status. Demographic features were compared using 
contingency table chi-square tests, age mean compared using t-test (two-tailed).  
 
● Overall survival information only was obtained for the whole cohort of cases. 
Kaplan-Meier method was used to analyse survival based on the predictor 
groups. The survival curves were compared using Log-Rank test. Estimated 
overall survival time was expressed as mean with 95% CI. Five-year survival rate 
was selected as an endpoint in the survival analysis, which is consistent with 
more commonly cited statistics in HNSCC.  
 
● p16 IHC staining was performed using the E6H4 antibody clone and assessed 
using H-score. The p16 positivity threshold was determined using ROC curve. 
The curve was plotted against p16 sensitivity and 1-specificity in HPV detection 
using RNAScope as the reference assay. The prognostic performance of p16 
biomarker was assessed using Kaplan-Meier method and Log-Rank test. 
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● α-SMA biomarker expression was assessed by performing IHC staining for the 
whole cohort. α-SMA expression distribution between OPSCC subtypes was 
assessed using contingency table chi-square tests. The prognostic value of α-
SMA biomarker was evaluated and compared in OPSCC subtypes using Kaplan-
Meier method and Log-Rank test. 
 
● An unadjusted Cox regression model (Univariate) was established to evaluate 
the hazard ratio (HR) for each predictor separately.  
 
● All statistical analyses were performed using SPSS (versions 23-26). p-
value<0.05 was considered significant. HR>1 indicated a positive correlation with 





3.4.1. Establishing the study cohort  
In this study, two retrospective pre-treated primary cohorts of OPSCC patients were 
employed. Cohort 1 consisted of 96 cases treated in the period between 1996-2005 
which were kindly shared by Professor Hisham Mehanna, University of Birmingham. 
These cases were originally part of the cohort for the Predictr-OPC study.  The cohort 
was provided in 10 unstained slides associated with relevant clinical information, HPV 
16/18 RNA ISH score and p16 H-score. However, 13 cases were excluded due to 
unavailable RNA ISH score (n=5) and missing survival-related information (n=8). The 
second cohort, “Cohort 2”, included 72 cases associated with all relevant clinical 
information, original diagnostic biopsy blocks and respective slides that were retrieved 
from the Sheffield Teaching Hospitals pathology reporting database, in the period 
between 2002-2012. During the histological examination and core selection, 12 cases 
were excluded due to insufficient tumour tissue availability (n=8) and insufficient survival 
information (n=4) (Figure 3.1). 
 
 
Figure 3.1: Flow-chart illustrating the establishment of the study cohort. 
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3.4.2. HPV-positive OPSCC prevalence and cohort 
characterisation  
RNAScope assay for HPV 16/18 was the utilised method for detecting HPV-driven 
OPSCC in the study cohort. In Cohort 1 the assay result was provided in terms of 
“positive” or “negative”. To identify HPV-associated OPSCC in “Cohort 2”, TMAs slides 
were subjected to HPV 16/18 RNAScope assay (Advanced Cell Diagnostics, CA, USA). 
The assay was conducted and scored according to the manufacturer’s instructions 
(Refer to section 2.4.21 for the detailed score information).  The full range of RNAScope 
scores (1-4) was observed in Cohort 2. RNAScope negative case was identified by the 




Figure 3.2: HPV16/18 mRNA expression in OPSCC cohort 2 using RNAScope assay. 1, The 
assay negative control, using bacterial gene DapB on OPSCC tissue section. 2, HPV16 & 18 
RNA-ISH positive controls, using known positive OPSCC case positive for HPV-DNA ISH, dark 
dots of stained HR-HPV RNA can be seen within the epithelial cells and nuclei (arrow). 3, 
RNAScope score 1 (40X magnification), 1-3 dots of stained HPV RNA can be seen per epithelial 
cell (arrow). 4, RNAScope score 2 (40X magnification), more than 3 dots per cell, also very few 
dot clusters are visible (arrow). 5, RNAScope score 3 (20X magnification), HPV RNA of more than 
10 dots/cells and less than 10% of the field has positive dot clusters. 6, RNAScope score 4, (20X 




3.4.2.1 HPV-positive Prevalence 
The HPV 16/18 prevalence across the whole study cohort was 60.8% (87/143), while 
39.2% (56/143) of the cohort was HPV 16/18 negative. Since the main study cohort 
consisted of two cohorts collected from different periods, we had to look at HPV 16/18 
prevalence separately in each small cohort for the comparison. The HPV-associated 
OPSCC percentage was 57.8% (48/83) in “Cohort 1” and 65% (39/60) in “Cohort 2”. 
 
3.4.2.2 Cohort characterisation based on HPV status 
According to HPV status, the study cohort was divided into two sub-groups, HPV-positive 
and HPV-negative. Descriptive comparisons for demographic and clinicopathologic 
variables are summarised in (Table 3.1). Patients' age distribution between the HPV-
positive and negative groups was comparable based on Chi-square comparison 
between age groups (p=0.71). The mean ages of the HPV-positive and negative groups 
were nearly identical: 56.1 years in the HPV-positive and 56.9 in the counterpart group 
(p=0.91), however, there was a little shift in HPV-negative group median toward the older 
age group (55 and 57.5, respectively). No gender predilection was observed in HPV-
OPSCC. Although the study cohort included a higher percentage of “Males” than 
“Females”, HPV-OPSCC distribution was comparable between both genders (p=0.65).  
Smoking information was obtained in 129 cases, categorised, generally, into “Never”, 
“Former” and “Current”. In the HPV positive group, the percentage of non-smokers was 
48.7% (38/78), while this percentage was lower in the HPV negative group: 13.7% (7/51). 
On the contrary, the current smoker subgroup of the HPV-negative group recorded a 
higher value than the HPV-positive group (56.8% and 25.6%, respectively). Statistically, 
smoking status categories revealed a significant difference between the two groups 
(p<0.001). In this study, TNM staging information was available according to the previous 
staging scheme (TNM7). Data represent the status at the time of diagnosis. We did not 
observe evident differences in T and N grades distribution between OPSCC entities 
(p=0.07). OPSCC cohort cases were distributed between stage III and stage VI, no 
earlier stages were detected. HPV-positive cases showed a higher percentage of stage 
VI than HPV-negative cases: 65.5% (57/87) and 46.4% (26/56), respectively. The 




Treatment modalities records were obtained in 73 cases. All cases received surgical 
resection for the primary tumour. Adjuvant radiotherapy was afforded for all the cases 
except 6 cases who, sadly, died a few months following the diagnostic date. 
Chemoradiotherapy was provided for 23.91% (11/46) of the HPV group, while 7.4% 
(2/27) of the non-HPV group received the treatment.  
 
Among the HPV group, 10.3% (9/87) developed recurrent disease, while the rest of the 
group remained disease-free at the last time seen. The non-HPV related group suffered 
a high percentage of tumour recurrence: 25% (14/56).  
 
Overall survival (OS) was only available for the study cohort, disease specific survival 
(DSS) may reflect evident differences between OPSCC subtypes rather than21 OS.  
Based on comparing the percentage of deaths in each group over 5 years of follow up, 
the HPV-positive group showed a lower figure of 15.9%, while this percentage was 
higher in the counterpart HPV negative group (38.2%). The prognostic value of HPV 
















N/A 5 (18.51) 1 (2.17) 
2 (7.40) 11 (23.91) 
20 (74.07) 34 (73.91) 











3.4.3. Prognostic potential of HPV-driven OPSCC 
The 5-year survival rate for the HPV-positive group was favourable compared with the 
HPV-negative group (Figure 3.3). The survival percentage for the HPV-positive cases 
was higher than in the counterpart group (84.1% against 62.5%). Log-rank statistical test 
revealed a significant difference between both OPSCC curves (p= 0.002) (Table 3.2). 
 
 
Figure 3.3: Better overall survival rate in HPV 16/18 positive group than HPV-negative 
group. The survival curve at 5-years follow-up concerning overall survival using Kaplan-Meier 
method. The red curve represents the HPV-OPSCC group (n=87) and the blue curve represents 
the non-HPV OPSCC group (n=54). Each drop-step in the curve illustrates a case of death. Each 
vertical line (Hash lines) on the curve indicates censored data. The HPV-positive group 






Table 3.2: Summary of Kaplan-Meier method for OPSCC based on HPV status  
 
 
3.4.4. Influence of smoking on OPSCC survival 
In OPSCC cohort characterisation, the smoking status at diagnosis revealed a significant 
difference between HPV-positive and HPV negative groups, although these data lack 
accuracy in the definitions of “Former” and “Current '' in terms of the number of packs 
and years since quitting the smoking habit. Here, we evaluated the effect of smoking 
status on OPSCC survival in both HPV groups based on smoking data at the time of 
diagnosis; smoking status during the treatment and follow-up periods was not 
documented. In the HPV-positive group, analysis of the obtained survival information for 
78 cases revealed no significant impact of smoking on HPV-positive group survival. The 
estimated survival time for “Never” and “Current” was 4.7 years and 4.6 years, 
respectively, while for “Former” it was 4.2 years, (p=0.48) (Figure 3.4).  
On the contrary, smoking habit seems to have had a significant negative impact on the 
survival of the HPV-negative group (n=51) based on smoking status: the “Never” group 
(n=7) showed a favourable clinical outcome over the 5 years, with a survival fraction of 
1, followed by former smoker patients (n=15), with a survival fraction of 0.86. The current 
smoker group (n=29) demonstrated the worst survival among the three categories, with 








Figure 3.4: 5-years overall survival rates in HPV-positive OPSCC cohort based on 
“smoking status at diagnosis”. Kaplan-Meier analysis for HPV-positive group (n=78) revealed 
no significant differences in the survival based on smoking status at diagnosis. Each drop-step 
in the curve illustrates a case of death. Each vertical line (Hash lines) on the curve 
indicates censored data Log-Rank p= 0.48.  
 
Figure 3.5: 5-years overall survival rates in HPV-negative OPSCC cohort based on 
“smoking status at diagnosis”. Kaplan-Meier analysis for HPV-negative group (n=51) revealed 
significant differences in survival based on smoking status at diagnosis. “Current” smoking group 
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showed the worst survival. Each drop-step in the curve illustrates a case of death. Each 
vertical line (Hash lines) on the curve indicates censored data  Log-Rank p= 0.001.  
3.4.5. p16 expression in OPSCC 
In the study cohort, we evaluated the diagnostic and prognostic performance of the 
surrogate biomarker p16. The cohort 1 TMAs were provided with p16 expression 
information as H-score values. Cohort 2 was subjected to an anti-p16 monoclonal 
antibody (clone E6H4) and the staining was scored using H-score. Examples of p16 
positivity are shown in relation to the commonly used thresholds: (1) diffuse strong 
staining in the nucleus and cytoplasm in >70% of tumour cells in the tissue. (2) diffuse 





Figure 3.6: Examples of different p16 expression thresholds in OPSCC. 1, strong 
cytoplasmic and nuclear p16 expression in >70% of the tumour. 2, an example of p16 intensity 
cut-off at >50%, with strong p16 expression in tumour cells. 3, varying patterns of p16 staining 




3.4.5.1. p16 expression distribution in relation to OPSCC subtypes 
p16 expression analysis was undertaken by evaluating H-score distribution among 
OPSCC sub-cohorts (Figure 3.7). Among the HPV-positive cases, 70.9% (61/87) 
demonstrated high H-score value ranges of 200-300. The lowest value among this group 
was “100” (n=1). In contrast, 27.5% (14/52) of the HPV-negative group showed 
expressions of 200-300, whilst the lowest value was “0”, seen in 58.8% (30/52) of the 
HPV-negative group. The difference in H-score means between the two groups was 
statistically significant (p<0.001) using t-test.      
 
Figure 3.7: p16 expression distribution in OPSCC cohort sub-groups. HPV-negative group 
(n=52) and HPV-positive group (n=87) illustrated contrasting patterns in p16 expression 
according to H-score values. HPV-positive cases were associated with higher H-scores, while the 





3.4.5.2. Diagnostic H-score threshold determination using ROC curve 
To assess p16 diagnostic and prognostic values in OPSCC, we first had to determine 
the H-score cut-off point for p16 positivity. ROC curve was selected to achieve the 
diagnostic cut-off point of p16 in HPV detection using RNAScope as a reference test. 
The curve was plotted between two axes of p16 sensitivity and 1-specificity values in 
HPV detection (Figure 3.8). 
Area under the curve (AUC= 0.87) displayed a good diagnostic performance of p16 in 
HPV 16/18 genotypes detection with a value close to “0.9” which indicated an excellent 
performance. ROC analysis presented a list of suggested diagnostic thresholds with the 
corresponding sensitivity and specificity (Appendix A.5). A threshold H-score of 144.5 
was selected for the highest sensitivity (97.7%) accompanied by acceptable specificity 
(72%) among the suggested thresholds.  
Figure 3.8: Diagnostic p16 H-score threshold determination using ROC curve. The curve 
plotted against p16 sensitivity and 1-specificity in HPV detection using RNAScope as a reference 




3.4.5.3. p16 prognostic value in OPSCC cohort 
Based on the ROC curve, H-score of 144.5 was selected as a cut-off point for p16 IHC 
expression positivity. In order to investigate the prognostic value of p16 expression in 
the OPSCC cohort, Kaplan-Meier method was conducted to establish the survival curves 
for OPSCC p16-positive and negative groups and Log-Rank tests assessed the 
significance between the curves (Figure 3.9). Over 5 years of follow up, 84.7% of the 
p16-positive group exhibited a better outcome with an estimated longer survival time (4.5 
years; 95%CI: 4.3-4.8), while 52.6% of p16-negative survived with shorter survival time 
estimation (3.3 years; 95%CI: 2.6-3.9). The difference between the two groups was 
statistically significant (p<0.001) (Table 3.3).  
 
 
Figure 3.9: Better overall survival rate in p16-positive group than p16-negative group. The 
survival curve at 5-years follow-up concerning overall survival using Kaplan-Meier method. The 
red curve represents the p16-positive group, and the blue curve represents the p16-negative 
group.). Each drop-step in the curve illustrates a case of death. Each vertical line (Hash lines) on 
the curve indicates censored data. The p16-positive group demonstrated a favourable prognosis 





Table 3.3: Summary of Kaplan-Meier method for OPSCC based on p16 expression  
 
3.4.5.4. Cohort stratification according to HPV status and p16 
expression  
p16 is considered the first-line test in routine clinical practice for detection of HPV-driven 
OPSCC. Due to p16 low specificity, specific HPV testing is highly recommended as a 
second-line test using either HPV-DNA ISH or PCR which were validated clinically. In 
this study, we investigated the performance of p16 against RNAScope and assessed the 
percentage of discordant cases. By matching HPV status with p16 expression, the 
OPSCC cohort was stratified into four classes. Among the cases, 60.4% (84/139) 
exhibited a p16 positive result in tumour areas harbouring HPV 16/18 RNAScope signals 
(class III). Meanwhile, 26% (36/137) of cases were negative for HPV 16/18 and p16 
expression (class I). Discordant results were observed in 10.8% of cases, which 
displayed p16 positivity, but no HPV 16/18 mRNA was detected (class II). This class 
represents the p16 false positive percentage, whereas there was a p16 false negative 
percentage in 1.4% of cases. Only 2 cases were positive for HPV16/18 but lacked 
overexpression of p16 (class IV). (Figure 3.10).  
 




Due to the small number of discordant cases in this study, the survival comparison 
between the stratified classes was not feasible. However, a highly significant correlation 
was found between the expression of p16 and the presence of HPV 16/18 (p<0.001). 
Survival curves illustrated that “Class I” had the worst outcome among all OPSCC 
classes, achieving the lowest survival fraction (Figure 3.11). 
 
 
Figure 3.11:  Overall survival curves for OPSCC cohort based on p16 and HPV 16/18 
expression using Kaplan-Meier method. OPSCC cohort stratified into 4 classes based on 
p16/HPV expression.  Class I (HPV and p16 negative) showed a lower survival fraction compared 
to Class III (HPV and p16 positive). Each drop-step in the curve illustrates a case of death. 








3.4.6. α-SMA expression in OPSCC 
To explore the presence of CAFs in the OPSCC microenvironment and investigate their 
prognostic value, TMA slides were subjected to IHC using an anti-ɑ-SMA monoclonal 
antibody (1:100, Sigma Aldrich, UK). The submandibular salivary gland tissue section 
was included as a positive control. Antibody-negative control was obtained by omitting 
the primary antibody incubation step on the submandibular salivary gland section. CAFs 
were identified by positive α-SMA staining and were distinguished from other 
inflammatory and endothelial cells-stained cells by their morphology and pattern of 
organisation. CAFs appeared as long and spindle-shaped with an elongated nucleus. 
Typically, in larger amounts, CAFs were arranged in long arrays patterns (Figure 3.12). 
ɑ-SMA immunopositivity was scored to “Low” and “High” based on positive staining 
amount. Following Kellermann et al. (2008) criteria, “Low” indicated a patchy/focal 
expression of less than 50% of the stroma, while High referred to a diffuse expression 





Figure 3.12. α-SMA IHC expression in OPSCC. Anti ɑ-SMA monoclonal antibody (1:100) was 
used for IHC staining. 1, positive control, submandibular salivary gland (myoepithelial-like cells) 
shows strong ɑ-SMA positivity. 2, ɑ-SMA negative control, the omission of ɑ-SMA antibody in 
submandibular gland serves as antibody negative control. 3, Low α-SMA expression. 4, High α-




3.4.6.1. α-SMA expression distribution in relation to OPSCC subtypes 
α-SMA expression was observed in both OPSCC entities in a comparable pattern. Within 
HPV-negative tissue, 46% expressed a high amount of α-SMA, while in HPV-positive 
tissue the percentage was 54.1%. Statistically, no significant difference was observed in 
α-SMA distribution between OPSCC subtypes (Chi-square p=0.36) (Figure 3.13). 
 
 
Figure: 3.13: α-SMA expression distribution in OPSCC cohort sub-groups. HPV-negative 
group (n=52) and HPV-positive group (n=87) displayed comparable patterns in α-SMA IHC. Chi-








3.4.6.2. α-SMA prognostic value in OPSCC 
The prognostic value of ɑ-SMA was evaluated firstly in total for the whole OPSCC cohort 
and then for the sub-cohorts, based on HPV-status. Kaplan-Meier method revealed 
better survival time in the “Low” α-SMA OPSCC group (4.4 years; 95% CI: 4-4.7) 
compared to the “High” α-SMA OPSCC group (4 years; 95% CI: 3.7-4.4). However, the 
Log-Rank comparison between both α-SMA survival curves was non-significant 
(p=0.12), indicating a weak correlation between α-SMA biomarker and OPSCC survival. 
On the contrary, in the HPV-positive sub-cohort, α-SMA expression revealed a significant 
prognostic value which further stratified survival in the HPV-positive group. “Low” α-SMA 
HPV-positive patients demonstrated a favourable clinical outcome compared to “High” 
α-SMA HPV-positive, (4.8 years; 95% CI:4.6-5) and (4.3 years; 95% CI:3.9-4.7), 
respectively, (p=0.02). In the HPV-negative group, both α-SMA survival curves showed 
an overlapped pattern throughout the 5 years of follow up, suggesting a weak prognostic 
value of α-SMA in HPV-negative cases (p=0.77) (Table 3.4) (Figures 3.14-16).  
 
Table 3.4: Summary of Kaplan-Meier method for assessing α-SMA biomarker 






Figure 3.14:  5-years overall survival rates in OPSCC cohort based on ɑ-SMA expression. 
Kaplan-Meier analysis for ɑ-SMA expression in OPSCC cohort (n=137). Log-Rank p= 0.12. ɑ-
SMA low expression cases showed better survival, although that was not significant. The blue 
curve represents the ɑ-SMA-negative group, and the red curve represents the ɑ-SMA-positive 
group). Each drop-step in the curve illustrates a case of death. Each vertical line (Hash lines) on 












Figure 3.15:  5-years overall survival rates in HPV-positive OPSCC group based on ɑ-SMA 
expression. Kaplan-Meier analysis for ɑ-SMA expression HPV-positive group (n=85). Log-Rank 
p= 0.02. Low ɑ-SMA expression significantly predicted better survival among the HPV-positive 
OPSCC group. The blue curve represents the ɑ-SMA-negative group, and the red curve 
represents the ɑ-SMA-positive group. Each drop-step in the curve illustrates a case of death. 




Figure 3.16:  5-years overall survival rates in HPV-negative OPSCC group based on ɑ-SMA 
expression. Kaplan-Meier analysis for ɑ-SMA expression HPV-negative group (n=52). Log-Rank 
p= 0.77. No significant prognostic value was identified for ɑ-SMA biomarker in HPV-negative 
OPSCC. The blue curve represents the ɑ-SMA-negative group, and the red curve represents the 
ɑ-SMA-positive group). Each drop-step in the curve illustrates a case of death. Each vertical line 









3.4.7. Cox regression model  
In the previous survival assessments, the Kaplan-Meier method was used with the null 
hypothesis: “there is no difference between the two populations’ survival curves”. This 
analysis examined the association of favourable outcomes with the presence and/or 
pattern of putative prognostic biomarkers. Looking at the other side of the coin, we aimed 
to measure the hazard of predictors in OPSCC mortality. Cox regression model 
(proportional hazards regression) was selected to provide further prognostic value for 
the cohort mortality “Hazard ratio, HR”. The model was established at the “Univariate” 
level to assess HR for each biomarker separately. A simultaneous “Multivariate” 
comparison of all the predictors’ strength will be presented and discussed in chapter 7. 
 
3.4.7.1. Unadjusted regression Model (Univariate) 
In the univariate model, HR is based on a single predictor where other predictors hold 
constant during the analysis, “unadjusted to other predictors’ effect”. In this model, HR 
reflects the hazard proportion based on a comparison between the predictor’s positive 
and negative groups and their strength in outcome prediction in OPSCC. If the HR is 
greater than 1, that is an indicator for a positive associated with the hazard and low 
survival prediction. If the HR is less than 1, then the predictor is associated with 
favourable survival, not the hazard, and in cases where it is equal to 1, that means the 
predictor does not affect the survival (Table 3.5) (Figure 3.17). 
HPV 16/18-negative status (RNAScope) was significantly associated with increased 
hazard compared to the HPV 16/18-positive counterpart (p=0.005). The mortality in the 
HPV-negative group was 2.68 higher compared to the negative group at any particular 
time (HR: 2.68, 95%CI: 1.35-5.31). On the other hand, HPV 16/18 positivity status 
exhibited a protective feature with HR=0.37 (95% CI; 0.18-0.73). 
Absence of p16 overexpression showed a relatively strong association with poor 
outcome (HR: 3.88, 95%CI: 1.95-7.72), while its positivity was linked to favourable 
survival with low HR: 0.25 (95% CI: 0.12-0.51). The difference in HR between the two 
groups was statistically significant (p<0.001).  
ɑ -SMA low expression showed an association with better survival in OPSCC cohort in 
total (HR: 0.60, 95%CI: 0.29-1.22); however, that was not statistically significant when 
compared with ɑ-SMA positive group (HR: 1.65, 95%CI: 0.81-3.37) (p= 0.16).  
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Table 3.5: Summary of Univariate regression model for OPSCC covariates.  
 
Figure 3.17: Forest plot illustrating the strength of study covariates. A Univariate model was 
established to obtain the hazard ratio values for each factor separately. HR (Red dot) presented 
with 95% CI upper and lower values. The dotted line represents the strength cut-off of HR (1). HR 




3.5. Discussion  
In this chapter, we presented our investigation of a retrospective cohort of primary pre-
treated OPSCC consisting of 143 FFPE tissue samples presented in tissue microarrays. 
HPV 16/18 mRNA ISH prevalence was 60.8% using RNAScope assay. The HPV-
positive group demonstrated a better survival rate than the counterpart (Log-Rank p= 
0.002) with low HR in the univariate model HR=0.37 (95% CI: 0.18-0.73). Available 
smoking data revealed a significant difference between two OPSCC subtypes (p<0.001); 
the HPV-negative group presented with a high percentage of “current'' smokers who 
demonstrated the worst survival fraction in OPSCC. p16 IHC H-score distribution showed 
a clear difference between OPSCC groups (p<0.001). Using ROC curve, H-score 
threshold “144.5” was selected for best diagnostic performance. p16 positivity provided 
a protective feature with superior survival for the positive group HR = 0.25 (95% CI: 0.12-
0.51) based on H-score threshold 144.5. Although High ɑ-SMA IHC expression was 
observed in both OPSCC subtypes, it provided further survival stratification in the HPV-
positive group, with significant potential prognostic value (Log-Rank p=0.02).  
 
3.5.1. HPV prevalence 
Currently, there is compelling evidence that HR-HPV is the primary cause of the 
increased incidence of OPSCC around the world. HPV 16/18, which was described 
originally as the main risk factor for cervical cancer, has been detected in a significant 
proportion of OPSCC, with an alarming increase in incidence recently. However, 
reporting HPV data within the literature requires caution considering several factors, 
including sociosexual diversity among the nations, the period in which the study was 
conducted and, most importantly, the robustness of HPV testing methods. 
The reported range of HPV-driven OPSCC worldwide is wide: 25%-74%, considering the 
scarce data from South America, Africa, and Asia (Gillison et al., 2000, Evans et al., 
2013, Würdemann et al., 2013, Franceschi, 2017, Dickstein et al., 2020). In this study, 
using RNAScope assay for HPV 16/18, HPV prevalence was 60.8% (87/143), while 
39.2% (56/143) of OPSCC was non-HPV 16/18 related. To compare the prevalence with 
studies located within the same time frame, we had to look at HPV 16/18 prevalence 
among the two small cohorts comprising the main study cohort because they were 
collected from different periods. Cohort 1 consisted of cases collected between 1996-
2005 (Oxford and Birmingham), and Cohort 2 of cases collected between 2002-2012 
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(Sheffield Teaching Hospitals). HPV 16/18 prevalence in these small cohorts was 57.8% 
(48/83) and 65% (39/60), respectively. Although the latest cohort showed higher HPV 
prevalence, we cannot consider that an increase in incidence occurred over the years 
because the two cohorts originated from different regions, without available previous 
data for the comparison. Generally, data from Europe demonstrates a significant steady 
increase in HPV-OPSCC incidence over the same time frame. In the period between 
(1995-1999) and (2000-2004), HPV incidence increased from 35.6% (95% CI: 26.5%-
44.7%) to 42.4% (95% CI: 35.6%-49.1%), and by 2015, it had risen to 49.5% (95% 
CI:36.4%-62.6%) (Stein et al., 2015). 
In the first UK nationwide study evaluating HPV prevalence between (2002-2011), 1710 
OPSCC cases were collected from 11 recruiting centres around the UK. The Sheffield 
and Birmingham centres did not take part in the study. The average percentage of HPV-
associated OPSCC identified across the centres was 51.8%. Among the 11 centres, 
Liverpool and London recorded the highest percentages (67.5% and 65.2%, 
respectively) and the lowest percentage was seen in Belfast (35.7%). The study is based 
on tier-wise diagnostic algorithms (p16 IHC, HPV DNA-ISH and/or PCR) for HPV 
detection. HPV DNA ISH probes covered 12 HPV genotypes, while PCR primers were 
used for the most common 24 genotypes. Among the tested HPV genotypes, the HPV 
16/18 percentage was 93.5% (95% CI, 91.5–95.1) (Schache et al., 2016).  
 
3.5.2. HPV Patient profile 
According to the above-mentioned study, Schache and team found the majority of HPV 
cases are located in younger age groups, whilst the HPV percentage is decreased in the 
older age groups (37.2% of ≥75 years vs 69.2% in age ≤ 45). The mean age for HPV-
positive OPSCC was 57.4 years which was statistically younger than among the HPV-
negative counterpart (61.4 years) (p<0.001). Here, in this study, we did not observe a 
significant difference in age between the HPV-positive and HPV-negative groups 
(p>0.05). The incidence of OPSCC in relation to patient age showed a bell shape pattern, 
regardless of HPV-status, which started with a few cases at an early age ≤ 45, peaked 
between ages 46 and 65, then declined around ≥66, which indicates that all the OPSCC 
cases can be considered as falling within middle-aged groups. This disagreement in age 
distribution might be attributed to the relatively small size of our cohort. 
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Over the last decades, HPV-positive OPSCC has been known as a disease affecting the 
middle-aged groups (45–64 years old), in particular, whilst non-HPV related OPSCC was 
linked to the elderly with a long history of tobacco and alcohol consumption. Recently, a 
few studies reported an evolving epidemiologic landscape of HPV-OPSCC population, 
with a significant shift in the age range spectrum toward older year groups (Zumsteg et 
al., 2016, Melina et al., 2018, Rettig et al., 2018 a, Rettig et al., 2018 b). Melina et al. 
(2018) reported a significant increase in age median in the study population (n=239) from 
53 years to 58 years, (p=.01), based on a timeline ranging from 1995-2013. However, 
the study population comprised a wide variety of ethnic groups, which might indicate the 
effect of diversity in sociosexual conditions among the study cohort. Another report, from 
the Westra group, presented the same significant shift in the mean age of the study 
cohort (n=1068), from 51.6 years to 58.5 years in cases collected between 2002 and 
2017 (Rettig et al., 2018 b). However, the determination of HPV-status was dependent 
solely on p16 IHC overexpression which was observed in 89.3% (954/1068) of the study 
cohort. The high HPV percentage in their study raises a concern regarding p16 low 
specificity. The p16 false positive percentage has been reported to be between 5% and 
20% in the literature; this fraction could be a reason behind the age range extension in 
this report.  
Much work is required to understand the evolving clinical profile for HPV-OPSCC 
patients and its clinical implications. The available clinical data demonstrated a 
concerningly high hazard ratio in the older HPV group compared to the younger age 
group (p<0.001) (Rettig et al., 2018 a), although HPV detection methods in this report 
were not stated clearly. The elderly group is the ideal age group for potentially gaining 
benefit from de-intensification protocols. Establishing a rigorous clinical trial 
incorporating the HPV-elderly group might reveal significant implications in the 
optimisation of de-intensification protocols.  
In this study, gender distribution among the HPV-positive and negative groups was 
similar (p>0.05), although the study incorporated more men than women (M:F ratio 
2.8:1). In the literature, there is no marked dominant effect of HPV infection linked with 
a specific gender. HPV-associated OPSCC has a varied distribution between both 
genders around the world. While the United States demonstrates a strong male 
predilection (Gillison et al., 2015), other reports across Europe showed the opposite 
trend, with greater increasing incidence in women than men (Evans et al., 2013, 
Henneman et al., 2015, Würdemann et al., 2017, Mirghani et al., 2019). Interpretation of 
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gender distribution across the geographic regions reflects the diversity in sociosexual 
behaviour among these populations (Gillison et al., 2015).  
 
3.5.3. Prognostic potential of RNAScope  
The prognostic value of RNAScope has been reported by a small number of studies in 
the literature (Ukpo et al., 2011, Schache et al., 2013, Craig et al., 2020). Although it 
demonstrated a strong correlation with survival, further clinical validation is still needed 
to prove its performance against p16 IHC. In this study, the HPV positive group showed 
a clear improvement in overall survival time compared to the non-HPV group over the 5 
years of follow up. Log-Rank test detected this significance between the survival curves 
of both HPV groups (p=0.002), whilst the univariate regression model displayed a lower 
hazard ratio with HPV-positive status than in the negative counterpart (p=0.005).  
Comparing RNAScope prognostic performance with p16, the latter showed more 
significant value in prognosis prediction (Log-Rank p<0.001) compared to HPV-curve 
values. Moreover, its prediction strength in the hazard ratio analysis presents a 
significant and superior factor in univariate analysis (p<0.001). According to the available 
limited data in the literature, RNAScope and p16 demonstrated equal prognostic value 
using the Kaplan-Meier method. However, based on an adjusted regression analysis, 
Ukpo et al. reported a stronger prognostic value in patient outcome stratification with p16 
than RNAScope using 7 hybridization HR-HPV probes, over a follow-up period of 14 
years (Ukpo et al., 2011). On the other hand, Craig et al. reported a comparable 
prognostic value between RNAScope and p16 (HR=0.26 and 0.31 respectively) using 
18 HR-HPV probes, over 5 years of follow-up (Craig et al., 2020). No multivariate 
analysis was reported in Schache et al. (2013).  
From the above, RNAScope showed a strong correlation with survival rate. Compared 
to p16, RNAScope showed an equivalent performance in univariate analysis; however, 
in the case of multivariate analysis, there was disagreement between the reports, the 
difference in HPV probes number possibly being a reason. Additionally, we should be 
aware of other prognostic influences that might have an impact on the multivariate 
comparison. In our study, the number of HPV probes used is a clear limitation. The 
RNAScope prognostic value could be minimised by linking cohort cases’ survival with 
the expression of two HPV genotypes only. Full validation of RNAScope prognostic 
strength clinically could end the era of diagnostic algorithms in clinical practice, especially 
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after the success of automated RNAScope validation (Anderson et al., 2016). Using a 
single test approach could minimise the risk of false-positive and false-negative results 
in the two-test approach. Besides, it would minimise the issues in test result interpretation 
due to the unique probe design that amplifies the signals specifically within a noise-free 
background. However, the financial implications of such a test are a challenge to be 
considered.  
3.5.4. Influence of smoking on OPSCC survival 
Due to the retrospective nature of sample and data collection, data concerning smoking 
and alcohol intake could not be reliably obtained. Smoking history was available in 129 
cases but with poor definition of the status in terms of date, pack number per year and 
history of smoking quitting. Based on smoking status, cases were put in three categories: 
Never, Former and Current. The distribution of cases in these categories revealed highly 
significant differences between the HPV-positive and negative groups (p<0.001). The 
HPV-positive cohort showed a higher percentage of “Never” versus the HPV-negative 
cohort which had a higher number with “Current” status. These findings suggest 
modifying the aetiological role of risk factors in OPSCC development. Notably, a small 
proportion in the study cohort was identified as “Never smoked” and “HPV-negative 
patient” (n=7). These cases could be attributed to other HR-HPV genotypes rather than 
HPV 16/18 or linked to heavy drinking of alcohol. 
Our data regarding the effect of smoking on survival needs to be interpreted with caution; 
firstly, we analysed the effect of “smoking status at diagnosis”, and this might have 
changed during the treatment and follow up periods. Most importantly, our data is based 
on overall survival analysis rather than disease-specific survival, which may not be the 
most appropriate parameter for outcome comparison. Tobacco use has general health 
complications, including cardiovascular and lung disease, besides the development of 
other malignancies (Roden et al., 2020). In our study, smoking status appeared to have 
no evident impact on the survival rate in the HPV-positive group (p=0.48); meanwhile, 
the HPV-negative group showed a significant sub-stratification in survival based on 
smoking status (p=0.001).  
Smoking has a significant negative impact on patient survival, regardless of HPV-status 
(Ang et al., 2010, Gillison et al., 2012, Chen et al., 2020). Smoking status at diagnosis 
and during treatment has been shown to be associated with treatment response, and 
increased risk of developing second primary tumours (Browman et al., 1993, Fountzilas 
et al., 1997, Khuri et al., 2006). Although HPV-infection is the main aetiological factor in 
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HPV-positive OPSCC development, the available evidence suggests that tobacco 
smoking might have an impact on HPV-associated OPSCC behaviour and treatment 
response (Hafkamp et al., 2008, Kumar et al., 2007), possibly because of an increased 
risk for both local recurrence and distant metastases (Maxwell et al., 2010). However, in 
our analysis, as many retrospective studies, smoking habits did not demonstrate an 
evident influence on HPV-associated OPSCC outcomes (Yin et al., 2018, Hawkins et al., 
2019, Roden et al., 2020).  
 
3.5.5.  p16 expression in OPSCC  
p16 expression distribution based on H-score values revealed a highly significant 
difference between HPV-positive and negative OPSCC (p<0.001). A completely negative 
p16 value (H-score = 0) was detected in 58.8% of the HPV negative group, whereas 
none of the HPV-positive group showed complete p16 negativity. p16 expression reflects 
the pathogenesis of HPV oncoprotein E6 and E7 in deregulated cell cycle-associated 
proteins (p16, pRB, cyclin D1 and p53) (Wiest et al., 2002). However, by other less well-
described mechanisms, p16 overexpression has been reported in a significant minority 
of non-HPV driven OPSCC (15-30%) (Sedghizadeh et al., 2016). This could in part be 
attributed to the normal structure of oropharyngeal mucosa. Reticulated epithelium lines 
the oropharyngeal crypt and can show a weak patchy pattern of p16 expression in the 
absence of HPV infection (Robinson et al., 2012, Moutasim et al., 2015).  
RNAScope assay was the selected approach in this study to detect the transcriptionally 
active E6 and E7 mRNA in FFPE tissue. Compared to “the gold standard test” in the 
fresh frozen tissue samples (E6 & E7 RT-PCR), RNAScope showed excellent sensitivity 
and superior specificity in FFPE tissue (Geo et al., 2013, Schache et al., 2013). 
Moreover, it revealed a promising diagnostic performance, higher than DNA-ISH and 
PCR, when compared to p16 IHC. In a study of 357 cases, comparing p16 expression 
with HPV available tests, RNAScope displayed the highest sensitivity (93.4%) and 
specificity (92.4%) over DNA-ISH (86.3% and 95.3%) and DNA PCR (83.5 and 89.1) 
(Randén-Brady et al., 2019). Similarly, Craig et al. (2020) introduced RNA-ISH using 
RNAScope technique as a superior test over DNA-ISH and PCR with 95% sensitivity 
and 100% specificity compared to p16. However, it is worth mentioning that in both 
previously mentioned studies, DNA-ISH probes covered 12 HPV genotypes only, 
whereas RNAScope probes covered 18 genotypes. In this study, we aimed to determine 
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the p16 H-score cut-off in OPSCC by utilising RNAScope super performance in FFPE 
tissue. 
p16 immunoreactivity cut-off is a controversial issue in the literature. CAP and AJCC 8th 
guidelines, in addition to the majority of authors, considered >70% of cells expressing 
p16 (H-score approx. 210) as the diagnostic threshold of p16, whilst many authors 
introduced a >50% positivity cut off (H-score approx. 150) as a reproducible and high 
specificity threshold (Singhi and Westra, 2010, Amin et al., 2017, Shelton et al., 2017, 
Fakary et al., 2018). In this study, we investigated the performance of a p16 H-score 
scheme in OPSCC. H-score was obtained by identifying the proportions of each stain’s 
intensity levels (0, 1+, 2+, or 3+) and then calculated according to the H-score formula 
(Hirsch et al., 2003, John, Liu and Tsao, 2009). Using ROC curve, 144.5 was selected 
as an acceptable H-score threshold with 97.7% sensitivity and 72% specificity 
(AUC=0.87).  The percentage of p16 false-positive cases was 10.8% of p16+/HPV- 
discordant cases. In the literature, 3-23% is the reported range of p16+/HPV- 
disagreement using DNA-ISH (Weinberger et al., 2006, Smeets et al., 2007). 
Jordan et al. (2012) investigated the previous diagnostic performance of p16 H-score on 
OPSCC compared to qRT-PCR E6/E7 mRNA findings on material extracted from FFPE 
(n=240). A threshold score of 60 was suggested as a cut-off point for H-score with 
91.56% (85.93%-95.07%) sensitivity and 90.41% (80.70%-95.69%) specificity.  
However, the calculation method relied on the cross product of the intensity score (0 to 
3) and the percent of tumour staining at the highest intensity only. No further survival 
correlation was provided in Jordan’s study. In our study, based on the H-score threshold 
(144.5), p16 demonstrated a strong prognostic factor in OPSCC (Log-Rank p<0.001). 
The prognostic strength for the hazard ratio is significant and superior in the univariate 
comparison (p<0.001). 
Concerning the prognostic significance of p16, UICC and AJCC accepted p16 IHC as a 
single test for HPV status determination in OPSCC in the 8th edition of the TNM 
classification of malignant tumours (Amin et al., 2017). However, one of the foremost 
shortcomings of using p16 IHC alone is the low specificity, which is responsible for a 
proportion of false-positive cases with poorer survival comparable to HPV-negative 
OPSCC, as we have found. It is possible that p16+/HPV- OPSCC represents an HPV-
unrelated subtype, not fully biologically characterised, which would not benefit from de-
intensification protocols (Albers, Qian, Kaufmann and Coordes, 2017). Consequently, 
mounting evidence has emphasised the significance of double positivity for p16 and an 
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HPV specific test (DNA ISH) in demonstrating improved diagnostic accuracy and 
prognostic value (Mena et al., 2018, Ragin et al., 2018, Craig et al., 2019, Craig et al., 
2020). In our cohort, stratifying the cases based on p16/HPV results revealed a small 
percentage of discordant cases.  We were not able to compare their clinical outcome 
due to the small size of classes II and IV. 
 
3.5.6. ɑ-SMA IHC expression in OPSCCs 
ɑ-SMA immunoreactivity in FFPE tissue is commonly used for detection of active CAF 
within tumour stroma, and its overexpression is considered indicative of an active tumour 
microenvironment (Ostman and Augsten, 2009, Marsh et al., 2011, Meng et al., 2011). 
CAFs are capable of inducing profound influences on tumour cell growth, behaviour and 
the response to treatment (Madar, Goldstein and Rotter, 2013, Akrish et al., 2016). In 
many solid tumours, CAF detection is linked to poorer survival; the presence of a 
myofibroblastic stroma has been reported to be associated with local recurrence and 
metastasis in tongue carcinomas (Kellermann et al., 2007). Additionally, it demonstrated 
a strong and independent prognostic factor in OSCC regardless of TNM staging (Marsh 
et al., 2011). From this aspect, the presence of CAFs within a tumour is becoming 
accepted as a predictor of clinical outcome, suggesting the value of further 
investigations.  
Here, we explored the presence of CAFs in OPSCC stroma in terms of ɑ-SMA 
expression distribution among two OPSCC subtypes and its correlation with the clinical 
outcomes. We observed a comparable distribution of ɑ-SMA expression in OPSCC 
subtypes. Among the HPV-positive group, 60.4% showed ɑ-SMA-high percentage whilst 
47% of HPV-negative showed a high-ɑ-SMA percentage; however, no statistically 
significant difference was detected (p=0.78).  
CAFs activation is a result of a reciprocal interaction between cancer cells and 
surrounding stroma, mediated by paracrine signals including cytokines, metabolites, and 
exosomes (Kalluri and Zeisberg, 2006, Cirri and Chiarugi, 2011, Peacock et al., 2018, 
Fiori et al., 2019). Undertaking in vitro characterisation of extracellular vesicles (EVs) 
using HPV-positive and HPV negative cell lines, Peacock et al. (2018) reported an 
increase in EV production by HPV-negative cell lines compared to HPV-positive, with 
overlapping miRNA content. Interestingly, stimulating normal oral fibroblasts cultures 
(n=3) with extracted EVs from both HPV cell lines revealed variable upregulation of ɑ-
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SMA expression, regardless of HPV status. One high-responder NOF culture showed 
marked ɑ-SMA expression with HPV-negative cell line (SCC89 and SCC72), whilst two 
other NOF cultures induced ɑ-SMA upregulation using EVs from HPV-positive cell lines 
(SCC90 and SCC2) (Peacock, 2018).  
To the best of our knowledge, a robust assessment of the presence of CAFs in OPSCC 
tissue has been limited to two published works. Rahrotaban and colleagues reported a 
comparison in ɑ-SMA expression “intensity” and ɑ-SMA amount “Percentage” in a 
relativity small cohort of OPSCC (n=44). Only ɑ-SMA expression percentage showed a 
significant result with a higher correlation with HPV-positive group (n=23) than HPV-
negative group (n=21) (p=0.02), and no further survival information was provided. HPV 
status determination in the study was based on Nested Polymerase Chain Reaction for 
common HPV genotypes (n=16) (Rahrotaban et al., 2019). In the second report, 
Oguejiofor et al. (2016) assessed ɑ-SMA IHC expression in a larger OPSCC cohort 
(n=139) and correlated the expression with the clinical outcomes. Their ɑ-SMA scoring 
scheme was based on the sum of “Intensity X Percentage” which was to some extent 
different from our score criteria of “Percentage only”. In their study, ɑ-SMA expression 
was significantly higher in the HPV-positive group (n=74/139) than the HPV-negative 
counterpart. Using a univariate regression model, higher ɑ-SMA expression was not 
associated with the clinical outcome in the whole cohort, HPV-positive only, or in HPV-
negative only groups. This observation disagreed with our finding in the HPV-positive 
group. We detected a significant association between ɑ-SMA survival curves in the HPV-
positive cohort (Log-Rank p=0.01) indicating better overall survival in the HPV+/Low ɑ-
SMA subgroup, whereas in the HPV-negative group, no correlation was found between 
ɑ-SMA and overall survival (p>0.05). 
According to our observations, the prognostic value of ɑ-SMA is related to the HPV-
status of OPSCC, and it suggests that CAFs derived from HPV-negative OPSCC may 
have a greater capability for supporting the tumour than CAFs from HPV-positive 
OPSCC stroma. This assumption proposes a crucial role of OPC cancer cells in CAF 
phenotype differentiation. Originally, CAFs were established from several cell types 
within the tumour microenvironment which undergo phenotypic transdifferentiation in 
response to educating signals from tumour cells. This interaction between tumour cells 
and CAFs appears to have additional characteristic features based on the genetic 
stability of cancer cells which is reflected in CAFs’ phenotype and behaviour (Hassona 
et al., 2013, Bolt 2015).  
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Further investigations are required to identify the interaction discrepancy between 
OPSCC subtypes and CAFs. α-SMA expression in HPV-positive tumours might be 
utilised as a potential prognostic tool for HPV-OPSCC stratification in de-intensifying 




This study is limited by the nature of retrospective research; thus, it has variation in 
patients’ management protocols, follow-up duration, lack of detailed information 
regarding the risk factors (sociosexual history, tobacco/drink use) and causes of patient 
censored data, which might reflect unperceived selection biases. The relatively small 
sample size must be considered during result interpretation, although the survival data 
and p16 performance were consistent with the vast majority of published work.  
 
Our research is TMA-based, which means each case was represented by a 1 mm tissue 
section in the TMAs slide. TMAs might raise concern in terms of case 
representativeness; however, the cores, ranging in number between 3 and 6, were 
selected thoroughly. The most compelling evidence suggests that small-sized cores 
have been proven as totally functional for HPV mRNA and p16 performance (Ukpo et 
al., 2011, Ma and Lewis, 2012). 
 
The survival information was limited to overall OS that might not reflect the nature of the 
disease. HPV-negative patients are typically have increased co-morbidities and 
therefore are more liable to death from “other” causes rather than OPSCC. 
 
We are also aware that the RNAScope probes were limited to HPV16 and HPV18 only. 
Other high-risk HPV genotypes could be associated with some HPV-negative cases; 
however, low percentages would be expected as HPV16 is responsible for more than 
90% of OPSCC cases.  
 
3.7. Summary of main findings and clinical implications 
This chapter investigated the diagnostic and prognostic performance of p16 H-score 
against RNAScope assay for the first time. We derived a p16 H-score cut-off of 144.5 as 
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a promising diagnostic and prognostic tool that demonstrated high sensitivity and 
acceptable low specificity compared to HPV 16/18 mRNA, in addition to the prognostic 
performance. This finding underpins the requirement for clinical validation of H-score 
performance that might be adopted as a tool addressing the partial stain dilemma 
between >70% and >50% positivity thresholds. We also identified a significant cohort of 
p16+/HPV- cases which reinforces the need for an HPV specific test, in addition to p16, 
for diagnosis.  
 
Our findings on ɑ-SMA provided a novel insight into the role of CAFs in HPV-positive 
OPSCC suggesting the pivotal role of tumour microenvironment in OPSCC outcomes 
discrepancy. Clinically, these findings urge a further study of the ɑ-SMA biomarker and 
clinical validation to assess its prognostic strength in HPV-positive OPSCC. The findings 
might provide a stratification within HPV-positive OPSCC for the best benefit of de-
intensifying protocols. Moreover, the proposed crucial influences of CAFs in the HPV-
OPSCC tumour microenvironment suggest introducing HPV-positive OPSCC as an 

































Fibroblasts are the dominant cell type within the tumour microenvironment (TME) of 
many tumour types. In the TME, fibroblasts are continuously exposed to varied chemical 
and physical stimuli that contribute to phenotype transdifferentiation known commonly 
as cancer-associated fibroblasts (CAFs). Compelling evidence based on single-cell RNA 
sequencing (scRNA-seq) (Puram et al., 2018), in addition to previous in vitro and in vivo 
observations, emphasised the concept of CAF heterogeneity. CAFs are a group of a 
highly heterogeneous population. The wide discrepancy between CAF subtypes is 
demonstrated in the protein expression profile, besides the capacity of CAFs to promote 
or inhibit the tumours. 
 
Active myofibroblastic CAFs and senescent CAFs are the most common phenotypes 
which have been studied intensively in the literature concerning OSCC. They exhibit 
distinct signatures, which, to some extent, is evident in the transcriptional profiles and 
activation pathways, however, the clinical implications of both phenotypes are still not 
well established (Biffi and Tuveson, 2021). The role of fibroblasts in the development of 
oral squamous cell carcinoma is well documented and has been extensively studied in 
our lab; normal oral fibroblasts (NOFs) were prompted to differentiate into a 
myofibroblastic phenotype and senescent phenotype. Both phenotypes were well 
characterised, and their molecular profile was thoroughly studied (Melling, 2015; Kabir 
et al., 2016; Abidin, 2017). In the previous chapter, HPV-positive OPSCC with 
myofibroblastic stroma demonstrated clinical poorer outcomes than HPV-positive 
OPSCC with a lower myofibroblast content, however, there is no established background 
related to OPSCC-derived fibroblasts. The present chapter focuses on the 
characterisation of the two most common phenotypes in OPSCC fibroblasts and 
compares them to what we have seen in NOFs. A better understanding of OPSCC 
fibroblast behaviour and modulation provides a solid framework for exploring initial 










4.2 Aims  
● To establish in vitro models of myofibroblastic-CAF and senescent-CAF models 
using NTFs  
 
● To isolate and characterise OPSCC CAF primary cultures.  
 
 
4.3  Experimental approach and Statistical analysis 
● Myofibroblastic phenotype was induced in NTF322, NTF6 and NTF10 using TGF-
β1 and the cell transdifferentiation was assessed by evaluating de novo 
expression of ɑ-SMA at transcript and protein level using qRT-PCR, western blot, 
and immunofluorescence assay. Further validation was performed using the 
collagen gel contraction assay to observe the generated contractile force in the 
TGF-β1 induced phenotype. Also, the secretory profile was assessed using IL6 
ELISA analysis.  
 
● Premature induced senescence (PIS) was induced in NTF322, NTF6 and NTF10 
using DNA damaging agent (H2O2). Phenotype induction was assessed by many 
investigations including defining SA-βgal activity, analysis of the upregulation of 
CDK inhibitors including CDKN2A (p16) and CDKN1A (p21) using western blot, 
monitoring the proliferative capacity and quantifying IL-6 production. 
 
● For CAF extraction, an enzymatic digestion protocol was followed to isolate CAFs 
from fragments of tonsillar carcinoma specimens using Collagenase-I. 
 
● Purification of CAFs’ primary culture was assessed by the analysis of CK6, HDL-
AL and CD31 mRNA expression to exclude keratinocyte, immune cell and 
endothelial cells contamination, respectively. 
 
● CAFs’ identity was examined by analysing a panel of CAF biomarkers including 





● Statistically, detection of non-normality is less likely among the data due to small 
sample numbers, however, Shapiro-Wilk test was used to check the normality 
due to its high sensitivity. For the comparison between two normally distributed 
samples’ mean, two-tailed unpaired t-test was used. In multiple data sets, one-
way analysis of variance (ANOVA) was used. 
 
● Data were presented graphically illustrating the mean with error bars 
demonstrating the standard deviation (SD). The probability of similar random 
result detection (p-value) was considered significant if (p<0.05). “N” followed by 
a number denotes the biological repeats, while “n” denotes the technical repeats. 


















4.4.1 Establish myofibroblastic-CAF model derived from 
OPSCC fibroblasts.  
TGF-β1 has been used widely in the literature in inducing myofibroblast phenotype. To 
establish reactive myofibroblastic phenotypes from NTF322, NTF6 and NTF10 cell 
cultures, cells were treated with 5 ng/ml of TGF-β1 for 24h, 48h, and 72h, following the 
previous protocol on oral fibroblast activation (Melling, 2015, Abidin, 2017). At present, 
the detection of α-SMA microfilaments is the commonly accepted method for the 
recognition of differentiated myofibroblasts. Phenotype transdifferentiation was 
confirmed and validated by assessing α-SMA expression at gene and protein levels. The 
contraction ability of developed actin microfilaments was observed using collagen gel 
contraction assay. Moreover, changes in the secretory profile of NTFs were investigated 
using IL-6 ELISA analysis.  
 
4.4.1.1 TGF-β1 upregulates α-SMA gene expression in NTFs 
For α-SMA gene analysis, NTF322, NTF6, and NTF10 were harvested, and total RNA 
was extracted and quantified. cDNA was constructed in 20µl volume using 400 ng of 
total RNA. α-SMA gene expression was quantified using delta CT values normalised to 
β2m. NTFs showed varied levels of α-SMA gene upregulation at different time points, 
with the highest expression level observed at 48 h in NTF322 and NTF6. NTF322 
expressed the highest level of α-SMA, (16 ± 4.2) fold at 48 h, whereas the gene 
expression levels at 24 h and 72 h were less, (4.5 ± 3.2 and 14 ± 1.4) fold, respectively. 
NTF 6 showed a similar pattern in α-SMA gene response at different time points; the 
initial lower expression was after the first 24 h, (8.6 ± 1.9) fold, followed by remarkable 
elevation at 48 h of (38.5 ± 2.12) fold. After 72 h, NTF6 showed a decrease of (23.5 ± 
9.1) fold. NTF 10 showed the highest upregulation of α-SMA in the first 24h, of (14.2 ± 
6.6) fold, then there was a steady decrease at 48h and 72h of (13.5 ± 3.5 and 10.2 ± 





Figure 4.1: α-SMA mRNA expression in TGF-β1-stimulated NTFs. NTF 322, NTF 6, and NTF 
10 were treated with 5 ng/ml TGF-β1 for 24 h, 48 h, and 72 h after being starved for the serum 
for 24 h. α-SMA expressions were variable between NTFs, with significant upregulation seen at 
48h in NTF322 and NTF6. Each bar on the figure represents the mean of relative α-SMA 
expression levels normalised to β2m. Statistical analysis was performed using Student’s t-test, 
and statistical significance is shown on the figure by *p<0.05. Error bars = SD for (N=3, n=3).  
 
4.4.1.2 TGF-β1 enhances α-SMA protein abundance in NTFs 
Anti-α-SMA monoclonal antibody was used for α-SMA detection whereas Anti-β-actin 
monoclonal antibody was used to normalise α-SMA expression. α-SMA protein 
abundances were recognised as a single band at ~42 kDa. The intensity of α-SMA 
protein expression was greater after TGF-β1 stimulation compared to the untreated cells, 
following a time-dependent response pattern. The effect of TGF-β1 stimulation on NTF 
10 revealed comparable expressions of α-SMA protein with control at different time 
points, with higher protein expression seen after 72 h. NTF322 and NTF6 showed a 
similar response to TGF-β1 stimulation, with remarkable protein abundance after the first 













Figure 4.2:  α-SMA protein expression in NTFs following TGF-β1 treatment. NTF 322, 
NTF 6, and NTF 10 were treated with 5 ng/ml TGF-β1 for 24 h (24h+), 48 h (48h+), and 72 h 
(72h+) after being starved for the serum for 24h. negative control were incubated with serum 
free media only (24h-), (48h-) and (72h-). Total protein lysates (20 µg) were separated on a 
15% SDS-PAGE gel and transferred to a nitrocellulose membrane for immunodetection. After 
membrane blocking using 5% (v:w) milk. A monoclonal α-SMA antibody (1:1000) was used 
to detect α-SMA protein and Anti-β-actin monoclonal antibody (1:3000) was used as a loading 
control after membrane stripping as in NTF322 and NTF10. NTF6 membrane was blotted by 
both antibodies at the same time. 
 
4.4.1.3 TGF-β1 enhances contraction of NTFs  
Collagen gel contraction assay was performed to assess the generated contractile force 
of NTFs after TGF-β1 stimulation. An in vitro three-dimensional contraction model of 
NTFs was constructed as described in section 2.1.10. Cells were incubated under 
mechanical tension conditions by leaving the lattices attached to the culture well. After 
48h, the collagen lattice was completely detached with a sterile spatula and incubated 
for 24 h, 48 h or 72 h with TGF-β1. At each time point, the lattices were photographed, 
and NTFs’ contractility was recorded by measuring the distance between the lattice disc 
and the well using Fiji-ImageJ (Figure 4.3). TGF-β1 significantly promoted the 
contraction ability of NTFs with time-dependent responses compared to their untreated 
counterparts. NTF322 showed a significant decrease in lattice disc at 48 h (2.6 ± 0.5mm) 
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and 72 h (3.6 ± 0.5mm) compared to the contraction in the first 24 h (2 ± 1mm; p<0.05). 
NTF6 demonstrated a marked gel contraction of (4 ± 0) mm (mean + SD) that was 
statistically significant at 48h and 72h (p<0.01). NTF10 exhibited the highest lattice 
contraction of 5 ± 0 mm (mean + SD) which peaked at 72 h. The difference between 
lattice contraction at 72 h and 24 h was significant (p<0.001). These findings represent 
the acquired mechanical property in NTFs following TGF-β1 stimulation, confirming the 














Figure 4.3: Matrix contraction ability of stimulated NTFs varies between different cultures. 
NTF322, NTF6, and NTF10 (2 x 104 cells) were seeded in 0.5 ml of collagen lattice solution in a 
24-well plate and left in the incubator for an hour at 37ºC. 1.0 ml of growth media was added on 
the top of the collagen gel lattice and the plate was incubated for 24 h. The next day, the cells 
were serum-starved for a further 24 h, then were treated with 5 ng/ml TGF-β1 before releasing 
the stressed gel matrix from the plate using a sterile spatula.  The gels were then incubated for 
72 h in the TGF-β1 stimulation experiment. Photographs of the gel disc were taken at 24 h, 48 h, 
and 72 h. TGF-β1 provoked actin fibre formation in NTFs that generated apparent mechanical 
stress across the collagen matrix. (A) Image of detached lattices after 72 h of TGF-β1 dose in 
NTF322, NTF6 and NTF10. (B) Gel contraction over time in NTF10. The black arrows illustrate 
the distances between the gel and the well border. The black dot line represent the gel disc. (C) 
Quantification of gel disc contraction used ImageJ.  Relative lattice contraction (mm) was 
obtained by measuring the distance between the gel and the well border. Error bars= SD of three 







4.4.1.4 TGF-β1 induces stress fiber formation in NTFs 
Immunofluorescence assay was performed to visualise α-SMA fibre formation within the 
cells after being incubated with TGF-β1 for 48 h.  NTF322, NTF6, and NTF10 were 
incubated with primary FITC-conjugated ɑ-SMA antibody (1:100) for 1.5h. The intensity 
of FITC expression (green) for each NTF culture was quantified using Image J by 
including the same number of cells in the observed field (Figure 4.4). TGF-β1 treatment 
provoked α-SMA stress fibre formation in NTFs compared to untreated cells which 
demonstrated little or no detectable auto-fluorescence. TGF-β1-treated NTFs showed 
the typical spindle shape with strong green staining of α-SMA myofilaments along the 
cell axes, whereas central nuclei-stained blue with DAPI stain. NTF322 and NTF10 
demonstrated statistically significant increases in FITC expression compared to the 
untreated cells with an approximate 3-fold and 3.7-fold, respectively, whereas NTF6 
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Figure 4.4: ɑ-SMA fibre formation in NTFs in response to TGF-ꞵ1 stimulation. (A) 
Representative photomicrographs demonstrated α-SMA basal and induced expression in 
OPSCC NTFs. Top panel represent SMA expression (high power) in NTF6.  NTF322, NTF6, and 
NTF10. Cells were stimulated with 5ng/ml TGF-ꞵ1 for 48 h then stained with Anti-α-SMA FITC-
conjugated antibody (1:100). The slide was then mounted on a microscope coverslip using a DAPI 
containing mounting medium.  High-power image clarifying α-SMA structure within the cell. 
(Magnification 60x). Fluorescent images were taken using a Zeiss 880 Airy-Scan confocal 
microscope (Carl Zeiss) at 40x magnification. (B) Quantification for detected ɑ-SMA fibres by 
image quantification was performed using Fiji-ImageJ. The negative control for each cell line was 
processed. Statistical analysis was performed using Student’s t-test, and statistical significance 












4.4.1.5 Potential alteration in NTFs’ secretory profile upon TGF-β1 
stimulation 
We performed IL-6 ELISA analysis to evaluate the changes in the secretory profile of 
stimulated NTF322, NTF6 and NTF10 following TGF-β1 incubation for 24h, 48h and 72h. 
NTF322 revealed a time-dependent increase in IL-6 production in both treated and 
untreated cells that peaked at 72 h (2.5 ± 1.4 pg/ml and 2.8 ± 0.8 pg/ml, respectively). 
By comparison to its counterpart, NTF322 showed no statistically significant difference. 
 
NTF6 and NTF10 showed the highest amount of IL-6 at 48h (6.9 ± 1.2 pg/ml and 4.7 ± 
0.05 pg/ml, respectively). NTF6 demonstrated a significant elevation in IL-6 when 
compared to controls at 48 h and 72 h time points (p<0.05), while NTF10 displayed a 
significant difference in IL6 expression at 48 h only (p<0.05). Variation in IL-6 amount 





















Figure 4.5: Variation in IL-6 upregulation in NTFs following TGF-β1 stimulation. NTF 322, 
NTF 6, and NTF 10 were treated with 5 ng/ml TGF-β1 for 24 h, 48 h, and 72 h after being starved 
for the serum for 24 h. The media was collected and subjected to IL6 ELISA analysis. Untreated 
cells were included as a negative control. (A) IL-6 ELISA analysis for NTF322. (B) IL-6 ELISA 
analysis for NTF6. (C) IL-6 ELISA analysis for NTF10. Y-axis denotes standardised IL-6 
concentration in pg/ml. Dot bars denote the untreated fibroblasts. IL-6 concentrations were 
optimised according to a fibroblast density of 10,000 cells. Statistical analysis was performed 
using Student’s t-test, and statistical significance is shown on the figure by *p<0.05. Error bars = 










4.4.2 Establishment of a senescent-CAF model using NTFs 
Fibroblasts within the tumour microenvironment undergo phenotypic changes as a result 
of cellular stress and ageing which affect the growth and proliferation of the cells. 
Senescent fibroblasts adopt a specific phenotypic state which is characterised by growth 
arresting and metabolic active secretome. These cellular alterations are evident by an 
upregulation in CDK inhibitors and changes in the expression profile that is known by the 
senescence-associated secretory phenotype (SASP). IL-6 is considered a canonical 
inflammatory factor among SASP (Naugler and Karin, 2008). An increase in β-gal 
enzyme activity also is considered a hallmark of senescence.  
In this section, we started by determining the senescence status of NTF322, NTF6 and 
NTF10 at the basal level, followed by premature senescence induction using DNA 
damaging agent (H2O2) and following the previously optimised protocol from our lab in 
NOFs (Kabir et al., 2016). NTFs were incubated with a single sublethal dose of H2O2 
(500mM) for 2 h, then maintained for 14 days with subculture at day 8. During this time, 
cells were incubated with normal growth media. On the last day, SA-β-gal assay was 
used to determine the percentage of the induced senescent cells. Trypan blue stain was 
used to ensure cells’ vitality at the end of the experiment.  
Notably, compared with untreated NTFs under the light microscope, H2O2-treated 
cultures demonstrated an alteration in cell morphology (Figure 4.6). NTF322 treated cells 
showed a larger, bulbous appearance with dark, prominent cytoplasm. NTF6-treated 
cells appeared more flattened with poorly defined edges and NTF10 cells displayed more 
heterogenicity in shape with more granular cytoplasm.  Trypan blue percentages were 
negligible in treated NTFs cultures, indicating cell vitality upon H2O2 treatment. NTF322 
(5% ± 0.5), NTF6 (3% ± 1) and NTF10 (6.3%± 0.5) (mean ± SD). 
 
4.4.2.1 SA-β-gal positivity in PIS 
 At basal levels, NTFs showed low percentages of SA-β-gal stained cells. NTF322: 2.3% 
± 0.21, NTF6: 3.2% ± 0.14 and NTF10: 3.7% ± 0.14 (mean ± SD). Following H2O2 
treatment, the percentage of SA-β-gal positivity increased dramatically in all NTFs 
cultures. NTF322 (59% ± 4.2) (p<0.01), NTF6 (65.6 ± 3.7) (p<0.001), and NTF10 (73 ± 



















Figure 4.6: Senescence status in NTFs. Images representing SA-β-gal stain at basal level and 
after H2O2 treatment in (A) NTF322, (B) NTF6, (C) NTF10 cells. Image 1, illustration for cell 
morphology at normal conditions. Image 2, SA-β-gal stain at normal conditions. Image 3, cell 
morphology upon H2O2 treatment. Image 4, SA-β-gal stain upon H2O2 treatment. Magnifications 
10x and 20x. (D) Quantification of SA-β-gal stain. The proportion of stained cells (blue precipitate) 
in 3 random fields (magnification 20x and 40x). Statistical analysis was performed using Student’s 
t-test, and statistical significance is shown on the figure by **p<0.01, ***p<0.001. Error bars = SD 
for (N=3, n=3). 
 
4.4.2.2 Overexpression of CDK inhibitors in PIS 
p16 and p21 overexpression have been utilised widely as biomarkers in the detection of 
senescent cells in vitro and in vivo (Kabir et al., 2016; Prieto, Graves and Baker, 2020). 
Their expression is linked to activation of growth arrest mediated by pRB and p53, the 
major tumour-suppressor pathways. H2O2-treated NTFs demonstrated marked 




Figure 4.7: Western blot analysis of p21 and p16. NTF322, NTF6 and NTF10 were treated 
with a single dose of 500mM H2O2 for 2 h, then the culture was maintained for 14 days. Protein 
expression of 20 µg of whole cell lysate per lane using anti-p21 antibody or anti-p16 antibody. 
H2O2 treated NTFs expressed marked levels of p16 and p21.  
 
4.4.2.3 Upregulation of IL-6 secretion in PIS   
The most prominent cytokine of the SASP is IL-6, which has been associated with 
induced senescence in DNA damaging and oncogenic stress conditions. We quantified 
IL-6 expression in NTFs at basal level and after H2O2 induction using ELISA analysis 
(Figure 4.8). All H2O2-treated NTFs showed an upregulation in IL-6 production. NTF6 
and NTF10 showed a significant increase compared to controls (23.4 ± 1.1 and 17.7 ± 
1.3 respectively: p<0.01). However, NTF322 showed insignificant elevation statistically 





Figure 4.8: Upregulation in IL6 production in NTFs following H2O2 exposure. NTF322, NTF6 
and NTF10 were treated with a single dose of 500mM H2O2 for 2 h, then the culture was 
maintained for 14 days. The media was collected and subjected to IL6 ELISA analysis. Untreated 
cells were included for the comparison. All treated NTFs showed an increase in IL-6 production. 
Samples number (n=6), Y-axis denotes standardised IL-6 concentration in Pg per ml. IL-6 
concentrations were optimised according to fibroblasts density at 10,000 cells. Statistical analysis 
was performed using Student’s t-test, and statistical significance is shown on the figure by 
**p<0.01, ***p<0.001. Error bars = SD for (N=3, n=3). 
 
4.4.3 Establishment of primary OPSCC CAF cultures  
To isolate stromal CAFs in the microenvironment of OPSCC, fragments of tonsillar tissue 
from tonsil HPV-positive carcinomas were subjected to collagenase I digestion. After 1 
week of the isolation procedure, CAF1 and CAF2 were seen outgrowing and remained 
attached to the culture plate. After establishing seeding and working stock of isolated 
CAFs, cultures were characterised according to their morphology, gene signature, and 
secretory profile. We tried to isolate further CAFs from fragments of the posterior third of 




4.4.3.1 Microscopic appearance of OPSCC CAFs 
Under the light microscope, CAF1 showed a mixture of long, spindle-shaped and flat 
irregular cells which varied in size. We noticed CAF1 tended to grow separately in 
random patterns, whereas CAF2 appeared more crowded and overlapped with larger 
volume and irregular morphology. At higher power examination, most CAF1 cells had a 
granular cytoplasm and enlarged nuclei with more than nucleolus. These microscopic 
features are distinct from NTFs which were included in this study. NTFs tend to have a 
smaller uniform appearance and form characteristic parallel arrays at the confluence 






































Figure 4.9: Microscopic appearance for OPSCC CAFs and NTFs. Arrows demonstrate the 
vacuolated cytoplasm. Representative photos were taken with an Olympus BX51 optical 
microscope at 10X and 40X magnifications. 
 
4.4.3.2 Primary CAF culture purification  
Purification of isolated CAFs cultures was confirmed by excluding other cell 
contamination. CAF1 and CAF2 were harvested, and total RNA was extracted and 
quantified.  cDNA was constructed at volume 20 µl using 400ng RNA. qRT-PCR analysis 
was carried out for the target genes utilising ꞵ2m, the housekeeping gene, for result 
normalisation. NTF6 was included for the comparison.  
Epithelial cells were excluded by assessing the gene expression of Cytokeratin 6 (CK6). 
It is one of the epithelial cell biomarkers. Keratins are dense networks of intermediate 
filament proteins distributed throughout the cytoplasm of epithelial cells. Normal oral 
keratinocyte 8 (NOK8) was included as a positive control for the CK6 expression. qRT-
PCR analysis revealed marked expression of CK6 in NOK8 (2.89 ± 0.25), while CAF1 
and CAF2 showed a minimal amount of CK6 expression (0.02 ± 0.03) and (0.10 ± 0.004) 
CAF2 (confluent) NTF322 (confluent) 
CAF1 (Higher power) CAF2 (Higher power) 
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(mean± SD), respectively. The difference was statistically significant (p<0.001), 
indicating high CAF cultures purity without epithelial cell contamination (Figure 4.10).   
 
 
Figure 4.10: OPSCC CAFs clear of epithelial cell contamination. CAF1 and CAF2 were 
collected, and total RNA was extracted and quantified. qRT-PCR was performed with the 
constructed cDNA to amplify the CK6 gene. β2m was utilised for result normalisation. NOK8 
represents the positive control and NTF6 represents the negative control. CAFs culture exhibited 
negligible expression of CK6 suggesting cultural purity. Statistical significance is shown on the 
figure by ***p<0.001, using one-way ANOVA. Error bars = SD of (N=2, n=3).  
 
Immune cell contamination was excluded by assessing the gene expressions of HLA-
DR (Human leukocyte antigen–DR isotype). HLA-DR is a cell surface receptor that 
presents at the human leukocyte which is expressed at high levels on professional 
antigen-presenting cells, and T lymphocytes in some autoimmune diseases (Viallard et 
al., 2001). Monocyte-derived macrophage (MDM) was included as a positive control. 
MDM demonstrated relatively high gene expression (0.07 ± 0.01) compared to CAF1, 






Figure 4.11: OPSCC CAFs clear of immune cell contamination. CAF1 and CAF2 were 
collected, and total RNA was extracted and quantified. qRT-PCR was performed with the 
constructed cDNA to amplify the HLA-DR gene. β2m was utilised for result normalisation. MDM 
represents positive control. CAFs culture exhibited a negligible expression of HLA-DR. Statistical 
significance is shown on the figure by ***p<0.001, using one-way ANOVA. Error bars = SD of 
(N=2, n=3).  
 
Endothelial cells contamination was excluded by assessing CD31 expression which is 
known as (Platelet endothelial cell adhesion molecule, PECAM-1). It is found at 
endothelial cell intercellular junctions, also detected on the surface of platelets, 
macrophages and lymphocytes (van Mourik et al., 1985). Human Dermal 
Microvascular Endothelial Cells (HDMEC) was included as a positive control. HDMEC 
demonstrated relatively high gene expression (0.6 ± 0.12) compared to CAF1, CAF2, 






Figure 4.12: OPSCC CAFs clear of endothelial cell contamination. CAF1 and CAF2 were 
collected, and total RNA was extracted and quantified. qRT-PCR was performed with the 
constructed cDNA to amplify the CD31 gene. β2m was utilised for result normalisation. HDMEC 
represents positive control. CAFs culture exhibited a negligible expression of HDMEC. Statistical 
significance is shown on the figure by ***p<0.001, using one-way ANOVA. Error bars = SD of 
(N=2, n=3).  
 
4.4.3.3 CAF biomarker expression 
CAF cultures were further explored for molecular characterisation to confirm the reactive 
nature of the CAFs and confirm their identity. A panel of biomarkers including α-SMA, 
FSP-1, FAP-ɑ, and PDGFRα were assessed at gene and protein levels. 
4.4.3.3.1 ɑ-SMA expression in OPSCC CAFs 
The basal level of expression in CAF1 and CAF2 was investigated using qRT-PCR and 
immunofluorescence assay. CAF2 showed a higher expression ɑ-SMA gene (2.1 ± 0.5 
fold) compared to CAF1 (0.4 ± 0.04) fold (mean± SD) (Figure 4.5). This pattern of 
expression was consistent with what we observed in ɑ-SMA immunofluorescence 
assessment. The tested cells revealed a heterogeneous expression pattern of ɑ-SMA 
stain, CAF2 displayed brighter green discrete fibers along the cell axes, whereas that 





To generate an in vitro model of myofibroblastic CAF phenotype, ɑ-SMA expression was 
induced further in CAFs using a single dose of TGF-β1 (5 ng/ml), following the previously 
optimised protocol from our lab (Abidin, 2017; Melling et al., 2018). Cells were serum-
starved then incubated with TGF-β1 for 48 h. TGF-β1 treatment resulted in a significant 
increase in ɑ-SMA expression in all treated cells compared with their untreated 
counterpart (p<0.05). CAF1 showed a significant increase in ɑ-SMA transcript 
expression of 4.5 ± 0.4 fold compared to β2m. CAF2 demonstrated a dramatic response 
to TGF-β1 that elevated ɑ-SMA expression to 34.7 ± 12 fold compared to β2m (Figure 
4.5). α-SMA staining was also evident and well-formed as cytoskeletal fibres were seen 
throughout the whole treated cell (Figure 4.14).   
 
 
Figure 4.13: α-SMA mRNA expression in OPSCC CAFs following TGFβ1 treatment. 
Assessment of basal αSMA mRNA (untreated cells) revealed significant expression in CAF2 
compared CAF1. CAFs (250,000 cells/ well) were seeded in 6 well plates, starved for serum (24 
h), then treated with TGFβ1 (5 ng/ml) for 24h. A significant upregulation in αSMA mRNA was 
seen in all tested cells (*=p<0.05), with the most striking increase in CAF2. Error bars= SD (N=3, 












Figure 4.14: α-SMA immunofluorescence expression in OPSCC CAFs. (A)  
Immunofluorescent representative photomicrographs demonstrated α-SMA basal and induced 
expression in OPSCC CAFs. Cell induction was performed by TGF-β1 (5 ng/ml) incubation (48 
h).  CAF2 displayed evident basal α-SMA expression. Images were taken using a confocal 
microscope (Zeiss 880 Airy Scan). Magnification (40X). (B) Quantification for detected ɑ-SMA 
fibers by image quantification was performed using Fiji-ImageJ. Error bar= SD (N=3, n=3).  
 
4.4.3.3.2 FAP-ɑ biomarker expression in OPSCC CAFs 
FAP-ɑ (Fibroblast Activation Protein Alpha) is a transmembrane glycoprotein that is 
expressed by reactive stromal fibroblasts during an injury response, fibrosis and certain 
types of tumours including 90% epithelial cancers (Servais and Erez, 2013; Berdiel-Acer 
et al., 2014; Kalluri, 2016). In this study, CAF1 and CAF2 showed the highest expression 
of FAP-ɑ mRNA normalised to β2m, (0.50 ± 0.09) and (0.42 ± 0.04), respectively, while 
NTF6 expressed the lowest value (0.26 ± 0.09) (mean ± SD) (Figure 4.15 A). This 
difference was statistically significant compared with CAF1 and with all tested cells 
(p<0.05). FAP-α immunofluorescence staining was observed in all tested cells in a 





                                                            (A)                                                                 
 
(B) 
Figure 4.15: FAP-α expression in OPSCC CAFs. (A), FAP-α mRNA expression in CAF1, CAF2, 
and NTF6. Error bars= SD (N=2, n=3). CAF1 and CA2 showed significant FAP-α expression 
compared to NTF6 (*p<0.05). Student’s t-test and one-way ANOVA were used for the statistical 
comparison. (B), Immunofluorescence staining of FAP-α, all tested cells exhibited evident 
homogenous FAP-α protein using (1:100) anti-FAP-α monoclonal antibody. Images were taken 




4.4.3.3.3 PDGFRα biomarker expression in OPSCC CAFs 
PDGFRα (platelet-derived growth factor receptor A or α) is a tyrosine-protein kinase that 
acts as a transmembrane protein receptor and is involved in the regulation of embryonic 
development, cell proliferation, and chemotaxis (Gotlib and Cools, 2008). It is expressed 
more widely over the larger fibroblast population than more specific biomarkers such as 
α-SMA. In this study, CAF2 demonstrated the highest expression of PDGFR1 mRNA 
(~0.22 fold). CAF1 and NTF6 showed relative expression of 0.13±0.12 fold and 0.12± 
0.04 fold, respectively.  None of these differences was statistically significant. (Figure 
4.16 A). Immunofluorescent staining showed a punctate pattern within the cell cytoplasm, 
however, as the nuclei also showed antibody positivity there is most likely significant 








 Figure 4.16: PDGFRA expression in OPSCC CAFs. (A), PDGFRA mRNA expression in CAF1, 
CAF2, and NTF6. All tested cells showed a comparable level of expression. Student’s t-test and 
one-way ANOVA were used for the statistical comparison. Error bars= SD (N=2, n=3). (B), 
Immunofluorescence staining of PDGFRA. CAF1 and CAF2 showed stained granular structures 
within their cytoplasm, however, this is most likely a non-specific reaction. Images were taken 









4.4.3.3.4 FSP-1 biomarker expression in OPSCC CAFs 
FSP-1 protein, (Fibroblast-specific protein 1) also called S100A4, is a calcium-binding 
protein localised in the cytoplasm and nucleus of a wide variety of cell types including 
CAFs. It is involved in cell differentiation and cell cycle progression (Cajone and Sherbet, 
1999). In the tumour microenvironment, FSP-1 derived-CAFs are linked to cancer cell 
invasion and metastasis, and they are considered an important factor in promoting 
cancer cell growth (Grum-Schwensen et al., 2005; Park, Jung and Koo, 2016). In this 
study, there was a trend towards higher FSP-1 mRNA levels in CAF1 and CAF2 (0.08 ± 
0.06 and 0.09 ± 0.02 fold respectively when compared to β2m), while NTF6 showed the 
lowest expression (0.04 ± 0.01) (mean ± SD) (Figure 4.17, A). However, there was no 
statistically significant difference between the tested cells following student’s t-test and 
one-way ANOVA test. The immunofluorescent analysis shows widespread expression 
throughout the cytoplasm and nucleus, with little on the cell membrane, which would be 
the predicted localisation. Again, it is likely that this pattern of expression is non-specific 








              (B) 
Figure 4.17: FSP-1 expression in OPSCC CAFs. (A), FSP-1 mRNA expression in CAF1, CAF2, 
and NTF6. Error bars= SD (N=2, n=3). CAF1 and CA2 showed higher FSP-1 expression 
compared to NTF6. Student’s t-test and one-way ANOVA were used for the statistical 
comparison. (B), Immunofluorescence staining of FSP-1. All tested cells exhibit evident 
homogenous FAP-α protein cytoplasmic and nuclear expression using (1:100) anti-FSP-1 
monoclonal antibody. Images were taken using a confocal microscope (Zeiss 880 airy Scan). 
Magnification (x40). 
 
4.4.4 Evaluation of senescence in OPSCC CAFs 
The heterogeneity in senescence among CAFs populations has been reported in OSCC-
derived CAFs (Patel et al., 2018). Herein, we evaluated the senescence status of isolated 
CAFs by assessing senescence features. CAF primary cultures showed a variable 
percentage of SA-β-gal positivity. CAF1 populations exhibited (39% ± 1.4) of SA-β-gal 
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(B) 
Figure 4.18: Senescence status in OPSCC CAFs. (A) Images representing SA-β-gal stain in 
CAFs at the basal level (magnification x20). Cells were seeded into a 12 well plate at a density of 
10,000 cells/well. Next day, cells were washed with PBS, fixed, and stained with X-gal staining 
solution for 24 h. (B) Quantification of SA-β-Gal stain. The number of stained cells (blue 
precipitate) in 3 random fields (magnification x20). CAF1 showed the highest percentage of 





4.4.4.1 Growth kinetic of OPSCC CAFs 
To assess the proliferation ability, cells were seeded at a density of 5,000 cell/ml in 6 
well-plate with 2ml growth media. Every 2 days, cells from one well of the 6 well-plate 
were detached and counted. By monitoring cells’ duplication rate over 12 days, CAFs 
and NTF6 showed a doubling in culture density on day 4, after being adapted to new 
cultures. Differences in proliferation rates between cultures were observed clearly at day 
12, however, this difference was not statistically significant (p> 0.05) (Figure 4.19). 
 
 
Figure 4.19: Growth kinetics of OPSCC CAFs. 5,000 cells of CAF1, CAF2, and NTF6 were 
plated into 6-well plates and incubated with the growth media. Cell counting was performed at 
two-day time intervals. CAF1 showed the slowest proliferation rate. Each line on the figure 
represents the mean of the relative cell number. Error bar = SD of three independent experiments. 
 
4.4.4.2 IL-6 secretory profile in OPSCC-derived CAFs 
The IL-6 ELISA assay was used to assess the basal secretory level of IL-6 in CAF1 and 
CAF2 (Figure 4.20). Both CAF1 and CAF2 produced higher concentrations of IL6 
compared to NTF6 (p<0.01). CAF2 showed the highest value with (103.5 ± 19), however, 





Figure 4.20: IL6 production in OPSCC CAFs. CAF1 and CAF2 showed significantly higher IL-
6 concentration than NTF6. Samples number (n=3), Y-axis denotes standardised IL-6 
concentration in pg per ml. IL-6 concentrations were optimised according to fibroblasts density at 
10,000 cells. Student’s t-test and one-way ANOVA were used for the statistical comparison. Data 














4.5 Discussion  
The purpose of this work at the beginning of our research was to establish a strong 
framework of understanding in OPSCC fibroblast phenotypes, as that has not been done 
before. Exploring the similarity or diversity of OPSCC fibroblast from OSCC fibroblasts 
is an essential step in investigating the role of the OPSCC TME in HPV-positive and 
HPV-negative OPSCC subtypes. 
 
In this chapter, we established in vitro models of the myofibroblastic-CAF phenotype and 
senescent-CAF phenotype derived from NTFs. The myofibroblastic phenotype was 
generated using a single dose of TGF- β1 (5 ng/mL) and confirmed by assessment of de 
novo ɑ-SMA gene and protein expressions. Premature induced senescent phenotype 
was induced using hydrogen peroxide (500 µM) and assessed by evaluating SA-β-gal 
activity and confirmed by assessment of p21, p16, and IL-6 expressions. The 
heterogeneity in fibroblasts’ responses was an evident feature in both models.  
 
Furthermore, we established primary CAFs cultures isolated from HPV+ tonsillar 
carcinomas. The molecular assessment of CAF cultures including CK6, HLA-DR and 
CD31 revealed the purity of other cell lineage contamination, while expression of FSP-1 
and PDGFR confirmed the fibroblast identity. Most importantly, significant FAP-α 
expression in CAF1 and CAF2 in relation to NTF6 indicated CAFs’ active status. 
Heterogeneity was evident in CAFs cultures too; CAF1 exhibited the senescent-CAF like 
feature by demonstrating a high ratio of SA-β-gal precipitation (39% ± 1.4) compared to 
CAF2’s low SA-β-gal percentage (0.5% ± 0.3). Another evident difference was observed 
in α-SMA upregulation on comparison of CAF1 and CAF2. The latter showed significant 
overexpression of α-SMA that was sensitive to further stimulation following a single dose 
of TGF-β1. 
 
4.5.1 Established CAF myofibroblastic phenotype in OPSCC 
We established an activated tonsil myofibroblastic model derived from NTFs, following 
the previous protocol in our lab in NOFs activation. Cells were stimulated with 5 ng/ml 
TGF-β1 at different time points, then the activation status was evaluated by analysing α-
SMA expression. NTFs phenotype differentiation was validated by assessing the 
alterations in cells' mechanical and secretory properties. The results showed a 
remarkable upregulation of de novo α-SMA at gene and protein levels after TGF-β1 
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stimulation which mostly peaked at 48h, with a corresponding increase in cytoskeletal 
fibers formation. Stimulated NTFs were also able to generate enough contractile force to 
shrink the stressed collagen lattice using collagen gel contraction assay. This activation 
was associated with slightly increased IL-6 production in NTF10 and NTF6 compared 
with untreated counterparts.  
 
TGF-β1 has been shown to promote fibroblast differentiation to myofibroblast phenotype 
in vivo and vitro (Desmouliere et al., 1993; Vaughan, Howard and Tomasek, 2000; 
Mellone et al., 2016). However, it is believed that TGF-β1 requires mechanical stress 
alongside to enhance cell differentiation. The mechanical stress promotes the 
differentiation into proto-myofibroblasts which are characterised by fibronexus adhesion 
complexes, fibronectin production and stress fiber formation (Tomasek et al., 2002). In 
presence of TGF-β1, proto-myofibroblasts become able to differentiate into a 
myofibroblastic phenotype that can exert contractile force on ECM, the feature that 
defines the contraction phase in wound healing process (Hinz et al., 2001). This 
description was observed clearly using the collagen gel contraction assay. NTFs were 
placed under a mechanical tension in the attached collagen lattice with the presence of 
TGF-β1. Once the collagen pad was released, the transformed myofibroblasts generated 
a contractile force in the collagen pad which reduced the disc diameter. 
 
In comparison with NOFs, our findings are in keeping with previous reports from our 
lab (Abidin, 2017; Melling et al., 2018). 5ng/ml of TGF-β1 was sufficient to upregulate α-
SMA expression in a time-dependent manner that peaked at 48h. This pattern of 
expression was also reported by Evans et al. (2003) and Zhang et al. (2005). The 48h 
time-duration may reflect the length of the negative feedback loop mediated by Smad7, 
the inhibitory regulator (Kavsak et al., 2000). In human peritoneal mesothelial cells, 
Smad2/3 (TGF-β1 receptors) was phosphorylated and upregulated 15 min after the 
stimulation with 5ng/ml of TGF-β1.  The Smad2/3 phosphorylation level is increased, 
allowing translocation into the nucleus where it provokes target genes transcription 
(Zhang et al., 2005). As a feedback circuit, Smad7 is upregulated simultaneously with 
Smad 2/3 activation, acting on TGF- degradation. Smad7 was observed reaching a 
remarkable level after 24h of TGF-β1 stimulation and peaked at 48h. 
  
Similar to NOFs, not all the tested NTFs cultures responded equally to TGF-β1. α-SMA 
showed variable levels of expression at gene and protein levels. This observation also 
was consistent with Chaudhri et al. (2013), supporting the previous data that α-SMA 
expression is diverse per cell. Cell-to-cell variation is described among the tissues in 
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terms of gene expression profile, morphology, and function, which might reflect the 
variations in response between NTFs cultures (Yuan et al., 2017). Fibroblast passage 
and TGF-β1 freshness also were considered factors (Chen and Thibeault, 2012a). 
 
4.5.2 Establishment of an NTF senescent phenotype 
Senescence can occur as a result of exposure to a variety of intracellular and 
extracellular stimuli, including DNA damage, telomere shortening, oncogenic stress, and 
Reactive Oxygen Species (ROS). Senescence status is characterised by cellular 
proliferation arrest accompanied by a range of morphologic, molecular, and behavioural 
changes that have been tentatively adopted as hallmarks for senescence. Here, in this 
section, we established and characterised a model of PIS in NTFs using Hydrogen 
peroxide which has been widely used to provoke persistent DNA damage response in a 
variety of cell types (Frippiat et al., 2001, 2002).  
 
To date, there is no specific biomarker for senescent cell detection, as there are many 
non-specific cellular changes that occur as a response to cellular stress. In practice, 
observing three signs collectively was recommended for senescence detection in vivo 
and in vitro (Sharpless and Sherr, 2015; Fafián-Labora and O’Loghlen, 2020). Lysosomal 
biogenesis enhancement is one hallmark of senescence. It results in the upregulation of 
lysosome number and content that can be observed clearly in the cell cytoplasm. 
Increase in the activity of the lysosomal enzyme SA-β-gal is utilised widely as a surrogate 
biomarker for senescence. In the earliest passage of tested NTFs, SA-β-gal percentages 
were negatable, however, following H2O2 treatment NTFs demonstrated a significant 
amount of accumulated β-galactosidase in their cytoplasm. The exact mechanism 
behind this phenomenon is still obscure; a recent report linked GLB1, the SA-β-gal 
enzyme coding gene, with the NOTCH1 pathway. NOTCH signalling has been reported 
to promote a type of cellular senescence (NOTCH-induced senescence) with 
characteristic SASP components (Kagawa et al., 2015; Hoare et al., 2016).  
 
Having mentioned above that none of the senescence biomarkers is specific, high 
lysosomal activity and accumulation of SA-β-gal also have been identified in non-
senescence cells. The stressed culturing condition was described as a reason in β-
galactosidase accumulation. Figure 4.21 shows an example of SA-β-gal stain 






Figure 4.21: Confluent NTF6 culture demonstrates high SA-β-gal positivity. Early passage 
culture of NTF6 was grown to confluence with the media changed every 5 days. SA-β-gal 
assessment revealed a high proportion of SA-β-gal staining cells. (Magnification x10). 
 
Morphological alterations and growth arrest are the observed features in senescent cells 
(Chandrasekhar, Sorrentino and Millis, 1983). An increase in cell size has been linked to 
the activation of mTOR pathway that integrates various stress signals (Lloyd, 2013). 
mTOR was found to be activated in response to premature senescence stimuli 
(Blagosklonny, 2012), in addition to normal ageing as a response to growth factors 
decline (Loffredo et al., 2013). Moreover, alterations in the cellular shape of the 
senescent cells were reported as a consequence of cytoskeletal microfilaments 
rearrangement; particularly, the production of vimentin is promoted by ATF6/NF-kB 
signalling pathway during senescence (Druelle et al., 2016).  
 
Morphological features have been observed more clearly in CAF1 and CAF2 cultures in 
early passages, although CAF2 demonstrated low SA-β-gal positivity and exhibited 
evident active myofibroblastic phenotype profile by expressing FAP-ɑ and ɑ-SMA. 
Changes in normal fibroblast morphology upon the activation and α-SMA upregulation 
were monitored thoroughly in Desai et al.’s work (Desai, Hsia and Schwarzbauer, 2014) 





Stable cell cycle arrest is another characteristic feature in senescent cells. It is mediated 
by activation of cell cycle proteins Rb and p53 and results in the engagement of various 
cyclin-dependent kinase inhibitors including CDKN2A, CDKN2B, and/or CDKN1A which 
encoding p16, p15, and/or p21 proteins, respectively. However, they are not senescence 
specific biomarkers, they were also detected in non-dividing somatic cells (Fafián-Labora 
and O’Loghlen, 2020). Both p16 and p21 over expressions were observed clearly at gene 
and protein level in H2O2-treated NTFs in this study.  
 
Although senescent cells are arrested cells, they are metabolically hyperactive 
compared to cells under normal conditions (James et al., 2015). They are known for their 
ability to produce a plethora of factors called collectively SASP which is considered the 
‘soul’ of senescence. SASP contents are not constant, they vary according to fibroblast 
cell and culturing conditions (Coppé et al., 2008). However, IL6 is considered a core 
cytokine secreted by senescent cells in both ageing and induced senescence. 
Quantification of IL6 production was our tool to assess the SASP secretory profile; we 
observed a significant IL6 overproduction in H2O2-induced NTFs compared by the 
control. This observation is in parallel with many other studies which have utilised IL-6 
overexpression as a senescence biomarker (Acosta et al., 2008; Bhaumik et al., 2009). 
 
Collectively, NTFs demonstrated CAFs senescence-phenotype like features following 
the treatment of DNA damaging agent. The senescent status induction was confirmed 
by observing the senescence hallmark features simultaneously, including SA-β-gal high 
positivity, p16/p21 over-expression, and IL-6 overproduction. 
 
4.5.3 CAFs isolation and characterisation  
In HNSCC, the most common approach in CAFs isolation is the explant technique with 
or without further enzymatic digestion (Custódio, Biddle and Tavassoli, 2020). This 
technique allows fibroblasts only to outgrow rather than another cell lineage. Other 
methods, including flow cytometry and differential trypsinization, also were utilised in 
CAF isolation (Johansson et al., 2012; Li et al., 2014). The lack of specific biomarkers 
for CAFs poses a challenge while considering a purified CAF culture. CAFs can originate 
from different sources and that might explain the variety of biomarker expression which 
is shared with the other cells from the same origin (Orimo and Weinberg, 2007; Cirri and 
Chiarugi, 2012; Shiga et al., 2015). The anatomical position and morphological 
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appearance were considered by many authors as characteristic features for CAFs 
identification (Liu et al., 2006; Potdar and Chaudhary, 2017). In this study, cells were 
isolated from fragments from tonsillar carcinoma using the enzymatic digestion method. 
Under the light microscope, CAFs revealed a distinctive morphology compared with 
NTFs. CAFs appeared flat, larger with variable shapes, and contained dark vacuolated 
cytoplasm. Notably, in high-density culture, CAFs crowd together in a disorderly manner, 
lacking the characteristic regular array pattern that specifies NTFs at confluency.  
However, in practice, CAF isolation is based on a consensus of other lineage exclusion 
combined with mesenchymal biomarker positivity (Xing, 2010; Ishii, Ochiai and Neri, 
2016). Lack of expression for epithelial, leukocyte, and endothelial biomarkers is the 
preferred approach to exclude CAFs culture contamination and confirm cultural 
homogeneity (Potdar and Chaudhary, 2017). The negativity of CK6, HLA-DR, and CD31 
biomarkers confirmed CAF purification in this study; meanwhile, confirming CAFs’ 
identity is a more challenging process. 
A number of the cell surface, extracellular, and intracellular proteins have been utilised 
to identify CAFs; nevertheless, to date, there is no specific biomarker for CAFs (Biffi and 
Tuveson, 2021). The positivity of mesenchymal biomarkers such as FSP-1, vimentin, 
and fibronectin provides sufficient evidence for CAFs' identity (Sugimoto et al., 2006). 
However, we should be aware these biomarkers are not specific for CAFs, they are also 
expressed by other cell types sharing the mesenchymal origin, including adipocytes, 
chondrocytes, and osteocytes (Ishii, Ochiai and Neri, 2016). Herein, both CAF1 and 
CAF2 showed a transcript positive for FSP-1 and PDGFRα biomarkers and their 
expressions were comparable to NTF6. Both biomarkers have been used collectively in 
vitro and in vivo studies for CAFs identification (Tomasek et al., 2002; Dangi-Garimella 
et al., 2011, 2013). Although FSP-1 is considered a specific biomarker for both normal 
and activated fibroblasts (Strutz et al., 1995), confirmation of another lineage 
contamination is still recommended. PDGRFs are general, stable biomarkers for 
fibroblasts at different environmental conditions (Madsen et al., 2015). However, they 
lack specificity for CAF detection, indicating an overall fibroblast population present in 
the tumour (Gascard and Tlsty, 2016).  
α-SMA and FAP-α expression/overlapping expression were used widely for activated 
fibroblast identification in wound healing, fibrosis, and tumours (Park et al., 1999; Serini 
and Gabbiani, 1999; Tchou et al., 2013; Kilvaer et al., 2015). However, recent 
accumulating evidence using scRNA-seq technique and multicolour flow cytometry 
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(Costa et al., 2018; Jackson et al., 2020) raised concerns regarding the specificity of 
some classic-CAFs; for instance, α-SMA expression was reported in other lineages such 
as pericyte, while its expression was lacking in other CAFs subtypes (Alarcon-Martinez 
et al., 2018; Bartoschek et al., 2018; Costa et al., 2018). FAP-α protein expression was 
also reported in several types of cells other than CAFs, including immune cells and 
certain cancer cells (Kikuchi et al., 2006; Österreicher et al., 2011). 
 
From the above, CAFs identification based on a combination of morphological 
appearance and a biomarker definition is a reliable practical approach. Following this 
method, we achieved pure primary CAF cultures of OPSCC. Although we observed a 
molecular heterogeneity in CAFs that originated from the same OPSCC subtype, 
similarities of CAFs signatures across different malignancies were reported recently 
using scRNA-seq (Salgueiredo-Giudice et al., 2011; Puram et al., 2018; Davidson et al., 
2020). Analysing the shared features in fibroblast from different tumour types may reveal 
a new promising therapeutic approach. 
 
4.5.4 OPSCC CAF phenotypes 
The reasons behind CAFs’ phenotypic heterogeneity have been studied intensively in 
the literature. Extracellular matrix composition and elasticity were reported as main 
factors directing CAFs phenotypic heterogeneity in the presence of TGF-ꞵ1 signalling 
(Chen and Thibeault, 2012b). In the Avery et al. study, fibroblast activation status was 
assessed on substrata of defined stiffness and composition. Low-stiffness ECM with 
high-fibronectin content was sufficient to drive FAPHi - α-SMAlow active phenotype 
development; meanwhile, high-collagen I in stiff ECM enhanced FAPlow- α-SMAHi 
myofibroblastic phenotype formation. Interestingly, each subtype of these activated 
fibroblasts has its gene expression signature which indicates distinct functionality in vitro. 
FAPHi activated fibroblasts displayed an ECM synthetic and proteolytic gene profiling 
property, whilst α-SMAHi reactive fibroblast showed a contractile and proliferative gene 
signature (Avery et al., 2018).  
 
Heterogeneity of CAFs subtypes was also correlated to the spatial distribution of the 
CAFs in tumour tissue specimens. In pancreatic ductal adenocarcinoma, CAFs 
population that showed upregulation of myofibroblasts biomarkers, such as α-SMA, was 
found to be located adjacent to cancer cells, while CAFs population with inflammatory 
secretion profile, such as IL-6, was located farther away, surrounded by dense stroma 
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(Biffi et al., 2019). Types of tumour and variation among patients were also proposed as 
factors regulating CAFs’ phenotypic diversity (Bozõky et al., 2013).  
 
In human cancer, two CAF phenotypes have been reported consistently in the literature, 
the myofibroblastic and non-myofibroblastic. Both phenotypes were described with 
characteristic features and linked to specific roles in TME. In this study, characterisation 
of CAFs phenotypes revealed heterogeneity among CAFs cultures that was evident in 
α-SMA expression levels and SA-β-gal stain positivity. CAF2 demonstrated active 
myofibroblast-like features by showing low SA-β-gal stain and expressing relatively high 
levels of α-SMA and FAP-α biomarkers. Interestingly, it exhibited a significant 
overexpression of α-SMA upon TGF-β1 induction compared with NTF6. A similar 
observation was reported by Kojima et al. (2010) suggesting a greater individual variation 
of α-SMA expression in CAFs than normal fibroblasts. Across various cancer types, the 
myofibroblastic CAF-phenotype is characterised by ECM signature; it becomes involved 
in tumour progression by generating an increasing tension in the stroma and promoting 
tumour cell invasion and metastasis (Levental, K. Yu, 2010; Lu, Weaver and Werb, 
2012).  Clinically, the significance of SMA-positive CAF in the tumour’s stroma was linked 
with the poor survival rates. 
 
CAF1 showed a senescent phenotype by displaying a significant uptake of SA-β-gal stain 
(39% ± 1.4). However, senescent fibroblasts commonly co-express a high level of α-
SMA. Interestingly, CAF1 showed low α-SMA basal level, and also showed the lowest 
value in gene upregulation in response to TGF-β1 compared with CAF2 and NTF6. This 
observation was consistent with Mellone and team’s findings in HNSCC-derived CAFs; 
they reported a weaker correlation between co-expression of SMA and SA-β-gal in 6 
strains of CAFs (r2=0.32) compared to 6 normal fibroblast cultures (r2=0.82). This 
inconsistency of co-expression was linked to the greater heterogeneity in CAFs 
population (Mellone et al., 2016).  
Generally, non-myofibroblastic CAFs share senescent fibroblast features. Senescence 
is considered a highly productive inflammatory phenotype sharing similar transcriptional 
profiles and signalling pathway activation, including interleukin, NF-kB and NOTCH 
pathways (Kuilman et al., 2008; Chien et al., 2011; Hoare et al., 2016). This difference 
in secretory profile supports our observations in the CAFs established models, as IL-6 




Moreover, non-myofibroblastic CAFs display a lower proliferation rate compared to 
myofibroblastic CAFs (Biffi et al., 2019). CAF1 had a low proliferation rate compared to 
CAF2, particularly at higher passages, although statistically, this difference was not 
significant. Functionally, in the tumour stroma, non-myofibroblastic CAFs secrete 
inflammatory SASP-like products and their pro-tumorigenic effects have been described 
(Krtolica et al., 2001). However, much work is required to understand the effects of 
inflammatory CAF-secreted factors on tumorigenicity (Biffi and Tuveson, 2021). 
 
4.6 Limitations 
We are aware although in vitro monolayer 2D cultures of fibroblasts can be useful to 
investigate some biological aspects of CAF, however, it has been reported that the 
transcriptome of CAFs cultured in vitro does not recapitulate the heterogeneity of CAFs 
in vivo (Puram et al., 2018). Other approaches, such as a short-term co-cultures that 
retain all cell populations found in tumours, of liquid-air interface models (Neal et al., 
2019) and multi-cell-type three-dimensional bio-printed tissues (Langer et al., 2019) are 
being implemented and optimised.  
According to the CAFs isolation protocol (Enzymatic digestion approach), a 
heterogeneous population of CAFs was isolated.  Theoretically, CAFs were isolated and 
characterised in a population of different subtypes from the single tumour. Among this 
isolated population, CAFs might display heterogeneity in the phenotypes and that might 
explain the percentage of the senescent population in CAF1 culture. Single-cell 
resolution techniques including laser microdissection, pressure catapulting and 
fluorescence-activated cell sorting provide the advantage of isolating a pure cell 
population for molecular comparisons. 
 
4.7 Summary of main findings and clinical implications 
Using NTFs, myofibroblastic and senescent models were established and characterised. 
The comparison between these models and previously established models derived from 
oral fibroblasts revealed no differences in the developed phenotypes in responses to 
TGF-β1 and H2O2 stimuli although they were extracted from different anatomical 
locations. This observation indicates that the biological differences in OPSCC subtypes 
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are mainly attributed to cancer cells and their capacity in modulation the underlying 
microenvironment. 
 
Two OPSCC-derived CAF cultures, originating from HPV-driven tumours, were 
established and characterised. To the best of knowledge, this is the first time CAFs were 
extracted from HPV-associated OPSCC. Establishment of OPSCC-CAFs cultures 
provides the opportunity for further investigations in vitro to understand OPSCC tumour 
cells and CAF crosstalk. 
 
Recognition of CAF characteristics in different phenotypes provides a framework for 
better understating of CAFs’ role in OPSCC. Moreover, it highlights the need to consider 

































































5.1 Introduction   
“No tumour is an island, entire of itself; every tumour is a piece of a continent.”  This 
quote is a paraphrase of the famous quote written by the English poet John Donne 
(Custódio, Biddle and Tavassoli, 2020). It summarises the available knowledge on 
epithelial solid tumour development and progression as dysfunctional tissues as a whole 
rather than an accumulation of a critical number of mutations in tumour cells (Hanahan 
and Weinberg, 2011). Efforts to develop cancer therapies have mainly been concerned 
with the malignant cell component, although non-malignant cells in the underlying tumour 
microenvironment (TME) substantially contribute to the progression of the tumour and 
cancer therapy resistance. In the last decade, there has been an increasing focus on the 
non-malignant mesenchymal components within the TME intending to understand the 
biology of complex interactions with the neighbouring malignant cells.  
The TME consists of several cell types which encompass fibroblasts, in addition to other 
immune cells, pericytes, endothelial cells, adipocytes, mesenchymal cells, in addition to 
the extracellular matrix. These normal residents in the tumour stroma have the capability 
to be stimulated by tumour cells and differentiate into more tumour-supportive 
phenotypes, especially, those demonstrating a cellular senescence-status (Lawrence et 
al., 2015). Induction of an activated CAF phenotype and the potentiation of tumour cell 
behaviour involves crosstalk between the TME and cancer cells. The cytokines TGF-β1, 
TNF-a and IL-1ɑ/β have been reported as epithelial cancer-derived factors in CAF 
activation. CAFs, in turn, secrete several factors includes TNF-a, IL-1ɑ/β, CCL7, 
Collagen 1, Activin A, , SDF-1, MMPS, IL-33, PGE2, HGF, and PDGF which have been 
implicated in tumour invasion, metastasis and resistance to cancer therapy (Leef and, 
Thomas, 2013; Togo et al., 2013; Sun et al., 2012). 
However, little is known about the role of the tumour microenvironment in HPV-positive 
and HPV-negative OPSCC subtypes. Much is unclear regarding the specific pathways 
of stromal activation and if this has a pivotal role in tumour cells modulation, regardless 
of HPV status. Previous work from our lab demonstrated evident differences between 
OPSCC subtypes in term of stroma modulation (Bolt et al., 2018; Peacock et al., 2018). 
Conditioned media-derived from HPV-negative cell lines (SCC89 & SCC72) and HPV-
positive cell lines (SCC90 & SCC2) were subjected to cytokine analysis previously in our 
lab using Raybiotech C2000 Human Cytokine Arrays (Raybio-technology, Norcross, 
USA, cat number: AAH-CYT-2000). (Appendix A.3) (Bolt, 2016). HPV-negative cell lines 
produced higher amounts of cytokines than the HPV-positive cells.  nevertheless, further 
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work is required to understand the early events in tumour-stroma activation and identify 























• To explore the secretome mediated crosstalk between tonsil derived fibroblasts 
and HPV-positive and HPV-negative OPSCC subtypes. 
 
5.3 Experimental approach and statistical analysis 
• Modelling of tumour-stroma interaction was established by incubating OPSCC 
fibroblasts for 24h with conditioned media collected from HPV-positive SCC 
(SCC2) or HPV-negative OPSCC cell lines (SCC89) (M1). This incubation was 
followed by another 24h incubation with serum-free media (M2) (Figure 5.1). 
Media collected from these interactions was subjected to cytokine multiplex array 
technique to screen a wide panel of cytokines that may play a role in the activated 
microenvironment. 
 
Figure 5.1: Illustration for conditioned media procedure. A, cell line conditioned 
media collection. B, Stimulation of fibroblast by cell line media and collection of the 
stimulated fibroblasts media (M1). C, incubation of fibroblast with normal media to get 
media2 
 
• An interactive co-culture model consisting of HPV-positive OPSCC or HPV-
negative OPSCC cell lines and OPSCC fibroblasts was performed using culturing 
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inserts (pores size= 0.4 μm) to validate the array results and identify which cell 
was contributing particular cytokines to the secretome (Figure 5.2). 
 
 
Figure 5.2: Illustration of transwell co-culture model. 
 
• Statistically, detection of non-normality is less likely among the data due to small 
sample numbers, however, Shapiro-Wilk test was used to check the normality 
due to its high sensitivity. For the comparison between two normally distributed 
samples’ mean, two-tailed unpaired t-test was used. In multiple data sets, one-
way analysis of variance (ANOVA) was used.  
 
• Data were presented graphically illustrating the mean with error bars 
demonstrating the standard deviation (SD). The probability of similar random 
result detection (p-value) was considered significant if (p<0.05). “N” followed by 
a number denotes the biological repeats, while “n” denotes the technical repeats. 












5.4 Results  
5.4.1 Cytokine analysis of OPSCC fibroblasts media following 
stimulation with OPSCC cell lines media 
5.4.1.1 CAF1  
From the previous observations in chapter 4, CAF1 demonstrated senescent-like 
features by displaying a high percentage of SA-gal and low proliferation rate. The basal 
secretory profile of CAF1 cells was determined by incubating the cells with normal growth 
media (Figure 5.3) or serum-free media (Figure 5.4). Noted from visual inspection and 





Figure 5.3 A & B: Cytokine Array analysis of CAF1 conditioned normal growth media (M1). 
(A) Representative image of the developed CAF1-M1 cytokine membrane. (B) The array map. 
The blue and yellow boxes in the array map denote the positive and negative array controls, 
respectively. Red box denotes factors present in CAF1-M1 conditioned media. Only CCL2 and 







Figure 5.3 C: Cytokine Array analysis of CAF1 conditioned normal growth media (M1). (C) Densitometry analysis of factors detected in CAF1-M1 conditioned 
media. Bars represent the mean of densitometry values of each array’s duplicate repeat spot. (Ref) denotes a positive control value that is used as a reference for 
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Figure 5.4 A & B: Cytokine Array analysis of CAF1 serum-free conditioned media (M2). (A) 
Representative image of the developed CAF1-M2 cytokine membrane. (B) The array map (Right). 
The blue and yellow boxes in the array map denote the positive and negative array controls, 
respectively. Red box denotes factors present in CAF1-M2 conditioned media. Only MMP2 showed 











Figure 5.4 C: Cytokine Array analysis of CAF1 serum-free conditioned media (M2). (C) Densitometry analysis of factors detected in CAF1-M2 conditioned 
media. Bars represent the mean of densitometry values of each array’s duplicate repeat spot. (Ref) denotes a positive control value that is used as a reference for 
result optimisation between the membranes. (NC) denotes array negative control spots.  MMP2 showed a modest expression compared to the reference bar. 
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Incubation of CAF1 with HPV-negative OPSCC cell line conditioned media (SCC89) 
demonstrated production of a larger number of cytokines with variable uptake densities, 
including CSTD, GM-CSF, IL-6, IL-8, KLK6, CCL2, MMP2, MMP3, OPN, GEP, SPARC 
and VEGF (Figure 5.5). Incubation of CAF1 with serum-free media following SCC89 
media stimulation revealed upregulation in CAF1 secretory profile includes CTSB, IL-6, 






Figure 5.5 A & B: Cytokine Array analysis of conditioned media taken following CAF1 stimulation 
with SCC89 CM (M1). (A) Representative image of the developed cytokine membrane for CAF1 media 
after SCC89 CM treatment (B) The array map. The blue and yellow boxes in the array map denote the 
positive and negative array controls, respectively. The red box denotes factors present in CAF1-SCC89-
M1 conditioned media.  Numerous cytokines showed densitometry uptakes, with CSTD, CCL2, MMP2 















Figure 5.5 C: Cytokine Array analysis of conditioned media taken following CAF1 stimulation with SCC89 CM (M1). (C) Densitometry analysis of factors 
detected in CAF1-SCC89-M1 conditioned media. Bars represent the mean densitometry values of each duplicate repeat spot. (Ref) denotes a positive control value 
that is used as a reference for result optimisation between the membranes. (NC) denotes array negative control spots. Analysis reveals varying levels of cytokine 









Figure 5.6 A&B: Cytokine Array analysis of CAF1 serum-free conditioned media following 
SCC89 CM stimulation (M2). (A) Representative image of the developed cytokine membrane 
for CAF1 serum-free media following SCC89 CM treatment. (B) The array map. The blue and 
yellow boxes in the array map denote the positive and negative array controls, respectively. The 
red box denotes factors present in CAF1-SCC89-M2 conditioned media. Relatively fewer 
cytokines are expressed compared to SCC89-CAF1 M1. The CCL2, MMP2 and MMP3 spots 










Figure 5.6 C: Cytokine Array analysis of CAF1 serum-free conditioned media following SCC89 CM stimulation (M2). (C) Densitometry analysis of CAF1-
SCC89-M2 conditioned media. Bars represent the mean of densitometry values of each array’s duplicate repeat spot. (Ref) denotes a positive control value that is 
used as a reference for values normalisation. (NC) denotes array negative control spots. A number of cytokines showed expression with fewer expression values 
compared to M1 conditioned medium. 
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The HPV-positive SCC2 cell line conditioned media induced less cytokine secretion from 
CAF1, namely, CSTD, IL-6, CCL2, MMP2, MMP3, SerpinE and VEGF (Figure 5.7). Also, 
fewer cytokines were detected in CAF1-M2 following SCC2 conditioned media 








Figure 5.7 A & B: Cytokine Array analysis of conditioned media taken following CAF1 
stimulation with SCC2 CM (M1). (A) Representative photo for developed cytokine membrane 
for CAF1 media after SCC2 CM treatment. (B) The array map. The blue and yellow boxes in the 
array map denote the positive and negative array controls, respectively. The red box denotes 
factors present in CAF1-SCC2-M1 conditioned media. A relatively low number of cytokines 







Figure 5.7 C: Cytokine Array analysis of conditioned media taken following CAF1 stimulation with SCC2 CM (M1). (C) Densitometry analysis 
of CAF1-SCC2-M1 conditioned media. Bars represent the mean of densitometry values of each array’s duplicate repeat spot. (Ref) denotes a positive 
control value that is used as a reference for values normalisation. (NC) denotes array negative control spots. Fewer cytokines were identified in 










Figure 5.8 A & B: Cytokine Array analysis of CAF1 serum-free conditioned media following 
SCC2 CM stimulation (M2). (A) Representative image of the developed cytokine membrane for 
CAF1 serum-free media following SCC2 CM treatment. (B) The array map. The blue and yellow 
boxes in the array map denote the positive and negative array controls, respectively. The red box 
denotes factors present in CAF1-SCC2-M2 conditioned media. A reduced number of cytokines 










Figure 5.8 C: Cytokine Array analysis of CAF1 serum-free conditioned media following SCC2 CM stimulation (M2 (C) Densitometry analysis of CAF1-SCC2-
M2 conditioned media. Bars represent the mean of densitometry values of each array’s duplicate repeat spot. (Ref) denotes a positive control value that is used as 




In characterisation work in chapter 4, CAF2 showed myofibroblastic phenotype features 
by expression high level of ɑ-SMA and low SA-β-gal percentage. The basal secretory 
profile of CAF2 cytokine was determined by incubating the cells with normal growth 
media (Figure 5.9) or serum-free media (Figure 5.10). MMP2 and SPARC were only the 








Figure 5.9 A & B: Cytokine Array analysis of CAF2 conditioned media (M1). (A) 
Representative image of the CAF2-M1 developed cytokine membrane. (B) The array map. The 
blue and yellow boxes in the array map denote the positive and negative array controls, 
respectively. Red box denotes factors present in CAF2-M1 conditioned media.  The large dark 









Figure 5.9 C: Cytokine Array analysis of CAF2 conditioned media (M1). (C) Densitometry analysis of factors detected in CAF2-M1 conditioned media. Bars 
represent the mean of densitometry values of each array’s duplicate repeat spot. (Ref) denotes a positive control value that is used as a reference for result 









Figure 5.10 A & B: Cytokine Array analysis of CAF2 serum-free conditioned media (M2). 
(A) Representative photo for CAF2-M2 developed cytokine membrane. (B) The array map. The 
blue and yellow boxes in the array map denote the positive and negative array controls, 
respectively. Red box denotes factors present in CAF2-M2 conditioned media. Evident 















Figure 5.10 C: Cytokine Array analysis of CAF2 serum-free conditioned media (M2). (C) Densitometry analysis of factors detected in CAF2-M2 conditioned 
media. Bars represent the mean of densitometry values of each array’s duplicate repeat spot. (Ref) denotes a positive control value that is used as a reference for 
result optimisation between the membranes. (NC) denotes array negative control spots. The basal CAF2 secretome consists of MMP2 and low levels of SPARC.      
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The cytokine expression profile of CAF2 culture stimulated with SCC89 conditioned 
media demonstrated a relatively high number of cytokines with variable densities, 
namely, CSTD, GM-CSF, C-Met, IL-6, IL-8, KLK6, CCL2, MMP2, MMP3, OPN, GEP, 
SerpinE, SPARC and VEGF (Figure 5.11). The range of cytokines identified in CAF2 
culture is reduced after replacing the SCC89 conditioned media with serum-free media 







Figure 5.11 A & B: Cytokine Array analysis of conditioned media taken following CAF2 
stimulation with SCC89 CM (M1). (A) Representative photo for developed cytokine membrane 
for CAF2 media after SCC89 CM treatment. (B) The array map. The blue and yellow boxes in the 
array map denote the positive and negative array controls, respectively. The red box denotes 
factors present in CAF2-SCC89-M1 conditioned media. Many cytokines were expressed with 







Figure 5.11 C: Cytokine Array analysis of conditioned media taken following CAF2 stimulation with SCC89 CM (M1). (C) Densitometry analysis of factors 
detected in CAF2-SCC89-M1 conditioned media. Bars represent the mean of densitometry values of each array’s duplicate repeat spot. (Ref) denotes a positive 
control value that is used as a reference for result optimisation between the membranes. (NC) denotes array negative control spots A wide variety of cytokines 










Figure 5.12 A & B: Cytokine Array analysis of CAF2 serum-free conditioned media 
following SCC89 CM stimulation (M2). (A) Representative image of the developed cytokine 
membrane for CAF2 serum-free media following SCC89 CM treatment. (B) The array map. The 
blue and yellow boxes in the array map denote the positive and negative array controls, 
respectively. The red box denotes factors present in CAF”-SCC89-M2 conditioned media. A 











Figure 5.12 C: Cytokine Array analysis of CAF2 serum-free conditioned media following SCC89 CM stimulation (M2). (C) Densitometry analysis of CAF2-
SCC89-M2 conditioned media. Bars represent the mean of densitometry values of each array’s duplicate repeat spot. (Ref) denotes a positive control value that is 
used as a reference for values normalisation. (NC) denotes array negative control spots. MMP2, CCL2 showed the highest expression. IL6 and IL8 were expressed 
at a comparable level to SCC89-CAF2 M1. 
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Similar to our observation in CAF1 stimulation, the SCC2 cell line conditioned media 
induced less cytokine secretion from CAF2 cells during the stimulation time (CAF2-M1), 
namely CSTD, IL-6, CCL2, MMP2, MMP3, SPARC and VEGF (Figure 5.13). Also, fewer 
cytokines were noted in CAF2-M2 following SCC2 conditioned media stimulation, 







Figure 5.13 A & B: Cytokine Array analysis of conditioned media taken following CAF2 
stimulation with SCC2 CM (M1). (A) Representative image of the developed cytokine membrane 
for CAF2 media after SCC2 CM treatment. (B) The array map. The blue and yellow boxes in the 
array map denote the positive and negative array controls, respectively. The red box denotes 
factors present in CAF2-SCC2-M1 conditioned media. Only CCL2 and MMP2 showed strong 







Figure 5.13 C: Cytokine Array analysis of conditioned media taken following CAF2 stimulation with SCC2 CM (M1) (C) Densitometry analysis of CAF2-
SCC2-M1 conditioned media. Bars represent the mean of densitometry values of each array’s duplicate repeat spot. (Ref) denotes a positive control value that is 
used as a reference for values normalisation. (NC) denotes array negative control spots. Compared with basal secretion, CCL2 and MMP2 showed upregulation 







Figure 5.14 A & B: Cytokine Array analysis of CAF2 serum-free conditioned media 
following SCC2 CM stimulation (M2). (A) Representative image of the developed cytokine 
membrane for CAF2 serum-free media following SCC2 CM treatment. (B) The array map. The 
blue and yellow boxes in the array map denote the positive and negative array controls, 
respectively. The red box denotes factors present in CAF2-SCC2-M2 conditioned media. MMP2 
was the most prominent spot followed by CCL2 and SPARC. A weak signal was detected in the 









Figure 5.14 C: Cytokine Array analysis of CAF2 serum-free conditioned media following SCC2 CM stimulation (M2). (C) Densitometry analysis of CAF2-
SCC2-M2 conditioned media. Bars represent the mean of densitometry values of each array’s duplicate repeat spot. (Ref) denotes a positive control value that is 




NTF322 conditioned media revealed a number of upregulated cytokines including, IL6, 
CCL2, MMP2, SerpinE, SPARC and VEGF (Figure 5.15) However, NTF322 serum-free 
media exhibited a relatively higher basal secretory profile which consists of MMP3, 








Figure 5.15 A & B: Cytokine Array analysis of NTF322 conditioned media (M1). (A) 
Representative image of the NTF322-M1 developed cytokine membrane. (B) The array map. The 
blue and yellow boxes in the array map denote the positive and negative array controls, 







Figure 5.15 C: Cytokine Array analysis of NTF322 conditioned media (M1). (C) Densitometry analysis of NTF322-M1 conditioned media. Bars 
represent the mean of densitometry values of each array’s duplicate repeat spot. (Ref) denotes a positive control value that is used as a reference 








Figure 5.16 A & B: Cytokine Array analysis of NTF322 serum-free conditioned media (M2). 
(A) Representative image of the NTF322-M2 developed cytokine membrane (B) The array map. 
The blue and yellow boxes in the array map denote the positive and negative array controls, 
respectively. Red boxes denote factors present in NTF322-M2 conditioned media. Only MMP2 











Figure 5.16 C: Cytokine Array analysis of NTF322 serum-free conditioned media (M2. (C) Densitometry analysis of NTF322-M2 conditioned media. Bars 
represent the mean of densitometry values of each array duplicate repeat spot. (Ref) denotes a positive control value that is used as a reference for values 
normalisation. (NC) denotes array negative control spots.  
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Incubation of NTF322 with SCC89 cell line media resulted in the production of a number 
of cytokines, seen with variable uptake density on the array, including CSTD, GM-CSF, 
IL-6, IL-8, KLK6, CCL2, MMP2, MMP3, OPN, GEP, SPARC and VEGF (Figure 5.17). 
Incubation of NTF322 with serum-free media following SCC89 conditioned media 
stimulation revealed upregulation in NTF322 secretory profile represented by CTSB, 







Figure 5.17 A & B: Cytokine Array analysis of conditioned media taken following NTF322 
stimulation with SCC89 CM (M1). (A) Representative image of the developed cytokine 
membrane for NTF322 media after SCC89 CM treatment (B) The array map. The blue and yellow 
boxes in the array map denote the positive and negative array controls, respectively. The red box 
denotes factors present in NTF322-SCC89-M1 conditioned media. A number of duplicated spots 







Figure 5.17 C: Cytokine Array analysis of conditioned media taken following NTF322 stimulation with SCC89 CM (M1). (C) Densitometry 
analysis of NTF322-SCC89-M1 conditioned media. Bars represent the mean of densitometry values of each array’s duplicate repeat spot. (Ref) 
denotes a positive control value that is used as a reference for values normalisation. (NC) denotes array negative control spots. CCL2, MMP2 and 









Figure 5.18 A & B: Cytokine Array analysis of NTF322 serum-free conditioned media 
following SCC89 CM stimulation (M2). (A) Representative image of the developed cytokine 
membrane for NTF322 serum-free media following SCC89 CM treatment (B) The array map. The 
blue and yellow boxes in the array map denote the positive and negative array controls, 
respectively. The red boxes denote factors present in NTF322-SCC89-M2 conditioned media. A 








Figure 5.18: Cytokine Array analysis of NTF322 serum-free conditioned media following SCC89 CM stimulation (M2). (C) Densitometry 
analysis of NTF322-SCC89-M2 conditioned media. Bars represent the mean of densitometry values of each array’s duplicate repeat spot. (Ref) 
denotes a positive control value that is used as a reference for values normalisation. (NC) denotes array negative control spots. 
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Cytokine analysis of SCC2 cell line conditioned media and NTF322 culture revealed a 
smaller range cytokine secretion including CSTD, DKK1, IL-6, IL-8, LDC, CCL2, MMP2, 
GEP SerpinE and VEGF when compared to SCC89-NTF322 (Figure 5.19). Also, fewer 
cytokines were noted in NTF322-M2 following SCC2 conditioned media stimulation 








Figure 5.19 A & B: Cytokine Array analysis of conditioned media taken following NTF322 
stimulation with SCC2 CM (M1). (A) Representative image of the developed cytokine membrane 
for NTF322 media after SCC2 CM treatment (B) The array map. The blue and yellow boxes in 
the array map denote the positive and negative array controls, respectively. The red boxes denote 
factors present in NTF322-SCC2-M1 conditioned media. A larger number of factors are 








Figure 5.19 C: Cytokine Array analysis of conditioned media taken following NTF322 stimulation with SCC2 CM (M1). (C) Densitometry analysis of NTF322-
SCC2-M1 conditioned media. Bars represent the mean of densitometry values of each array’s duplicate repeat spot. (Ref) denotes a positive control value that is 










Figure 5.20 A & B: Cytokine Array analysis of NTF322 serum-free conditioned media 
following SCC2 CM stimulation (M2). (A) Representative image of the developed cytokine 
membrane for NTF322 serum-free media following SCC2 CM treatment. (B) The array map. The 
blue and yellow boxes in the array map denote the positive and negative array controls, 
respectively. The red box denotes factors present in NTF322-SCC2-M2 conditioned media. Less 












Figure 5.20 C: Cytokine Array analysis of NTF322 serum-free conditioned media following SCC2 CM stimulation (M2). (C) Densitometry 
analysis of NTF322-SCC2-M2 conditioned media. Bars represent the mean of densitometry values of each array’s duplicate repeat spot. (Ref) 
denotes a positive control value that is used as a reference for values normalisation. (NC) denotes array negative control spots. MMP2 is the 
prominent cytokine following SCC2 media stimulation.  
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5.4.2 A summary of cytokine array analysis 
Data presented in the previous cytokine arrays analysis is summarised in the following 
tables. Tables 5.1- 5.3 summarise cytokines production in response to M1 in all tested 
OPSCC fibroblasts. Tables 5.4-5.6 summarise cytokines production in OPSCC 
fibroblasts response to M2. 
Table 5.1: Summary of cytokines produced in M1: CAF1 incubated with SCC89 or 
SCC2 conditioned media. 
 
 
Table 5.2: Summary of cytokines upregulated in CAF2 during incubation with 





Table 5.3: Summary of cytokines produced during the incubation of NTF322 with 
SCC89 or SCC2 conditioned media (M1). 
 
 
Table 5.4: Summary of cytokines produced in CAF1 serum-free media following a 




Table 5.5: Summary of cytokines produced in CAF2 serum-free media following a 




Table 5.6: Summary of cytokines produced in NTF322 serum-free media following 
a period of  SCC89 or SCC2 conditioned media stimulation (M2).  
 
 
From the above previous tables, we can conclude that M1 contained more cytokines 
compared to M2. The former consists of a mixture of cancer cell line conditioned media 
plus fibroblast media under the activation condition, while the latter represents fibroblasts 
media only after short incubation with OPSCC cell lines media. Moreover, all stimulated 
OPSCC fibroblasts stimulated secretion of a wide range of cytokines produced in 
response to SCC89, but much less so in response to SCC2. This remarkable difference 
was also evident when comparing the relevant  M1 and M2 analyses. 
OPN, KLK6 and GM-CSF were detected exclusively in SCC89 M1, and they were not 
observed in SCC2 M1. Furthermore, IL-6 and IL-8 were secreted exclusively from 
fibroblasts upon SCC89 conditioned media incubation (M2), and they were not 
expressed in response to SCC2 CM.  Other factors, including CCL2 and MMP3, were 
secreted in response to both OPSCC cell lines incubation. 
 
MMP2 was the detectable factor in CAF1 and CAF2 basal secretome that was 
upregulated during activation with cell line CM. However, stimulated CAF1 showed a 
wider range of cytokines produced in response to both cell lines stimulation compared to 
CAF2. Notably, NTF322 produces a wider range of cytokines at M2 than CAFs and 








5.4.3 OPN basal level in OPSCC 
OPN expression was assessed in additional OPSCC cell lines, SCC90 (HPV-positive 
cell line) and SCC72 (HPV-negative cell line). Firstly, we investigated OPN basal 
expression in all OPSCCs used in this study. qRT-PCR analysis showed differences in 
OPN expression between the four cell lines. SCC89 and SCC72 (HPV-negative) 
displayed higher values of OPN mRNA expression (relative to β2m). This difference was 
statistically significant compared to the HPV-positive cell lines SCC90 and SCC2 
(p<0.05) (Figure 5.21). 
 
Figure 5.21: High basal level of OPN mRNA in HPV-negative cell lines compared HPV-
positive cell lines. The cells pellets were collected, and RNA extraction was performed. cDNA 
was constructed at volume 20μl using 400ng of the RNA. OPN mRNA expression was analysed 
using the qRT-PCR technique. OPN fold change compared to ꞵ2m. Data represent the mean of 
(N=3,n=3). Error bars= SD. Statistical analysis was determined using two-tailed Student t-test 








5.4.4 Interactive co-culture validation for arrays findings  
The interactive approach was selected to validate the cytokine array findings and explore 
the molecular changes in the co-cultured cells. NTF10 were added to the interactive co-
culture experiment for further results validation.  
 
Transwell inserts (pore size 0.4 μm) were utilised in the co-culture model bringing the 
advantages of fluid movement and secretion transportation between two cultures 
through the pores in the membrane without direct physical contact. Cultivation in a 
separate compartment provides the feasibility of analysing the two cell types used in the 
experiment without adding additional steps for sorting the cells. To do so, 3x105 cancer 
cells were grown in growth media on cell culture inserts then co-cultured for 48h with 
50,000 cells of NTF3, NTF10, CAF1 or CAF2 plated in a 6-well plate. (NTF10 was added 
for further result validation). ELISA analysis was performed to detect and quantify the 
secreted cytokines in the co-culture media. Since the numbers of two cell populations 
were approximate in all models, target concentration was not subjected to cell number 
optimisation. qRT-PCR analysis was performed to identify the source of secretion in the 
co-culture model, also to provide an accurate comparison in target expression levels in 
monoculture and co-culture models.  
 
In the cytokine array analysis, OPN was produced in all M1s related to SCC89 only, not 
SCC2. Corresponding to this observation, IL-6 also was secreted particularly from 
SCC89-induced fibroblasts only. OPN and IL6 have been described in a few studies as 
candidates in a reciprocal communication loop between the tumour cells and CAFs in 
OSCC (Qin et al., 2018). Expression of OPN and IL6 in tumours have been associated 
with tumour cell migration, poor therapeutic response, and poorer clinical outcomes 
(Chen et al., 2013). CAF-derived IL6 enhances cancer cell metastasis and growth via 
induction of cancer-derived OPN transcription. Both candidates were suggested as 
prognostic biomarkers in a number of human tumours including OSCC, however, their 
expression patterns have not been investigated in OPSCC as yet.  Thus, OPN and IL6 









5.4.4.1 Osteopontin   
ELISA analysis 
To confirm the association between OPN and OPSCC subtypes, OPN ELISA analysis 
was used for media collected from OPSCC co-cultures. SCC89-fibroblast co-cultures 
demonstrated a higher level of OPN production while the majority of SCC2-fibroblast co-
cultures failed to produce a detectable amount of OPN using DuoSet ELISA set 
(sensitivity range 4000-62.5 pg/ml). The differences between co-cultured SCC89s were 
not statistically significant using One-way ANOVA (p>0.05). Figure 5.22 and Table 5.7 
illustrate OPN expression values in the co-culture models. 
 
 
Figure 5.22: Higher levels of OPN protein secretion in SCC89-fibroblast co-cultures than 
in SCC2-fibroblast co-cultures. SCC89 or SCC2 (3x105 cells) were co-cultured with OPSCC 
fibroblasts (CAF1, CAF2, NTF322, NTF10) (50,000 cells) using transwell insert (0.45 μm) for 48h. 
The collected media was subjected to OPN ELISA analysis. Samples number (n=8), Y-axis 
denotes standardised OPN concentration in Pg per ml. Blue bars denote SCC89 co-cultures. Red 
bars denote SCC2 co-cultures. Only SCC89 co-cultures showed apparent OPN expression. Error 
bars= SD. Data represent the mean of (N=3, n=3) in the attached table. Statistical analysis was 




Table 5.7: Summary of OPN ELISA findings in SCC89 & SCC2 co-culture models 
Co-culture model = (OPN mean ± SD) 
(Pg/ml) 
Co-culture model = (OPN mean ± SD) 
(Pg/ml) 
p value 
SCC89-CAF1 = (352.6 ± 83) SCC2-CAF1 = (0.0 ± 0.0) < 0.01 
SCC89-CAF2 = (690 ± 312.6) SCC2-CAF2 = (0.0 ± 0.0) < 0.05 
SCC89-NTF322 = (741.6 ± 272.5) SCC2-NTF322 = (8.2 ± 14.2) < 0.01 
SCC89-NTF10 = (874.5 ± 52.3) SCC2-NTF10 = (0.0 ± 0.0) < 0.001 
 
 
mRNA analysis (qRT-PCR) 
To identify the source of OPN secretion, qRT-PCR analysis was performed on RNA 
extracted from the co-cultured cells. ꞵ2m was selected as an internal reference gene to 
compare target expression in both populations as it showed a similar level of expression: 
mean of ꞵ2m ct value in fibroblasts was 16.69 ± 0.39, while in the cancer cell lines this 
was 16.8 ± 0.99. OPN qRT-PCR findings were as follows (Figure 5.23): SCC89 cells in 
different co-culture models were the main source of OPN production. Moreover, Among 
the co-cultured SCC89s, SCC89-CAF1 displayed the highest production of OPN while 
SCC89-NTF10 showed the lowest value. The differences between co-cultured SCC89s 
were statistically significant using one-way ANOVA test (p<0.05). Comparing OPN 
expression between SCC89 and SCC2 in co-culture models revealed statistically 








Table 5.8: Summary of OPN mRNA expression in SCC89s & SCC2s upon 
interactive co-culturing for 48h. 
(OPN mean ± SD) 
Fold change in relation to β2m 
(OPN mean ± SD) 
Fold change in relation to β2m 
p-value 
SCC89 (CAF1) = (0.025 ± 0.004) SCC2 (CAF1) = (0.0002 ± 0.0001) < 0.01 
SCC89 (CAF2) = (0.015 ± 0.004) SCC2 (CAF2) = (0.0001 ± 0.000) < 0.05 
SCC89 (NTF322) = (0.017 ± 0.001) SCC2 (NTF322) = (0.0001± 0.000) < 0.01 




























Figure 5.23: Higher OPN mRNA upregulation in SCC89 than SCC2 from different fibroblasts co-culture models. SCC89 or SCC2 (3x105 cells) were co-
cultured with OPSCC fibroblasts (CAF1, CAF2, NTF322, NTF10) (50,000 cells) using transwell insert (0.45 μm) for 48h. The cells pellets were collected, and RNA 
extraction was performed. cDNA was constructed at volume 20μl using 500ng of the RNA. OPN mRNA expression was analysed using the qRT-PCR technique. 
Untreated cells were included for comparison. Blue bars denote HPV-negative co-cultures (SCC89). Red bars denote HPV-positive co-cultures (SCC2). Co-cultured 
SCC89s showed higher OPN mRNA expression compared to Co-cultured SCC2s. OPN fold change compared to ꞵ2m. Data represent the mean of (N=3, n=3) 
except co-cultured cancer cells (N=2.n=3). Error bars= SD. Statistical analysis was determined using two-tailed Student t-test with *p < 0.05 and **p < 0.01. 
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5.4.4.2 Interleukin -6 
ELISA analysis 
IL6 ELISA analysis provided further validation to arrays’ findings and demonstrated a 
difference between the co-culture models. SCC89 co-cultures showed higher IL6 
expression than SCC2 co-cultures and these differences presented statistically 
significant values (Table 5.9). Assessing the differences between SCC89 co-cultures, 
one-way ANOVA test revealed a significant difference (p<0.01) that also was observed 
between SCC2s co-cultures (p<0.001) (Figure 5.24). 
 
Table 5.9: summary of OPN ELISA findings in SCC89 & SCC2 co-culture models 
Co-culture model = (IL-6 mean ± SD) 
(Pg/ml) 
Co-culture model = (IL-6 mean ± SD) 
(Pg/ml) 
p value 
SCC89-CAF1 = (824.3 ± 75.2) SCC2-CAF1 = (357.4 ± 35.9) <0.001 
SCC89-CAF2 = (752.3 ± 425.7) SCC2-CAF2 = (270.4 ± 16.5) ns 
SCC89-NTF322 = (1276.8 ± 383) SCC2-NTF322 = (178.8 ± 20.3) < 0.01 






Figure 5.24: Higher levels of IL-6 protein with SCC89-fibroblast co-cultures than SCC2-
fibroblast cocultures. SCC89 or SCC2 (3x105 cells) were co-cultured with OPSCC fibroblasts 
(CAF1, CAF2, NTF322, NTF10) (50,000 cells) using transwell inserts (0.45 μm) for 48h. The 
collected media was subjected to IL-6 ELISA analysis. Samples number (n=8), Y-axis denotes 
standardised IL-6 concentration in pg per ml. Blue bars denote SCC89 co-cultures. Red bars 
denote SCC2 co-cultures. SCC89 co-cultures showed higher IL-6 expression. Data represent the 
mean of (N=3, n=3). Error bars = SD. Statistical analysis was determined using two-tailed Student 
t-test with *p<0.05,   **p < 0.01 and ***p< 0.0001. 
 
mRNA analysis (qRT-PCR) 
IL-6 qRT-PCR analysis demonstrated that fibroblasts were the main source for IL-6 
production in the co-culture models. A specific association between IL6 mRNA 
expression and SCC89-fibroblast cultures was evident that showed significant 





Table 5.10: Summary of IL-6 mRNA expression in SCC89s & SCC2s upon 











(IL-6 mean ± SD)  Fold change in 
relation to β2m 
(IL-6 mean ± SD)  Fold change in 
relation to β2m 
p-value 
CAF1 (SCC89) = (0.25 ± 0.07) CAF1 (SCC2) = (0.013 ± 0.013) < 0.05 
CAF2 (SCC89) = (0.08 ± 0.01) CAF2 (SCC2) = (0.005 ± 0.004) < 0.01 
NTF322 (SCC89) = (0.22 ± 0.03) NTF322 (SCC2) = (0.005 ± 0.005) < 0.001 














Figure 5.25: Higher IL-6 mRNA upregulation in SCC89 than SCC2 from different fibroblasts co-culture models. SCC89 or SCC2 (3x105 cells) were co-
cultured with OPSCC fibroblasts (CAF1, CAF2, NTF322, NTF10; 50,000 cells) using transwell insert (0.45 μm) for 48h. The cell pellets were collected, and RNA 
extraction was performed. cDNA was constructed using 500ng RNA and IL-6 mRNA expression was analysed using qRT-PCR. Untreated cells were included for 
comparison. Blue bars denote HPV-negative’s co-cultures (SCC89). Red bars denote HPV-positive’s co-cultures (SCC2). Co-cultured SCC89s showed higher IL-
6 mRNA expression compared to Co-cultured SCC2s. IL-6 fold change compared to ꞵ2m. Data represent the mean of (N=3,n=3), except co-cultured cancer cells 
(N=2,n=3). Error bars= SD. Statistical analysis was determined using two-tailed Student t-test with *p < 0.05 and **p < 0.01. 
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5.5 Discussion  
The purpose of this chapter is to identify novel candidates in the crosstalk between 
tumour cells and fibroblasts in the OPSCC subtypes. Our aim was based on the 
accumulating evidence on the pivotal role of CAFs in tumour development and 
progression and how that might relate to the distinct clinical courses of both OPSCC 
entities.   
 
Previous work from our research group demonstrated, for the first time, that HPV-
negative OPSCC cell lines, not HPV-positive, have a greater capacity to promote the 
secretion of pro-invasive secretome that includes HGF and IL-6 from normal oral 
fibroblasts. The effect of these factors was studied thoroughly using a 3D-model and 
further validated by using Foretinib, the clinically available c-MET inhibitor (Bolt et al., 
2018). Here, in this chapter, we identified further potential mediators of the initial 
crosstalk between fibroblasts and HPV-negative cell lines using cytokine expression 
profiling. We detected GM-CSF, OPN, and KLK6 as factors expressed exclusively with 
HPV-negative cell line co-cultures. Moreover, cytokine analysis of stimulated fibroblasts 
media demonstrated an alteration in their secretory profile to a more pro-inflammatory 
secretome that was characterised by IL6 and IL8 production. ELISA analysis on media 
from interactive co-culture provided validation for the previous findings, while further 
gene analysis of co-cultured cells revealed their sources of production.  
 
5.5.1 Cytokines expressed exclusively in HPV-negative cell line 
(M1)  
Many in vitro investigations demonstrated different approaches in normal fibroblasts 
activation, including co-culturing models with the cancer cells (Li, Zhou and Gao, 2018; 
Kim et al., 2019), incubation with tumour-derived microvesicles (Peacock et al., 2018; 
Jiang et al., 2019), and using activation and senescence inducers (Kabir et al., 2016; 
Kim et al., 2018; Melling et al., 2018; Wei et al., 2019). Upon co-culturing, activated 
fibroblasts demonstrated a group of changes including cell morphology (Kim et al., 2019), 
ECM proteins (Kaukonen et al., 2016), and miRNAs expression (Shen et al., 2017). In 
this study, the initial events in fibroblasts activation were observed through the passively 
co-cultured model by incubating the fibroblasts with cell line conditioned media for 24hr. 
We observed significant differences in cytokine production between HPV-positive and 
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HPV-negative OPSCC co-cultures as an early response. Densitometry analysis, the 
array analysis of HPV-negative cell line media with the included fibroblasts (SCC89-M1), 
exhibited expression of a plethora of cytokines, many of which are known for their 
association with the cellular senescence and ageing, namely, OPN, GM-CSF and KLK6 
which were detected exclusively in all HPV-negative co-culture media.  
 
OPN: is a pleiotropic phosphorylated glycoprotein that possesses numerous functions 
that have been involved in bone remodelling, inflammation and wound healing. In human 
cancers, OPN is considered a critical mediator of stromal-epithelial interactions both in 
vitro and in vivo (Pazolli et al., 2009). Overexpression of OPN has been reported for 34 
different types of human cancer implicated in invasion, angiogenesis and metastasis 
processes. Whole-genome transcriptional profiling for senescent fibroblasts identified 
OPN as one of the most highly elevated transcripts compared to the normal fibroblasts 
(Pazolli et al., 2009). OPN will be discussed in detail in Chapters 6 and 7. 
 
GM-CSF: The granulocyte-macrophage colony-stimulating factor (GM-CSF) is an 
essential regulator of granulopoiesis and neutrophil functions. It is produced by 
macrophages, fibroblasts and epithelial cells, playing an important role in inflammatory 
responses in autoimmune disease (Tlsty, 2001; Lotfi et al., 2019). In human tumours, 
GM-CSF is considered one of the core features of the SASP besides IL-6, IL-8, GRO-α, 
MCP-1 (Coppé et al., 2008). In HNSCC, high expression of GM-CSF significantly 
correlated with invasion and poor prognosis (Ninck et al., 2003).   
KLK6: Kallikrein is a subgroup of serine proteases. Kallikrein 6 (KLK6) is known to be 
an age-related protease expressed at high levels in the central nervous system and its 
level in the body fluids increases with age (Bayani and Diamandis, 2011). Dysregulation 
in KLK6 expression is a common feature in human tumours. It shows proteolytic 
properties in the degradation of ECM proteins in vitro (Ghosh et al., 2004). KLK6 also is 
implicated in tissue remodelling and promotes tumour progression via facilitating 
migration and invasion processes (Borgoño and Diamandis, 2004). Although KLK6 
overexpression was linked with worse clinical outcomes in ovarian and colorectal 
cancers (Shan et al., 2007; Inoue et al., 2010), in other carcinomas it has been found to 
be downregulated, such as in renal cell carcinoma and salivary gland tumours (Petraki 




5.5.2 Effects of OPSCC cells basal secretion in the results of M1 
analyses 
Understanding of the molecular and genetic changes associated with OPSCC subtypes 
might explain differences in M1 contents between SCC89 and SCC2. Over the last few 
decades, the genetic profile of OSCC has been well established (Kim and Califano, 2004; 
Hunter, Parkinson and Harrison, 2005). Master genetic changes in OSCC include 
changes at chromosomes 3p (telomerase repressor) (Cuthbert et al., 1999), 9p (INK4A 
locus) (Sharpless and Depinho, 1999) and 17p (p53) (Baker et al., 1989). These 
locations are essential checkpoints in cellular senescence and the cell cycle. In HPV 
positive HNSCC, the only occasional chromosomal loss has been detected, with these 
features outlined above impaired or bypassed by HPV oncogene expression. However, 
in HPV-negative HNSCC, gross deletions of whole or large parts of chromosomal arms 
are an early essential process for tumour formation (Braakhuis et al., 2004). Based on 
this understanding, oral dysplastic lesions and OSCC have been categorised according 
to their genome stability, related to the number of copy gene alterations, including loss 
of heterozygosity TP53 and CDKN2A. The genetically unstable subtype of OSCC (GU-
OSCC) is characterised by several genetic mutations and senescent status (Loughran 
et al., 1997; Weber et al., 1998; Pickering et al., 2014), while genetically stable OSCC 
(GS-OSCC) has fewer genetic alterations/mutations and retains wild type p53 (Agrawal 
et al., 2011; Stransky et al., 2011; Pickering et al., 2014). HR-HPV-associated SCC is 
considered a genetically stable tumour, harbouring less genetic mutation and loss of 
heterozygosity on chromosome 3p and retaining active p53 and pRb pathways 
(Braakhuis et al., 2004; Parkinson, James and Prime, 2016).  
It is believed that the genetic stability status exerts remarkable impacts on the evolving 
microenvironment. Signalling pathways via Ras, p53, p21, and p16 generates a high 
level of Reactive Oxygen Species (ROS), which are considered potentially critical factors 
for the induction and maintenance of cellular senescence (Lawless et al., 2012). CAF 
senescence is a characteristic early event in GU-OSCC which is thought to be a 
consequence of the exposure to tumour-derived ROS, besides the effects of chemicals 
toxins in tobacco cigarettes (Coppé et al., 2008; Salem, Sotgia and Lisanti, 2013; 
Hassona et al., 2014).  
In distinction, GS-OSCC demonstrates an intact senescence programme owing to 
relatively low levels of ROS production (Parkinson, James and Prime, 2016), additionally, 
to the low production of the inflammatory-mediator (IL-1β) within tumour-derived 
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secretome. IL-1 is a master regulator in senescence, allowing spread from cell to cell in 
TME via a paracrine pathway (Costea et al., 2013). It is considered the key to 
establishing an inflammatory TME (Wu et al., 2016). In published work from our 
lab, HPV-negative OPSCC cell lines (SCC89 and SCC72) expressed a remarkable level 
of IL-1β production which, in turn, promoted significant upregulation of a broad spectrum 
of CXC, CX3CL and CCL chemokines from NTF6, while that was not evident in HPV-
positive OPC cells (SCC90 and SCC2) (Al-Sahaf et al., 2019). This work was in 
agreement with our array findings to some extent. It provided a further explanation of the 
M1 differences between OPSCC subtypes. 
The senescent status of CAFs in CAFs-derived from GU-OSCC and GS-OSCC was 
evaluated by a limited number of studies (Lim et al., 2011; Hassona et al., 2013, 2014). 
They reported a higher percentage of SA-b-gal positivity, besides an upregulation in pro-
inflammatory proteins by fibroblasts from GU-OSCC compared to GS-OSCC CAFs. 
Functional analysis of the secretome derived from GU-OSCC-CAFs revealed pro-
tumorigenic roles promoting keratinocyte invasion in vitro (Krtolica et al., 2001; Pazolli et 
al., 2009; Hassona et al., 2013). In our lab, the concept of genetic stability in OSCC has 
been evaluated in OPSCC based on OPSCC subtypes aetiology. Normal fibroblasts 
were incubated for 13 days fed by HPV-negative cell lines media (SCC89 and SCC72) 
or HPV-positive cell lines media (SCC90 and SCC2). Fibroblasts showed senescence 
features by significantly upregulating SA-β-gal percentage with HPV-negative cell lines, 
while only a few scant traces of SA-β-gal were observed with HPV-positive cell lines.  
To sum up, OPSCC demonstrated two distinct genetic profiles based on HPV-status. 
These differences are also reflected in the underlying TME activation that was evident in 
the transitory early response seen in the difference in M1 cytokines production when 
comparing SCC89 and SCC2.  
 
5.5.3 Pro-inflammatory signature of activated OPSCC 
fibroblasts (M2) 
After 24h of cell line media incubation, fibroblasts were incubated for a further 24h with 
serum-free media to observe the acquired (late) alternation in fibroblast phenotype and 
secretome. Omitting serum from the growth media provides consistent reproducible 
results and avoids contamination by other interfering factors which may be present within 
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the exogenous serum. M2 contained fewer cytokines compared to M1. It represents the 
fibroblast's initial response to OPSCC cell lines stimulation and that might explain the 
differences in M2 between SCC89 and SCC2 stimulated fibroblasts. Fibroblasts that had 
been incubated with SCC89 cell line media released a relatively larger number of 
cytokines including IL-6 and IL-8 which were completely absent in SCC2-related 
fibroblast M2. IL-6 and IL-8 are closely collaborating pro-inflammatory chemokines. Both 
factors participate in the control of essential hallmarks of tumour development and 
progression, including migration, proliferation, survival, senescence, and differentiation 
(Jayatilaka et al., 2017; Njainday et al., 2018). Although we observed their upregulation 
in response to SCC89 specifically, other reports consider IL6 overexpression is a non-
specific cellular mechanism that occurs as a part of the adaption process into altered or 
new environmental conditions (Son et al., 2015; Kim et al., 2018). 
The heterogeneity in fibroblasts was evident in culture reaction with OPSCC cell line 
media. Although both CAF1 and CAF2 are derived from the same OPSCC subtype and 
exhibited a comparable basal secretome, stimulated CAF1 showed higher numbers of 
cytokines in response to SCC89 and SCC2 cell lines. This observation might be ascribed 
to the senescent status of CAF1 culture and its high producible capability in SASP 
release. According to our finding in chapter 4, CAF1 showed a non-myofibroblastic CAF 
like feature which is more known for the highly productive inflammatory profile than the 
myofibroblastic counterpart. 
We did not detect an established active secretome in CAFs at a basal level.  Similar 
observations were also reported in the Erez et al. (2009) study, where CAFs derived 
from mouse cervical tumours (HPV16 transgenic mouse model) did not express the 
inflammatory gene signature compared to CAFs from mammary adenocarcinomas in a 
similar model. This observation might be attributed to the origin of the included CAFs, 
since both CAF1 and CAF2 were extracted from HPV-positive OPSCC, which, it is 
surmised, carries fewer genetic mutations background and less ability to stimulate 
normal fibroblasts as we discussed above. Moreover, the anatomical position also was 
proposed as a reason behind genome-wide heterogeneity in 47 normal fibroblasts strains 
across the human body. Tissue-specific expressions exhibited consistent and distinct 
gene expression profiles depending on their anatomical positional (Rinn et al., 2006). 
Furthermore, an evident desmoplastic stroma response was identified in specific types 
of tumours including mammary and pancreatic ductal adenocarcinoma (Erez et al., 
2009). However, further investigations are required, associated with the presence of 
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CAFs derived from HPV-negative OPSCC, for molecular comparisons and better 
understanding. 
NTF322 demonstrated an active reaction in response to SCC89 cell lines media that was 
comparable to the CAF1 and CAF2, however, NTF322 did not show cytokines 
upregulation upon SCC2 cell line incubation (M2). This observation is in keeping with the 
finding by Bolt et al. (2018) using NOFs. The upregulated NTF322 secretory profile 
following SCC89 incubation indicated acquisition of CAF phenotype to some extent. 
CXCL1 was reported by Kim et al. (2018) as a key regulator in NOF activation via an 
autocrine pathway. In their study, 3 NOFs cultures were co-cultured with the OSCC cell 
line (YD-10B) at different time points. NOFs showed transformation into a senescent 
CAFs-like phenotype by demonstrating a significant SA-β-gal positivity at 48h (p<0.05). 
This alternation in NOF phenotype was associated with significant upregulation of 
CXCL1 in co-cultured NOFs, rather than in NOFs in monoculture. Incubation of NOFs 
with a CXCL1-neutralising antibody revealed a significant decrease in SA-β-gal 
percentage (p<0.05). In our lab, CXCL1 was overexpressed in activated NTF6 following 
HPV-negative cell lines media incubation (SCC89 and SCC72) compared to NTF6 in 
monoculture. Interestingly, HPV-positive cell lines (SCC90 and SCC2) failed to induce 
CXCL1 expression in co-cultured NTF6 (Al-Sahaf et al., 2019). From the above, NTF322 
demonstrated a CAF-like secretome in reaction to SCC89 cell line media, but not to 
SCC2. Further investigations are required to understand the underlying signalling 
pathways in NTFs activation.  
 
5.5.4 Candidates in interactive co-culture models 
The indirect interactive model was established to validate the cytokines array findings in 
M1 and M2. Although the co-culturing conditions were different from conditioned media 
co-culture models in terms of incubation time and the active nature of communication 
between cells, it provided consistent validated results and additional insight into the cell 
origin of the particular cytokines. ELISA analysis showed a significant upregulation in 
OPN and IL-6 in the SCC89 interactive models exclusively, these findings consistent with 
M1 and M2 observations. Direct comparisons between OPN and IL6 levels in mono-
cultures and co-cultures were not valid due to the difference in cell population number 
that was implicated in cytokines production. OPN has been reported to be produced from 
different sources in the TME including senescent CAFs and tumour cells. Alternatively, 
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we utilised the extracted mRNA from the co-cultured cells to explore the source of 
production. OPN qRT-PCR analysis revealed that co-cultured SCC89 was the main 
source of OPN in SCC89 co-culture models. On the other hand, IL6 mRNA qRT-PCR 
analysis revealed that activated fibroblasts were the main source of IL-6 production in 
SCC89 co-culture models and its overexpression was driven by SCC89 incubation. 
Mono-culture fibroblasts showed a significantly low level of IL-6. These results were 
consistent with the Qin et al. (2018) observations. Qin and team showed that CAF-
derived IL-6-mediated expression of OPN. They studied the effect of αvβ3 blockade (an 
integrin, and an OPN receptor) on IL-6 production. Functional analysis of IL-6 and OPN 
in OPSCC will be discussed in detail in Chapter 7.  
Quantifications of the transcriptome and secretome response of OPSCC fibroblasts upon 
the interactive model also revealed heterogeneity between co-cultured fibroblasts 
(CAF1, CAF2, NTF322 and NTF10). NTF322 and CAF2 responses to the co-culture 
models demonstrated a comparable pattern, which was different from CAF1. CAF1 
showed unrelated patterns in protein and mRNA expressions in the interactive model, 
where OPN and IL-6 ELISA analysis demonstrated the highest expression with SCC89-
CAF1 co-culture; conversely, qRT-PCR analysis presented the lowest values. This 
discrepancy between protein/gene expression might be related to the phenotypic status 
of CAF1. According to the characterisation work in chapter 4, CAF1 exhibited a 
senescent phenotype feature by displaying a high percentage of SA-𝛽-gal positivity. The 
senescent condition was reported with an influence on a post-transcriptional modification 
which might lead to inconsistency in protein/gene levels of expression (Lai et al., 2019).  
 
5.6 Limitations 
It is worth mentioning that the indirect co-culture models used (passive co-culture and 
interactive coculture) are still rather simple and are likely not completely representative 
of cell interactions. True physical contact between the two populations in presence of 
signals from other cell types in the tumour microenvironment may reveal different or 
additional findings.  
 
The multiplex cytokines array was conducted for only one repeat, due to the kit’s high 
expense, nevertheless, analysis of a single repeat mandated the use of 
another technique to validate the results, as we have done. Cytokine array demonstrated 
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high-quality results. All the membranes’ backgrounds were clear from contamination and 
produced a consistent densitometry reading throughout the whole membrane. It 
exhibited reproducible results, as became obvious through monitoring the expression 
and intensity of basal secretory profile for each culture, also by comparing the 
densitometry reading for the duplicate repeat spots within a single array membrane.  As 
a technical limitation, a multiplex array presents a semi-quantitative result that is 
recommended to be followed by ELISA for target quantification as we have done. We 
further acknowledge the fact that our observations are built on a limited number of 
OPSCC cell lines. Moreover, CAF cultures were both HPV positive tumour derived. Use 
of the CAFs from an HPV-negative tumour will be essential for better understanding and 
comparison.  
 
5.7 Summary of the main findings and clinical implications  
In this chapter, we reported for the first time a number of cytokines secreted particularly 
with HPV-negative OPSCC cell line, namely OPN, KLK6 and GM-CSF, in addition to 
other cytokines produced under all conditions.  
 
Molecular analysis of interactive co-culture models identified the source of OPN and IL6 
production. At the basal level, more OPN was produced by HPV-negative cell lines than 
HPV-positive cell lines. Upon 48h of interactive co-culturing, only HPV-negative cell lines 
demonstrated significantly higher levels IL-6 overexpression indicated active crosstalk 
between cancer cells and fibroblasts  
These findings underpin the need for a better understanding of the role of TME in 
OPSCC development and progression. Further investigations of OPN and IL6 crosstalk 
might introduce promising prognostic and diagnostic indicators as well as potential 





Chapter 6: Functional analysis of candidates identified by 





















6.1. Introduction  
In the study cohort, we observed that CAFs are a common feature of the stroma in 
OPSCC, regardless of HPV status, however, it provided a potential clinical significance 
in the HPV-positive group. Despite the compelling evidence for a tumour-supportive role 
of CAFs, the detailed molecular mechanisms behind CAFs transition in OPSCC are 
largely unclear. Cytokine array profiling identified OPN as a factor expressed in one of 
the OPSCC cell lines which corresponded to an elevation of IL-6 production in fibroblasts 
in co-cultured models. These findings suggest crosstalk between OPSCC cancer cells 
and fibroblasts may be mediated by OPN and IL-6. OPN is highly expressed in healing 
wounds and fibrotic lesions in addition to its involvement in myofibroblast differentiation 
(Lenga et al., 2008). However, few reports have evaluated its role in CAF functionality.  
The involvement of tumour-derived OPN in CAF phenotype development was described 
in breast tumour, where OPN has been shown as a sufficient factor in fibroblasts 
activation (Sharon et al., 2015, Prasanna et al., 2021). In HNSCC, CAF-derived IL-6 was 
identified as the major upstream molecule that triggers the induction of tumour-derived 
OPN which enhances tumour cell growth, migration, and invasion (Qin et al., 2018). In 
addition to its secretion by tumour cells, OPN was expressed by the senescent CAFs, 
that mediated signalling events impacting neoplastic progression in preneoplastic 



















Figure 6.1: Conceptual model of cancer cell and fibroblast crosstalk mediated by OPN and 
IL-6. As it has been described in different human tumours, OPN and IL-6 showed functional 
effects on cancer cells and fibroblast. (A), CAF-derived IL-6 has been shown as major inducers 
for tumour-derived OPN that enhance tumour cell proliferation and invasion in vitro. (B), 
senescent dermal fibroblasts have been described as a promoter for pre-neoplastic cells 
transformation using immortalized keratinocytes cell line (HaCaT). (C), In breast tumour, tumour-
derived OPN was introduced as a crucial factor for normal fibroblasts reprogramming into 
myofibroblastic CAFs phenotype. 
 
In this chapter, we aimed to identify the role of OPN and IL6 as novel mediators of 
interactions between CAFs and OPSCC tumour cells. We sought to explore the 
functional effect of OPN on fibroblast differentiation based on our observation in 
fibroblast phenotypic characterisation in chapter 4. Moreover, we aimed to identify if OPN 
induces IL-6 production in fibroblasts.  We also aimed to test if IL-6 is sufficient for 
tumour-derived OPN production.  
In addition to its impact on TME components, OPN also has a well-established role in 
tumour behaviour in terms of promoting migration and invasion of the tumour cells. Here, 
we planned to explore the downstream pathways of OPN interaction with OPSCC cell 
lines, to establish a molecular understanding of OPN mechanism in OPSCC modulation.  
However, due to time restrictions affected by pandemic national lockdown, parts of this 





● To investigate the effects of OPN on OPSCC fibroblast phenotype. 
 
● To assess if OPN directly stimulates IL-6 production in OPN-induced fibroblasts 
by targeting CD44v6, one of OPN receptors.  
 
● To investigate CD44-dependent MAPK activation in OPSCC cancer cells 
mediated by OPN. 
 
● To identify if tumour-derived OPN production in OPSCC cells is driven by IL-6. 
 
6.3. Experimental approach and statistical analysis  
● OPSCC fibroblasts were treated with recombinant OPN (rOPN), followed by the 
assessment of resultant phenotype; the contraction ability of OPN-induced 
fibroblasts was assessed using collagen contraction gel. Senescent status was 
assessed using the SA-β-gal assay. 
 
● The effect of OPN on IL-6 production was assessed in rOPN-induced fibroblasts 
using IL-6 qRT-PCR and ELISA analysis. The effect of CD44V6 blocking antibody 
was evaluated by monitoring IL-6 production upon rOPN-induction. Next, to test 
if OPN was responsible for IL-6 production, OPSCC fibroblasts were incubated 
with OPSCC conditioned media after 1 hr of CD44v6 blocking. However, due to 
time restrictions, only NTF322 was assessed in this experiment.  
 
● OPSCC cancer cells were treated with rOPN, and CD44 expression was 
assessed using immunofluorescence staining and western blot. Alterations in 
p38 MAPK phosphorylation were assessed using western blot.  
 
● The effect of IL6 on tumour-derived OPN production was tested by incubating 
OPSCC cell lines with recombinant IL6 (rIL-6). OPN qRT-PCR and ELISA 




● Statistically, detection of non-normality is less likely among the data due to small 
sample numbers, however, Shapiro-Wilk test was used to check the normality 
due to its high sensitivity. For the comparison between two normally distributed 
samples’ mean, two-tailed unpaired t-test was used. In multiple data sets, one-
way analysis of variance (ANOVA) was used. 
 
● Data were presented graphically illustrating the mean with error bars 
demonstrating the standard deviation (SD). The probability of similar random 
result detection (p-value) was considered significant if (p<0.05). “N” followed by 
a number denotes the biological repeats, while “n” denotes the technical repeats. 
























6.4. Results  
6.4.1 OPN induces alteration in NTFs morphology 
Under the light microscope, NTF322 and NTF10 displayed alterations in cell morphology 
following 48h incubation with a single dose of 180 ng/ml of rOPN. This dose was 
determined thoroughly in an optimising study reported by Weber et al., (2015). Moreover, 
the 180ng/ml dose has worked well in other studies (Driver et al., 2015; Che et al., 2018). 
NTF322 showed darker cytoplasm and a larger cell body. NTF10 appeared more 




Figure 6.2: Alterations in NTFs morphology following rOPN induction. NTF322 and NTF10 
were incubated with 180ng/ml of rOPN for 48h. Under the light microscope, both cultures 
displayed morphological changes. Images were taken with an Olympus BX51 optical microscope 





6.4.2 OPN potentially enhances the contraction in OPSCC 
fibroblasts. 
The collagen gel contraction assay was performed to assess the contractility of OPSCC 
fibroblasts. According to our observations in chapter 4, an active myofibroblastic like CAF 
showed a significant contractile ability compared to the control. An in vitro three-
dimensional contraction model of NTF322, NTF10 and CAF2 were constructed as 
described in section 2.1.10. Cells were incubated under mechanical tension conditions 
by leaving the lattices attached to the culture well. After 48h, the collagen lattice was 
completely detached with a sterile spatula and incubated for a further 48h with the 
addition (or absence) of 180 ng/ml OPN. At the end of the experiment, NTFs contractility 
was recorded by measuring the distance between the lattice disc and the well using Fiji-
ImageJ (Figure 6.3).  
Untreated cells showed different capacity in gel contraction. The CAF2 lattice disc was 
the smallest, followed by NTF10 then NTF322 (p<0.001). OPN enhanced the contraction 
ability of OPSCC fibroblasts to some extent compared to their untreated. CAF2 showed 
a significant decrease in lattice disc size (4.6 ± 0.1mm) compared by the control (3.2 ± 
0.2mm) (p<0.001). NTF10 demonstrated a degree of gel contraction of 1.8 ± 0.6mm 
(p<0.05). However, NTF322 showed a negligible amount of contraction (0.13 + 0.1) 
(mean + SD) compared to the control that showed 0 contraction (p=0.05). However, 
compared to the myofibroblastic model in chapter 4, this is considered a slight increase 
in the acquired mechanical properties in NTFs following OPN induction (please refer to 
figure 4.3 for the comparison).  
Notably, untreated CAF2 showed high capability for collagen disc contraction, which 
suggested an active myofibroblastic phenotype. This observation is in agreement with 












Figure 6.3: Matrix contraction ability of stimulated NTFs varies between different cultures. 
(A) Image of detached lattices for NTF322, NTF10 and CAF2 floating in the growth media. (B) 
Image of the gel disc for NTF322, NTF10 and CAF2.  NTF322, NTF10, and CAF2 (2 x 104 cells) 
were seeded in 0.5 ml of collagen lattice solution in a 24-well plate and left in the incubator for an 
hour at 37ºC. 1.0 ml of growth media was added on the top of the collagen gel lattice and the 
plate was incubated for 24h. The next day, the cells were serum-starved for a further 24h, then 
were treated with 180 ng/ml OPN before releasing the stressed gel matrix from the plate using a 
sterile spatula.  The gels were then incubated for 48h in the OPN stimulation experiment. OPN 






Figure 6.3 C: Matrix contraction ability of stimulated NTFs varies between different 
cultures. Quantification of gel disc contraction used ImageJ.  Relative lattice contraction (mm) 
was obtained by measuring the distance between the gel and the well border. Statistical analysis 
was performed using Student’s t-test to compare between the treated culture and its counterparts. 
One-way ANOVA was used to compare the difference between the untreated cultures or treated 
cultures. Statistical significance is shown on the figure by *p<0.05, ***p<0.001. Data represent 











6.4.3 Senescence assessment in rOPN-treated fibroblasts 
In a characterisation process for the evolving OPN-induced fibroblast phenotype, SA-β-
gal assay was performed to evaluate the senescence status of OPSCC fibroblasts 
following OPN induction. Senescence analysis was performed for NTFs 322 and NTF10 
only (Figure 6.4). No evident increase in SA-β-gal positivity percentage was detected in 







Figure 6.4: Senescence status in OPN-induced NTFs. (A) Images representing SA-β-gal stain 
at basal level and after OPN treatment in NTF322 and NTF10. Images were taken with an 
Olympus BX51 optical microscope at 10X magnifications. (B) Quantification of SA-β-gal stain. 
The proportion of stained cells (blue precipitate) in 3 random fields at magnification 20x. Statistical 










6.4.4 OPN induces a slight increase in IL-6 production in OPSCC 
fibroblasts  
Next, we assessed the level of IL-6 production to identify mediators of the phenotypic 
change, but also to test the hypothesis of a reciprocal tumour-stroma loop in OPSCC 
mediated by OPN and IL-6 (Qin et al., 2018). Alteration in IL-6 production was assessed 
at the transcript and secretory levels. NTF10 and CAF2 showed a slight increase in IL-6 
transcript following rOPN treatment, however, statistically, it revealed a significant 
difference (p<0.05 and p<0.01). NTF322 showed a minimum upregulation in IL-6 mRNA 
expression with no statistically significant value. The fold change compared to β2m was 
(0.08 ± 0.00) (mean ± SD) (Figure 6.5). This marginal increase in IL-6 production upon 
rOPN induction may indicate an alteration in OPSCC fibroblast phenotypes, however, 
further validation includes the assessment of ɑ-SMA and FAP expressions is required to 









Figure 6.5: IL-6 upregulation following rOPN treatment. OPSCC Fibroblasts were cultured in 
T75 cm2 flasks in growth media up to 70% confluency then treated with 180ng/ml rOPN for 48h. 
The cell pellet was collected, and cDNA was constructed using 120 ng/ml of total RNA. qRT-PCR 
was used to analyse IL-6 expression, normalised to β2m. NTF10 and CAF2 expressed slightly 
increased IL-6 transcript levels compared to the untreated counterparts (p<0.01). Statistical 
analysis was performed using Student’s t-test, and statistical significance is shown on the figure 





IL-6 ELISA analysis revealed an increase in IL-6 concentration in OPSCC fibroblasts 
media following rOPN treatment. NTF10 showed relatively high increases compared to 
the control and other included fibroblasts cultures (137 ± 3.72 pg/ml; p<0.001). NTF322 
showed a slight increase in IL-6 production that was statistically significant (12.5 ± 2.1 
pg/ml; p<0.05). CAF2 showed a marginal increase that was comparable to the untreated 
counterpart (p>0.05) (Figure 6.6). 
 
 
Figure 6.6: Increase in IL6 production in NTFs following OPN treatment. NTF322, NTF10 
and CAF2 were treated with a single dose of 180ng/ml OPN for 48h. The media was collected 
and subjected to IL6 ELISA analysis. Untreated cells were included for the comparison. All treated 
NTFs showed an increase in IL6 production. Samples number (n=6), Y-axis denotes standardised 
IL-6 concentration in pg/ml. IL-6 concentrations were optimised according to fibroblasts density 
at 10,000 cells. Statistical analysis was performed using Student’s t-test, and statistical 
significance is shown on the figure by **p<0.01, ***p<0.001. Data represent the mean of (N=3, 





6.4.5 Targeting of CD44v6 potentially reduces IL-6 production in 
rOPN stimulated fibroblasts  
At the cellular level, OPN has two cell surface binding sites; the N-terminal region of OPN 
binds to integrins, whereas C-terminal region interacts with CD44 (Weber et al., 1996; 
Rangaswami, Bulbule and Kundu, 2006). CD44 is a family of plasma membrane 
glycoproteins encoded by a single gene on chromosome 11. It is composed of at least 
20 exons, 10 of them are expressed simultaneously giving the standard form CD44s, 
while the rest are variant exons that are subjected to alternative splicing, generating 
many isoforms (Screaton et al., 1992). CD44 variants have been found to be associated 
with advanced H&N cancer: CD44v6 is an oncogenic variant that is strongly expressed 
by more than 95% of HNSCC (Heider et al., 2004). Its expression is largely restricted to 
advanced-stage of tumours and is more associated with metastatic cancers (Rail and 
Rustgi, 1995). In the Sharon et al., (2015) study, the ability of secreted OPN to activate 
mammary fibroblasts relied upon the receptors CD44 and αVβ3 integrin, moreover, 
targeting OPN binding sites using blocking antibodies inhibited fibroblast activation in 
vitro and remarkably attenuated tumour growth and fibroblast activation in vivo. 
In OPSCC, we tested the effect of blocking CD44v6 on IL-6 production, cells were 
incubated with 5µg/ml of CD44var (v6) monoclonal antibody (VFF-18) (eBioscience™, 
UK). It has a blocking property (inhibiting antibody) by prohibiting further molecular 
binding without reacting with the ligand-binding site. It has been used in Phase I clinical 
trial targeting immunoconjugate bivatuzumab mertansine in HNSCC (Riechelmann et al., 
2008). Also, has been shown to work effectively in vitro in many reports at the same 
concentration (5µg/ml). (Afify, Purnell and Nguyen, 2009; Gutjahr et al., 2018; Khan et 
al., 2021). 
Incubation of NTF10 with CD44v6 blocking antibody for 1 h before rOPN induction 
revealed a significant reduction in the IL-6 mRNA fold change (p<0.05). This effect was 
less evident with NTF322. However, the latter has low baseline IL-6 transcripts and 
showed a slight, but insignificant, elevation in IL-6 following rOPN induction. Blocking 
with CD44v6 antibody resulted in a marginal decrease in IL-6 in rOPN-induced NTF322 
(p>0.05) (Figure 6.7). Quantification of secreted IL-6 demonstrated a clearer difference 
between the NTFs’ cultures. rOPN-treated NTF10 showed a significant reduction in IL-6 
release following CD44v6 blocking (137.0 ± 3.7 to 60.8 ± 15.3; p<0.05), while rOPN-





Figure 6.7: Variable reduction in IL-6 expression following CD44v6 blocking in rOPN 
treated fibroblasts. NTF322 and NTF10 were grown up to 70% confluence in T75 flasks. Cells 
were cultured with 5µl/ml of anti-CD44v6 AB for 1 h, followed by incubation with 180 ng/ml of 
rOPN for 24 h. Untreated counterparts were incubated with serum-free media only without 
blocking antibody. Cells were collected, and RNA extracted. cDNA was constructed using 400ng 
of total RNA. qRT-PCR was used to assess IL-6 transcript expression normalised to β2m. Only 
NTF10 showed a response to rOPN induction and CD44v6 antibody blocking (p<0.05) and 








Figure 6.8: Variation in IL-6 protein secretion following CD44v6 blocking in rOPN treated 
NTFs.  NTF 322 and NTF 10 were cultured up to 70% confluence in T75 flask. Cells were 
incubated with 5 µl/ml of anti-CD44v6 AB for 1 h, followed by incubation with 180 ng/ml of rOPN 
for 24 h. Untreated counterparts were incubated with serum-free media only without blocking 
antibody. The media was collected and subjected to IL6 ELISA analysis. Untreated cells were 
included as a negative control.  Y-axis denotes standardised IL-6 concentration in pg/ml. IL-6 
concentrations were optimised according to a fibroblast density of 10,000 cells. Statistical analysis 
was performed using Student’s t-test, and statistical significance is shown on the figure by 
*p<0.05. **p<0.01 and p<0.001. Error bars = SD for (N=3, n=3). 
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6.4.6 Targeting CD44v6 potentially reduces IL-6 production in 
NTF322 following OPSCC CM stimulation 
Following evaluating CD44v6 antibody efficiency on IL-6 reduction in NTFs. We tested 
our hypothesis that OPN is necessary for inducing IL-6 in NTFs. However, due to the 
time and lab restriction upon the epidemic, only NTF322 was tested in the CD44v6 
blocking experiment. Although NTF10 was more responsive than NTF322 on rOPN 
treatment, we assumed that might reflect clearly on the CD44v6 blocking step. 
NTF322 culture was incubated with anti-CD44v6 antibody for 1h before incubation with 
OPSCC cell line conditioned media (CM) for 24 h. SCC2, SCC89 and SCC72 CM were 
prepared as described in section 2.1.1. Untreated cells were incubated with serum-free 
media before cell line media stimulation. At the end of the experiment, cells and media 
were collected for IL-6 analysis. 
OPSCC cell lines conditioned media induced high variable concentrations of IL-6 from 
NTF322 at the transcript and secretory levels. SCC89 and SCC72 CM promoted NTF322 
to overexpress IL-6 transcript at a higher fold change than in SCC2 (p<0.01 one-way 
ANOVA) (Figure 6.9). ELISA analysis also showed the same pattern in NTF322 
response to different OPSCC cell line CM stimulation (p<0.01). NTF322 responded to 
cell lines CM incubation by a high upregulation in IL-6 production levels (Figure 6.10).   
CD44v6 blocking also revealed different effects on IL-6 reduction in NTF322 culture-
stimulated with OPSCC cell lines CM. NTF322 induced with SCC2 CM showed a 
reduction in IL-6 transcript fold from (0.009 ± 0.01 to 0.003 ± 0.004 fold) compared to 
β2m. This reduction was accompanied by a decrease in IL-6 release on ELISA analysis 
(155.8 ±118 to 93.6 ± 71.8 pg/ml). However, that was not a statistically significant 
difference (p>0.05).  
The CD44v6 antibody blocking effect was evident the most with SCC89-CM-induced 
NTF322 cells. It was able to significantly reduce the IL-6 upregulation at the gene and 
protein level (p<0.05).  On contrary, CD44v6 antibody failed to show a blocking effect in 




















Figure 6.9: Variable reduction in IL-6 expression following CD44v6 blocking in cell lines 
treated fibroblasts. NTF322 and NTF10 were grown up to 70% confluence in T75 flasks. Cells 
were cultured with 5 µl/ml of anti-CD44v6 AB for 1h, followed by incubation with SCC2, SCC89 
or SCC72 CM for 24h. Untreated counterparts were incubated with serum-free media only without 
blocking antibody. Cells were collected, and RNA extracted. cDNA was constructed using 120 ng 
of total RNA. qRT-PCR was used to assess IL-6 transcript expression normalised to β2m. Anti-
CD44v6 AB showed a blocking effect in NTFSCC89-CM-treated NTF322 (p<0.05) using 






Figure 6.10: Variation in IL-6 protein secretion following CD44v6 blocking in cell line 
treated NTFs.  NTF 322 and NTF 10 were cultured up to 70% confluence in T75 flasks. Cells 
were incubated with 5 µl/ml of anti-CD44v6 AB for 1h, followed by incubation with SCC2, SCC89 
or SCC72 CM for 24h. Untreated counterparts were incubated with serum-free media only without 
blocking antibody. The media was collected and subjected to IL6 ELISA analysis.  Y-axis denotes 
standardised IL-6 concentration in pg/ml. IL-6 concentrations were optimised according to a 
fibroblast density of 10,000 cells. Statistical analysis was performed using Student’s t-test, and 




6.4.7 OPN effects on OPSCCs 
In the previous sections, we investigated the functional effects of OPN on OPSCC 
fibroblasts and observed that OPN was sufficient to establish a myofibroblastic CAF-like 
phenotype in a subset of NTFs. Here, we aimed to identify the effects of OPN production 
on OPSCC cancer cells by exploring the activated downstream pathways mediated by 
OPN binding. We assessed the activation of CD44 and p38 MAPK pathway upon rOPN 
induction. Mitogen-activated protein kinase (MAPKs) are known to be involved in the 
regulation of OPN mediated signalling via CD44 and integrins, in different tumour types. 
p38 is a member of the MAPK family reported to be involved in the regulation of many 
cellular functions, including cell stress response, proliferation, differentiation and cell 
migration, among other molecules (Shinohara et al., 2008; Chen et al., 2009). It 
contributes to the epithelial-mesenchymal transition of the tumour cells which in turn 
facilitates the acquisition of invasion and migration capabilities (Bhowmick et al., 
2001). Activation of the p38 MAPK signalling cascade is triggered by many 
environmental stresses and inflammatory cytokines including OPN (New and Han, 
1998). . In OPSCC, the relevance of the p38 MAPK pathway in the context of tumour 
formation has yet to be investigated.  
Cytokine profiling of OPSCC cell lines revealed an exclusive expression of OPN in the 
HPV-negative OPSCC cell line (SCC89). In this experiment, SCC72 was included for 
further validation, whereas SCC2 (HPV-positive) was included for comparison as a 
negative control. MCF7 (Breast cancer cell line) was included as a positive control 
(Hiscox et al., 2012). The MCF7 cell line was provided kindly by Dr Simon Whawell. Cells 
were incubated with 180ng/ml rOPN for 48h, then CD44 expression was assessed using 
immunofluorescent staining using unconjugated CD44 antibody (Proteintech. UK) and 
by detection of protein abundance using western blot.  
At the basal level, immunofluorescent staining showed a remarkable difference in CD44 
expression. SCC89 and SCC72 cells showed a faint expression of cell surface CD44 
expression, while that was completely lacking in SCC2 (Figure 6.11). Upon rOPN 
induction, all the tested cancer cells, including SCC2, showed a characteristic glowing 





This pattern of expression was not observed exactly in the CD44 antibody-blotted 
membrane. At the basal level, only MCF7, the positive control, showed a faint band of 
CD44 protein expression, while there were no detectable bands in HPV-negative 
OPSCC lanes. Optimising the technical protocol with a longer exposure time might reveal 
a consistent result. However, rOPN-induced SCC72 and SCC89 displayed evident 
variable CD44 protein abundance, while SCC2 showed a relatively weak band. However, 
the result of this blot is required validation by normalising with the internal control 














Figure 6.11: CD44 expression in OPSCC upon rOPN induction. (A) Representative 
photomicrographs demonstrating CD44 basal and induced expression in SCC72, SCC89 and 
SCC2 cells. MCF7 was included as a positive control. Cells were stimulated with 180ng/ml OPN 
for 48h then stained with anti CD44 antibody (1:200, 1567-1-AP, Proteintech, UK)). The slide was 
then mounted on a microscope coverslip using a DAPI-containing mounting medium. CD44 faint 
expression was observed in HPV-negative cell lines, but not in SCC2. Following OPN induction, 
an increase in CD44 expression was observed in all OPSCC cell lines. Fluorescent images were 
taken using a Zeiss 880 Airy-Scan confocal microscope (Carl Zeiss) at 40x magnification. (B) 
Quantification for detected CD44 by image quantification was performed using Fiji-ImageJ. The 
negative control for each cell line was processed and denoted by the black bar. Statistical analysis 
was performed using Student’s t-test, and statistical significance is shown on the figure by 
*p<0.05, **p<0.01. Error bars = SD for (N=2). 
 
Figure 6.12: Western blot analysis of CD44 in OPSCC following rOPN induction. SCC72, 
SCC89 and SCC2 were incubated with 180ng/ml rOPN for 48h. The experiment controls were 
incubated with serum-free media only. MCF7 was included as a positive control. Lysate protein 
(30 µg) of whole cell were subject CD44 antibody (Proteintech, UK).  
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6.4.8 IL-6 effect on tumour-derived OPN production in OPSCC 
To test the ability of IL-6 to induce OPN production in OPSCC cells, the OPSCC cell lines 
were incubated with rIL-6 (Peprotech, UK). A dose of 15ng/ml rIL-6 was chosen, as this 
has been shown to be sufficient for induction in previously reported optimising work on 
the tumour cells (Chen et al., 2018). Thp-1 monocytes were included as a positive control 
(Uchibori et al., 2017). Thp1 was provided kindly by Dr Emilia Barker. Alterations in OPN 
expression were assessed using OPN qRT-PCR and ELISA analysis. No significant 
changes in OPN level were detected following IL-6 treatment at the transcript or 
secretory levels, even in the positive control. (Figure 6.13 and 6.14). The experiment 
requires further optimisation including a dose response, as a change would have been 
expected in Thp-1. A higher dose of 50 ng/ml has been reported in HNSCC (Sun et al., 
2014), which would be worth a further trial.  
 
Figure 6.13: No detectable changes in tumour-derived OPN transcript in OPSCC 
following rIL-6 induction. OPSCC cell lines were cultured in a T75 cm2 flask in growth 
media up to 70% confluency then treated with 15ng/ml rIL-6 for 48h. Cell pellets were 
collected, and cDNA was constructed using 500 ng/ml of total RNA. qRT-PCR was used 
to analyse OPN expression, normalised to β2m. Thp-1 was included as a positive control. 




Figure 6.14: No detectable changes in tumour-derived OPN secretory level in OPSCC 
following rIL-6 induction. SCC89, SCC72 and SCC2 were treated with a single dose of 15ng/ml 
OPN for 48h. The media was collected and subjected to OPN ELISA analysis. Untreated cells 
were included for the comparison. Thp-1 was included as a positive control. No evident changes 
were observed at OPN level. Samples number (n=8), Y-axis denotes standardised OPN 
concentration in Pg per ml. OPN concentrations were optimised according to fibroblasts density 









6.5 Discussion  
In this chapter, we have investigated the effects of OPN on OPSCC fibroblasts. As it has 
been described, OPN has the ability to reprogram normal fibroblasts into a myofioblastic 
CAF phenotype (Sharon et al.,2015, Prasanna et al., 2021), however, our limited 
investigation in this chapter showed alteration in NTFs phenotype that warrant further 
investigation and validation. OPN-induced NTFs showed morphological changes 
besides enhancement in fibroblasts contractility to some extent, however, these were 
less marked TGF-ꞵ1- induced NTFs described in chapter 4, figure 4.3. We observed a 
marginal increase in IL-6 production following OPN treatment, but it is neglectable 
compared to the cell line CM effect on NTF322. However, in Sharon et al. (2015) work, 
IL-6 upregulation was not a feature in evolving CAFs phenotype among other 
proinflammatory factors. Targeting CD44v6 attenuated the production of IL-6 in rOPN-
induced NTF10. However, blocking of CD44v6 on NTF322 before OPSCC CM 
incubation revealed a variable degree of IL-6 reduction. Preliminary data based on 
immunofluorescence assay; OPSCC cancer cell lines demonstrated activation of CD44 
in response to OPN treatment that was more evident in HPV-negative cell lines.  
6.5.1 Osteopontin effects on NTFs  
Despite the compelling evidence supporting CAFs’ central role in facilitating tumour 
progression, very little is known regarding the mechanisms of normal resident fibroblast 
activation. Tumour and immune cell derived molecules have been proposed as factors 
in fibroblasts activation (Erez et al., 2009; Elkabets et al., 2011; Sahai et al., 2020). 
Nevertheless, the characterisation of signalling network mediating fibroblast activation is 
still largely unresolved. TGF-β1 has been identified as one of the most predominant 
regulators in fibroblast activation. It regulates several pro-fibrotic activities including 
fibroblast proliferation, and the fibroblast-to-myofibroblast differentiation (Lewis et al., 
2004; Hinz et al., 2012; Meng, Nikolic-Paterson and Lan, 2016, Melling et al., 2015). 
Tumour-derived inflammatory modulators including SDF1, IL-1 α and IL-1β were shown 
as a promoter in CAF activation. Other factors derived from different cell types also were 
proposed as candidates that could be involved in fibroblasts activation including PDGF, 
IL-4, and insulin-like growth factor II (Powell et al., 1999). 
The functional role of OPN in stroma activation was described firstly in cardiac and 
dermal fibroblasts as an essential component in the autocrine activation pathway 
mediated by TGF-β1. In cardiac and dermal OPN-null fibroblasts, cells showed a 
significant reduction in response to TGF-β1 stimulation; there was no overexpression of 
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the activation protein signature including α-SMA and fibronectin. Additionally, they 
exhibited 50% less proliferation and resistance to detachment by shear force, also they 
showed a 3-fold reduction in collagen gel contraction compared by wild-type fibroblasts. 
Furthermore, knockdown of OPN wide-type fibroblasts using small interfering RNA 
reduced α-SMA expression response to TGF-β1 to levels comparable with OPN-null 
cells (Lenga et al., 2008). The OPN pro-fibrotic effect has been studied intensively in 
wound healing and fibrosis-related diseases. OPN-null mice have altered wound healing 
processes with healing wounds containing smaller collagen fibrils and disorganised ECM 
(Liaw et al., 1998). Moreover, knockdown of the OPN gene revealed altered healing 
patterns and significantly reduced scarring (Mori, Shaw and Martin, 2008; Hunter et al., 
2012). In lung fibrosis, OPN has shown a critical role in airway remodelling. The 
functional role of OPN is largely based on pro-fibrogenic myofibroblast stimulation. It 
initiates the fibroblasts activation, migration, adhesion, and proliferation through a 
cytokine signalling pathway (Oh et al., 2015). 
The impact of OPN in CAF activation was reported by two breast cancer research studies 
(Sharon et al., 2015, Prasanna et al., 2021).  These studies demonstrated that OPN is 
required, and sufficient, to reprogram normal fibroblasts to myofibroblasts functionally 
and molecularly. Furthermore, CAF-driven OPN enhanced EMT and angiogenesis via 
SDF-1 expression. In this study, stimulation of NTFs using rOPN alone induced some 
phenotypic alterations, including the cell morphology, gene transcription and secretory 
profile. Under the light microscope, rOPN-induced NTFs displayed changes in cell 
morphology compared to the untreated cells which retain the spindle-shaped quiescent 
appearance. As has been discussed in chapter 4, alteration in fibroblast shape is a non-
specific feature in fibroblast phenotypic change. To specify the evolving induced 
phenotype, we performed collagen gel contraction assay and SA-β-gal assay. According 
to the characterisation work in chapter 4, the active myofibroblastic like phenotype 
displayed high capability in gel contraction, while premature induced senescent 
phenotype showed an elevated percentage of SA-β-gal-stained cells. In this chapter, 
rOPN-induced CAF2 and NTF10 showed a degree in the collagen disc contraction 
compared with the untreated fibroblasts, while NTF322 showed a neglectable amount of 
contraction. Assessment of SA-β-gal assay has shown no evident increase in SA-β-gal 
positive percentage in this chapter. 
This ability to shrink a free collagen lattice indicated the increase in fibroblast contractility 
and phenotype differentiation into myofibroblastic CAFs as we have observed in chapter 
4, however, we did observe that much increase in NTFs contractility moreover, we were 
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not able to assess and compare ɑ-SMA formation in this chapter to confirm the active 
transition in NTFs phenotype. In a similar experiment on dermal fibroblasts, Hunter et 
al., (2012) showed a significant increase in contractility, migration, and proliferation of 4 
different dermal fibroblasts cultures in response to rOPN induction (50nM). While 
knockdown of the OPN gene using an OPEN-directed RNA aptamer (OPN-R3) showed 
significant inhibition of OPN-induced effects on fibroblast cultures (Hunter et al., 2012). 
The exact mechanism behind fibroblasts activation is still unknown, but it implies an 
increase in α-SMA or other microfilaments that may be involved in cell contractility 
(Hunter et al., 2012).  
Prasanna et al., (2021) study assessed the molecular alteration in CAFs driven by 
tumour-derived OPN, the evolving CAFs phenotypes showed an overexpression in ɑ-
SMA and FAP at gene and protein levels. Their study reported the crosstalk between 
tumour cells and stromal fibroblasts that leads to tumour progression mediated by 
tumour-derived OPN and fibroblasts-derived CXCL12. Sharon et al., (2015) work in 
mammary fibroblasts demonstrated that tumour-derived OPN has the capability to 
induce normal mammary fibroblasts differentiation into a myofibroblastic CAF active 
phenotype. The evolving active phenotype showed a high capacity for gel contraction 
and upregulation in the pro-inflammatory secretory profile, but not including IL-6. Breast 
cancer is one of the desmoplastic tumour types in the human body. It is characterised 
by profound myofibroblast infiltration that correlates with tumour progression, invasion 
and poor survival (Yamashita et al., 2012).  
Next, we tested IL-6 upregulation in rOPN-induced fibroblasts to assess the phenotypic 
changes in OPSCC fibroblasts and investigate the hypothesis of the epithelial-stromal 
stimulatory loop in OPSCC mediated by OPN and IL-6 expression. We observed a slight 
increase in IL-6 upregulation at the transcript and secretory profiles, however, the 
heterogeneity of fibroblast responses was evident. NTF10 showed the highest increase 
in IL-6 expression, while NTF322 showed the lowest values of IL6 at the basal and 
induced level. In Qin et al., (2018) study, blocking one of the OPN receptors showed a 
partial decrease in the effects of OPN, while the combination of more than receptor 
blocker resulted in a significant effect. We observed a significant reduction in IL-6 




6.5.2 Targeting CD44v6 potentially reduces IL-6 production in 
NTF322 following OPSCC CM stimulation 
Incubation of NTF322 with HPV-negative cell line media (from SCC89 and SCC72) 
resulted in greater upregulation of IL-6 production in NTF322 cultures than in the HPV 
positive cell line (SCC2) counterparts. This in keeping with our findings in chapter 5 using 
co-culturing models. The HPV-negative co-cultured model showed a significant 
upregulation in IL-6 compared to the HPV-positive model. Here, in this chapter, we aimed 
to test whether the tumour derived OPN in cell line CM will induce an activated fibroblast 
phenotype. The appropriate methodology to answer this question required targeting of 
both OPN binding sites (CD44 and integrins), however, our work was limited to CD44v6 
blockade.  
Blocking of CD44v6 in NTF322 showed a variable degree of IL-6 reduction. In SCC89-
induced NTF322, there was a significant decrease in IL6 production with the presence 
of CD44v6 blocking antibody. SCC2-induced NTF322 cells showed a lower production 
in IL-6 at a transcript and secretory levels, but that did not reach the statistically 
significant limit (p<0.05). The partial reduction in IL-6 production was expected as we 
targeted only one ligand-binding site of OPN. The discrepancy in IL-6 reduction in 
CD44v6-targeted NTF322s suggested the variable capacity of OPSCC cell lines in 
fibroblasts activation. OPSCC cell line media contain a plethora of factors that might be 
involved in IL-6 upregulation besides OPN such as HGF (Bolt et al., 2018). Interestingly, 
SCC72-induced NTF322 showed no evident reduction in IL-6 production in response to 
CD44v6 antibody. This result reminded us of Bolt, (2016) findings on OPSCC cell lines 
using ORISTM Assay Cell Migration. In this experiment, the HPV-negative cell lines 
(SCC89 and SCC72), but not the HPV-positive cell lines, showed a significant migration 
in response to M2 (induced fibroblast media). However, only SCC72 showed a 
comparable significant migration when it was incubated M1 media (SCC72 CM and 
fibroblast media). The result suggested that HPV-negative cell lines were able to induce 
a fibroblast response capable of promoting additional void closure in the migration 
assays, nevertheless, the significance of the additional migration in SCC72 M1 may be 
linked to an inductive pathway unique to SCC72-fibroblast interactions (Bolt, 2016). 
6.5.3 Effects of OPN on OPSCC 
CD44 expression is regulated through specific signalling networks including epigenetic 
mechanisms, miRNAs and transcriptional factors (reviewed in Chen et al., 2018). 
Proinflammatory cytokines such as IL-1β, IL-6, IL-1, IL-4, IL-13, and TGF-β1 were also 
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reported as inducers that drive CD44 activity (Foster et al., 1998; Ibrahim et al., 2006). 
OPN/CD44 expression was shown to be correlated positively with cancer progression in 
different tumour types (Sun et al., 2013; Qiu et al., 2014). The OPN/CD44 interaction 
was reported to mediate signalling pathways that induce stem cell-like properties, tumour 
migration and radiation resistance (Desai, Rogers and Chellaiah, 2007; Pietras et al., 
2014).  
We have seen that the HPV-negative cell line (SCC89) showed a higher basal OPN 
secretion compared with the HPV-positive cell line (SCC2). Moreover, fibroblast co-
cultured SCC89s demonstrated significant upregulation in OPN when compared with 
SCC2s counterparts (Figure 5.20). Here, in our preliminary findings, we observed that 
OPN/CD44 association is more evident with HPV-negative cell lines compared to SCC2. 
This observation could be linked to the p53 degree of integrity in OPSCC subtypes. As 
HPV-negative tumour carries p53 mutations and HPV-positive counterpart displayed 
inactivation of p53 due to the expression of HPV E6 oncoprotein. Under normal condition, 
p53 inhibits the expression of CD44 via the interaction with a non-canonical p53-binding 
sequence in the CD44 promoter. This binding enables the non-malignant cells to respond 
to stress-induced p53-dependent cytostatic and pro-apoptotic signals. A lack of p53 
function has a de-repressing effect on CD44 expression which appears as an essential 
factor for tumour cell growth (Godar et al., 2008).  
Besides the involvement of CD44 signalling in tumour cells invasion and metastasis, 
typically, CD44 positive cells demonstrated stem-like properties with increased 
resistance to chemotherapy and radiotherapy in HNSCC (Chen et al., 2010; Wang and 
Bourguignon, 2011). These features suggest that CD44 may be useful as a prognostic 
biomarker (Lin and Ding, 2017; Wang et al., 2019). Indeed, higher CD44 expression in 
tissue was correlated with advanced stages and poor clinical outcome in HNSCC (Chen 
et al., 2014). In OPSCC, CD44 IHC expression showed a strong CD44 membrane 
staining in p16 negative OPSCC while p16 positive OPSCC showed none or light 
staining in membrane and cytoplasm (Cohen et al., 2017). Assessment of the prognostic 
value of CD44 IHC expression in HPV-DNA positive OPSCC revealed a superior 
advantage associated with disease-specific survival compared with p16 IHC expression 
that showed a correlation with overall survival only (Näsman et al., 2013).  
In this chapter, we also planned to investigate the change in p38 MAPK phosphorylation 
ratio in OPSCC in response to OPN incubation. The specificity of OPN activation 
cascade also requires further validation targeting OPN and CD44. The clinical 
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significance of p38 MAPK involvement in OPSCC tumours has yet to be investigated 
thoroughly. Activation of p38 MAPKs has been shown as a key factor in the production 
of many cytokines, such as IL-1, TNF-α, and IL-6, which have pro-inflammatory, and 
angiogenic effects (Kumar, Boehm and Lee, 2003). p38 MAPK was reported to support 
crucial functions facilitating tumour cell invasion. It induced the expression of the matrix 
metalloproteinases MMP1, MMP3, and MMP13, which in turn regulate matrix 
remodelling and degradation (Pourgholami and Morris, 2008), besides its active 
contribution in epithelial-mesenchymal transition that enhances invasion and migrating 
capabilities (Bhowmick et al., 2001; Neil A. Bhowmick et al., 2001; Huang et al., 2017). 
In cervical cancer cells, activation of p38 MAPK has been shown to be driven by 
OPN/CD44 expression, mediating NF-kB activation. The downstream activation 
subsequently resulted in NF-kB–dependent expression of furin, which enhanced the 
tumour growth in vivo (Kumar et al., 2010).  
6.6 Limitations  
We are aware that this chapter has not covered its stated aims. Our assessment on 
OPN-induced phenotype still requires further confirmation by doing ɑ-SMA and FAP 
expression assessment. Moreover, including a larger number of NTFs' cultures is crucial 
before drawing the conclusion.  
Targeting of OPN in this chapter was limited to CD44v6 receptor only. A combination of 
CD44 and integrins blocking is essential to assess thoroughly the effects of OPN on 
OPSCC fibroblasts. Furthermore, in this chapter, we were not able to analyse OPN 
signaling pathway mediated by CD44 and p38 MAPK.  
6.7 Summary of main findings and clinical implications 
To some extent, some findings in this chapter require further validation by future work, 
as they highlighted new areas for the research in OPSCC: 
We investigated for the first time the functional role of OPN on OPSCC fibroblasts and 
cancer cells. We observed alteration in a subtype of NTF. Moreover, targeting CD44v6 
showed a reduction in IL-6 derived on rOPN stimulation NTF10. Although our 
assessment underpins further investigations, it may provide new molecular insight into 
the understanding of CAFs development induced by OPN. Targeting the dynamic 
interaction between tumour cells and CAFs is a much-needed approach to cancer 
therapy. We have seen that targeting CD44v6 in NTF induced by OPSCC cell line CM 
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resulted in varying degrees of IL-6 reduction. Targeting integrins in addition to CD44v6 
might reveal a potential cancer therapeutic target in OPSCC.  
The immunofluorescence assay showed overexpression in CD44 in response to OPN 
treatment. Further analysis on involvement of CD44 and p38 MAPK pathway activation 
in OPSCC cell lines is required. Understanding of OPN downstream signaling in OPSCC 











































Many researchers are extensively studying novel tumour biomarkers owing to important 
potential applications in early diagnosis, and therapy modulation. In the clinical setting, 
the diagnosis and evaluation of cancer are mainly based on the clinical and histo-
morphologic assessment. However, molecular biomarkers are more quantifiable and 
may be more reflective of underlying disease mechanisms. In the in vitro sections of this 
thesis, tumour-derived OPN has shown an exclusive association with one subtype of 
OPSCC only (HPV-negative). Moreover, it has demonstrated the ability to modulate 
normal fibroblasts into the more active secretory phenotype. However, our observations 
were based on an in vitro model with the absence of the majority of TME components 
and associated essential signalling pathways.  OPN, as a multifunctional protein, has 
been known for its functions in promoting tumour cell migration, metastasis and tumour 
survival. It has been suggested by many authors as a prognostic biomarker (Crawford, 
Matrisian and Liaw, 1998; Danzaki et al., 2016), however, the prognostic value of OPN 
expression in OPSCC tissue has not been assessed. Here, in the last chapter, we aimed 
to examine OPN and IL-6 expression in OPSCC tissue in a validation step of our in vitro 
findings. Moreover, we aimed to determine their prognostic performance in OPSCC 
using IHC and RNAScope assays.  
Unfortunately, our research has been affected by the national lockdown measures 
against COVID 19 pandemic. Only OPN IHC assay was performed for the whole OPSCC 
cohort, and we were not able to do OPN ISH. Moreover, IL-6 RNAScope was performed 












● Validate the cytokine array findings regarding OPN and IL-6 expression in 
OPSCC tissue. 
 
● Determine OPN IHC threshold in OPSCC and evaluate its prognostic 
performance. 
 
7.3. Experimental approach and statistical analysis  
● OPN biomarker expression was assessed by performing IHC staining for the 
study cohort. OPN threshold of expression was assessed using ROC curves. 
Demographic comparison between OPN groups was performed using Chi-
square test. 
 
• The prognostic value of OPN as a biomarker was evaluated and compared in 
OPSCC subtypes using Kaplan-Meier method, Log-Rank test and Unadjusted 
Cox regression model (Univariate). 
 
• IL-6 RNAScope was performed only for cohort 2. IL-6 prognostic value was 
evaluated using Kaplan-Meier method and Log-Rank tests. 
 
● The prognostic strength of the study biomarkers, collectively, was evaluated 
using multivariate Cox regression model. 
 
● All analysis performed using SPSS (versions 23-26). p-value<0.05 was 









7.4.1. OPN IHC Antibody Titration  
To evaluate OPN IHC expression in OPSCC, the study cohort was subjected to OPN 
IHC staining using OPN antibody (22952, Proteintech, UK). We started by antibody 
titration following the manufacturer's instructions to select the most appropriate antibody 
concentration. TMA slides were subjected to both the highest and lowest suggested 
antibody concentration: 1:50 and 1:200. Under the light microscope, stained slides with 
(1:50) antibody concentration “OPN1” showed a non-specific high-intensity pattern that 
covers the majority of cores, without displaying a degree of specificity between tumour 
and stroma expressions. The demarcation between the tumour islands and stroma was 
obscured by the deep overlapped staining (Figures 7.1). On other hand, 1:200 antibody 
concentration “OPN2” showed a clearer background between the stained tumour 
islands. Also, there was an evident difference in staining intensity within the same core.  
This dynamic range in OPN stain suggested 1:200 antibody dilution is the most 















Figure 7.1: Dynamic range in OPN IHC stain using different antibody dilutions. 
Matched slides were subjected to 1:50 (right panels) and 1:200 (left panels) using OPN 
antibody (Proteintech, UK). 
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7.4.2. OPN IHC stain patterns in OPSCC tumour cells 
7.4.2.1 OPN IHC assay controls 
7.4.2.1.1. Positive control. 
A placenta tissue section was provided kindly by Prof. Craig Murdoch to serve as OPN 
IHC positive control. OPN has been detected in the human uterus during peri-
implantation, suggesting a role in implantation and placentation. Also, its function was 
linked to cell-cell and cell-ECM communication within the uterus and placenta (Johnson 
et al., 2003). In this study, placenta tissue showed a strong brown immuno-staining of 
the chorionic villi, which indicated the optimum staining protocol (Figure 7.2).  
 
 
Figure 7.2: IHC staining of OPN expression in the placenta. Example of positive 
immunostaining for OPN in human tissue (OPN antibody positive control). 
 
7.4.2.1.2. Non-malignant OP tissue. 
To assess OPN IHC expression in OPSCC, we had a look at OPN expression in non-
malignant OP structures (Figure 7.3).  OPN was expressed by the immune cells and 
lymphoid tissue at different intensities. Macrophages’ foci appeared in large deeply 




Figure 7.3: OPN expression in normal OP tissue. Sections were subjected to OPN antibody at 
1:200 dilution (Proteintech, UK). Arrows pointed to macrophage foci spots. 
 
7.4.2.2 Complete OPN-negative or positive stain pattern in OPSCC. 
A complete absence of OPN expression was noticed in a limited number of the tissue 
cores which further indicated OPN antibody specificity (Figure 7.4). On the contrary, full-
thickness OPN positivity with a homogenous intensity was detected in a larger number 
of tissue cores (Figure 7.5). Notably, the surrounding stroma showed a degree of OPN 





Figure 7.4: Complete OPN-negative OPSCC tissue. The section was subjected to OPN 
antibody at 1:200 dilution (Proteintech, UK). 
 
 
Figure 7.5 A: Full-thickness OPN expression in OPSCC. The section was subjected to OPN 
antibody at 1:200 dilution (Proteintech, UK). Notice the strong OPN staining in tumour islands 











Figure 7.5 B: Full-thickness OPN expression in OPSCC. The section was subjected to OPN 
antibody at 1:200 dilution (Proteintech, UK). Notice the strong OPN staining in both the tumour 
islands and the stroma. 
 
 
Figure 7.5 C: Full-thickness OPN expression in OPSCC. The section was subjected to OPN 
antibody at 1:200 dilution (Proteintech, UK). Notice the strong OPN staining in stroma while 






7.4.2.3 OPN partially stained OPSCC.  
Due to the nature of the IHC assay, the immunostaining has a wide dynamic range 
between two ends of strong immunopositivity and completely negative immuno-stain. 
The OPN IHC assay in OPSCC showed a wide variety of staining patterns that range 
between a score of  4 - 8 (Figure 7.6).  OPN positive cells showed strong brown staining 
for part of the epithelium thickness, however, in some tissue sections, OPN positive 
portion was most prominent toward the top (superficial) part of the epithelium or in the 
edges of the tumour islands. By the comparison with H&E-stained slides, some OPSCC 
tissue sections showed a degree of terminal differentiation in the higher epithelium layers 
which correlated with OPN expression. This observation suggests that OPN 
overexpression may relate to cell differentiation. However, in other cases, this pattern 
might be a demonstration of the functional crosstalk between stromal cells and adjacent 
cancer cells in OPN overexpression. Cancer cells that were located in direct interaction 
with stroma cells, mainly CAFs, might be induced intensively via CAF paracrine signalling 
mediated by OPN overexpression. 
In some sections, with large tumour islands, OPN expression was toward the centre, 
which suggested the functional expression of OPN in hypoxic tissue. OPN was identified 
as a hypoxia regulator among other factors in HNSCC (Byers et al., 2011). High OPN 
levels were correlated with tumour hypoxia and worse outcomes in HNSCC (Courter et 
al., 2010).  We also noticed that the stroma was heavily infiltrated by deeply stained 
stroma cells that were merged and overlapped the tumour islands. These are most likely 
immune cells, which were not included in the in vitro model. It was unclear if the OPN 
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      (B) 
Figure 7.6 A: OPN partially stained OPSCC. (A) OPN IHC assay using 1:200 antibody 
dilution (Proteintech, UK). (B) Corresponding H/E slide. Notice OPN expression in tumour 













Figure 7.6 B: Partial OPN staining in OPSCC. (A) OPN IHC assay using 1:200 antibody dilution 
(Proteintech, UK). (B) Corresponding H/E slide. Notice OPN expression in tumour cells which in 












Figure 7.6 C: OPN partially stained OPSCC. (A) OPN IHC assay using 1:200 antibody dilution 
(Proteintech, UK). (B) Corresponding H/E slide. Notice the outer-layer expression of OPN in 
tumour island which may relate to tumour cell differentiation. Also noticed the heavily infiltrated 







Figure 7.6 D: OPN partially stained OPSCC. (A) OPN IHC assay using 1:200 antibody dilution 
(Proteintech, UK). (B) Corresponding H/E slide. Notice the outer-layer expression of OPN in 
tumour island which most likely linked to tumour cells differentiation, however, expression of OPN 
the centre of tumour islands is most likely related to the hypoxia. A and B imges represent the 














Figure 7.6 E: OPN partially stained OPSCC. (A) OPN IHC assay using 1:200 antibody dilution 
(Proteintech, UK). (B) Corresponding H/E slide. Notice the heavily stained stroma which 






7.4.3 OPN expression distribution in OPSCC subtypes 
OPN IHC score was based on the assessment of OPN stain intensity in the tumour cells 
(0=absent, 1=weak, 2=moderate, 3=strong) multiply by the score of stained percentage 
of epithelium thickness (0=<5%, 1=<25%, 2=<50%, 3=<75, 4=75-100%). The scoring 
scale ranged from 0-12. During the stain scoring, we observed different values of OPN 
score in TMAs’ cores (2,4,6,8,9,12). However, for each case, we selected the highest 
score among the relative tissue cores. The final OPN score for the cases ranges between 
(4, 8, and 12). We started the data analysis by assessing OPN expression in OPSCC 
subtypes and testing if there is a relationship between OPN expression and HPV status 
(Figure 7.7). Interestingly, OPN scores were distributed in a comparable pattern in both 
OPSCC groups. In addition to HPV-negative OPSCC, many HPV-positive OPSCC cases 
also expressed a high amount of OPN. Moreover, a low OPN expression score was 
observed in some cases of both OPSCC subtypes. Chi-square test (p=0.71). 
Figure 7.7: OPN IHC expression distribution based on HPV status in OPSCC cohort. Total 
case number: HPV-positive group (n=86) and HPV-negative group (n=50). IHC was undertaken 
at 1:200 OPN antibody dilution (Proteintech, UK). No evident difference between the two HPV 





7.4.4 Prognostic threshold determination for OPN IHC 
Following OPN IHC scoring, we had to establish the positive cut-off point for OPN IHC 
in OPSCC, as that has not been done rigorously in the literature. We followed a 
mathematical approach to determine OPN IHC threshold robustly using ROC curves. 
Our calculation is based on the clinical correlation between OPN expression and patient 
prognosis. OPN overexpression was correlated by the majority of authors with diseases 
severity and poorer clinical outcomes (Coppola et al., 2004; Kita et al., 2006; Chien et 
al., 2009). ROC curve was plotted in relation to OPN sensitivity and 1-specificity in cohort 
survival prediction (Figure 7.8).  
However, ROC curve analysis indicated a weak correlation between OPN IHC 
expression and prognosis. The curve was located under the reference number with area 
under the curve less than 0.5 (AUC= 0.4). Moreover, the test suggested two thresholds 
of “6” and “10” which displayed poor performance in mortality detection. The threshold 
of 6 showed relatively high sensitivity (84%) accompanied by low specificity (14%), while 










Figure 7.8: Prognostic OPN IHC threshold determination in OPSCC using ROC curve. The 
curve plotted OPN IHC sensitivity against 1-specificity in survival prediction of the OPSCC cohort. 
The curve showed a weak association with poor survival (AUC<0.9) and suggested different 





Based on OPN immunostaining, the study cohort was distributed around 3 groups of 
OPN IHC score (score 4, score 8, and score12). By utilising this difference in expression, 
we classified the study cohort into “Low”, “Moderate” and “High” OPN IHC expression, 
respectively. 
 
7.4.5 OPSCC cohort characterisation based on OPN IHC 
expression 
The study cohort has been categorised into three groups based on the OPN IHC score 
(Table 7.1). The percentage of HPV positive cases in the low OPN group was 83% 
(n=18) while it was 61.5% and 60% in the Moderate and High OPN groups, respectively. 
The distributions of age and gender showed no statistically significant differences 
between OPN groups (p>0.05), however, M:F ratio was relatively higher in the Low OPN 
group (5:1). Smoking habits also showed comparable data distribution (p=0.56). 
Interestingly, the current smoker percentage among OPN groups was almost the same 
(around 38%). Moderate and Low OPN groups showed a comparable pattern of T grade 
status, no evident difference was detected in T1/T2 and T3/T4 distribution (40.3% and 
55.5% and 59.6% and 44.4% in Moderate and Low groups, respectively).  The high OPN 
group showed a larger percentage of T1/T2 than T3/T4 (66.1% and 33.8%, respectively). 
The differences in T stage distribution between OPN groups was statistically significant 
(p=0.02). However, no evident difference was detected in N status nor overall TNM stage 
(p>0.05), although the Low OPN group showed a higher percentage of stage IV (76.4%, 
n=13/18). On the contrary, the High OPN group showed the largest percentage of non-
recurrent disease (93.7%, n=60/64). Moreover, the largest surviving proportion was 
observed in the High OPN group (84.1%) followed by the Low group (72.2%) (Log-rank 








Table 7.1: Summary of demographic comparison in OPSCC cohort based on 








7.4.6 OPN IHC prognostic value in OPSCC 
The ROC curve failed to produce an acceptable diagnostic threshold for OPN IHC 
concerning the cohort's worst prognosis. The result might indicate that OPN has no 
correlation with OPSCC survival or could provide a protective feature. However, to 
evaluate this association accurately, we performed the survival analysis comparing the 
OPN IHC subgroups (High, Moderate and Low). The test was performed for the whole 
cohort, HPV-negative OPSCC group only and HPV-positive OPSCC group only.  
 
7.4.6.1. Kaplan-Meier method 
Kaplan-Meier method demonstrated interesting results by demonstrating that the High 
OPN group had superior overall survival compared to the Moderate and Low OPN 
groups. This feature is more evident in HPV-positive group (p=0.06), and the whole 
cohort in total (p=0.07) than in HPV-negative group (p=0.19). However, p-value did not 
reach the significance limit (p<0.05) (Figures 7. 9-11). Moderate and Low OPN showed 
a relationship with low survival to some extent. The low OPN group showed lower 
survival in HPV-positive group with an estimated mean of 4.1 years (95% CI; 2.7- 5.4), 
while, in HPV-negative, the moderate group displayed a lower survival estimate of 2.9 
years (95% CI; 1.9- 3.8) (Table 7.2). 
 





Figure 7.9: Overall survival rates in the whole study cohort based on OPN expression. The 
survival curve at 5-years follow-up showing overall survival using Kaplan-Meier method. The 
green curve represents the High OPN group (n=66), the blue curve represents the Moderate OPN 
group (n=52), and the red curve represents the Low OPN group (n=18). Each drop-step in the 
curve illustrates a case of death. Each vertical line (Hash lines) on the curve indicates censored 












Figure 7.10: Overall survival rates in HPV-positive group based on OPN 
expression. The survival curve at 5-years follow-up concerning overall survival using 
Kaplan-Meier method. The green curve represents the High OPN group (n=44), the blue 
curve represents the Moderate OPN group (n=31), and the red curve represents the Low 
OPN group (n=11). Each drop-step in the curve illustrates a case of death. Each vertical 
line (Hash lines) on the curve indicates censored data. The High OPN curve demonstrated 











Figure 7.11: Overall survival rates in HPV-negative group based on OPN 
expression. The survival curve at 5-years follow-up concerning overall survival using 
Kaplan-Meier method. The green curve represents the High OPN group (n=22), the blue 
curve represents the Moderate OPN group (n=21), and the red curve represents the Low 
OPN group (n=7). Each drop-step in the curve illustrates a case of death. Each vertical 
line (Hash lines) on the curve indicates censored data. Low OPN curve demonstrated 
the worst survival fraction. Log-rank p= 0.19. 
 
7.4.6.2. Univariate Cox regression Model (Unadjusted)  
Based on the Kaplan Meier method, the high OPN group demonstrated the longest 
survival in all tested cohorts. This observation led to further investigation to assess HR 
in this group compared to Moderate and Low OPN groups (M/L).  Using a univariate 
regression model, High OPN expression was confirmed as a significant independent 
prognostic factor in the whole study cohort, regardless of HPV status (p=0.03). High OPN 
OPSCC group showed a lower hazard ratio compared to the M/L OPN group that 
demonstrated a higher risk with 2.26-fold (95% CI: 1.07-4.75). However, by evaluating 
OPN prognostic performance in OPSCC based on HPV positivity, High OPN was 
identified as a “protective” feature in the HPV-positive group (p=0.05), but not in the HPV-
negative (p=0.26) (Table 7.3, Figure 7.12).  
280 
 











Figure 7.12: Forest plot illustrates OPN hazard ratios according to Univariate regression 
model. Univariate model was established to obtain the OPN hazard ratio in the whole group, 
HPV-positive group only and HPV-negative group only. HR (Red dot) presented with 95% CI 
upper and lower values. The dotted line represents the strength cut-off of HR (1). HR before the 
line indicates a weak correlation with the hazard (mortality) and vice versa. High OPN showed a 




7.4.6.3. IL-6 RNAScope analysis in OPSCC  
IL-6 mRNA expression assessment in OPSCC was performed on freshly baked slides to 
ensure RNA integrity using RNAScope RNA ISH. Cohort 1 was provided as already 
baked tissue sections, and it was not possible to access fresh sections in a timely manner 
due to the lockdown. In cohort 2, IL-6 transcript signals were observed to a variable 
extent in cohort 2 sections, however, the normal tonsils cores also showed a high 
abundance of IL-6 expression (Figure 7.13). Notably, in some OPSCC sections, IL-6 was 








Figure 7.13: IL-6 RNAScope expression in normal tonsillar tissue. Arrows pointed to IL-6 


















                   
(B) 
Figure 7.14: IL-6 RNAScope expression in the stroma in relation to invasive front sites. A 
and B magnifications 20x and 40x, respectively.  Arrows pointed to IL-6 mRNA expression.  
 
7.4.6.4. Distribution of IL-6 RNAScope expression in OPSCC cohort 
The expression of IL-6 signals has been evaluated and scored for OPSCC stroma 
according to a modified scoring scheme from Yu et al., (2015).  In their scoring scheme, 
IL-6 expression was classified into 4 levels according to the number of positive cells: 0, 
no cells. 1, areas with 5-10 positive cells per 20x field. 2, areas with 11-25 positive cells 
per 20x field. 3, areas with 26-50 positive cells per 20x. 4, areas of more than 50 positive 
cells per 20x field. 
We grouped those 4 levels into 2 groups: group 1 “Low IL-6” (≥26 positive cells) and 
group 2 “High IL-6” (≤25 positive cells). By looking at IL-6 RNAScope distribution in 
OPSCC based on HPV status, there was no significant difference between HPV-positive 
and negative groups (p=0.77). Both groups showed a high expression of IL-6 transcripts 
with comparable values. 37.5% in HPV-positive group n=14/39, and 40% in HPV-




Table 7.4: Distribution of IL-6 RNAScope expression in OPSCC
 
 
7.4.6.5. Prognostic value of IL-6 in OPSCC 
Assessment of the prognostic value of IL-6 mRNA expression in cohort 2 (n=54) based 
on IL-6 mRNA revealed no statistical significance between HPV-positive and negative 
OPSCCs (Log-rank p= 0.84) High IL-6 group (n=20) and Low IL-6 group (n=34) showed 
a similar mean survival time (4.4 years, 95% CI: 3.8-5) and (4.3 years, 95% CI: 3.8-4.7) 
(Table 7.5, figure 7.15).  
 










Figure 7.15: Overall survival rate in OPSCC based on IL-6 RNAScope.  The overall survival 
curve at 5-years follow-up using Kaplan-Meier method. The red curve represents the High IL-6 
OPSCC group (n=20) and the blue curve represents the Low IL-6 OPSCC group (n=34). Each 
drop-step in the curve illustrates a case of death. Each vertical line on the curve illustrates the 
last time seen for a live case. There was no difference in overall survival between the two tested 








Time since diagnosis (years) 
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7.4.7. Multivariate Cox model for the study biomarkers  
Multivariate models provide a risk stratification of all of the tested predictors at the same 
time. HR, here, is adjusted to the other factors in the analysis, not to the control group of 
the same predictor. p-value here is testing the difference between the HR of positive 
predictor and negative predictor based on the adjusted model result. 
The well-established HPV-related biomarker p16 demonstrated strong independent 
performance even in the adjusted model. Negative p16 status was strongly associated 
with mortality with relatively high HR=5.52 (95% CI: 2.6-11.4), while p16 expression was 
associated with survival (HR= 0.18; 95% CI: 0.08-0.37). The difference between the two 
HRs is statistically significant (p<0.001). 
ɑ-SMA biomarker expression in the whole study cohort displayed better performance in 
multivariate assessment than the univariate. ɑ-SMA HR revealed a significant 
association with the hazard considering the other covariates. By the comparison with 
tested positive predictors, High ɑ-SMA expression was associated significantly with the 
hazard (Mortality) (HR=2.2; 95% CI: 1.06-4.7) (p=0.011). On the other side, Low ɑ-SMA 
expression provides a favourable indication for the survival compared with other 
predictors adjusted in the test (HR=0.45; 95% CI: 0.21-0.95). This alteration in the 
predictive significance in multivariate compared with univariate is a result of including 
variable (or set of variables) in the regression equation that increases the predictive validity 
of another, known as “Suppressor effect” (Tzelgov and Henik, 1991). This type of results 
should be interpreted cautiously considering the clinical implications.  
The comparison of OPN biomarker strength in OPSCC with p16 and ɑ-SMA biomarkers 
revealed a significant independent predictive value of OPN biomarker in OPSCC. High 
OPN OPSCC population demonstrated low HR (0.37; 95% CI: 0.17-0.79) compared to 








Table 7.6: Multivariate Cox regression model on the whole study cohort based on 











Figure 7.14: Forest plot illustrates the strength of the study’s biomarkers expression 
according to the multivariate regression model. Adjusted model (multivariate) was established 
to obtain biomarkers hazard ratios in the whole study group. HR (Red dot) presented with 95% 
CI upper and lower values. The dotted line represents the strength cut-off of HR (1). HR before 




This is the first study evaluating OPN IHC expression in an established OPSCC cohort. 
Due to time restrictions, our assessment was limited to IHC assay only that revealed 
interesting novel findings. Our study reported High OPN IHC expression as an 
independent predictive biomarker in OPSCC associated positively with overall survival 
using univariate and multivariate regression models (p-value = 0.03 and 0.01, 
respectively). We attempted to analyse the available data rigorously and correlate the 
findings with the available knowledge and our understanding in the field, however, a 
number of questions have been raised during the results’ discussion that requires further 
investigation. Validation of our novel finding in OPSCC might provide a further feature 
for OPSCC patient selection for de-intensifying therapy protocols. 
7.5.1. OPN expression in OPSCC 
OPN expression in normal human tissue has been investigated using a multifaceted 
approach including in situ hybridisation, immunohistochemistry, and northern blot for 
frozen tissue.  OPN protein deposition in FFPE tissue was identified prominently at the 
luminal surfaces of the salivary glands, gastrointestinal tract, urinary and reproductive 
tracts, lung, and breast tissue (Brown et al., 1992). Moreover, OPN IHC expression was 
observed clearly in the central and peripheral nervous system (Kunii et al., 2009), sweat 
gland duct (Ogbureke and Fisher, 2007), hair follicles and sebaceous glands (Chang et 
al., 2008). According to the human protein atlas, normal tonsillar tissue is devoid of OPN 
protein expression. In normal lymphoid tissue, OPN protein expression is confined to the 
non-germinal centre cells only (Tissue expression of SPP1 - Summary - The Human 
Protein Atlas, 2021). However, in this study, we included a number of non-malignant 
tonsil and lymph node sections that showed a varying degree of OPN staining intensity 
ranging between weak and moderate. The degree of OPN expression in these sections 
has raised a concern regarding the OPN immunopositivity threshold in OPSCC. The 
expression of OPN in non-malignant tonsils might be attributed to an inflammatory 
mechanism in response to other pathogens that trigger pro-inflammatory cytokines 
expression including OPN. High OPN expression was reported in non-malignant lymph 
nodes, and it has been included as an OPN-positive control in some studies (Li et al., 
2012). Here, the first question has been raised: should we follow the available suggested 
thresholds in the literature with OP tissues despite the inflammatory nature of the 




OPN expression showed a strong correlation with specific tumours from different body 
sites. In a study of 350 tissue sections from different body tumours, High OPN expression 
was observed in all of the tissue from the gastric carcinoma sections (100%). Colorectal 
carcinomas, transitional cell carcinomas of the renal pelvis, and pancreatic carcinomas 
all showed a high percentage of OPN overexpression compared to normal counterparts 
(85%, 82% and 81%, respectively). Renal cell carcinomas, lung and oesophageal 
carcinomas also demonstrated a relatively high percentage of OPN positivity ranging 
from 72-70%. Moreover, OPN high expression was detected in 58% of HNSCC sections 
(n=60, including 5 cases of OPSCC) (Coppola et al., 2004). Notably, the published 
images in Coppola’s paper represented strong OPN stain in OSCC cells within a clear 
background. The adjacent stroma showed a scant expression of OPN. In contrast, in our 
OPSCC cohort, we detected High OPN expression in 48.5% (n=66/136) with comparable 
distribution in both OPSCC subtypes, however, in the majority of OPSCC sections, the 
associated stroma was extensively stained.   
In our study, the cohort showed a wide variation of OPN expression, regardless of HPV 
status. In both HPV-positive and negative groups, we observed High, Moderate and Low 
OPN expressions. Interestingly, 83% of the Low OPN group (n=15/18) were HPV-
positive. Despite the small number of cases in the Low OPN group, this observation is 
consistent with our in vitro finding in OPSCC cell lines. In an early response to short-term 
co-culturing with OPSCC fibroblasts, only the HPV-negative cell line (SCC89) 
demonstrated a significant upregulation in OPN, not the HPV-positive cell line (SCC2), 
which might suggest a tendency of OPN association with HPV-negative OPSCC. 
However, High OPN expression was detected also in HPV-positive OPSCC tissue to a 
great extent in this study.  
The challenging dilemma in this chapter was the determination of the OPN IHC staining 
threshold. Due to the subjective nature of IHC scoring, there is always a possibility of 
interobserver variability in threshold definition and risk of bias. Since ours was the first 
study that has investigated OPN IHC in an OPSCC cohort, we tried to establish the OPN 
cut-off based on a robust mathematical approach using ROC curves. However, the curve 
analysis revealed an expected result by demonstrating a weak correlation between OPN 
expression and poor survival.  Kita et al. (2006) suggested a definition of positive OPN 
carcinoma tissue based on their observation in oesophageal squamous cell carcinoma. 
They considered the expression of OPN in more than 10% as the OPN positive cut off. 
By reviewing Kita’s paper images, OPN immune-localisation was confined to carcinoma 
with intensity ranges between moderate and high, however, there was no detectable 
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OPN expression in the surrounding stroma. This threshold has been adopted by a large 
number of studies in OSCC which linked OPN expression with worse outcome 
parameters including advance T grade and N status. Notably, the OSCC stroma did not 
show evident OPN expression as we have seen in OPSCC (Chien et al., 2008, 2009; 
Luo et al., 2015). Again, our previous first question has been highlighted here:  is the 
extensively stained stroma in OPSCC linked to the histological nature of OP tonsil tissue 
or is it attributable to technical issues related to the antibody concentration and the 
antigen retrieval method? Can we adopt Kita’s threshold in OPSCC? However, we have 
seen some sections with complete immune-negativity; also, in some High OPN sections, 
the stroma displayed a weak pattern of staining which suggests that the immune-reactive 
specificity of the antibody is reasonable. We have seen OPN in the cytoplasm and nuclei 
of the cancer cells and that was reported before (Junaid et al., 2007; Shinohara et al., 
2008). As ours is the first study that detected OPN IHC expression in OPSCC, we 
preferred to adhere to the manufacturer’s instructions in the selection of antibody 
dilutions to be within the recommended limit. 
From our point of view, adoption of the cut off proposed by Kita et al. (2006) in OPSCC 
is dependent, to an extent, on accurate recognition of the cellular source of OPN 
production in tissue using OPN ISH, especially in partially stained cases. The TME 
comprises several inflammatory cells and a network of signalling pathways. OPN has 
been shown to be produced and released by peritumoral inflammatory cells, mainly 
macrophages, dendritic cells and T cells (Shinohara et al., 2005). There is an assumption 
by many authors that not all detected OPN protein in cancer cells is tumour-derived. 
They postulate that secreted stromal-derived OPN could be integrated into cancer cells 
through cell surface receptors (Brown et al., 1994; Erkvliet et al., 1998). This assumption 
has been supported by Brown and co-workers. In various types of solid tumours, OPN 
ISH expression showed an intimate association with macrophages adjacent to cancer 
cells, while there was no detectable OPN mRNA in related cancer cells (Brown et al., 
1994).  
However, that does not imply that all the partially stained epithelium is OPN-negative. 
The localisation of stained cancer cells at the uppermost layers of the epithelium 
thickness might also suggest the source of OPN secretion in relation to its function in 
malignant cell transformation and tumour progression. OPN overexpression has been 
correlated with malignant cell transformation and dedifferentiation (Senger, Wirth and 
Hynes, 1979). In OSCC and other tumours, the reports have shown that OPN expression 
has increased from lower to higher histological grades (Korita, Wakai and Shirai, 2008; 
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Subramani et al., 2015; Aravind et al., 2017). Moreover, the intensity of OPN expression 
was observed to gradually increase from normal epithelium to dysplastic cells that 
showed a moderate intensity of expression, while in the invasive front, tumour islands 
demonstrated strong OPN staining intensity (Chien et al., 2009; Lakshmi et al., 2019). 
Another possible explanation of partially/low stained superficial epithelial layers and 
higher expression in the basal compartment is a close approximation with cells in the 
TME. We have shown in chapter 5 that OPN was significantly upregulated in cancer cells 
in response to crosstalk with OPSCC fibroblasts. Accumulation of OPN stain at the 
centre of tumour islands also suggested the functional role of OPN in hypoxic tissue. 
OPN expression has shown to be strongly modulated by hypoxia in vitro (Wohlleben et 
al., 2015); moreover, its protein expression in tissue has demonstrated a strong 
correlation with oxygenation parameters in advanced HNC and worse prognosis (Bache 
et al., 2006). However, this assumption requires further assessment of hypoxia 
biomarkers in OPSCC cohort. 
7.5.2. High OPN OPSCC characteristics  
 Analysis of the clinical features in the High OPN OPSCC group revealed results 
inconsistent with the available data in the literature. In the majority of studies, 
overexpression of OPN was associated with poor differentiation, advanced T and N 
stage beside the high tendency to develop a recurrent tumour (Chien et al., 2009; Weber, 
Lett and Haubein, 2010). In our cohort, T stage distribution showed a significant 
difference among OPN groups (p=0.02). The High OPN group comprised more cases 
with smaller tumour size (T1/T2 comprised 66.1%) than larger tumours. Moreover, the 
High OPN group showed the highest percentage of recurrence-free patients (93.7%).  
Despite these clinical parameters being distinct and not mutually unrelated, the clinical 
presentation of the poorly differentiated, high-grade tumour is more likely to be 
disseminated and consequently develop a high stage tumour. Although the molecular 
mechanisms behind these events are overlapping, OPN is found to be associated with 
all of them, which may explain the positive correlation between OPN overexpression and 
poor clinical outcomes. However, our observation, based on OPN IHC, showed no 
detectable differences in clinical parameters between Low, Moderate and High; on the 
contrary, the High OPN group showed smaller tumour size and less recurrence 




7.5.3. OPN IHC prognostic value in OPSCC 
The ROC curve analysis indicated a weak correlation between OPN IHC overexpression 
and poor prognosis. The test was followed by Kaplan-Meier method to investigate 
thoroughly the prognostic value of OPN staining in OPSCC according to available data. 
We preferred to assess and compare the survival curve for each OPN IHC group (High, 
Moderate and Low) to understand the nature of Moderate group expression. Surprisingly, 
the survival curves revealed expected contradictory results in the OPSCC cohort, as the 
High OPN group showed a longer survival time compared to other OPN groups. This 
difference was evident in the HPV-positive group (p=0.06) rather than in the HPV-
negative group (p=0.19). This finding is contrary to the known functions of OPN in several 
tumours where High OPN expression has been correlated with high T stage, N stage 
and high clinical-stage, suggesting that OPN may be involved in tumour metastasis and 
progression (Chien et al., 2008; Cho et al., 2008; Chiu et al., 2010; Li et al., 2012). 
The survival curve of Moderate OPN group showed better survival than Low OPN in the 
HPV-positive cohort, while in HPV-negative, it overlapped the High OPN curve, 
demonstrating a low survival fraction in both groups.  In the whole cohort, the survival 
curves were influenced by the strength of the survival features in HPV groups. High OPN 
curve demonstrated the best survival time over the other groups, however, that was not 
statistically significant (p=0.07). Based on Kaplan Meier findings, we postulated that the 
High OPN group is a distinct population in the OPSCC cohort with better survival 
features. We assessed our hypothesis by exploring the hazard ratio of High OPN 
expression against M/L groups. In the whole cohort, High OPN provides a protective 
feature demonstrated in low HR (HR=0.44; 95% CI; 0.2-0.93) compared to M/L group 
(HR=2.26; 95% CI; 1.07- 4.75; p= 0.03) at univariate model. Moreover, HPV-positive 
group showed marginally significant HR differences (p=0.05), while HPV-negative 
demonstrated no differences statistically (p=0.26). The predictive ability of OPN 
expression remained evident in the multivariate model, including p16 and α-SMA 
biomarkers (p=0.01). The evidence above indicated that High OPN IHC expression is a 
protective feature in OPSCC, regardless of HPV status, but this feature is more 
prominent in HPV-positive group. This contradictory novel finding has raised the second 
important question in this chapter: Why did High OPN expression show a distinct role in 
OPSCC?  
At the moment, there is no direct answer to this question. There are many assumptions 
that might be related to an OPN mediated tumour-suppression effect; however, further 
investigation is needed to understand this correlation. The first possible explanation is 
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related to the source of OPN production; in solid tumours, OPN is secreted by cancer 
cells and cells in the tumour microenvironment (host-derived as described by some 
authors). Both types interact in a complex process characterised by antagonistic 
functional roles as was evident in vivo using an OPN-null animals’ models (Crawford, 
Matrisian and Liaw, 1998; Hsieh et al., 2012). Absence of stromal-derived OPN 
accelerated the growth and progression of the tumour cells and developed a greater 
number of metastases compared with wild-type animals. The difference in tumour growth 
was inversely correlated with the degree of macrophage infiltration (Crawford, Matrisian 
and Liaw, 1998). This process was thought to be mediated through the ability of stromal-
derived OPN in macrophage chemoattractant via elicitation of an early innate 
inflammatory response, in addition to its ability in enhancing the survival of inflammatory 
cells (Hsieh et al., 2012). On the other side, tumour-derived OPN was demonstrated as 
a potentially destructive and inhibitor factor to the macrophages besides its ability in 
promoting metastasis growth and survival (Hsieh et al., 2012). 
The second possible explanation was related to the distinct functions of OPN form; OPN 
has two froms that can be generated from the same mRNA transcript. However, the 
alternation in transduction mechanism resulted in the formation of two different forms 
with distinct biological roles (Inoue and Shinohara, 2011). OPN was widely known as an 
extracellular secretory protein that has been described generally in cancer research, with 
its dark side in promoting and facilitating tumour cell proliferation, migration. In striking 
contrast, some, but not many, reports have demonstrated that OPN inhibits tumour 
progression and correlates with favourable survival (Collins et al., 2012; Danzaki et al., 
2016; Franklin et al., 2019). This promising side of OPN was linked mostly to the 
intracellular OPN form (iOPN) rather than the secreted OPN (sOPN) (Inoue and 
Shinohara, 2011). iOPN is a non-secretory form of OPN that was detected in different 
cell types, localised into the cytoplasm and cell nuclei. In the tumour microenvironment, 
iOPN is synthesised mainly by macrophages, T cells and dendritic cells and was linked 
to several immune mechanisms. It is identified as an adaptor molecule in signalling 
pathways downstream of innate immune receptors (Shinohara et al., 2012). The innate 
immune system is the first line of defence against HPV infection which is mediated by a 
variety of mechanisms’ involvement, including macrophages and NK cells recruitment; 
however, the innate immune response to HPV infection in OPSCC is incompletely 
understood and we do not know if it is mediated by iOPN.  
The integrity of the natural killer (NK) defences is considered a vital innate immune 
function in host defences against pathogens and cancer development. iOPN has been 
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identified as a crucial molecular component for the maintenance of functional NK cells, 
including NK expansion and differentiation. Deficiency in iOPN leads to a significant 
decrease in NK infiltration in tumour stroma (Danzaki et al., 2016). Moreover, it results 
in impaired expansion of long-lived NK cells and evolving incomplete responses to viral 
infection and the tumour cells (Leavenworth et al., 2015). In a transgenic 
adenocarcinoma of the mouse prostate, deficiency of stromal-derived OPN reduces NK 
infiltration into the tumour. For further confirmation for the in vivo finding, NK derived from 
OPN-deficient mice demonstrated a decrease in migration ability toward the cancer cells 
compared to NK cells from wild-type mice in vitro (Danzaki et al., 2016). To this point, 
some questions have been raised. Does the iOPN isoform relate to the stromal-derived 
OPN in terms of the regulatory and activation processes? Are they both referring to the 
same molecule under different nomenclatures? Thus far, these questions have not been 
answered. 
The role of OPN in T cell activation was the last possible explanation; in OPSCC, 
oncogenic HPV-infection presents viral antigens that elicit specific antibody and T cell 
responses. These reactions are thought to be due to the tight anatomical proximity of 
infected mucosa and immune tissue in OP (Kreimer et al., 2017; Welters et al., 2018). T 
cells are believed to contribute to tumour rejection and long-term immune surveillance. 
Moreover, it has been shown that T-cells are further promoted to mediate anti-tumour 
immunity upon radiation treatment (Manukian et al., 2019). CD8+ cytotoxic T 
lymphocytes are the central component of the host adaptive immune system. Extensive 
CD8+ T cell infiltration was correlated with overall survival in HNSCC, regardless of HPV 
status (Punt et al., 2016; Welters et al., 2018; Kemnade et al., 2020), which suggested 
that T cell response is promoted by HPV oncogenic infection and irradiation that might 
contribute to an enhanced T-cell response in HPV-associated tumours. In graft versus 
host disease, CD8+ action was facilitated through the host-derived OPN expression.  It 
is involved in the initiation, activation, and survival of CD8+ against the recipient organ 
(Zhao et al., 2011; Kawakami et al., 2017).  However, the role of tumour-derived OPN in 
CD8+ lymphocytes has been reported with contradictory effects. It acts as an immune 
checkpoint to suppress T cell activation and has been correlated with decreased patient 
survival in colon carcinoma (Klement et al., 2018). Molecular analysis of OPN forms in 
dendritic cells and T cells revealed that dendritic cells can express high levels of iOPN 
rather than sOPN, whereas the reverse is true of activated T cells (Shinohara et al., 
2005). The next question was raised here: Does stroma sOPN provide the same anti-
tumour immunity feature as iOPN? 
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7.5.4. IL-6 RNAScope expression in OPSCC 
IL-6 RNAScope analysis was limited to a small number of cases (cohort 2, n=54). High 
IL-6 mRNA expression was observed in both HPV-positive and negative OPSCC 
(p=0.7); however, IL-6 expression did not correlate with the survival of the tested 
population. IL-6 has been reported as an independent prognostic biomarker in several 
types of tumours including HNSCC, where high IL-6 expression in tissue has been 
related to tumour recurrence, metastasis and poor survival (Choudhary et al., 2016; 
Kobawala et al., 2016; Ahmad et al., 2018). Here, in OPSCC, IL-6 transcript expression 
was detected in non-malignant lymphoid tissues which might be a part of an inflammatory 
mechanism attributed to recurrent chronic infection (Todorović and Zvrko, 2013), 
although in some sections, IL-6 expression signals were located intimately with stroma-
adjacent cancer cells, suggesting specific reactions in stroma cells to cancer cells 
paracrine signalling pathways. The histology of the anatomical site could be a reason 
behind our findings, while the cohort’s small size may be another factor. Our separate 
observation for Cohort 2’s performance indicated it is an underpowered cohort. Further 
validation with a larger cohort is essential.  
 
7.5.5 Concluding remarks 
Cytokine profiling data showed that OPN was a factor expressed exclusively by an HPV-
negative cell line, not the HPV-positive cell line. However, our data are limited to two 
OPSCC cell lines and the cytokine assessment was based on the early short response. 
OPN IHC assessment revealed no differences in OPN expression at different score 
levels, as even in HPV-negative OPSCC, some cases showed low OPN expression. 
However, the exact source of detected OPN in IHC assay is obscure, and this reflects a 
limitation in our co-culture model that is devoid of the presence of the immune cells, the 
second important component in TME.  
Based on IHC evaluation, high OPN expression was correlated positively with the 
favourable prognosis. Nevertheless, determination of OPN source is a fundamental key 
to understand the biological function of OPN expression in OPSCC: is the protective 
function of OPN in OPSCC attributable to tumour-derived OPN or stromal-derived OPN? 
In situ hybridisation for OPN mRNA would be an optimum method to answer this question 
by providing the feasibility to score OPN expression in tumour cells and stromal cells 
independently. Using digital software such as Qupath software may aid in this process 
effectively. Moreover, assessment of the clinical significance of secreted OPN in OPSCC 
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patient serum is another important issue that has not been investigated thoroughly. This 
may expose the other face of OPN (sOPN) that was known widely for its correlation with 
poor clinical outcome.  
7.6. Limitations 
We are aware that our method of assessment still needs further investigation by 
evaluating OPN mRNA expression that might provide the feasibility to identify the amount 
of stromal-derived OPN in OPSCC and establish a separate scoring of the epithelial and 
stromal compartments using quantitative staining analysis on the digital images. 
Moreover, the IHC assay was performed using a single type of polyclonal antibody only. 
In the Kunii et al. (2009) study, OPN polyclonal antibody performance has been 
assessed against the monoclonal counterpart. Monoclonal OPN antibody was reported 
with slight advantages over the polyclonal OPN antibody. The use of a combination of 
both antibodies was recommended. 
 
7.7. Summary of main findings and clinical implications: 
This is the first study to assess OPN IHC expression in OPSCC in detail. OPN has shown 
different patterns of staining that have been seen in both OPSCC entities. Nevertheless, 
the High OPN expressing OPSCC sub-population demonstrated superior survival. 
Multivariate regression analysis confirmed High OPN expression as an independent 
prognostic factor in OPSCC. However, performing OPN ISH is essential to identify the 
cellular source of OPN in OPSCC and confirm our results. Validation of this finding might 
introduce OPN as a prognostic biomarker in OPSCC that could be utilised for patient 
selection for de-intensification protocols. 
Because of the general understanding of OPN as a factor facilitating tumour formation 
and progression, OPN is now considered a target for cancer therapy. However, as there 
is, in some circumstances an anti-tumorigenic role for OPN, as reported here (and by 
some other investigators), targeting OPN may also reduce the antitumorigenic features 
of OPN in this tumour. Thus, further investigation, including characterisation of OPN 
isoforms in OPSCC, might provide novel candidates for target therapy or avoid the loss 



























8.1 General discussion 
 
Squamous cell carcinoma is the most common tumour type in HNC, a group of cancers  
characterised by aggressive behaviour and high morbidity and mortality rates within the 
first five years from diagnosis (Johnson et al., 2020). In 2018, more than 890,000 new 
cases were diagnosed with 450,000 deaths (Bray, Ferlay and Soerjomataram, 2018). 
Based on Global Cancer Observatory (GLOBOCAN) estimation, HNSCC incidence is 
projected to rise further by a third in the next decade to reach 1.08 million new cases in 
2030 (Ferlay et al., 2019). However, the risk factors attributed to the HNSCC burden vary 
worldwide. Whereas the consumption of alcohol and tobacco in different forms are the 
common risk factors in Southeast Asia, high prevalence in HNSCC in western countries 
is attributed to HPV-associated OPSCC (Hashibe et al., 2007; Mehanna et al., 2013). 
The prevalence of HPV-positive OPSCC in epidemic regions was reported to be more 
than two-thirds of all OPSCC (70%). In our cohort, the prevalence of the HPV16/18 
genotypes were 60.8% of all included cases (87/143). 
 
Clinically, HPV-associated OPSCC patients demonstrate different clinical presentation 
and clinical outcomes from the non-HPV related counterparts. HPV-patients tend to be 
non-smoker males within the middle age group and from a high socioeconomic 
background. Most importantly, they demonstrated better prognosis regardless of therapy 
strategy protocols (Ang et al., 2010). HR-HPV status in OPSCC is well documented as 
a reliable prognostic factor for tumour progression, and we observed a longer estimated 
overall survival time (p= 0.002) in the HPV-positive group compared to HPV-negative 
OPSCC indicated by a high hazard ratio in the univariate regression model (HR: 2.68; 
95%CI: 1.35-5.31, p=0.005). Comparing smoking habit data between OPSCC entities 
emphasises the etiological role of HPV in OPSCC development; HPV-positive group 
contained significantly fewer smokers than the HPV-negative counterpart (p<0.001). The 
status of smoking habit at diagnosis (Never, Former and Current) provided a further 
clinical feature for outcome prediction of HPV-negative (p<0.001).  
 
Several techniques have been utilised for HPV detection in tissue materials that 
demonstrated varying diagnostic values. However, besides the diagnostic performance, 
researchers were also considering the prognostic value of these techniques, to be 
utilised effectively in clinical trials. According to recent AJCC guidelines, identification of 
HPV status in OPSCC has become a fundamental requirement in the clinical setting and 
that based on p16 IHC positivity. In comparison with different HPV detection methods, 
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p16 has many advantages given the simplicity, feasibility and low cost, besides high 
prognostic value. However, due to the evident shortcomings in p16 IHC specificity, other 
HPV specific tests based on nucleic acid detection were recommended in step-wise 
algorithms, particularly, in non-epidemic regions. Our assessment for p16 IHC 
performance against RNAScope assay revealed acceptable sensitivity of 97.6%, and 
relatively low specificity (72%), nevertheless, it revealed better prognostic value than 
RNAscope assay. It is worth mentioning here that p16 positivity was based on H-score 
threshold 144.5 that was selected mathematically using ROC curve. 144.5 H-score 
threshold is most likely to be consistent with >50% positivity threshold. Since the low 
specificity of p16 IHC has been improved by the combination with an HPV specific test, 
further validation is warranted to assess the prognostic performance of >50% p16 
positivity threshold, which may provide a more accurate prediction of OPSCC survival 
than >70% positivity threshold. 
 
The reasons behind better HPV-positive OPSCC outcomes still are not fully clear. 
Different explanations have been proposed by many authors which include, the patient’s 
general condition: patients with HPV-positive tumours usually present younger in age, 
with good performance status, and fewer comorbidities (Ang and Sturgis, 2012). Higher 
radio-sensitivity is another factor for the improved outcome that might be the result of an 
intact apoptotic response to radiation (Fakhry et al., 2017). Moreover, the difference in 
genetic alterations is another possible factor. HR-HPV-associated SCC is considered a 
genetically stable tumour, harbouring less genetic mutations and loss of heterozygosity 
on chromosome 3p and retaining active p53 and pRb pathways (GS-OSCC) (Braakhuis 
et al., 2004; Parkinson, James and Prime, 2016), while non-HPV OSCC is characterised 
by several genetic mutations and gross deletions of whole or large parts of chromosomal 
arms including loss of heterozygosity TP53 and CDKN2A which indicates it considered 
as a genetically unstable subtype of OSCC (GU-OSCC) (Braakhuis et al., 2004). The 
genetic landscape of tumour cells has its evident reflection in the underlying TME. In 
response to tumour-derived oncogenic signals, the TME continually changes to support 
tumour cell progression (Lim et al., 2011; Quail and Joyce, 2013). In OSCC, fibroblasts 
derived from GU-OSCC showed high senescence percentage and distinct inflammatory 
profiles from GS-OSCC-derived fibroblasts (Lim et al., 2011; Hassona et al., 2013, 2014). 
Moreover, studies from our lab demonstrated differences in normal fibroblasts early 
responses to OPSCC cell lines conditioned media. HPV-negative cell lines conditioned 
media showed a larger amount of secretome (Bolt, 2016) that demonstrated a high ability 
to modulate the secretory profile of fibroblasts to a more inflammatory profile (Bolt et al., 
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2018; Peacock et al., 2018; Al-Sahaf et al., 2019). This concept promoted us to 
investigate in-depth the early crosstalk between OPSCC tumour cells and fibroblast. This 
aspect may provide additional therapeutic options to treat malignant carcinomas. 
 
CAFs are the major component of the cellular part of the ECM that plays a crucial role in 
tumour progression and chemoresistance in OSCC among other tumour types (Fiori et 
al., 2019; Sun et al., 2019; Mughees et al., 2021). Conversely, in some reports from 
pancreatic ductal adenocarcinoma and breast cancer, CAFs were reported to exert 
tumour-suppressive effects in the TME (Rhim et al., 2014; Brechbuhl et al., 2017). 
Upregulation of α-SMA has been reported in GU-OSCC-derived CAFs (Lim et al., 2011), 
and was linked with poor prognosis in OSCC tissue material (Dourado et al., 2018). In 
OPSCC, we have observed a comparable distribution of α-SMA expression in HPV-
positive OPSCC and HPV-negative OPSCC, although the latter is considered GU-
OPSCC. However, expression of α-SMA biomarker is not specific for myofibroblastic 
CAFs phenotype, it was also upregulated in senescent fibroblasts via TGF-β/Smad 
signalling provoked by reactive oxygen species (Oh, Lee and Wagers, 2014). 
 
Traditional CAFs molecular biomarker and scRNA-seq analysis demonstrated that the 
term” CAF” represent a wide heterogeneous family with subtypes of distinct biomarker 
expression and functionality phenotype which are believed to be attributed to diversity in 
CAF origin (Kidd et al., 2012; Prime et al., 2017). scRNA-seq analysis revealed also 
intra-tumour heterogeneity in CAFs subtypes within the same tumour type (Galbo, Zang 
and Zheng, 2021). We observed this heterogeneity using molecular biomarkers 
expression during CAFs cultures characterisation. Although CAF1 and CAF2 were 
extracted from the same tumour type (HPV-positive OPSCC), the latter displayed 
myofibroblastic CAF-like phenotype by overexpressing α-SMA, while the former showed 
a high percentage of SA-β-gal stain and a larger number of inflammatory profile 
upregulation following cell line media incubation (Table 5.4 & 5.5). This provided us with 
both major phenotypes in our CAF established models (myofibroblastic CAF model and 
a senescent CAF model) a better understanding of OPSCC CAFs phenotypes. 
 
In a recent scRNA-seq study that profiled CAFs from HNSCC, lung cancer and 
melanoma, six pan-CAF subtypes were detected, each with a distinct genetic profile and 
functional role (Galbo, Zang and Zheng, 2021). myCAF subtype was reported with 
activated fibroblast biomarker and upregulation in smooth muscle-related contractive 
genes. The high ability of the myCAF subtype in ECM remodelling and activation of 
underlying pathways associated with smooth muscle cell contraction is thought the main 
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factors behind the worse clinical outcomes. iCAF subtype showed upregulation of gene 
sets related to interleukin signalling pathways, moreover, the iCAF-2 subtype showed 
expression of IL-6 gene exclusively (Galbo, Zang and Zheng, 2021). These observations 
suggested that iCAF subtypes are most likely to be associated with an inflammatory 
TME, implicated in cancer cell stemness and cancer therapy resistance (Su et al., 2018). 
A better understanding of CAFs molecular heterogeneity provides a potential explanation 
of CAFs functional role in TME. In this study, evaluating the clinical significance of CAFs 
based on α-SMA expression revealed a potential prognostic value in HPV-positive group 
only (p=0.02). Low α-SMA subgroup demonstrated better overall survival than High α-
SMA counterpart in HPV-positive group. This observation may suggest a different 
functional role of CAF subtypes in OPSCC driven by the diversity in OPSCC signalling 
pathways.  
 
Cytokine profiling introduced novel candidates that were particularly expressed by the 
HPV-negative cell line (M1), but not by the HPV-positive counterpart, that includes OPN, 
KLK6 and GM-CSF. These factors were associated with senescence, ageing and tumour 
metastasis (Borgoño and Diamandis, 2004; Coppé et al., 2008; Zhao et al., 2018). We 
also observed modulation in the secretory profile of OPSCC fibroblasts with IL-6 and IL-
8 upregulation following co-culturing with HPV-negative OPSCC conditioned media 
(M2). We chose to focus on OPN and IL-6 as they were previously described as 
candidates in a dynamic communication loop between the tumour cells and CAFs in 
OSCC (Qin et al., 2018). Targeting the reciprocal interaction between tumour cells and 
CAFs is a much-needed approach to cancer therapy. Our initial investigations 
determined that the HPV-negative tumour cell was the main source of OPN in the 
interactive co-culture models, and IL-6 was upregulated in fibroblast in response to the 
HPV-negative cell line only. This novel finding indicates the presence of early reciprocal 
crosstalk between HPV-negative cell line and fibroblast mediated by OPN and IL-6.  
 
As a multifunctional molecule, OPN is known as a pro-fibrotic factor that has been 
implicated in various fibrosis-related diseases in the lung and cardiac muscle. It has been 
described as an essential factor in dermal fibroblast activation through the TGF-β1 
pathway. In breast cancer, tumour-derived OPN showed the ability to reprogram normal 
fibroblasts into myofibroblastic CAFs phenotypes with evident contractility, α-SMA 
upregulation and proinflammatory secretory profile, however, IL-6 was not a prominent 
feature in the secretome of these OPN-induced CAFs. Our preliminary investigation 
showed a degree of phenotypic modulation in one NTF culture following rOPN induction, 
with enhanced contractility and slight upregulation of IL-6. These observations warrant 
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further validation using a larger number of cultures, moreover, fibroblast activation status 
should be confirmed by assessing the expression of fibroblasts activation biomarker, 
such as α-SMA. 
 
The reciprocal relationship hypothesis between OPN and IL-6 was tested in one 
direction: we assessed the effect of OPN on IL-6 upregulation. Due to time restriction, 
only one NTF culture (NTF322) was tested and that by targeting the CD44v6 receptor 
alone. OPN has a number of binding sites, including the CD44 receptor and integrins. 
Blocking one of the OPN receptors showed a partial decrease in the effects of OPN in 
OSCC, while the combination of more than receptor blocker resulted in a significant 
reduction in OPN effects (Qin et al., 2018). We observed a degree of IL-6 reduction in 
rOPN-induced NTF, where that was variable in NTF322-induced with cell line 
conditioned media.  
 
Overexpression of OPN in tissue has been linked with disease progression in poor 
prognosis in HNSCC, however, in other a handful of reports demonstrated a favourable 
prognosis value for OPN in pancreas cancer (Collins et al., 2012; Danzaki et al., 2016; 
Franklin et al., 2019). In OPSCC, we observed a strong correlation between high OPN 
IHC expression and a better prognosis. This finding highlights the heterogeneous 
functions of OPN forms and isoforms concerning tumour development and progression. 
OPN functions reported as pro-tumorigenic or anti-tumorigenic according to cell type and 
tumour microenvironment (Lamort et al., 2019). Therefore, further investigation on OPN 
source in OPSCC is needed, which may provide new insights to depict the difference in 















8.2 Conclusion  
 
This study was conducted in a new complex research area concerning the role of CAFs 
in OPSCC subtypes. All the presented data here are original and novel. Although not all 
study’s aims were covered due to the time restrictions imposed due to the COVID-19 
pandemic, the available findings established a strong framework of understanding. The 
isolation and characterisation of OPSCC fibroblasts described here provide a novel 
insight into the role of CAFs in OPSCC mediated by OPSCC cancer cell and CAF 
crosstalk that was evident in HPV-negative cell line. Moreover, it is proposed that ɑ-SMA 
has the potential as a prognostic biomarker for HPV-positive OPSCC stratification. Our 
analysis of OPN in OPSCC demonstrated a positive correlation between OPN 
overexpression and survival that warrants further investigations. 
 
8.2.1 Summary of each chapters’ main findings and clinical 
implications 
Chapter 3: A p16 H-score cut off of 144.5 is a promising diagnostic and prognostic tool 
that demonstrated high sensitivity and acceptable low specificity compared to HPV 16/18 
mRNA, in addition to the predictive performance. This finding underpins the requirement 
of clinical validation of H-score performance that might be adopted as a tool addressing 
the partial stain dilemma between >70% and >50% positivity thresholds. 
 Our findings propose ɑ-SMA expression for further study and clinical validation to 
assess its predictive strength in HPV-positive OPSCC. The findings might provide a 
stratification tool within HPV-positive OPSCC cohorts for the best benefit of de-
intensifying protocols. Moreover, the proposed crucial influences of CAFs in HPV-
OPSCC tumour microenvironment suggest introducing HPV-positive OPSCC as an 
option of the emerging potential targeting strategies in cancer therapy. 
 
Chapter 4: The establishment of OPSCC-CAF co-cultures provides the opportunity for 
further investigations in vitro to aid our understanding of OPSCC tumour cells and CAF 
crosstalk. Recognition of CAF characteristics in different phenotypes provides a 
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framework for better understating of CAFs’ varied role in OPSCC. Moreover, it highlights 
the need to consider multiple parameters for the analysis of CAF activation.  
  
Chapter 5: We have reported, for the first time a number of cytokines secreted 
particularly by HPV-negative OPSCC cell line namely, OPN, KLK6 and GM-CSF, in 
addition to other cytokines produced under all conditions. Molecular analysis of 
interactive co-culture models identified the source of OPN and IL6 production. At the 
basal level, more OPN was produced by HPV-negative cell lines than HPV-positive cell 
lines. Upon 48h of interactive co-culturing, only HPV-negative cell lines demonstrated 
significantly higher levels IL-6 overexpression indicated active crosstalk between cancer 
cells and fibroblasts. These findings underpin the need for better understating the role of 
TME in OPSCC development and progression. 
  
Chapter 7: This is the first study to assess OPN expression in OPSCC in detail. OPN 
has shown different patterns of staining that have been seen in both OPSCC entities. 
Nevertheless, the High OPN expressing OPSCC sub-population demonstrated superior 
survival. Multivariate regression analysis confirmed High OPN expression as an 
independent predictive in OPSCC. However, performing OPN ISH is essential to identify 
the cellular source of OPN in OPSCC and confirm our results. Validation of this finding 
may allow for the development of OPN as a predictive biomarker in OPSCC that could 
be utilised for patient selection in de-intensification protocols. Given the general 
understanding of OPN as a factor facilitating tumour formation and progression, OPN is 
now considered a target for cancer therapy. However, as there is, in some circumstances 
an anti-tumorigenic role for OPN, as reported here (and by some other investigators), 
targeting OPN may also reduce the antitumorigenic features of OPN in this tumour. 
Further investigation, including characterisation of OPN isoforms in OPSCC, might 
provide novel candidates for targeted therapy or avoid the loss of helpful features of OPN 





























• Validataion α-SMA biomarker prognostic value of in a larger OPSCC cohort. 
Determination of HPV status here should be performed using a higher number of 
RNAScope probes.  
 
Chapter 4: 
• Perform scRNA-seq analysis for CAF1 and CAF2 in addition to CAFs cultures 
extracted from HPV-negative OPSCC. Genetic characterisation of OPSCC CAFs 
may expose the heterogeneity of genetic signature for both subtypes. 
Identification of the genetic landscape CAFs may explain different functional role 
in OPSCC stroma and that by referring to The Cancer Genome Atlas (TCGA). 
This work may provide new insights into how OPSCC entities may benefit from 
CAF subtype targeted therapy. 
 
Chapter 5: 
• In the validation process to cytokines arrays findings, CCL2 refractory level was 
assessed using ELISA assay. We noticed higher upregulation in CCL2 level in 
SCC89-fibroblast co-cultured model than SCC2 counterpart. This difference was 
evident with NTFs more than CAFs (Figure 9.1). CCL2 has been reported to exert 
its effect in the recruitment of circulating monocytes in vivo and in a 3D ex-vivo 
model from breast cancer (Jia et al., 2015) Recruitment of macrophages into TME 
mediated by CAFs was reported with different molecular pathways such as 
stromal cell-derived factor 1 (SDF1)/CXCL12 in prostate cancer (Comito et al., 
2014). Investigation of the functional role of CCL2 in OPSCC macrophage 

















Figure 9.1: Higher levels of CCL2 protein secretion in SCC89-fibroblast co-cultures 
than in SCC2-fibroblast co-cultures. SCC89 or SCC2 (3x105 cells) were co-cultured 
with OPSCC fibroblasts (CAF1, CAF2, NTF322, NTF10) (50,000 cells) using transwell 
insert (0.45 μm) for 48h. The collected media was subjected to CCL2 ELISA analysis. 
Samples number (n=8), Y-axis denotes standardised CCL2 concentration in Pg per ml. 
Blue bars denote SCC89 co-cultures. Red bars denote SCC2 co-cultures. Only SCC89 
co-cultures showed apparent OPN expression. Error bars= SD. Data represent the mean 
of (N=3, n=3). Statistical analysis was determined using two-tailed Student t-test with **p 
< 0.01. 
 
• Further investigation of candidates identified by cytokines profiling (KLK6, GM-
CSF) including identification of their production source, the effect on OPSCC 
tumour cells and fibroblasts. 
 
• Investigate OPSCC-CAFs crosstalk at the direct contact approach using a 3-
dimensional organoid model and analysis the sorting cells. The addition of the 
immune cells (macrophage or T-cell) to the 3D-model may reveal the significance 






• In this chapter, the effects of OPN on NTFs activation still require further 
investigation and validation by assessing fibroblasts activation biomarkers in 
larger NTFs cultures numbers.  
 
• In addition to CD44v6 targeting, integrin blocking needs to be assessed to 
understand the correlation between OPN/IL-6 production loop.  
 
• Investigate the effect of IL-6 on OPN derived OPSCC cell lines using a higher IL-
6 dose (50 ng/ml). 
 
• Investigate OPN/CD44/p38 signalling pathway in OPSCC and assess the 
functional role ofp38 expression in OPSCC using functional assays.   
 
Chapter 7: 
• Investigate the possibility of the construction of customised in situ hybridisation 
probes for different OPN mRNA isoforms and types (sOPN and iOPN). 
Identification of OPN source of production may clarify the correlation between 
OPN forms and survival. 
 
• Conducting CD44 IHC assay for the TMA study cohort may reveal further insights 











A.1 HPV profiling for OPSCC cell lines 
 
Name Dilution Other G16 G18 
SCC2 1 in 4156 N P N 
SCC2 1 in 20781 N P N 
SCC2 1 in 33 N P N 
SCC2 1 in 7.5 N P N 
SCC2 1 in 166 N P N 
 
Name Dilution Other G16 G18 
SCC90 1 in 831 N P N 
SCC90 1 in 7.5 N P N 
SCC90 1 in 4156 N P N 
SCC90 1 in 33 N P N 
SCC90 1 in 20781 N P N 
SCC90 1 in 166 N P N 
 
Name Dilution Other G16 G18 
SCC72 1 in 4156 N N N 
SCC72 1 in 831 N N N 
SCC72 1 in 166 N N N 
SCC72 1 in 20781 N N N 




G18 G16 Other Dilution Name 
N N N 1 in 33 SCC89 
N N N 1 in 20781 SCC89 
N N N 1 in 831 SCC89 
N N N 1 in 7.5 SCC89 
N N N 1 in 166 SCC89 
 
Table A.1: Cell lines screening using Roche 6800 instrument for HPV16 (G16) and 














A.2 :  The cytokine arrays (Number ARY026) - Full details.  
The full name of cytokines presented in the proteome profiler Human XL Oncology Array 
kit (Catalogue number ARY026, R&D Systems, Inc., Minneapolis, US) that have been 








A.3 Raybiotech cytokine arrays map   
Maps of Cytokine arrays Raybiotech C2000 Human Cytokine Arrays (Raybio-
technology, Norcross, USA, cat number: AAH-CYT-2000) that have been used by Bolt 





















A.4 Tissue microarrays map 









































Abdel-Hafiz, S. M., Hamdy, H. E. M., Khorshed, F. M., Aboushousha, T. S., Safwat, G., Saber, M. A., 
Seleem, M. and Soliman, A. H. (2018) ‘Evaluation of osteopontin as a biomarker in Hepatocellular 
carcinomas in Egyptian patients with chronic HCV cirrhosis’, Asian Pacific Journal of Cancer 
Prevention, 19(4), pp. 1021–1027. doi: 10.22034/APJCP.2018.19.4.1021. 
Abidin, A. (2017) Role of microRNAs in Determining the Cancer-associated Fibroblast Phenotype. 
Ph.D. Univrsity of Sheffield. 
Acosta, J. C., O’Loghlen, A., Banito, A., Guijarro, M. V., Augert, A., Raguz, S., Fumagalli, M., Da Costa, 
M., Brown, C., Popov, N., Takatsu, Y., Melamed, J., d’Adda di Fagagna, F., Bernard, D., Hernando, E. 
and Gil, J. (2008) ‘Chemokine Signaling via the CXCR2 Receptor Reinforces Senescence’, Cell, 
133(6), pp. 1006–1018. doi: 10.1016/j.cell.2008.03.038. 
Afify, A., Purnell, P. and Nguyen, L. (2009) ‘Role of CD44s and CD44v6 on human breast cancer cell 
adhesion, migration, and invasion’, Experimental and Molecular Pathology, 86(2), pp. 95–100. doi: 
10.1016/j.yexmp.2008.12.003. 
Agorku, D. J., Langhammer, A., Heider, U., Wild, S., Bosio, A. and Hardt, O. (2019) ‘CD49b, CD87, 
and CD95 Are Markers for Activated Cancer-Associated Fibroblasts Whereas CD39 Marks Quiescent 
Normal Fibroblasts in Murine Tumor Models’, Frontiers in Oncology, 9(8), pp. 1–13. doi: 
10.3389/fonc.2019.00716. 
Agrawal, N., Frederick, M. J., Pickering, C. R., Bettegowda, C., Chang, K., Li, R. J., Fakhry, C., Xie, T. 
X., Zhang, J., Wang, J., Zhang, N., El-Naggar, A. K., Jasser, S. A., Weinstein, J. N., Treviño, L., 
Drummond, J. A., Muzny, D. M., Wu, Y., Wood, L. D., Hruban, R. H., Myers, J. N. (2011). Exome 
sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in 
NOTCH1. Science, 333(6046), pp. 1154–1157. https://doi.org/10.1126/science.1206923. 
Ahmad, N., Ammar, A., Storr, S. J., Green, A. R., Rakha, E., Ellis, I. O. and Martin, S. G. (2018) ‘IL-6 
and IL-10 are associated with good prognosis in early stage invasive breast cancer patients’, Cancer 
Immunology, Immunotherapy. Springer Berlin Heidelberg, 67(4), pp. 537–549. doi: 10.1007/s00262-
017-2106-8. 
Aiuti, A., Cicchini, C., Bernardini, S., Fedele, G., Amicone, L., Fantoni, A. and Tripodi, M. (1998) 
‘Hematopoietic support and cytokine expression of murine-stable hepatocyte cell lines (MMH)’, 
Hepatology, 28(6), pp. 1645–1654. doi: 10.1002/hep.510280626. 
Akrish, S. J., Rachmiel, A., Sabo, E., Vered, M. and Ben-Izhak, O. (2017) ‘Cancer-associated 
fibroblasts are an infrequent finding in the microenvironment of proliferative verrucous leukoplakia-
associated squamous cell carcinoma’, Journal of Oral Pathology and Medicine, 46(5), pp. 353–358. 
doi: 10.1111/jop.12503. 
Al-Sahaf, S., Hunter, K. D., Bolt, R., Ottewell, P. D. and Murdoch, C. (2019) ‘The IL-1/IL-1R axis 
induces greater fibroblast-derived chemokine release in human papillomavirus-negative compared to 
positive oropharyngeal cancer’, International Journal of Cancer, 144(2), pp. 334–344. doi: 
10.1002/ijc.31852. 
Alarcon-Martinez, L., Yilmaz-Ozcan, S., Yemisci, M., Schallek, J., Kılıç, K., Can, A., Di Polo, A., & 
Dalkara, T. (2018). Capillary pericytes express α-smooth muscle actin, which requires prevention of 




Albers, A. E., Qian, X., Kaufmann, A. M. and Coordes, A. (2017) ‘Meta analysis: HPV and p16 pattern 
determines survival in patients with HNSCC and identifies potential new biologic subtype’, Scientific 
Reports, 7(1), pp. 1–14. doi: 10.1038/s41598-017-16918-w. 
Alphonso, A. and Alahari, S. K. (2009) ‘Stromal cells and integrins: Conforming to the needs of the 
tumor microenvironment’, Neoplasia, 11(12), pp. 1264–1271. doi: 10.1593/neo.91302. 
Alt, E., Welte, G., Li, J., Hennessy, B. T., Devarajan, E., Krishnappa, S., Pinilla, S., Droll, L. and Jotzu, 
C. (2010) ‘Adipose tissue-derived stem cells differentiate into carcinoma-associated fibroblast-like cells 
under the influence of tumor-derived factors’, Analytical Cellular Pathology, 33(2), pp. 61–79. doi: 
10.3233/ACP-CLO-2010-0535. 
Amin, M. B., Greene, F. L., Edge, S. B., Compton, C. C., Gershenwald, J. E., Brookland, R. K., Meyer, 
L., Gress, D. M., Byrd, D. R. and Winchester, D. P. (2017) ‘The Eighth Edition AJCC Cancer Staging 
Manual: Continuing to build a bridge from a population-based to a more “personalized” approach to 
cancer staging’, CA: A Cancer Journal for Clinicians, 67(2), pp. 93–99. doi: 10.3322/caac.21388. 
Anderson, C. M., Zhang, B., Miller, M., Butko, E., Wu, X., Laver, T., Kernag, C., Kim, J., Luo, Y., 
Lamparski, H., Park, E., Su, N. and Ma, X. J. (2016) ‘Fully Automated RNAscope In Situ Hybridization 
Assays for Formalin-Fixed Paraffin-Embedded Cells and Tissues’, Journal of Cellular Biochemistry, 
2208(5), pp. 2201–2208. doi: 10.1002/jcb.25606. 
Ang, K. K., Harris, J., Wheeler, R., Weber, R., Rosenthal, D. I., Nguyen-Tân, P. F., Westra, W. H., 
Chung, C. H., Jordan, R. C., Lu, C., Kim, H., Axelrod, R., Silverman, C. C., Redmond, K. P. and Gillison, 
M. L. (2010) ‘Human Papillomavirus and Survival of Patients with Oropharyngeal Cancer’, New 
England Journal of Medicine, 363(1), pp. 24–35. doi: 10.1056/NEJMoa0912217. 
Aravind, T., Janardhanan, M., Rakesh, S., Savithri, V., & Unnikrishnan, U. G. (2017). 
Immunolocalization of osteopontin in dysplasias and squamous cell carcinomas arising from oral 
epithelium. Journal of oral and maxillofacial pathology : JOMFP, 21(1), pp. 18–23. 
https://doi.org/10.4103/0973-029X.203764. 
Arina, A., Idel, C., Hyjek, E. M., Alegre, M. L., Wang, Y., Bindokas, V. P., Weichselbaum, R. R. and 
Schreiber, H. (2016) ‘Tumor-associated fibroblasts predominantly come from local and not circulating 
precursors’, Proceedings of the National Academy of Sciences of the United States of America, 
113(27), pp. 7551–7556. doi: 10.1073/pnas.1600363113. 
Assidi, M., Gomaa, W., Jafri, M., Hanbazazh, M., Al-Ahwal, M., Pushparaj, P., Al-Harbi, A., Al-Qahtani, 
M., Buhmeida, A. and Al-Maghrabi, J. (2019) ‘Prognostic value of Osteopontin (SPP1) in colorectal 
carcinoma requires a personalized molecular approach’, Tumor Biology, 41(9), pp. 1–11. doi: 
10.1177/1010428319863627. 
Attieh, Y. and Vignjevic, D. M. (2016) ‘The hallmarks of CAFs in cancer invasion’, European Journal of 
Cell Biology. Elsevier GmbH., 95(11), pp. 493–502. doi: 10.1016/j.ejcb.2016.07.004. 
Augsten M. (2014). Cancer-associated fibroblasts as another polarized cell type of the tumor 
microenvironment. Frontiers in oncology, 4(62). https://doi.org/10.3389/fonc.2014.00062. 
Avery, D., Govindaraju, P., Jacob, M., Todd, L., Monslow, J. and Puré, E. (2018) ‘Extracellular matrix 
directs phenotypic heterogeneity of activated fibroblasts’, Matrix Biology. Elsevier B.V., 67, pp. 90–
106. doi: 10.1016/j.matbio.2017.12.003. 
Avirović, M., Matušan-Ilijaš, K., Damante, G., Fabrro, D., Cerović, R., Juretić, M., Grahovac, B., Jonjić, 
N. and Lučin, K. (2013) ‘Osteopontin expression is an independent factor for poor survival in oral 
321 
 
squamous cell carcinoma: A computer-assisted analysis on TMA sections’, Journal of Oral Pathology 
and Medicine, 42(8), pp. 620–626. doi: 10.1111/jop.12055. 
Baker, S. J., Fearon, E. R., Nigro, J. M., Hamilton, S. R., Preisinger, A. C., Jessup, J. M., vanTuinen, 
P., Ledbetter, D. H., Barker, D. F., Nakamura, Y., White, R., & Vogelstein, B. (1989). Chromosome 17 
deletions and p53 gene mutations in colorectal carcinomas. Science. 244(4901), pp. 217–221. 
https://doi.org/10.1126/science.2649981. 
Bayani, J., & Diamandis, E. P. (2011). The physiology and pathobiology of human kallikrein-related 
peptidase 6 (KLK6). Clinical chemistry and laboratory medicine, 50(2), pp. 211–233. 
https://doi.org/10.1515/CCLM.2011.750 
Bartoschek, M., Oskolkov, N., Bocci, M., Lövrot, J., Larsson, C., Sommarin, M., Madsen, C. D., 
Lindgren, D., Pekar, G., Karlsson, G., Ringnér, M., Bergh, J., Björklund, Å. and Pietras, K. (2018) 
‘Spatially and functionally distinct subclasses of breast cancer-associated fibroblasts revealed by 
single cell RNA sequencing’, Nature Communications. Springer US, 9(1). doi: 10.1038/s41467-018-
07582-3. 
Beaty, B. T., Moon, D. H., Shen, C. J., Amdur, R. J., Weiss, J., Grilley-Olson, J., Patel, S., Zanation, 
A., Hackman, T. G., Thorp, B., Blumberg, J. M., Patel, S. N., Weissler, M. C., Yarbrough, W. G., Sheets, 
N. C., Parker, J. S., Hayes, D. N., Weck, K. E., Ramkissoon, L. A., Mendenhall, W. M., Dagan, R., Tan, 
X., Gupta, G. P. and Chera, B. S. (2020) ‘PIK3CA mutation in HPV-associated OPSCC patients 
receiving deintensified chemoradiation’, Journal of the National Cancer Institute, 112(8), pp. 855–858. 
doi: 10.1093/jnci/djz224. 
Beausejour, C. M., Krtolica, A., Galimi, F., Narita, M., Lowe, S. W., Yaswen, P. and Campisi, J. (2003) 
‘Reversal of human cellular senescence: roles of the p53 and p16 pathways’, The EMBO Journal, 
22(16), pp. 4212–4222. doi: 10.1093/emboj/cdg417. 
Behera, R., Kumar, V., Lohite, K., Karnik, S. and Kundu, G. C. (2010) ‘Activation of JAK2/STAT3 
signaling by osteopontin promotes tumor growth in human breast cancer cells’, Carcinogenesis, 31(2), 
pp. 192–200. doi: 10.1093/carcin/bgp289. 
Benzerdjeb, N., Tantot, J., Blanchet, C., Philouze, P., Mekki, Y., Lopez, J., & Devouassoux-
Shisheboran, M. (2021). Oropharyngeal squamous cell carcinoma: p16/p53 immunohistochemistry as 
a strong predictor of HPV tumor status. Histopathology, 10.1111/his.14350. Advance online 
publication. https://doi.org/10.1111/his.14350. 
Berdiel-Acer, M., Sanz-Pamplona, R., Calon, A., Cuadras, D., Berenguer, A., Sanjuan, X., Paules, M. 
J., Salazar, R., Moreno, V., Batlle, E., Villanueva, A. and Molleví, D. G. (2014) ‘Differences between 
CAFs and their paired NCF from adjacent colonic mucosa reveal functional heterogeneity of CAFs, 
providing prognostic information’, Molecular Oncology, 8(7), pp. 1290–1305. doi: 
10.1016/j.molonc.2014.04.006. 
Berg, T. and Archambault, A. (2010) ‘Small-molecule inhibitors of protein–protein interactions’, Protein-
Protein Complexes: Analysis, Modeling and Drug Design, 514, pp. 318–339. doi: 
10.1142/9781848163409_0012. 
Bernard, H.U., Burk, R. D., Chen, Z., van Doorslaer, K., Hausen, H. zur and de Villiers, E.M. (2010) 
‘Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic 
amendments’, Virology. Academic Press, 401(1), pp. 70–79. doi: 10.1016/J.VIROL.2010.02.002. 
Bhaumik, D., Scott, G. K., Schokrpur, S., Patil, C. K., Orjalo, A. V., Rodier, F., Lithgow, G. J. and 
Campisi, J. (2009) ‘MicroRNAs miR-146a/b negatively modulate the senescence-associated 
322 
 
inflammatory mediators IL-6 and IL-8’, Aging, 1(4), pp. 402–411. doi: 10.18632/aging.100042. 
Bhowmick, N. A., Ghiassi, M., Bakin, A., Aakre, M., Lundquist, C. A., Engel, M. E., Arteaga, C. L. and 
Moses, H. L. (2001) ‘Transforming growth factor-β1 mediates epithelial to mesenchymal 
transdifferentiation through a RhoA-dependent mechanism’, Molecular Biology of the Cell, 12(1), pp. 
27–36. doi: 10.1091/mbc.12.1.27. 
Bhowmick, N.A., Zent, R., Ghiassi, M., McDonnell, M. and Moses, H. L. (2001) ‘Integrin β1 Signaling 
is Necessary for Transforming Growtn Factor-β Activation of p38MAPK and Epithelial Plasticity’, 
Journal of Biological Chemistry.  2001 ASBMB. Currently published by Elsevier Inc; originally published 
by American Society for Biochemistry and Molecular Biology., 276(50), pp. 46707–46713. doi: 
10.1074/jbc.M106176200. 
Biffi, G., Oni, T. E., Spielman, B., Hao, Y., Elyada, E., Park, Y., Preall, J. and Tuveson, D. A. (2019) 
‘Il1-induced Jak/STAT signaling is antagonized by TGFβ to shape CAF heterogeneity in pancreatic 
ductal adenocarcinoma’, Cancer Discovery, 9(2), pp. 282–301. doi: 10.1158/2159-8290.CD-18-0710. 
Biffi, G. and Tuveson, D. A. (2021) ‘Diversity and Biology of Cancer-Associated Fibroblasts’, 
Physiological reviews, 101(1), pp. 147–176. doi: 10.1152/physrev.00048.2019. 
Bishop, J. A. (2015) ‘Histopathology of human papillomavirus-related oropharyngeal carcinoma: a 
review of classic and variant forms’, Diagnostic Histopathology, 21, pp. 70–76. doi: 
10.1016/j.mpdhp.2015.02.001. 
Bishop, J. A., Ma, X. J., Wang, H., Luo, Y., Illei, P. B., Begum, S., Taube, J. M., Koch, W. M. and 
Westra, W. H. (2012) ‘Detection of transcriptionally active high-risk HPV in patients with head and neck 
squamous cell carcinoma as visualized by a novel E6/E7 mRNA in situ hybridization method’, 
American Journal of Surgical Pathology, 36(12), pp. 1874–1882. doi: 
10.1097/PAS.0b013e318265fb2b. 
Blagosklonny, M. V. (2012) ‘Cell cycle arrest is not yet senescence, which is not just cell cycle arrest: 
Terminology for TOR-driven aging’, Aging, 4(3), pp. 159–165. doi: 10.18632/aging.100443. 
Bolt, R. (2016) Novel Biomarkers  in the Management of HPV-Positive &  -Negative Oropharyngeal 
Carcinoma. Ph.D, University of Sheffield. 
Bolt, R., Foran, B., Murdoch, C., Lambert, D. W., Thomas, S. and Hunter, K. D. (2018) ‘HPV-negative, 
but not HPV-positive, oropharyngeal carcinomas induce fibroblasts to support tumour invasion through 
micro-environmental release of HGF and IL-6’, Carcinogenesis, 39(2), pp. 170–179. doi: 
10.1093/carcin/bgx130. 
Borgoño, C. A. and Diamandis, E. P. (2004) ‘The emerging roles of human tissue kallikreins in cancer’, 
Nature Reviews Cancer, 4(11), pp. 876–890. doi: 10.1038/nrc1474. 
Bourassa, B., Monaghan, S., & Rittling, S. R. (2004). Impaired anti-tumor cytotoxicity of macrophages 
from osteopontin-deficient mice. Cellular immunology, 227(1), pp. 1–11. 
https://doi.org/10.1016/j.cellimm.2004.01.001. 
Bouvard, V., Baan, R., Straif, K., Grosse, Y., Secretan, B., El Ghissassi, F., Benbrahim-Tallaa, L., 
Guha, N., Freeman, C., Galichet, L. and Cogliano, V. (2009) ‘A review of human carcinogens--Part B: 
biological agents.’, The lancet oncology, 10(4), pp. 321–322. doi: 10.1016/s1470-2045(09)70096-8. 
Bova, R. J., Quinn, D. I., Nankervis, J. S., Cole, I. E., Sheridan, B. F., Jensen, M. J., Morgan, G. J. and 
Hughes, C. J. (2001) ‘Cyclin D1 expression predicts reduced survival in early stage carcinoma of the 
323 
 
anterior tongue’, Australian Journal of Otolaryngology, 4(1), pp. 41–46. 
Bozõky, B., Savchenko, A., Csermely, P., Korcsmáros, T., Dúl, Z., Pontén, F., Székely, L. and Klein, 
G. (2013) ‘Novel signatures of cancer-associated fibroblasts’, International Journal of Cancer, 133(2), 
pp. 286–293. doi: 10.1002/ijc.28035. 
Braakhuis, B. J., Snijders, P. J., Keune, W. J., Meijer, C. J., Ruijter-Schippers, H. J., Leemans, C. R. 
and Brakenhoff, R. H. (2004) ‘Genetic patterns in head and neck cancers that contain or lack 
transcriptionally active human papillomavirus’, Journal of the National Cancer Institute, 96(13), pp. 
998–1006. doi: 10.1093/jnci/djh183. 
Bramwell, V. H, Doig, G. S., Tuck, A. B., Wilson, S. M., Tonkin, K. S., Tomiak, A., Perera, F., 
Vandenberg, T. A. and Chambers, A. F. (2006) ‘Serial plasma osteopontin levels have prognostic value 
in metastatic breast cancer’, Clinical Cancer Research, 12(11 I), pp. 3337–3343. doi: 10.1158/1078-
0432.CCR-05-2354. 
Bray, F., Ferlay, J. and Soerjomataram, I. (2018) ‘Global Cancer Statistics 2018 : GLOBOCAN 
Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries’, pp. 394–424. doi: 
10.3322/caac.21492. 
Brechbuhl, H. M., Finlay-Schultz, J., Yamamoto, T. M., Gillen, A. E., Cittelly, D. M., Tan, A. C., Sams, 
S. B., Pillai, M. M., Elias, A. D., Robinson, W. A., Sartorius, C. A. and Kabos, P. (2017) ‘Fibroblast 
subtypes regulate responsiveness of luminal breast cancer to estrogen’, Clinical Cancer Research, 
23(7), pp. 1710–1721. doi: 10.1158/1078-0432.CCR-15-2851. 
Brown, L. F., Berse, B., Water, L. Van De, Papadopoulos-sergiou, A., Perruzzi, C. A., Manseau, E. J., 
Dvorak, H. F. and Senger, D. R. (1992) ‘Expression and Distribution of Osteopontin in Human Tissues : 
Widespread Association with Luminal Epithelial Surfaces’, 3(10), pp. 1169–1180. 
Brown, L. F., Papadopoulos-Sergiou, A., Berse, B., Manseau, E. J., Tognazzi, K., Perruzzi, C. A., 
Dvorak, H. F., & Senger, D. R. (1994). Osteopontin expression and distribution in human 
carcinomas. The American journal of pathology, 145(3), pp. 610–623. 
Budu, V. A., Decuseară, T., Balica, N. C., Mogoantă, C. A., Rădulescu, L. M., Chirilă, M., Maniu, A. A., 
Mistra, D. M., Muşat, G. C., Oprişcan, I. C. and Georgescu, M. G. (2019) ‘The role of hpv infection in 
oropharyngeal cancer’, Romanian Journal of Morphology and Embryology, 60(3), pp. 769–773. 
Burd, E. M. (2003) ‘Human papillomavirus and cervical cancer’, Clinical Microbiology Reviews, 16(1), 
pp. 1–17. doi: 10.1128/CMR.16.1.1-17.2003. 
Burk, R. D., Chen, Z., Harari, A., Smith, B. C., Kocjan, B. J., Maver, P. J. and Poljak, M. (2011) 
‘Classification and nomenclature system for Human Alphapapillomavirus variants: general features, 
nucleotide landmarks and assignment of HPV6 and HPV11 isolates to variant lineages’, Acta 
Dermatovenrol Alip Panonica Adriat, 20(3), pp. 113–123. 
Byers, L. A., Holsinger, F. C., Kies, M. S., William, W. N., El-naggar, A. K., Lee, J. J., Hu, J., Lopez, 
A., Tran, H. T., Du, Z., Ang, K. K., Glisson, B. S., Raso, M. G., Ignacio, I., Myers, J. N., Hong, W., 
Papadimitrakopoulou, V., Scott, M. and Heymach, J. V (2011) ‘Serum signature of hypoxia-regulated 
factors is associated with progression after induction therapy in head and neck squamous cell cancer’, 
9(6), pp. 1755–1763. doi: 10.1158/1535-7163.MCT-09-1047.Serum. 
Bzhalava, D., Eklund, C., & Dillner, J. (2015). International standardization and classification of human 
papillomavirus types. Virology, 476, pp. 341–344. https://doi.org/10.1016/j.virol.2014.12.028. 
324 
 
Caja, L., Dituri, F., Mancarella, S., Caballero-Diaz, D., Moustakas, A., Giannelli, G. and Fabregat, I. 
(2018) ‘TGF-β and the tissue microenvironment: Relevance in fibrosis and cancer’, International 
Journal of Molecular Sciences, 19(5). doi: 10.3390/ijms19051294. 
Cajone, F. and Sherbet, G. V. (1999) ‘Stathmin is involved in S100A4-mediated regulation of cell cycle 
progression’, Clinical and Experimental Metastasis, 17(10), pp. 865–871. doi: 
10.1023/A:1006778804532. 
Camussi, G., Deregibus, M. C., Bruno, S., Cantaluppi, V. and Biancone, L. (2010) ‘Exosomes / 
microvesicles as a mechanism of cell-to-cell communication’, Kidney International. Elsevier Masson 
SAS, 78(9), pp. 838–848. doi: 10.1038/ki.2010.278. 
Cantor, H. and Shinohara, M. L. (2009) ‘Regulation of T-helper-cell lineage development by 
osteopontin: The inside story’, Nature Reviews Immunology, 9(2), pp. 137–141. doi: 10.1038/nri2460. 
Carpén, T., Saarilahti, K., Haglund, C., Markkola, A., Tarkkanen, J., Hagström, J., Mattila, P., & Mäkitie, 
A. (2018). Tumor volume as a prognostic marker in p16-positive and p16-negative oropharyngeal 
cancer patients treated with definitive intensity-modulated radiotherapy. Comparative Study. 194(8), 
pp. 759–770. https://doi.org/10.1007/s00066-018-1309-z. 
Castello, L. M., Raineri, D., Salmi, L., Clemente, N., Vaschetto, R., Quaglia, M., Garzaro, M., Gentilli, 
S., Navalesi, P., Cantaluppi, V., Dianzani, U., Aspesi, A., & Chiocchetti, A. (2017). Osteopontin at the 
Crossroads of Inflammation and Tumor Progression. Mediators of inflammation, 2017, 4049098. 
https://doi.org/10.1155/2017/4049098 
Celetti, A., Testa, D., Staibano, S., Merolla, F., Guarino, V., Castellone, M. D., Iovine, R., Mansueto, 
G., Somma, P., De Rosa, G., Galli, V., Melillo, R. M. and Santoro, M. (2005) ‘Overexpression of the 
cytokine osteopontin identifies aggressive laryngeal squamous cell carcinomas and enhances 
carcinoma cell proliferation and invasiveness’, Clinical Cancer Research, 11(22), pp. 8019–8027. doi: 
10.1158/1078-0432.CCR-05-0641. 
Chakraborty, D., Viveka, T. S., Arvind, K., Shyamsundar, V., Kanchan, M., Alex, S. A., 
Chandrasekaran, N., Vijayalakshmi, R., & Mukherjee, A. (2018). A facile gold nanoparticle-based 
ELISA system for detection of osteopontin in saliva: Towards oral cancer diagnostics. Clinica chimica 
acta; international journal of clinical chemistry, 477, pp. 166–172. 
https://doi.org/10.1016/j.cca.2017.09.009. 
Chan, P. K., Luk, A. C., Park, J. S., Smith-McCune, K. K., Palefsky, J. M., Konno, R., Giovannelli, L., 
Coutlée, F., Hibbitts, S., Chu, T. Y., Settheetham-Ishida, W., Picconi, M. A., Ferrera, A., De Marco, F., 
Woo, Y. L., Raiol, T., Piña-Sánchez, P., Cheung, J. L., Bae, J. H., Chirenje, M. Z., Banks, L. (2011). 
Identification of human papillomavirus type 58 lineages and the distribution worldwide. The Journal of 
infectious diseases, 203(11), pp.1565–1573. https://doi.org/10.1093/infdis/jir157. 
Chandrasekhar, S., Sorrentino, J. A. and Millis, A. J. (1983) ‘Interaction of fibronectin with collagen: 
age-specific defect in the biological activity of human fibroblast fibronectin.’, Proceedings of the 
National Academy of Sciences of the United States of America, 80(15), pp. 4747–4751. doi: 
10.1073/pnas.80.15.4747. 
Chang, P., Harkins, L., Hsieh, Y., Hicks, P., Sappayatosok, K., Yodsanga, S., Swasdison, S., 
Chambers, A. F., Elmets, C. A. and Ho, K. (2008) ‘Osteopontin Expression in Normal Skin and Non-
melanoma Skin Tumors The Journal of Histochemistry & Cytochemistry’, 56(1), pp. 57–66. doi: 
10.1369/jhc.7A7325.2007. 
Chaudhri, V. K., Salzler, G. G., Dick, S. A., Buckman, M. S., Sordella, R., Karoly, E. D., Mohney, R., 
325 
 
Stiles, B. M., Elemento, O., Altorki, N. K., & McGraw, T. E. (2013). Metabolic alterations in lung cancer-
associated fibroblasts correlated with increased glycolytic metabolism of the tumor. Molecular cancer 
research : MCR, 11(6), 579–592. https://doi.org/10.1158/1541-7786.MCR-12-0437-T. 
Che, C., Liu, J., Yang, J., Ma, L., Bai, N. and Zhang, Q. (2018) ‘Osteopontin is essential for IL-1β 
production and apoptosis in peri-implantitis’, Clinical Implant Dentistry and Related Research, 20(3), 
pp. 384–392. doi: 10.1111/cid.12592. 
Chen, C., Zhao, S., Karnad, A. and Freeman, J. W. (2018) ‘The biology and role of CD44 in cancer 
progression: Therapeutic implications’, Journal of Hematology and Oncology. Journal of Hematology 
& Oncology, 11(1), pp. 1–23. doi: 10.1186/s13045-018-0605-5. 
Chen, J., Yang, P., Xiao, Y., Zhang, Y., Liu, J., Xie, D., Cai, M. and Zhang, X. (2017) ‘Overexpression 
of α-sma-positive fibroblasts (CAFs) in nasopharyngeal Carcinoma predicts poor prognosis’, Journal 
of Cancer, 8(18), pp. 3897–3902. doi: 10.7150/jca.20324. 
Chen, J., Zhou, J., Lu, J., Xiong, H., Shi, X. and Gong, L. (2014) ‘Significance of CD44 expression in 
head and neck cancer: A systemic review and meta-analysis’, BMC Cancer, 14(1), pp. 1–9. doi: 
10.1186/1471-2407-14-15. 
Chen, L., Mayer, J. A., Krisko, T. I., Speers, C. W., Wang, T., Hilsenbeck, S. G. and Brown, P. H. 
(2009) ‘Inhibition of the p38 kinase suppresses the proliferation of human ER-negative breast cancer 
cells’, Cancer Research, 69(23), pp. 8853–8861. doi: 10.1158/0008-5472.CAN-09-1636. 
Chen, S. Y., Massa, S., Mazul, A. L., Kallogjeri, D., Yaeger, L., Jackson, R. S., Zevallos, J. and Pipkorn, 
P. (2020) ‘The association of smoking and outcomes in HPV-positive oropharyngeal cancer: A 
systematic review’, American Journal of Otolaryngology - Head and Neck Medicine and Surgery. 
Elsevier, 41(5), p. 102592. doi: 10.1016/j.amjoto.2020.102592. 
Chen, W, J., Li, C., Pierson, C. R., Finlay, J. L. and Lin, J. (2018) ‘Blocking interleukin-6 signaling 
inhibits cell viability/proliferation, glycolysis, and colony forming activity of human medulloblastoma 
cells’, International Journal of Oncology, 52(2), pp. 571–578. doi: 10.3892/ijo.2017.4211. 
Chen, X., Luther, G., Zhang, W., Nan, G., Wagner, E. R., Liao, Z., Wu, N., Zhang, H., Wang, N., Wen, 
S., He, Y., Deng, F., Zhang, J., Wu, D., Zhang, B., Haydon, R. C., Zhou, L., Luu, H. H. and He, T. C. 
(2013) ‘The E-F hand calcium-binding protein s100a4 regulates the proliferation, survival and 
differentiation potential of human osteosarcoma cells’, Cellular Physiology and Biochemistry, 32(4), 
pp. 1083–1096. doi: 10.1159/000354508. 
Chen, X. and Thibeault, S. (2012a) ‘Cell–cell interaction between vocal fold fibroblasts and bone 
marrow mesenchymal stromal cells in three-dimensional hyaluronan hydrogel’, Physiology & behavior, 
176(1), pp. 100–106. doi: 10.1002/term.1757.Cell. 
Chen, X and Thibeault, S. L. (2012b) ‘Response of fibroblasts to transforming growth factor-β1 on two-
dimensional and in three-dimensional hyaluronan hydrogels’, Tissue Engineering - Part A, 18(23–24), 
pp. 2528–2538. doi: 10.1089/ten.tea.2012.0094. 
Chen, Y. W., Chen, K. H., Huang, P. I., Chen, Y. C., Chiou, G. Y., Lo, W. L., Tseng, L. M., Hsu, H. S., 
Chang, K. W. and Chiou, S. H. (2010) ‘Cucurbitacin I suppressed stem-like property and enhanced 
radiation-induced apoptosis in head and neck squamous carcinoma-derived CD44 +ALDH1+ cells’, 
Molecular Cancer Therapeutics, 9(11), pp. 2879–2892. doi: 10.1158/1535-7163.MCT-10-0504. 
326 
 
Chien, C. Y., Su, C. Y., Chuang, H. C., Fang, F. M., Huang, H. Y., Chen, C. M., Chen, C. H., & Huang, 
C. C. (2008). Clinical significance of osteopontin expression in T1 and T2 tongue cancers. Head & 
neck, 30(6), pp. 776–781.https://doi.org/10.1002/hed.20783. 
 
Chien, C., Su, C., Chuang, H., Fang, F. and Huang, H. (2009) ‘Comprehensive study on the prognostic 
role of osteopontin expression in oral squamous cell carcinoma’, Oral Oncology. Elsevier Ltd, 45(9), 
pp. 798–802. doi: 10.1016/j.oraloncology.2008.12.006. 
Chien, Y., Scuoppo, C., Wang, X., Fang, X., Balgley, B., Bolden, J. E., Premsrirut, P., Luo, W., Chicas, 
A., Lee, C. S., Kogan, S. C. and Lowe, S. W. (2011) ‘Control of the senescence-associated secretory 
phenotype by NF-κB promotes senescence and enhances chemosensitivity’, Genes and 
Development, 25(20), pp. 2125–2136. doi: 10.1101/gad.17276711. 
Chiu, Y., Tu, H., Wang, I., Wu, C., Chang, K. and Liu, T. (2010) ‘The implication of osteopontin (OPN) 
expression and genetic polymorphisms of OPN promoter in oral carcinogenesis’, Oral Oncology. 
Elsevier Ltd, 46(4), pp. 302–306. doi: 10.1016/j.oraloncology.2010.01.018. 
Cho, H., Hong, S. W., Oh, Y. J., Kim, M. A., Kang, E. S., Lee, J. M., Kim, S. W., Kim, S. H., Kim, J. H., 
Kim, Y. T., & Lee, K. (2008). Clinical significance of osteopontin expression in cervical cancer. Journal 
of cancer research and clinical oncology, 134(8), pp. 909–917. https://doi.org/10.1007/s00432-007-
0351-5. 
Choudhary, M. M., France, T. J., Teknos, T. N. and Kumar, P. (2016) ‘Interleukin-6 role in head and 
neck squamous cell carcinoma progression Production and Hosting by Elsevier on behalf of KeAi’, 
World Journal of Otorhinolaryngology-Head and Neck Surgery, 2, pp. 90–97. doi: 
10.1016/j.wjorl.2016.05.002. 
Christensen, B., Petersen, T. E. and Sørensen, E. S. (2008) ‘Post-translational modification and 
proteolytic processing of urinary osteopontin’, Biochemical Journal, 411(1), pp. 53–61. doi: 
10.1042/BJ20071021. 
Chu, A., Genden, E., Posner, M. and Sikora, A. (2013) ‘A patient-centered approach to counseling 
patients with head and neck cancer undergoing human papillomavirus testing: a clinician’s guide.’, The 
oncologist. AlphaMed Press, 18(2), pp. 180–9. doi: 10.1634/theoncologist.2012-0200. 
Cirri, P., & Chiarugi, P. (2011). Cancer associated fibroblasts: the dark side of the coin. American 
journal of cancer research, 1(4), pp. 482–497. 
Cirri, P. and Chiarugi, P. (2012) ‘Cancer-associated-fibroblasts and tumour cells: A diabolic liaison 
driving cancer progression’, Cancer and Metastasis Reviews, 31(1–2), pp. 195–208. doi: 
10.1007/s10555-011-9340-x. 
Clemente, N., Raineri, D., Cappellano, G., Boggio, E., Favero, F., Soluri, M., Dianzani, C., Comi, C., 
Dianzani, U. and Chiocchetti, A., 2016. Osteopontin Bridging Innate and Adaptive Immunity in 
Autoimmune Diseases. Journal of Immunology Research, 2016, pp.1-15. 
Cohen, E. R., Reis, I. M., Gomez, C., Pereira, L., Freiser, M. E., Hoosien, G. and Franzmann, E. J. 
(2017) ‘Immunohistochemistry Analysis of CD44, EGFR, and p16 in Oral Cavity and Oropharyngeal 
Squamous Cell Carcinoma’, Otolaryngology - Head and Neck Surgery (United States), 157(2), pp. 
239–251. doi: 10.1177/0194599817700371. 
Collins, A. L., Rock, J., Malhotra, L., Frankel, W. L. and Bloomston, M. (2012) ‘Osteopontin Expression 
is Associated with Improved Survival in Patients with Pancreatic Adenocarcinoma’, Bone, 23(1), pp. 
1–7. doi: 10.1245/s10434-012-2337-z.Osteopontin. 
327 
 
Comito, G., Giannoni, E., Segura, C. P., Barcellos-De-Souza, P., Raspollini, M. R., Baroni, G., 
Lanciotti, M., Serni, S. and Chiarugi, P. (2014) ‘Cancer-associated fibroblasts and M2-polarized 
macrophages synergize during prostate carcinoma progression’, Oncogene. Nature Publishing Group, 
33(19), pp. 2423–2431. doi: 10.1038/onc.2013.191. 
Coppé, J.P., Desprez, P.Y., Krtolica, A. and Campisi, J. (2010) ‘The Senescence-Associated Secretory 
Phenotype: The Dark Side of Tumor Suppression’, Annual Review of Pathology: Mechanisms of 
Disease, 5(1), pp. 99–118. doi: 10.1146/annurev-pathol-121808-102144. 
Coppé, J.P., Patil, C. K., Rodier, F., Sun, Y., Muñoz, D. P., Goldstein, J., Nelson, P. S., Desprez, P.-
Y. and Campisi, J. (2008) ‘Senescence-Associated Secretory Phenotypes Reveal Cell-
Nonautonomous Functions of Oncogenic RAS and the p53 Tumor Suppressor’, PLoS Biology. Edited 
by J. Downward. Public Library of Science, 6(12), p. e301. doi: 10.1371/journal.pbio.0060301. 
Coppola, D., Szabo, M., Boulware, D., Muraca, P., Alsarraj, M., Chambers, A. F., & Yeatman, T. J. 
(2004). Correlation of osteopontin protein expression and pathological stage across a wide variety of 
tumor histologies. Clinical cancer research: an official journal of the American Association for Cancer 
Research, 10(11), pp. 184–190. https://doi.org/10.1158/1078-0432.ccr-1405-2. 
Corey, A. S. and Hudgins, P. A. (2012) ‘Radiographic Imaging of Human Papillomavirus Related 
Carcinomas of the Oropharynx’, Head and Neck Pathology, 6(S1), pp. 25–40. doi: 10.1007/s12105-
012-0374-3. 
Costa, A., Kieffer, Y., Scholer-Dahirel, A., Pelon, F., Bourachot, B., Cardon, M., Sirven, P., Magagna, 
I., Fuhrmann, L., Bernard, C., Bonneau, C., Kondratova, M., Kuperstein, I., Zinovyev, A., Givel, A. M., 
Parrini, M. C., Soumelis, V., Vincent-Salomon, A. and Mechta-Grigoriou, F. (2018) ‘Fibroblast 
Heterogeneity and Immunosuppressive Environment in Human Breast Cancer’, Cancer Cell. Elsevier, 
33(3), pp. 463-479.e10. doi: 10.1016/j.ccell.2018.01.011. 
Costa, A., Scholer-Dahirel, A. and Mechta-Grigoriou, F. (2014) ‘The role of reactive oxygen species 
and metabolism on cancer cells and their microenvironment’, Seminars in Cancer Biology. Elsevier 
Ltd, 25, pp. 23–32. doi: 10.1016/j.semcancer.2013.12.007. 
Costea, D. E., Hills, A., Osman, A. H., Thurlow, J., Kalna, G., Huang, X., Murillo, C. P., Parajuli, H., 
Suliman, S., Kulasekara, K. K., Johannessen, A. C. and Partridge, M. (2013) ‘Identification of two 
distinct carcinoma-associated fibroblast subtypes with differential tumor-promoting abilities in oral 
squamous cell carcinoma’, Cancer Research, 73(13), pp. 3888–3901. doi: 10.1158/0008-5472.CAN-
12-4150. 
Courter, D., Cao, H., Kwok, S., Kong, C., Banh, A., Kuo, P., Bouley, D. M., Vice, C., Brustugun, O. T., 
Denko, N. C., Koong, A. C., Giaccia, A. and Le, Q. T. (2010) ‘The RGD domain of human osteopontin 
promotes tumor growth and metastasis through activation of survival pathways’, PLoS ONE, 5(3). doi: 
10.1371/journal.pone.0009633. 
Craig, S. G., Anderson, L. A., Moran, M., Graham, L., Currie, K., Rooney, K., Robinson, M., Bingham, 
V., Cuschieri, K. S., McQuaid, S., Schache, A. G., Jones, T. M., McCance, D., Salto-Tellez, M., 
McDade, S. S. and James, J. A. (2020) ‘Comparison of molecular assays for HPV testing in 
oropharyngeal squamous cell carcinomas: A population-based study in Northern Ireland’, Cancer 
Epidemiology Biomarkers and Prevention, 29, pp. 31–38. doi: 10.1158/1055-9965.EPI-19-0538. 
Craig, S. G., Anderson, L. A., Schache, A. G., Moran, M., Graham, L., Currie, K., Rooney, K., Robinson, 
M., Upile, N. S., Brooker, R., Mesri, M., Bingham, V., McQuaid, S., Jones, T., McCance, D. J., Salto-
Tellez, M., McDade, S. S. and James, J. A. (2019) ‘Recommendations for determining HPV status in 
patients with oropharyngeal cancers under TNM8 guidelines: a two-tier approach’, British Journal of 
328 
 
Cancer. Springer US, 120(8), pp. 827–833. doi: 10.1038/s41416-019-0414-9. 
Crawford, H. C., Matrisian, L. M., & Liaw, L. (1998). Distinct roles of osteopontin in host defense activity 
and tumor survival during squamous cell carcinoma progression in vivo. Cancer research, 58(22), 
5206–5215. 
Custódio, M., Biddle, A. and Tavassoli, M. (2020) ‘Portrait of a CAF: The story of cancer-associated 
fibroblasts in head and neck cancer’, Oral Oncology. Elsevier, 110(8), pp. 104972. doi: 
10.1016/j.oraloncology.2020.104972. 
Cuthbert, A. P., Bond, J., Trott, D. A., Gill, S., Broni, J., Marriott, A., Khoudoli, G., Parkinson, E. K., 
Cooper, C. S. and Newbold, R. F. (1999) ‘Telomerase repressor sequences on chromosome 3 and 
induction of permanent growth arrest in human breast cancer cells’, Journal of the National Cancer 
Institute, 91(1), pp. 37–45. doi: 10.1093/jnci/91.1.37. 
D’Souza, G., Kreimer, A. R., Viscidi, R., Pawlita, M., Fakhry, C., Koch, W. M., Westra, W. H. and 
Gillison, M. L. (2007) ‘Case–Control Study of Human Papillomavirus and Oropharyngeal Cancer’, New 
England Journal of Medicine, 356(19), pp. 1944–1956. doi: 10.1056/NEJMoa065497. 
Dai, J., Peng, L., Fan, K., Wang, H., Wei, R., Ji, G., Cai, J., Lu, B., Li, B., Zhang, D., Kang, Y., Tan, M., 
Qian, W. and Guo, Y. (2009) ‘Osteopontin induces angiogenesis through activation of PI3K/AKT and 
ERK1/2 in endothelial cells’, Oncogene, 28(38), pp. 3412–3422. doi: 10.1038/onc.2009.189. 
Dangi-Garimella, S., Krantz, S. B., Barron, M. R., Shields, M. A., Heiferman, M. J., Grippo, P. J., 
Bentrem, D. J. and Munshi, H. G. (2011) ‘Three-dimensional collagen I promotes gemcitabine 
resistance in pancreatic cancer through MT1-MMP-mediated expression of HMGA2’, Cancer 
Research, 71(3), pp. 1019–1028. doi: 10.1158/0008-5472.CAN-10-1855. 
Dangi-Garimella, S., Sahai, V., Ebine, K., Kumar, K. and Munshi, H. G. (2013) ‘Three-Dimensional 
Collagen I Promotes Gemcitabine Resistance In Vitro in Pancreatic Cancer Cells through HMGA2-
Dependent Histone Acetyltransferase Expression’, PLoS ONE, 8(5), pp. 1–9. doi: 
10.1371/journal.pone.0064566. 
Danos, O., Katinka, M., & Yaniv, M. (1982). Human papillomavirus 1a complete DNA sequence: 
a novel type of genome organization among papovaviridae. The EMBO journal, 1(2), pp.231–
236. 
Danzaki, K., Kanayama, M., Alcazar, O. and Shinohara, M., 2016. Osteopontin has a protective 
role in prostate tumor development in mice. European Journal of Immunology, 46(11), pp.2669-
2678. 
Darling, M. R., Jackson-Boeters, L., Daley, T. D. and Diamandis, E. P. (2006) ‘Human kallikrein 6 
expression in salivary gland tumors’, Journal of Histochemistry and Cytochemistry, 54(3), pp. 337–
342. doi: 10.1369/jhc.5A6803.2005. 
Davidson, S., Efremova, M., Riedel, A., Mahata, B., Pramanik, J., Huuhtanen, J., Kar, G., Vento-
Tormo, R., Hagai, T., Chen, X., Haniffa, M. A., Shields, J. D. and Teichmann, S. A. (2020) ‘Single-Cell 
RNA Sequencing Reveals a Dynamic Stromal Niche That Supports Tumor Growth’, Cell Reports. 
ElsevierCompany., 31(7), pp. 107628. doi: 10.1016/j.celrep.2020.107628. 
Demaria, M., O’Leary, M. N., Chang, J., Shao, L., Liu, S., Alimirah, F., Koenig, K., Le, C., Mitin, N., 
Deal, A. M., Alston, S., Academia, E. C., Kilmarx, S., Valdovinos, A., Wang, B., De Bruin, A., Kennedy, 
B. K., Melov, S., Zhou, D., Sharpless, N. E., Muss, H. and Campisi, J. (2017) ‘Cellular senescence 




Denhardt, D. T., Noda, M., O’Regan, A. W., Pavlin, D. and Berman, J. S. (2001) ‘Osteopontin as a 
means to cope with environmental insults: Regulation of inflammation, tissue remodeling, and cell 
survival’, Journal of Clinical Investigation, 107(9), pp. 1055–1061. doi: 10.1172/JCI12980. 
Desai, B., Rogers, M. J. and Chellaiah, M. A. (2007) ‘Mechanisms of osteopontin and CD44 as 
metastatic principles in prostate cancer cells’, Molecular Cancer, 6, pp. 1–16. doi: 10.1186/1476-4598-
6-18. 
Desai, V. D., Hsia, H. C. and Schwarzbauer, J. E. (2014) ‘Reversible modulation of myofibroblast 
differentiation in adipose-derived mesenchymal stem cells’, PLoS ONE, 9(1), pp. 1–12. doi: 
10.1371/journal.pone.0086865. 
Desmouliere, A., Geinoz, A., Gabbiani, F. and Gabbiani, G. (1993) ‘Transforming growth factor-β1 
induces α-smooth muscle actin expression in granulation tissue myofibroblasts and in quiescent and 
growing cultured fibroblasts’, Journal of Cell Biology, 122(1), pp. 103–111. doi: 10.1083/jcb.122.1.103. 
Desmouliere, A., Redard, M., Darby, I. and Gabbiani, G. (1995) ‘Apoptosis mediates the decrease in 
cellularity during the transition between granulation tissue and scar’, American Journal of Pathology, 
146(1), pp. 56–66. 
Dickstein, D. R., Egerman, M. A., Bui, A. H., Doucette, J. T., Sharma, S., Liu, J., Gupta, V., Miles, B. 
A., Genden, E., Westra, W. H., Misiukiewicz, K., Posner, M. R., & Bakst, R. L. (2020). A new face of 
the HPV epidemic: Oropharyngeal cancer in the elderly. Oral oncology, 109, 104687. Advance online 
publication. https://doi.org/10.1016/j.oraloncology.2020.104687. 
Dimri, G., Lee, X., Basile, G., Acosta, M., Scott, G., Roskelley, C., Medrano, E., Linskens, M., 
Rubelj, I. and Pereira-Smith, O., 1995. A biomarker that identifies senescent human cells in 
culture and in aging skin in vivo. Proceedings of the National Academy of Sciences, 92(20), 
pp.9363-9367. 
Dionísio de Sousa, I. J., Marques, D. S., Príncipe, C., Portugal, R. V., Canberk, S., Prazeres, H., Lopes, 
J. M., Gimba, E., Lima, R. T., & Soares, P. (2020). Predictive Biomarkers and Patient Outcome in 
Platinum-Resistant (PLD-Treated) Ovarian Cancer. Diagnostics (Basel, Switzerland), 10(8), 525. 
https://doi.org/10.3390/diagnostics10080525. 
Dourado, M. R., Guerra, E. N. S., Salo, T., Lambert, D. W. and Coletta, R. D. (2018) ‘Prognostic value 
of the immunohistochemical detection of cancer-associated fibroblasts in oral cancer: A systematic 
review and meta-analysis’, Journal of Oral Pathology and Medicine, 47(5), pp. 443–453. doi: 
10.1111/jop.12623. 
Driver, J., Weber, C., Callaci, J., Kothari, A., Zapf, M., Roper, P., Borys, D., Franzen, C., Gupta, 
G., Wai, P., Zhang, J., Denning, M., Kuo, P. and Mi, Z., 2015. Alcohol Inhibits Osteopontin-
dependent Transforming Growth Factor-β1 Expression in Human Mesenchymal Stem 
Cells. Journal of Biological Chemistry, 290(16), pp.9959-9973. 
Druelle, C., Drullion, C., Deslé, J., Martin, N., Saas, L., Cormenier, J., Malaquin, N., Huot, L., 
Slomianny, C., Bouali, F., Vercamer, C., Hot, D., Pourtier, A., Chevet, E., Abbadie, C. and Pluquet, O. 
(2016) ‘ATF6a regulates morphological changes associated with senescence in human fibroblasts’, 
Oncotarget, 7(42), pp. 67699–67715. doi: 10.18632/oncotarget.11505. 
Dulauroy, S., Di Carlo, S. E., Langa, F., Eberl, G. and Peduto, L. (2012) ‘Lineage tracing and genetic 
330 
 
ablation of ADAM12 + perivascular cells identify a major source of profibrotic cells during acute tissue 
injury’, Nature Medicine, 18(8), pp. 1262–1270. doi: 10.1038/nm.2848. 





AE27$CEstByCountryTable$X4_19-AE27> [Accessed 20 March 2021]. 
Elkabets, M., Gifford, A. M., Scheel, C., Nilsson, B., Reinhardt, F., Bray, M. A., Carpenter, A. E., 
Jirström, K., Magnusson, K., Ebert, B. L., Pontén, F., Weinberg, R. A. and McAllister, S. S. (2011) 
‘Human tumors instigate granulin-expressing hematopoietic cells that promote malignancy by 
activating stromal fibroblasts in mice’, Journal of Clinical Investigation, 121(2), pp. 784–799. doi: 
10.1172/JCI43757. 
Elmusrati, A., 2020. The Role of Cancer Associated Fibroblasts in Bone Invasive Oral Squamous Cell 
Carcinoma. Ph.D. University of Sheffield. 
Elmusrati, A. A., Pilborough, A. E., Khurram, S. A. and Lambert, D. W. (2017) ‘Cancer-associated 
fibroblasts promote bone invasion in oral squamous cell carcinoma’, British Journal of Cancer. Nature 
Publishing Group, 117(6), pp. 867–875. doi: 10.1038/bjc.2017.239. 
El-Naggar AK, Chan JKC, Grandis JR, Slootweg PJ. WHO Classification of Head and Neck Tumours. 
(2017) ISBN: 9789283224389. 
Erez, N., Truitt, M., Olson, P. and Hanahan, D. (2009) ‘Cancer-Associated Fibroblasts Are Activated 
in Incipient Neoplasia to Orchestrate Tumor-Promoting Inflammation in an NF-κB-Dependent Manner’, 
Cancer Cell, 17, pp. 135–147. doi: 10.1016/j.ccr.2009.12.041. 
Erkvliet, N. K., Aad, Z. S., Oig, G. S. D. and Hambers, A. F. C. (1998) ‘Osteopnotin in expression in a 
group of lymph node negative breast cancer patients’, Human Cancer. 79(5), pp. 502–508.  
doi:10.1002/(SICI)1097-0215(19981023)79. 
Evans, M., Newcombe, R., Fiander, A., Powell, J., Rolles, M., Thavaraj, S., Robinson, M., & Powell, 
N. (2013). Human Papillomavirus-associated oropharyngeal cancer: an observational study of 
diagnosis, prevalence and prognosis in a UK population. BMC cancer, 13, 220. 
https://doi.org/10.1186/1471-2407-13-220. 
Eyden, B., Banerjee, S. S., Shenjere, P. and Fisher, C. (2009) ‘The myofibroblast and its tumours’, 
Journal of Clinical Pathology, 62(3), pp. 236–249. doi: 10.1136/jcp.2008.061630. 
Fafián-Labora, J. A. and O’Loghlen, A. (2020) ‘Classical and Nonclassical Intercellular Communication 
in Senescence and Ageing’, Trends in Cell Biology, 30(8), pp. 628–639. doi: 
10.1016/j.tcb.2020.05.003. 
Fakhry, C., Lacchetti, C., Rooper, L. M., Jordan, R. C., Rischin, D., Sturgis, E. M., Bell, D., Lingen, M. 
W., Harichand-Herdt, S., Thibo, J., Zevallos, J. and Perez-Ordonez, B. (2018) ‘Human papillomavirus 
testing in head and neck carcinomas: ASCO clinical practice guideline endorsement of the college of 
American pathologists guideline’, Journal of Clinical Oncology, 36(31), pp. 3152–3161. doi: 
10.1200/JCO.18.00684. 
Ferreira, L. B., Tavares, C., Pestana, A., Pereira, C. L., Eloy, C., Pinto, M. T., Castro, P., Batista, R., 
Rios, E., Sobrinho-Simões, M., Pereira Gimba, E. R. and Soares, P. (2016) ‘Osteopontin-a splice 
331 
 
variant is overexpressed in papillary thyroid carcinoma and modulates invasive behavior’, Oncotarget, 
7(32), pp. 52003–52016. doi: 10.18632/oncotarget.10468. 
Ferris, R. L., Martinez, I., Sirianni, N., Wang, J., Gollin, S. M., Johnson, J. T. and Khan, S. (2005) 
‘Human papillomavirus-16 associated squamous cell carcinoma of the head and neck ( SCCHN ): A 
natural disease model provides insights into viral carcinogenesis’, Euorpean Journal of Cancer. 41, 
pp. 807–815. doi: 10.1016/j.ejca.2004.11.023. 
Fiori, M. E., Di Franco, S., Villanova, L., Bianca, P., Stassi, G. and De Maria, R. (2019) ‘Cancer-
associated fibroblasts as abettors of tumor progression at the crossroads of EMT and therapy 
resistance’, Molecular Cancer. Molecular Cancer, 18(1), pp. 1–16. doi: 10.1186/s12943-019-0994-2. 
Fischer, K. R., Durrans, A., Lee, S., Sheng, J., Li, F., Wong, S. T. C., Choi, H., El Rayes, T., Ryu, S., 
Troeger, J., Schwabe, R. F., Vahdat, L. T., Altorki, N. K., Mittal, V. and Gao, D. (2015) ‘Epithelial-to-
mesenchymal transition is not required for lung metastasis but contributes to chemoresistance’, 
Nature. Nature Publishing Group, 527(7579), pp. 472–476. doi: 10.1038/nature15748. 
Fisher, L. W. and Ogbureke, K. U. E. (2007) ‘SIBLING Expression Patterns in Duct Epithelia Reflect 
the Degree of Metabolic Activity’, 55(4), pp. 403–409. doi: 10.1369/jhc.6A7075.2007. 
Fisher, L. W., Torchia, D. A., Fohr, B., Young, M. F. and Fedarko, N. S. (2001) ‘Flexible structures of 
SIBLING proteins, bone sialoprotein, and osteopontin’, Biochemical and Biophysical Research 
Communications, 280(2), pp. 460–465. doi: 10.1006/bbrc.2000.4146. 
Flajollet, S., Tian, T. V., Flourens, A., Tomavo, N., Villers, A., Bonnelye, E., Aubert, S., Leroy, X. and 
Duterque-Coquillaud, M. (2011) ‘Abnormal expression of the ERG transcription factor in prostate 
cancer cells activates osteopontin’, Molecular Cancer Research, 9(7), pp. 914–924. doi: 10.1158/1541-
7786.MCR-10-0537. 
Fordyce, C. A., Patten, K. T., Fessenden, T. B., DeFilippis, R. A., Hwang, E. S., Zhao, J. and Tlsty, T. 
D. (2012) ‘Cell-extrinsic consequences of epithelial stress: Activation of protumorigenic tissue 
phenotypes’, Breast Cancer Research, 14(6). doi: 10.1186/bcr3368. 
Foster, C. T., Gualdrini, F. and Treisman, R. (2017) ‘Mutual dependence of the MRTF-SRF and YAP-
TEAD pathways in cancer-associated fibroblasts is indirect and mediated by cytoskeletal dynamics’, 
Genes and Development, 31(23–24), pp. 2361–2375. doi: 10.1101/gad.304501.117. 
Foster, D. S., Jones, R. E., Ransom, R. C., Longaker, M. T. and Norton, J. A. (2018) ‘The evolving 
relationship of wound healing and tumor stroma’, JCI insight, 3(18). doi: 10.1172/jci.insight.99911. 
Foster, L., Arkonac, B., Sibinga, N., Shi, C., Perrella, M. and Haber, E., 1998. Regulation of CD44 
Gene Expression by the Proinflammatory Cytokine Interleukin-1β in Vascular Smooth Muscle 
Cells. Journal of Biological Chemistry, 273(32), pp.20341-20346. 
Frangogiannis, N. G., Michael, L. H. and Entman, M. L. (2000) ‘Myofibroblasts in reperfused myocardial 
infarcts express the embryonic form of smooth muscle myosin heavy chain (SMemb)’, Cardiovascular 
Research, 48(1), pp. 89–100. doi: 10.1016/S0008-6363(00)00158-9. 
Franklin, O., Billing, O., Öhlund, D., Berglund, A., Herdenberg, C., Wang, W., Hellman, U. and Sund, 
M. (2019) ‘Novel prognostic markers within the CD44-stromal ligand network in pancreatic cancer’, 
Journal of Pathology: Clinical Research, 5(2), pp. 130–141. doi: 10.1002/cjp2.122. 
Franzen, A. and Heinegard, D. (1985) ‘Isolation and characterization of two sialoproteins present only 
in bone calcified matrix’, Biochemical Journal, 232(3), pp. 715–724. doi: 10.1042/bj2320715. 
332 
 
Frippiat, C., Chen, Q. M., Zdanov, S., Magalhaes, J. P., Remacle, J. and Toussaint, O. (2001) 
‘Subcytotoxic H2O2 Stress Triggers a Release of Transforming Growth Factor-β1, Which Induces 
Biomarkers of Cellular Senescence of Human Diploid Fibroblasts’, Journal of Biological Chemistry, 
276(4), pp. 2531–2537. doi: 10.1074/jbc.M006809200. 
Frippiat, C., Dewelle, J., Remacle, J. and Toussaint, O. (2002) ‘Signal transduction in H2O2-induced 
senescence-like phenotype in human diploid fibroblasts’, Free Radical Biology and Medicine, 33(10), 
pp. 1334–1346. doi: 10.1016/S0891-5849(02)01044-4. 
Gabbiani, G., Ryan, G. and Majno, G., 1971. Presence of modified fibroblasts in granulation tissue 
and their possible role in wound contraction. Experientia, 27(5), pp.549-550. 
Galbo, P. M., Jr, Zang, X., & Zheng, D. (2021). Molecular Features of Cancer-associated Fibroblast 
Subtypes and their Implication on Cancer Pathogenesis, Prognosis, and Immunotherapy 
Resistance. Clinical cancer research : an official journal of the American Association for Cancer 
Research, 10.1158/1078-0432.CCR-20-4226. Advance online publication. 
https://doi.org/10.1158/1078-0432.CCR-20-4226. 
Galván, J. A., García-Martínez, J., Vázquez-Villa, F., García-Ocaña, M., García-Pravia, C., Menéndez-
Rodríguez, P., González-del Rey, C., Barneo-Serra, L. and de los Toyos, J. R. (2014) ‘Validation of 
COL11A1/procollagen 11A1 expression in TGF-β1-activated immortalised human mesenchymal cells 
and in stromal cells of human colon adenocarcinoma’, BMC Cancer, 14(1), pp. 1–12. doi: 
10.1186/1471-2407-14-867. 
Gao, G., Chernock, R. D., Gay, H. A., Thorstad, W. L., Zhang, T. R., Wang, H., Ma, X. J., Luo, Y., 
Lewis, J. S. and Wang, X. (2012) ‘A novel RT-PCR method for quantification of human papillomavirus 
transcripts in archived tissues and its application in oropharyngeal cancer prognosis’, International 
Journal of Cancer, 132(4), pp. 882–890. doi: 10.1002/ijc.27739. 
Gao, G., Johnson, S. H., Kasperbauer, J. L., Eckloff, B. W., Tombers, N. M., Vasmatzis, G. and Smith, 
D. I. (2014) ‘Mate pair sequencing of oropharyngeal squamous cell carcinomas reveals that HPV 
integration occurs much less frequently than in cervical cancer’, Journal of Clinical Virology. Elsevier 
B.V., 59(3), pp. 195–200. doi: 10.1016/j.jcv.2013.12.006. 
Gascard, P. and Tlsty, T. D. (2016) ‘Carcinoma-associated fibroblasts: Orchestrating the composition 
of malignancy’, Genes and Development, 30(9), pp. 1002–1019. doi: 10.1101/gad.279737.116. 
Ghosh, M. C., Grass, L., Soosaipillai, A., Sotiropoulou, G. and Diamandis, E. P. (2004) ‘Human 
kallikrein 6 degrades extracellular matrix proteins and may enhance the metastatic potential of tumour 
cells’, Tumor Biology, 25(4), pp. 193–199. doi: 10.1159/000081102. 
Gillison, M. L., Chaturvedi, A. K., Anderson, W. F. and Fakhry, C. (2015) ‘Epidemiology of human 
papillomavirus-positive head and neck squamous cell carcinoma’, Journal of Clinical Oncology, 33(29), 
pp. 3235–3242. doi: 10.1200/JCO.2015.61.6995. 
Gillison, M. L., D’Souza, G., Westra, W., Sugar, E., Xiao, W., Begum, S. and Viscidi, R. (2008) ‘Distinct 
Risk Factor Profiles for Human Papillomavirus Type 16–Positive and Human Papillomavirus Type 16–
Negative Head and Neck Cancers’, JNCI: Journal of the National Cancer Institute, 100(6), pp. 407–
420. doi: 10.1093/jnci/djn025. 
Gillison, M. L., Koch, W. M., Capone, R. B., Spafford, M., Westra, W. H., Wu, L., Zahurak, M. L., Daniel, 
R. W., Viglione, M., Symer, D. E., Shah, K. V. and Sidransky, D. (2000) ‘Evidence for a Causal 
Association Between Human Papillomavirus and a Subset of Head and Neck Cancers’, Journal of the 
National Cancer Institute. Oxford University Press, 92(9), pp. 709–720. doi: 10.1093/jnci/92.9.709. 
333 
 
Givel, A. M., Kieffer, Y., Scholer-Dahirel, A., Sirven, P., Cardon, M., Pelon, F., Magagna, I., Gentric, 
G., Costa, A., Bonneau, C., Mieulet, V., Vincent-Salomon, A. and Mechta-Grigoriou, F. (2018) ‘MiR200-
regulated CXCL12β promotes fibroblast heterogeneity and immunosuppression in ovarian cancers’, 
Nature Communications. Springer US, 9(1). doi: 10.1038/s41467-018-03348-z. 
Gkretsi, V., Stylianou, A., Papageorgis, P., Polydorou, C. and Stylianopoulos, T. (2015) ‘Remodeling 
components of the tumor microenvironment to enhance cancer therapy’, Frontiers in Oncology, 5(10). 
doi: 10.3389/fonc.2015.00214. 
Godar, S., Ince, T. A., Bell, G. W., Feldser, D., Donaher, J. L., Bergh, J., Liu, A., Miu, K., Watnick, R. 
S., Reinhardt, F., McAllister, S. S., Jacks, T. and Weinberg, R. A. (2008) ‘Growth-Inhibitory and Tumor- 
Suppressive Functions of p53 Depend on Its Repression of CD44 Expression’, Cell, 134(1), pp. 62–
73. doi: 10.1016/j.cell.2008.06.006. 
Gotlib, J. and Cools, J. (2008) ‘Five years since the discovery of FIP1L1-PDGFRA: What we have 
learned about the fusion and other molecularly defined eosinophilias’, Leukemia, 22(11), pp. 1999–
2010. doi: 10.1038/leu.2008.287.  
Greaney-Davies, F., Risk, J., Robinson, M., Liloglou, T., Shaw, R. and Schache, A., 2020. Essential 
characterisation of human papillomavirus positive head and neck cancer cell lines. Oral Oncology, 103, 
p.104613. 
Griffin, H., Soneji, Y., Van Baars, R., Arora, R., Jenkins, D., Van De Sandt, M., Wu, Z., Quint, W., Jach, 
R., Okon, K., Huras, H., Singer, A. and Doorbar, J. (2015) ‘Stratification of HPV-induced cervical 
pathology using the virally encoded molecular marker E4 in combination with p16 or MCM’, Modern 
Pathology, 28(7), pp. 977–993. doi: 10.1038/modpathol.2015.52. 
Grum-Schwensen, B., Klingelhofer, J., Berg, C. H., El-Naaman, C., Grigorian, M., Lukanidin, E. and 
Ambartsumian, N. (2005) ‘Suppression of tumor development and metastasis formation in mice lacking 
the S100A4(mts1) gene’, Cancer Research, 65(9), pp. 3772–3780. doi: 10.1158/0008-5472.CAN-04-
4510. 
Guertin, D. A. and Sabatini, D. M. (2007) ‘Defining the Role of mTOR in Cancer’, Cancer Cell, 12(1), 
pp. 9–22. doi: 10.1016/j.ccr.2007.05.008. 
Gutjahr, J. C., Szenes, E., Tschech, L., Asslaber, D., Schlederer, M., Roos, S., Yu, X., Girbl, T., 
Sternberg, C., Egle, A., Aberger, F., Alon, R., Kenner, L., Greil, R., Orian-Rousseau, V. and Hartmann, 
T. N. (2018) ‘Microenvironment-induced CD44v6 promotes early disease progression in chronic 
lymphocytic leukemia’, Blood, 131(12), pp. 1337–1349. doi: 10.1182/blood-2017-08-802462. 
Hafkamp, H. C., Manni, J. J., Haesevoets, A., Voogd, A. C., Schepers, M., Bot, F. J., Hopman, A. H. 
N., Ramaekers, F. C. S. and Speel, E. J. M. (2008) ‘Marked differences in survival rate between 
smokers and nonsmokers with HPV 16-associated tonsillar carcinomas’, International Journal of 
Cancer, 122(12), pp. 2656–2664. doi: 10.1002/ijc.23458. 
Han, C., Liu, T. and Yin, R. (2020) ‘Biomarkers for cancer-associated fibroblasts’, Biomarker Research. 
Biomarker Research, 8(1), pp. 1–8. doi: 10.1186/s40364-020-00245-w. 
Hanahan, D. and Weinberg, R. A. (2011) ‘Hallmarks of cancer: The next generation’, Cell. Elsevier 
Inc., 144(5), pp. 646–674. doi: 10.1016/j.cell.2011.02.013. 
Hao, C., Cui, Y., Hu, M., Zhi, X., Zhang, L., Li, W., Wu, W., Cheng, S. and Jiang, W. G. (2017) ‘OPN-
a splicing variant expression in non-small cell lung cancer and its effects on the bone Metastatic 




Hassona, Y., Cirillo, N., Heesom, K., Parkinson, E. K. and Prime, S. S. (2014) ‘Senescent cancer-
associated fibroblasts secrete active MMP-2 that promotes keratinocyte dis-cohesion and invasion’, 
British Journal of Cancer. doi: 10.1038/bjc.2014.438. 
Hassona, Y., Cirillo, N., Lim, K. P., Herman, A., Mellone, M., Thomas, G. J., Pitiyage, G. N., Parkinson, 
E. K. and Prime, S. S. (2013) ‘Progression of genotype-specific oral cancer leads to senescence of 
cancer-associated fibroblasts and is mediated by oxidative stress and TGF-β’, Carcinogenesis, 34(6), 
pp. 1286–1295. doi: 10.1093/carcin/bgt035. 
Hawkins, P. G., Mierzwa, M. L., Bellile, E., Jackson, W. C., Malloy, K. M., Chinn, S. B., Spector, M. E., 
Shuman, A. G., Stucken, C. L., McLean, S. A., Bradford, C. R., Prince, M. E., Carey, T. E., Worden, F. 
P., Swiecicki, P. L., Taylor, J., Wolf, G. T., Eisbruch, A., & Casper, K. A. (2019). Impact of American 
Joint Committee on Cancer Eighth Edition clinical stage and smoking history on oncologic outcomes 
in human papillomavirus-associated oropharyngeal squamous cell carcinoma. Head & neck, 41(4), pp. 
857–864. https://doi.org/10.1002/hed.25336. 
Heck, J. E., Berthiller, J., Vaccarella, S., Winn, D. M., Smith, E. M., Shan’gina, O., Schwartz, S. M., 
Purdue, M. P., Pilarska, A., Eluf-Neto, J., Menezes, A., McClean, M. D., Matos, E., Koifman, S., Kelsey, 
K. T., Herrero, R., Hayes, R. B., Franceschi, S., Wünsch-Filho, V., Fernández, L., Daudt, A. W., 
Curado, M. P., Chen, C., Castellsagué, X., Ferro, G., Brennan, P., Boffetta, P. and Hashibe, M. (2010) 
‘Sexual behaviours and the risk of head and neck cancers: a pooled analysis in the International Head 
and Neck Cancer Epidemiology (INHANCE) consortium.’, International journal of epidemiology. Oxford 
University Press, 39(1), pp. 166–81. doi: 10.1093/ije/dyp350. 
Heider, K. H., Kuthan, H., Stehle, G. and Munzert, G. (2004) ‘CD44v6: A target for antibody-based 
cancer therapy’, Cancer Immunology, Immunotherapy, 53(7), pp. 567–579. doi: 10.1007/s00262-003-
0494-4. 
Hendawi, N., Niklander, S., Allsobrook, O., Khurram, S. A., Bolt, R., Doorbar, J., Speight, P. M. and 
Hunter, K. D. (2020) ‘Human papillomavirus (HPV) can establish productive infection in dysplastic oral 
mucosa, but HPV status is poorly predicted by histological features and p16 expression’, 
Histopathology, 76(4), pp. 592–602. doi: 10.1111/his.14019. 
Herfs, M., Yamamoto, Y., Laury, A., Wang, X., Nucci, M. R. and Mclaughlin-drubin, M. E. (2012) ‘A 
discrete population of squamocolumnar junction cells implicated in the pathogenesis of cervical 
cancer’, 109(26). doi: 10.1073/pnas.1202684109. 
Hinz, B., Mastrangelo, D., Iselin, C. E., Chaponnier, C., & Gabbiani, G. (2001). Mechanical tension 
controls granulation tissue contractile activity and myofibroblast differentiation. The American journal 
of pathology, 159(3), pp.1009–1020. https://doi.org/10.1016/S0002-9440(10)61776-2. 
Hinz, B., Phan, S. H., Thannickal, V. J., Galli, A., Bochaton-Piallat, M.-L. and Gabbiani, G. (2007) ‘The 
Myofibroblast: One Function, Multiple Origins’, The American Journal of Pathology. Elsevier, 170(6), 
pp. 1807–1816. doi: 10.2353/AJPATH.2007.070112. 
Hinz, B., Phan, S. H., Thannickal, V. J., Prunotto, M., Desmoulire, A., Varga, J., De Wever, O., Mareel, 
M. and Gabbiani, G. (2012) ‘Recent developments in myofibroblast biology: Paradigms for connective 
tissue remodeling’, American Journal of Pathology. Elsevier Inc., 180(4), pp. 1340–1355. doi: 
10.1016/j.ajpath.2012.02.004. 
Hirsch, F. R., Varella-Garcia, M., Bunn, P. A., Di Maria, M. V, Veve, R., Bremmes, R. M., Barón, A. E., 
Zeng, C. and Franklin, W. A. (2003) ‘Epidermal growth factor receptor in non-small-cell lung 
335 
 
carcinomas: correlation between gene copy number and protein expression and impact on prognosis.’, 
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 21(20), pp. 
3798–807. doi: 10.1200/JCO.2003.11.069. 
Hiscox, S., Baruha, B., Smith, C., Bellerby, R., Goddard, L., Jordan, N., Poghosyan, Z., Nicholson, R. 
I., Barrett-Lee, P. and Gee, J. (2012) ‘Overexpression of CD44 accompanies acquired tamoxifen 
resistance in MCF7 cells and augments their sensitivity to the stromal factors, heregulin and 
hyaluronan’, BMC Cancer. BMC Cancer, 12(1), p. 1. doi: 10.1186/1471-2407-12-458. 
Hoare, M., Ito, Y., Kang, T. W., Weekes, M. P., Matheson, N. J., Patten, D. A., Shetty, S., Parry, A. J., 
Menon, S., Salama, R., Antrobus, R., Tomimatsu, K., Howat, W., Lehner, P. J., Zender, L. and Narita, 
M. (2016) ‘NOTCH1 mediates a switch between two distinct secretomes during senescence’, Nature 
Cell Biology, 18(9), pp. 979–992. doi: 10.1038/ncb3397. 
Hong, A. M., Martin, A., Chatfield, M., Jones, D., Zhang, M., Armstrong, B., Lee, C. S., Harnett, G., 
Milross, C., Clark, J., Elliott, M., Smee, R., Corry, J., Liu, C., Porceddu, S., Rees, G. and Rose, B. 
(2013) ‘Human papillomavirus, smoking status and outcomes in tonsillar squamous cell carcinoma’, 
International Journal of Cancer, 132(12), pp. 2748–2754. doi: 10.1002/ijc.27956. 
Hoos, A. and Cordon-Cardo, C. (2001) ‘Tissue microarray profiling of cancer specimens and cell lines: 
opportunities and limitations.’, Laboratory Investigation, 81(10), pp. 1331–8. doi: 
10.1038/labinvest.3780347. 
Howard, J., Dwivedi, R. C., Masterson, L., Kothari, P., Quon, H., & Holsinger, F. C. (2018). De-
intensified adjuvant (chemo)radiotherapy versus standard adjuvant chemoradiotherapy post transoral 
minimally invasive surgery for resectable HPV-positive oropharyngeal carcinoma. The Cochrane 
database of systematic reviews, 12(12), CD012939. 
https://doi.org/10.1002/14651858.CD012939.pub2. 
Hsieh, Y.-H., Margaret Juliana, M., Ho, K. J., Kuo, H. C., Van Der Heyde, H., Elmets, C. and Chang, 
P. L. (2012) ‘Host-derived osteopontin maintains an acute inflammatory response to suppress early 
progression of extrinsic cancer cells’, International Journal of Cancer, 131(2), pp. 322–333. doi: 
10.1002/ijc.26359. 
Huang, C. C., Qiu, J. T., Kashima, M. L., Kurman, R. J., & Wu, T. C. (1998). Generation of type-specific 
probes for the detection of single-copy human papillomavirus by a novel in situ hybridization 
method. Modern pathology : an official journal of the United States and Canadian Academy of 
Pathology, Inc, 11(10), pp. 971–977. 
Huang, R. H., Quan, Y. J., Chen, J. H., Wang, T. F., Xu, M., Ye, M., Yuan, H., Zhang, C. J., Liu, X. J. 
and Min, Z. J. (2017) ‘Osteopontin promotes cell migration and invasion, and inhibits apoptosis and 
autophagy in colorectal cancer by activating the p38 MAPK signaling pathway’, Cellular Physiology 
and Biochemistry, 41(5), pp. 1851–1864. doi: 10.1159/000471933. 
Hui, E. P., Sung, F. L., Yu, B. K. H., Wong, C. S. C., Ma, B. B. Y., Lin, X., Chan, A., Wong, W. L. and 
Chan, A. T. C. (2008) ‘Plasma osteopontin, hypoxia, and response to radiotherapy in nasopharyngeal 
cancer’, Clinical Cancer Research, 14(21), pp. 7080–7087. doi: 10.1158/1078-0432.CCR-08-0364. 
Huibregtse, J. M., Scheffner, M. and Howley, P. M. (1991) ‘A cellular protein mediates association of 
p53 with the E6 oncoprotein of human papillomavirus types 16 or 18’, EMBO Journal, 10(13), pp. 
4129–4135. doi: 10.1002/j.1460-2075.1991.tb04990.x. 
Hunter, C., Bond, J., Kuo, P. C., Selim, M. A. and Levinson, H. (2012) ‘The role of osteopontin and 
osteopontin aptamer (OPN-R3) in fibroblast activity’, Journal of Surgical Research. Elsevier Inc, 
336 
 
176(1), pp. 348–358. doi: 10.1016/j.jss.2011.07.054. 
Hunter, K. D., Parkinson, E. K. and Harrison, P. R. (2005) ‘Profiling early head and neck cancer’, 
Nature Reviews Cancer, 5(2), pp. 127–135. doi: 10.1038/nrc1549. 
Ibrahim, E. M., Stewart, R. L., Corke, K., Blackett, A. D., Tidy, J. A. and Wells, M. (2006) ‘Upregulation 
of CD44 expression by interleukins 1, 4, and 13, transforming growth factor-β1, estrogen, and 
progestogen in human cervical adenocarcinoma cell lines’, International Journal of Gynecological 
Cancer, 16(4), pp. 1631–1642. doi: 10.1111/j.1525-1438.2006.00637.x. 
Inoue, M. and Shinohara, M. L. (2011) ‘Intracellular osteopontin (iOPN) and immunity’, Immunologic 
Research, 49(1–3), pp. 160–172. doi: 10.1007/s12026-010-8179-5. 
Inoue, Y., Yokobori, T., Yokoe, T., Toiyama, Y., Miki, C., Mimori, K., Mori, M. and Kusunoki, M. (2010) 
‘Clinical significance of human Kallikrein7 gene expression in colorectal cancer’, Annals of Surgical 
Oncology, 17(11), pp. 3037–3042. doi: 10.1245/s10434-010-1132-y. 
Ishii, G., Ochiai, A. and Neri, S. (2016) ‘Phenotypic and functional heterogeneity of cancer-associated 
fibroblast within the tumor microenvironment’, Advanced Drug Delivery Reviews. Elsevier B.V., 99, pp. 
186–196. doi: 10.1016/j.addr.2015.07.007. 
Jackson, H. W., Fischer, J. R., Zanotelli, V. R. T., Ali, H. R., Mechera, R., Soysal, S. D., Moch, H., 
Muenst, S., Varga, Z., Weber, W. P. and Bodenmiller, B. (2020) ‘The single-cell pathology landscape 
of breast cancer’, Nature. Springer US, 578(7796), pp. 615–620. doi: 10.1038/s41586-019-1876-x. 
Jain, R. K., Martin, J. D. and Stylianopoulos, T. (2014) ‘The role of mechanical forces in tumor growth 
and therapy’, Annual Review of Biomedical Engineering, 16, pp. 321–346. doi: 10.1146/annurev-
bioeng-071813-105259. 
James, E. L., Michalek, R. D., Pitiyage, G. N., De Castro, A. M., Vignola, K. S., Jones, J., Mohney, R. 
P., Karoly, E. D., Prime, S. S. and Parkinson, E. K. (2015) ‘Senescent human fibroblasts show 
increased glycolysis and redox homeostasis with extracellular metabolomes that overlap with those of 
irreparable DNA damage, aging, and disease’, Journal of Proteome Research, 14(4), pp. 1854–1871. 
doi: 10.1021/pr501221g. 
Jia, R., Liang, Y., Chen, R., Liu, G., Wang, H., Tang, M., Zhou, X., Wang, H., Yang, Y., Wei, H., Li, B., 
Song, Y., & Zhao, J. (2016). Osteopontin facilitates tumor metastasis by regulating epithelial-
mesenchymal plasticity. Cell death & disease, 7(12), e2564. https://doi.org/10.1038/cddis.2016.422. 
Jia, X. H., Du, Y., Mao, D., Wang, Z. L., He, Z. Q., Qiu, J. D., Ma, X. B., Shang, W. T., Ding, D. and 
Tian, J. (2015) ‘Zoledronic acid prevents the tumor-promoting effects of mesenchymal stem cells via 
MCP-1 dependent recruitment of macrophages’, Oncotarget, 6(28), pp. 26018–26028. doi: 
10.18632/oncotarget.4658. 
Jiang, E., Xu, Z., Wang, M., Yan, T., Huang, C., Zhou, X., Liu, Q., Wang, L., Chen, Y., Wang, H., Liu, 
K., Shao, Z. and Shang, Z. (2019) ‘Tumoral microvesicle–activated glycometabolic reprogramming in 
fibroblasts promotes the progression of oral squamous cell carcinoma’, FASEB Journal, 33(4), pp. 
5690–5703. doi: 10.1096/fj.201802226R. 
Johansson, A. C., Ansell, A., Jerhammar, F., Lindh, M. B., Grénman, R., Munck-Wikland, E., Östman, 
A. and Roberg, K. (2012) ‘Cancer-associated fibroblasts induce matrix metalloproteinase-mediated 
cetuximab resistance in head and neck squamous cell carcinoma cells’, Molecular Cancer Research, 
10(9), pp. 1158–1168. doi: 10.1158/1541-7786.MCR-12-0030. 
337 
 
John, T., Liu, G. and Tsao, M.-S. (2009) ‘Overview of molecular testing in non-small-cell lung cancer: 
mutational analysis, gene copy number, protein expression and other biomarkers of EGFR for the 
prediction of response to tyrosine kinase inhibitors’, Oncogene, 28, pp. S14–S23. doi: 
10.1038/onc.2009.197. 
Johnson, G. A., Burghardt, R. C., Bazer, F. W. and Spencer, T. E. (2003) ‘Osteopontin : Roles in 
Implantation and Placentation 1’, 1471(7), pp. 1458–1471. doi: 10.1095/biolreprod.103.020651. 
Jones, D. A., Mistry, P., Dalby, M., Fulton-Lieuw, T., Kong, A. H., Dunn, J., Mehanna, H. M. and Gray, 
A. M. (2020) ‘Concurrent cisplatin or cetuximab with radiotherapy for HPV-positive oropharyngeal 
cancer: Medical resource use, costs, and quality-adjusted survival from the De-ESCALaTE HPV trial’, 
European Journal of Cancer. Elsevier Ltd, 124, pp. 178–185. doi: 10.1016/j.ejca.2019.10.025. 
Jones, D. L. and Münger, K. (1996) ‘Interactions of the human papillomavirus E7 protein with cell cycle 
regulators’, Seminars in Cancer Biology, 7(6), pp. 327–337. doi: 10.1006/scbi.1996.0042. 
Jordan, R. C., Lingen, M. W., Perez-ordonez, B., He, X., Pickard, R., Koluder, M., Jiang, B., Wakely, 
P., Xiao, W., Gillison, M. L., Francisco, S. and Francisco, S. (2019) ‘HHS Public Access’, 36(7), pp. 
945–954. doi: 10.1097/PAS.0b013e318253a2d1.Validation. 
Junaid, A., Moon, M. C., Harding, G. E. J. and Zahradka, P. (2007) ‘Osteopontin localizes to the 
nucleus of 293 cells and associates with polo-like kinase-1’, American Journal of Physiology - Cell 
Physiology, 292(2), pp. 919–926. doi: 10.1152/ajpcell.00477.2006. 
Jung, Y., Kim, J. K., Shiozawa, Y., Wang, J., Mishra, A., Joseph, J., Berry, J. E., McGee, S., Lee, E., 
Sun, H., Wang, J., Jin, T., Zhang, H., Dai, J., Krebsbach, P. H., Keller, E. T., Pienta, K. J., & Taichman, 
R. S. (2013). Recruitment of mesenchymal stem cells into prostate tumours promotes 
metastasis. Nature communications, 4, p. 1795. https://doi.org/10.1038/ncomms2766 
Kabir, T. D., Leigh, R. J., Tasena, H., Mellone, M., Coletta, R. D., Parkinson, E. K., Prime, S. S., 
Thomas, G. J., Paterson, I. C., Zhou, D., McCall, J., Speight, P. M. and Lambert, D. W. (2016) ‘A miR-
335/COX-2/PTEN axis regulates the secretory phenotype of senescent cancer-associated fibroblasts’, 
Aging, 8(8), pp. 1608–1635. doi: 10.18632/aging.100987. 
Kagawa, S., Natsuizaka, M., Whelan, K. A., Facompre, N., Naganuma, S., Ohashi, S., Kinugasa, H., 
Egloff, A. M., Basu, D., Gimotty, P. A., Klein-Szanto, A. J., Bass, A. J., Wong, K. K., Diehl, J. A., Rustgi, 
A. K. and Nakagawa, H. (2015) ‘Cellular senescence checkpoint function determines differential 
Notch1-dependent oncogenic and tumor-suppressor activities’, Oncogene. Nature Publishing Group, 
34(18), pp. 2347–2359. doi: 10.1038/onc.2014.169. 
Kallioniemi, O.-P., Wagner, U., Kononen, J. and Sauter, G. (2001) ‘Tissue microarray technology for 
high-throughput molecular profiling of cancer’, Human Molecular Genetics. Oxford University Press, 
10(7), pp. 657–662. doi: 10.1093/hmg/10.7.657. 
Kalluri, R. (2016) ‘The biology and function of fibroblasts in cancer’, Nature Reviews Cancer. Nature 
Publishing Group, 16(9), pp. 582–598. doi: 10.1038/nrc.2016.73. 
Kalluri, R. and Zeisberg, M. (2006) ‘Fibroblasts in cancer’, Nature Reviews Cancer, 6(5), pp. 392–401. 
doi: 10.1038/nrc1877. 
Kanzaki, R. and Pietras, K. (2020) ‘Heterogeneity of cancer-associated fibroblasts: Opportunities for 
precision medicine’, Cancer Science, 111(8), pp. 2708–2717. doi: 10.1111/cas.14537. 
Katabi, N. and Lewis, J. S. (2017) ‘Update from the 4th Edition of the World Health Organization 
338 
 
Classification of Head and Neck Tumours: What Is New in the 2017 WHO Blue Book for Tumors and 
Tumor-Like Lesions of the Neck and Lymph Nodes’, Head and Neck Pathology. Springer US, 11(1), 
pp. 48–54. doi: 10.1007/s12105-017-0796-z. 
Kaukonen, R., Mai, A., Georgiadou, M., Saari, M., De Franceschi, N., Betz, T., Sihto, H., Ventelä, S., 
Elo, L., Jokitalo, E., Westermarck, J., Kellokumpu-Lehtinen, P. L., Joensuu, H., Grenman, R. and 
Ivaska, J. (2016) ‘Normal stroma suppresses cancer cell proliferation via mechanosensitive regulation 
of JMJD1a-mediated transcription’, Nature Communications, 7. doi: 10.1038/ncomms12237. 
Kavsak, P., Rasmussen, R. K., Causing, C. G., Bonni, S., Zhu, H., Thomsen, G. H., & Wrana, J. L. 
(2000). Smad7 binds to Smurf2 to form an E3 ubiquitin ligase that targets the TGF beta receptor for 
degradation. Molecular cell, 6(6), pp. 1365–1375. https://doi.org/10.1016/s1097-2765(00)00134-9 
Kawakami, K., Minami, N., Matsuura, M., Iida, T., Toyonaga, T., Nagaishi, K., Arimura, Y., Fujimiya, 
M., Uede, T. and Nakase, H. (2017) ‘Osteopontin attenuates acute gastrointestinal graft-versus-host 
disease by preventing apoptosis of intestinal epithelial cells’, Biochemical and Biophysical Research 
Communications. Elsevier Ltd, 485(2), pp. 468–475. doi: 10.1016/j.bbrc.2017.02.047. 
Kellermann, M. G., Sobral, L. M., da Silva, S. D., Zecchin, K. G., Graner, E., Lopes, M. A., Kowalski, 
L. P. and Coletta, R. D. (2008) ‘Mutual paracrine effects of oral squamous cell carcinoma cells and 
normal oral fibroblasts: Induction of fibroblast to myofibroblast transdifferentiation and modulation of 
tumor cell proliferation’, Oral Oncology, 44(5), pp. 509–517. doi: 10.1016/j.oraloncology.2007.07.001. 
Kellermann, M G, Sobral, L. M., Silva, S. D. da, Zecchin, K. G., Graner, E., Lopes, M. A., Nishimoto, 
I., Kowalski, L. P. and Coletta, R. D. (2007) ‘Myofibroblasts in the stroma of oral squamous cell 
carcinoma are associated with poor prognosis’, Histopathology, 51(6), pp. 849–853. doi: 
10.1111/j.1365-2559.2007.02873.x. 
Kemnade, J. O., Elhalawani, H., Castro, P., Yu, J., Lai, S., Ittmann, M., Mohamed, A. S. R., Lai, S. Y., 
Fuller, C. D., Sikora, A. G. and Sandulache, V. C. (2020) ‘CD8 infiltration is associated with disease 
control and tobacco exposure in intermediate-risk oropharyngeal cancer’, Scientific Reports, 10(1), pp. 
1–10. doi: 10.1038/s41598-019-57111-5. 
Khan, F., Gurung, S., Gunassekaran, G. R., Vadevoo, S. M. P., Chi, L., Permpoon, U., Haque, M. E., 
Lee, Y. K., Lee, S. W., Kim, S. and Lee, B. (2021) ‘Identification of novel CD44v6-binding peptides that 
block CD44v6 and deliver a pro-apoptotic peptide to tumors to inhibit tumor growth and metastasis in 
mice’, Theranostics, 11(3), pp. 1326–1344. doi: 10.7150/thno.50564. 
Khan, Z. and Marshall, J. F. (2016) ‘The role of integrins in TGFβ activation in the tumour stroma’, Cell 
and Tissue Research, 365, pp. 657–673. doi: 10.1007/s00441-016-2474-y. 
Khuri, F. R., Lee, J. J., Lippman, S. M., Kim, E. S., Cooper, J. S., Benner, S. E., Winn, R., Pajak, T. F., 
Williams, B., Shenouda, G., Hodson, I., Fu, K., Shin, D. M., Vokes, E. E., Feng, L., Goepfert, H. and 
Hong, W. K. (2006) ‘Randomized phase III trial of low-dose isotretinoin for prevention of second primary 
tumors in stage I and II head and neck cancer patients’, Journal of the National Cancer Institute, 98(7), 
pp. 441–450. doi: 10.1093/jnci/djj091. 
Kidd, S., Spaeth, E., Watson, K., Burks, J., Lu, H., Klopp, A., Andreeff, M. and Marini, F. C. (2012) 
‘Origins of the tumor microenvironment: Quantitative assessment of adipose-derived and bone 
marrow-derived stroma’, PLoS ONE, 7(2). doi: 10.1371/journal.pone.0030563. 
Kikuchi, N., Horiuchi, A., Osada, R., Imai, T., Wang, C., Chen, X. and Konishi, I. (2006) ‘Nuclear 
expression of S100A4 is associated with aggressive behavior of epithelial ovarian carcinoma: An 




Kilvaer, T. K., Khanehkenari, M. R., Hellevik, T., Al-Saad, S., Paulsen, E. E., Bremnes, R. M., Busund, 
L. T., Donnem, T. and Martinez, I. Z. (2015) ‘Cancer associated fibroblasts in stage I-IIIA NSCLC: 
Prognostic impact and their correlations with tumor molecular markers’, PLoS ONE, 10(8), pp. 1–15. 
doi: 10.1371/journal.pone.0134965. 
Kim, D. K., Kim, E. K., Jung, D. W. and Kim, J. (2019) ‘Cytoskeletal alteration modulates cancer cell 
invasion through RhoA-YAP signaling in stromal fibroblasts’, PLoS ONE, 14(3), pp. 1–21. doi: 
10.1371/journal.pone.0214553. 
Kim, E. K., Moon, S., Kim, D. K., Zhang, X. and Kim, J. (2018) ‘CXCL1 induces senescence of cancer-
associated fibroblasts via autocrine loops in oral squamous cell carcinoma’, PLoS ONE, 13(1), pp. 1–
17. doi: 10.1371/journal.pone.0188847. 
Kim, M. M. and Califano, J. A. (2004) ‘Molecular pathology of head-and-neck cancer’, International 
Journal of Cancer, 112(4), pp. 545–553. doi: 10.1002/ijc.20379. 
Kinugasa, Y., Matsui, T. and Takakura, N. (2014) ‘CD44 expressed on cancer-associated fibroblasts 
is a functional molecule supporting the stemness and drug resistance of malignant cancer cells in the 
tumor microenvironment’, Stem Cells, 32(1), pp. 145–156. doi: 10.1002/stem.1556. 
Kita, Y., Natsugoe, S., Okumura, H., Matsumoto, M., Uchikado, Y., Setoyama, T., Owaki, T., Ishigami, 
S. and Aikou, T. (2006) ‘Expression of Osteopontin in oesophageal squamous cell carcinoma’, British 
Journal of Cancer, 95(5), pp. 634–638. doi: 10.1038/sj.bjc.6603296. 
Klein, S., Quaas, A., Quantius, J., Löser, H., Meinel, J., Peifer, M., Wagner, S., Gattenlöhner, S., 
Wittekindt, C., von Knebel Doeberitz, M., Prigge, E. S., Langer, C., Noh, K. W., Maltseva, M., 
Reinhardt, H. C., Büttner, R., Klussmann, J. P., & Wuerdemann, N. (2021). Deep Learning Predicts 
HPV Association in Oropharyngeal Squamous Cell Carcinomas and Identifies Patients with a 
Favorable Prognosis Using Regular H&E Stains. Clinical cancer research : an official journal of the 
American Association for Cancer Research, 27(4), pp. 1131–1138. https://doi.org/10.1158/1078-
0432.CCR-20-3596. 
Klement, J. D., Paschall, A. V., Redd, P. S., Ibrahim, M. L., Lu, C., Yang, D., Celis, E., Abrams, S. I., 
Ozato, K. and Liu, K. (2018) ‘An osteopontin/CD44 immune checkpoint controls CD8+ T cell activation 
and tumor immune evasion’, Journal of Clinical Investigation, 128(12), pp. 5549–5560. doi: 
10.1172/JCI123360. 
Klussmann, J. P., Gültekin, E., Weissenborn, S. J., Wieland, U., Dries, V., Dienes, H. P., Eckel, H. E., 
Pfister, H. J., & Fuchs, P. G. (2003). Expression of p16 protein identifies a distinct entity of tonsillar 
carcinomas associated with human papillomavirus. The American journal of pathology, 162(3), pp. 
747–753. https://doi.org/10.1016/S0002-9440(10)63871-0. 
Kobawala, T. P., Trivedi, T. I., Gajjar, K. K., Patel, D. H., Patel, G. H. and Ghosh, N. R. (2016) 
‘Significance of Interleukin-6 in Papillary Thyroid Carcinoma’, Journal of Thyroid Research, 2016. doi: 
10.1155/2016/6178921. 
Kojima, Y., Acar, A., Eaton, E. N., Mellody, K. T., Scheel, C., Ben-Porath, I., Onder, T. T., Wang, Z. C., 
Richardson, A. L., Weinberg, R. A. and Orimo, A. (2010) ‘Autocrine TGF-β and stromal cell-derived 
factor-1 (SDF-1) signaling drives the evolution of tumor-promoting mammary stromal myofibroblasts’, 
Proceedings of the National Academy of Sciences of the United States of America, 107(46), pp. 
20009–20014. doi: 10.1073/pnas.1013805107. 
340 
 
Kónya, J., Veress, G., Hernádi, Z., Soós, G., Czeglédy, J. and Gergely, L. (1995) ‘Correlation of human 
papillomavirus 16 and 18 with prognostic factors in invasive cervical neoplasias’, Journal of Medical 
Virology. Wiley Subscription Services, Inc., A Wiley Company, 46(1), pp. 1–6. doi: 
10.1002/jmv.1890460102. 
Korita, P. V, Wakai, T. and Shirai, Y. (2008) ‘Overexpression of osteopontin independently correlates 
with vascular invasion and poor prognosis in patients with hepatocellular carcinoma’, Human 
Pathology. Elsevier Inc., 39(12), pp. 1777–1783. doi: 10.1016/j.humpath.2008.05.006. 
Kreimer, A. R., Clifford, G. M., Boyle, P. and Franceschi, S. (2005) ‘Human papillomavirus types in 
head and neck squamous cell carcinomas worldwide: A systemic review’, Cancer Epidemiology 
Biomarkers and Prevention, 14(2), pp. 467–475. doi: 10.1158/1055-9965.EPI-04-0551. 
Kreimer, A. R., Johansson, M., Yanik, E. L., Katki, H. A., Check, D. P., Kuhs, K. A. L., Willhauck-
Fleckenstein, M., Holzinger, D., Hildesheim, A., Pfeiffer, R., Williams, C., Freedman, N. D., Huang, W. 
Y., Purdue, M. P., Michel, A., Pawlita, M., Brennan, P. and Waterboer, T. (2017) ‘Kinetics of the Human 
Papillomavirus Type 16 E6 Antibody Response Prior to Oropharyngeal Cancer’, Journal of the National 
Cancer Institute, 109(8), pp. 1–9. doi: 10.1093/jnci/djx005. 
Krishnamurthy, J., Torrice, C., Ramsey, M. R., Kovalev, G. I., Al-Regaiey, K., Su, L. and Sharpless, N. 
E. (2004) ‘Ink4a/Arf expression is a biomarker of aging’, Journal of Clinical Investigation, 114(9), pp. 
1299–1307. doi: 10.1172/JCI22475. 
Kristensen, S. R. and Petersen, P. H. (1988) ‘Quiescent fibroblasts in a cellular model system’, 
Scandinavian Journal of Clinical and Laboratory Investigation, 48(5), pp. 413–417. doi: 
10.1080/00365518809085750. 
Krtolica, A. and Campisi, J. (2002) ‘Cancer and aging : a model for the cancer promoting effects of the 
aging stroma’, 34, pp. 1401–1414. 
Krtolica, A., Parrinello, S., Lockett, S., Desprez, P.-Y. and Campisi, J. (2001) ‘Senescent fibroblasts 
promote epithelial cell growth and tumorigenesis: A link between cancer and aging’, Proceedings of 
the National Academy of Sciences, 98(21), pp. 12072–12077. doi: 10.1073/pnas.211053698. 
Krtolica, A., Parrinello, S., Lockett, S., Desprez, P. Y., & Campisi, J. (2001). Senescent fibroblasts 
promote epithelial cell growth and tumorigenesis: a link between cancer and aging. Proceedings of the 
National Academy of Sciences of the United States of America, 98(21), pp. 12072–12077. 
https://doi.org/10.1073/pnas.211053698. 
Kuilman, T., Michaloglou, C., Vredeveld, L. C. W., Douma, S., van Doorn, R., Desmet, C. J., Aarden, 
L. A., Mooi, W. J. and Peeper, D. S. (2008) ‘Oncogene-Induced Senescence Relayed by an Interleukin-
Dependent Inflammatory Network’, Cell. Cell Press, 133(6), pp. 1019–1031. doi: 
10.1016/J.CELL.2008.03.039. 
Kumar, B., Cordell, K. G., Lee, J. S., Prince, M. E., Tran, H. H., Wolf, G. T., Urba, S. G., Worden, F. 
P., Chepeha, D. B., Teknos, T. N., Eisbruch, A., Tsien, C. I., Taylor, J. M. G., Silva, N. J. D., Yang, K., 
Kurnit, D. M., Bradford, C. R. and Carey, T. E. (2008) ‘Response to Therapy and Outcome in 
Oropharyngeal Cancer are Associated with Biomarkers Including HPV, EGFR, Gender and Smoking’, 
International Journal of Radiation Oncology, Biology, Physics, 69(19), pp. 1–6. doi: 
10.1200/JCO.2007.12.7662.EGFR. 
Kumar, S., Boehm, J. and Lee, J. C. (2003) ‘P38 MAP kinases: Key signalling molecules as therapeutic 




Kumar, V., Behera, R., Lohite, K., Karnik, S. and Kundu, G. C. (2010) ‘P38 Kinase Is Crucial for 
Osteopontin-Induced Furin Expression That Supports Cervical Cancer Progression’, Cancer 
Research, 70(24), pp. 10381–10391. doi: 10.1158/0008-5472.CAN-10-1470. 
Kunii, Y., Yoshiaki, H., Shin-ichi, N., Masahiro, M. and Seitoh, T. (2009) ‘The immunohistochemical 
expression profile of osteopontin in normal human tissues using two site-specifi c antibodies reveals a 
wide distribution of positive cells and extensive expression in the central and peripheral nervous 
systems’, pp. 155–161. doi: 10.1007/s00795-009-0459-6. 
Laberge, R.-M., Sun, Y., Orjalo, A. V., Patil, C. K., Freund, A., Zhou, L., Curran, S. C., Davalos, A. R., 
Wilson-Edell, K. A., Liu, S., Limbad, C., Demaria, M., Li, P., Hubbard, G. B., Ikeno, Y., Javors, M., 
Desprez, P.-Y., Benz, C. C., Kapahi, P., Nelson, P. S. and Campisi, J. (2015) ‘MTOR regulates the 
pro-tumorigenic senescence-associated secretory phenotype by promoting IL1A translation’, Nature 
Cell Biology, 17(8), pp. 1049–1061. doi: 10.1038/ncb3195. 
Lai, R. W., Lu, R., Danthi, P. S., Bravo, J. I., Goumba, A., Sampathkumar, N. K. and Benayoun, B. A. 
(2019) ‘Multi-level remodeling of transcriptional landscapes in aging and longevity’, BMB Reports, 
52(1), pp. 86–108. doi: 10.5483/BMBRep.2019.52.1.296. 
Jeyasivanesan, D. L., Mohamed, S. P., Pandiar, D., & Basheer, S. (2019). Immunohistochemical 
analysis of osteopontin expression in oral squamous cell carcinoma. Indian journal of dental research 
: official publication of Indian Society for Dental Research, 30(4), 539–543. 
https://doi.org/10.4103/ijdr.IJDR_474_17. 
Lambrechts, D., Wauters, E., Boeckx, B., Aibar, S., Nittner, D., Burton, O., Bassez, A., Decaluwé, H., 
Pircher, A., Van den Eynde, K., Weynand, B., Verbeken, E., De Leyn, P., Liston, A., Vansteenkiste, J., 
Carmeliet, P., Aerts, S. and Thienpont, B. (2018) ‘Phenotype molding of stromal cells in the lung tumor 
microenvironment’, Nature Medicine. Springer US, 24(8), pp. 1277–1289. doi: 10.1038/s41591-018-
0096-5. 
Lamort, A. S., Giopanou, I., Psallidas, I. and Stathopoulos, G. T. (2019) ‘Osteopontin as a Link between 
Inflammation and Cancer: The Thorax in the Spotlight’, Cells, 8(8), pp. 1–20. doi: 
10.3390/cells8080815. 
Langer, E. M., Allen-Petersen, B. L., King, S. M., Kendsersky, N. D., Turnidge, M. A., Kuziel, G. M., 
Riggers, R., Samatham, R., Amery, T. S., Jacques, S. L., Sheppard, B. C., Korkola, J. E., Muschler, J. 
L., Thibault, G., Chang, Y. H., Gray, J. W., Presnell, S. C., Nguyen, D. G., & Sears, R. C. (2019). 
Modeling Tumor Phenotypes In Vitro with Three-Dimensional Bioprinting. Cell reports, 26(3), pp. 608–
623.e6. https://doi.org/10.1016/j.celrep.2018.12.090. 
Lassen, P., Eriksen, J. G., Hamilton-Dutoit, S., Tramm, T., Alsner, J. and Overgaard, J. (2009) ‘Effect 
of HPV-associated p16INK4A expression on response to radiotherapy and survival in squamous cell 
carcinoma of the head and neck’, Journal of Clinical Oncology, 27(12), pp. 1992–1998. doi: 
10.1200/JCO.2008.20.2853. 
Lawless, C., Jurk, D., Gillespie, C. S., Shanley, D., Saretzki, G., von Zglinicki, T. and Passos, J. F. 
(2012) ‘A stochastic step model of replicative senescence explains ROS production rate in ageing cell 
populations’, PLoS ONE, 7(2), pp. 1–7. doi: 10.1371/journal.pone.0032117. 
Lawrence, M. S., Sougnez, C., Lichtenstein, L., Cibulskis, K., Lander, E., Gabriel, S. B., Getz, G., Ally, 
A., Balasundaram, M., Birol, I., Bowlby, R., Brooks, D., Butterfield, Y. S. N., Carlsen, R., Cheng, D., 
Chu, A., Dhalla, N., Guin, R., Holt, R. A., Jones, S. J. M., Lee, D., Li, H. I., Marra, M. A., Mayo, M., 
Moore, R. A., Mungall, A. J., Robertson, A. G., Schein, J. E., Sipahimalani, P., Tam, A., Thiessen, N., 
Wong, T., Protopopov, A., Santoso, N., Lee, S., Parfenov, M., Zhang, Jianhua, Mahadeshwar, H. S., 
342 
 
Tang, J., Ren, X., Seth, S., Haseley, P., Zeng, D., Yang, Lixing, Xu, A. W., Song, X., Pantazi, A., 
Bristow, C. A., Hadjipanayis, A., Seidman, J., Chin, L., Park, P. J., Kucherlapati, R., Akbani, R., 
Casasent, T., Liu, W., Lu, Y., Mills, G., Motter, T., Weinstein, J., Diao, L., Wang, J., Hong Fan, Y., Liu, 
J., Wang, K., Auman, J. T., Balu, S., Bodenheimer, T., Buda, E., Hayes, D. N., Hoadley, K. A., Hoyle, 
A. P., Jefferys, S. R., Jones, C. D., Kimes, P. K., Liu, Yufeng, Marron, J. S., Meng, S., Mieczkowski, 
P. A., Mose, L. E., Parker, J. S., Perou, C. M., Prins, J. F., Roach, J., Shi, Y., Simons, J. V., Singh, D., 
Soloway, M. G., Tan, D., Veluvolu, U., Walter, V., Waring, S., Wilkerson, M. D., Wu, J., Zhao, N., 
Cherniack, A. D., Hammerman, P. S., Tward, A. D., Pedamallu, C. S., Saksena, G., Jung, J., Ojesina, 
A. I., Carter, S. L., Zack, T. I., Schumacher, S. E., Beroukhim, R., Freeman, S. S., Meyerson, M., Cho, 
J., Noble, M. S., DiCara, D., Zhang, H., Heiman, D. I., Gehlenborg, N., Voet, D., Lin, P., Frazer, S., 
Stojanov, P., Liu, Yingchun, Zou, L., Kim, J., Muzny, D., Doddapaneni, H. V., Kovar, C., Reid, J., 
Morton, D., Han, Y., Hale, W., Chao, H., Chang, K., Drummond, J. A., Gibbs, R. A., Kakkar, N., 
Wheeler, D., Xi, L., Ciriello, G., Ladanyi, M., Lee, W., Ramirez, R., Sander, C., Shen, R., Sinha, R., 
Weinhold, N., Taylor, B. S., Aksoy, B. A., Dresdner, G., Gao, J., Gross, B., Jacobsen, A., Reva, B., 
Schultz, N., Sumer, S. O., Sun, Y., Chan, T. A., Morris, L. G., Stuart, J., Benz, S., Ng, S., Benz, C., 
Yau, C., Baylin, S. B., Cope, L., Danilova, L., Herman, J. G., Bootwalla, M., Maglinte, D. T., Laird, P. 
W., Triche, T., Weisenberger, D. J., Van Den Berg, D. J., Agrawal, N., Bishop, J., Boutros, P. C., Bruce, 
J. P., Byers, L. A., Califano, J., Carey, T. E., Chen, Z., Cheng, H., Chiosea, S. I., Cohen, E., Diergaarde, 
B., Egloff, A. M., El-Naggar, A. K., Ferris, R. L., Frederick, M. J., Grandis, J. R., Guo, Y., Haddad, R. 
I., Harris, T., Hui, A. B. Y., Lee, J. J., Lippman, S. M., Liu, F. F., McHugh, J. B., Myers, J., Ng, P. K. S., 
Perez-Ordonez, B., Pickering, C. R., Prystowsky, M., Romkes, M., Saleh, A. D., Sartor, M. A., Seethala, 
R., Seiwert, T. Y., Si, H., Van Waes, C., Waggott, D. M., Wiznerowicz, M., Yarbrough, W. G., Zhang, 
Jiexin, Zuo, Z., Burnett, K., Crain, D., Gardner, J., Lau, K., Mallery, D., Morris, S., Paulauskis, J., Penny, 
R., Shelton, C., Shelton, T., Sherman, M., Yena, P., Black, A. D., Bowen, J., Frick, J., Gastier-Foster, 
J. M., Harper, H. A., Leraas, K., Lichtenberg, T. M., Ramirez, N. C., Wise, L., Zmuda, E., Baboud, J., 
Jensen, M. A., Kahn, A. B., Pihl, T. D., Pot, D. A., Srinivasan, D., Walton, J. S., Wan, Y., Burton, R. A., 
Davidsen, T., Demchok, J. A., Eley, G., Ferguson, M. L., Mills Shaw, K. R., Ozenberger, B. A., Sheth, 
M., Sofia, H. J., Tarnuzzer, R., Wang, Z., Yang, Liming, Zenklusen, J. C., Saller, C., Tarvin, K., Chen, 
C., Bollag, R., Weinberger, P., Golusiński, W., Golusiński, P., Ibbs, M., Korski, K., Mackiewicz, A., 
Suchorska, W., Szybiak, B., Curley, E., Beard, C., Mitchell, C., Sandusky, G., Ahn, J., Khan, Z., Irish, 
J., Waldron, J., William, W. N., Egea, S., Gomez-Fernandez, C., Herbert, L., Bradford, C. R., Chepeha, 
D. B., Haddad, A. S., Jones, T. R., Komarck, C. M., Malakh, M., Moyer, J. S., Nguyen, A., Peterson, 
L. A., Prince, M. E., Rozek, L. S., Taylor, E. G., Walline, H. M., Wolf, G. T., Boice, L., Chera, B. S., 
Funkhouser, W. K., Gulley, M. L., Hackman, T. G., Hayward, M. C., Huang, M., Rathmell, W. K., 
Salazar, A. H., Shockley, W. W., Shores, C. G., Thorne, L., Weissler, M. C., Wrenn, S., Zanation, A. 
M., Brown, B. T. and Pham, M. (2015) ‘Comprehensive genomic characterization of head and neck 
squamous cell carcinomas’, Nature, 517(7536), pp. 576–582. doi: 10.1038/nature14129. 
Leavenworth, J. W., Verbinnen, B., Wang, Q., Shen, E. and Cantor, H. (2015) ‘Intracellular osteopontin 
regulates homeostasis and function of natural killer cells’, Proceedings of the National Academy of 
Sciences of the United States of America, 112(2), pp. 494–499. doi: 10.1073/pnas.1423011112. 
LeBleu, V. S. and Kalluri, R. (2018) ‘A peek into cancer-associated fibroblasts: Origins, functions and 
translational impact’, DMM Disease Models and Mechanisms, 11(4), pp. 1–9. doi: 
10.1242/dmm.029447. 
Lee, B. Y., Han, J. A., Im, J. S., Morrone, A., Johung, K., Goodwin, E. C., Kleijer, W. J., DiMaio, D. and 
Hwang, E. S. (2006) ‘Senescence-associated β-galactosidase is lysosomal β-galactosidase’, Aging 
Cell, 5(2), pp. 187–195. doi: 10.1111/j.1474-9726.2006.00199.x. 
Leemans, C. R., Braakhuis, B. J., & Brakenhoff, R. H. (2011). The molecular biology of head and neck 
cancer. Nature reviews. Cancer, 11(1), 9–22. https://doi.org/10.1038/nrc2982. 
Lenga, Y., Koh, A., Perera, A. S., McCulloch, C. A., Sodek, J. and Zohar, R. (2008) ‘Osteopontin 




Levental, K. Yu, H. (2010) ‘Matrix Crosslinking Forces Tumor Progression by Enhancing Integrin 
signaling’, Bone, 23(1), pp. 1–20. doi: 10.1016/j.cell.2009.10.027.Matrix. 
Lewis, J. S. (2020) ‘Human Papillomavirus Testing in Head and Neck Squamous Cell Carcinoma in 
2020: Where Are We Now and Where Are We Going?’, Head and Neck Pathology. Springer US, 14(2), 
pp. 321–329. doi: 10.1007/s12105-019-01117-y. 
Lewis, J. S., Chernock, R. D. and Chernock, R. D. (2014) ‘Human papillomavirus and Epstein Barr 
virus in head and neck carcinomas: suggestions for the new WHO classification.’, Head and neck 
pathology. Springer, 8(1), pp. 50–8. doi: 10.1007/s12105-014-0528-6. 
Lewis, M. P., Lygoe, K. A., Nystrom, M. L., Anderson, W. P., Speight, P. M., Marshall, J. F. and 
Thomas, G. J. (2004) ‘Tumour-derived TGF-β1 modulates myofibroblast differentiation and promotes 
HGF/SF-dependent invasion of squamous carcinoma cells’, British Journal of Cancer. Nature 
Publishing Group, 90(4), pp. 822–832. doi: 10.1038/sj.bjc.6601611. 
Li, H., Courtois, E. T., Sengupta, D., Tan, Y., Chen, K. H., Goh, J. J. L., Kong, S. L., Chua, C., Hon, L. 
K., Tan, W. S., Wong, M., Choi, P. J., Wee, L. J. K., Hillmer, A. M., Tan, I. B., Robson, P. and 
Prabhakar, S. (2017) ‘Reference component analysis of single-cell transcriptomes elucidates cellular 
heterogeneity in human colorectal tumors’, Nature Genetics. Nature Publishing Group, 49(5), pp. 708–
718. doi: 10.1038/ng.3818. 
Li, J., Yang, G. Z., Zhu, Z. M., Zhou, Z. Y., & Li, L. (2012). Osteopontin is overexpressed in colorectal 
carcinoma and is correlated with P53 by immunohistochemistry. Experimental and therapeutic 
medicine, 3(4), 621–624. https://doi.org/10.3892/etm.2012.465. 
Li, X., Xu, Q., Wu, Y., Li, J., Tang, D., Han, L. and Fan, Q. (2014) ‘A CCL2/ROS autoregulation loop is 
critical for cancer-associated fibroblasts-enhanced tumor growth of oral squamous cell carcinoma’, 
Carcinogenesis, 35(6), pp. 1362–1370. doi: 10.1093/carcin/bgu046. 
Li, Y. yin, Zhou, C. X. and Gao, Y. (2018) ‘Interaction between oral squamous cell carcinoma cells and 
fibroblasts through TGF-β1 mediated by podoplanin’, Experimental Cell Research. Elsevier Inc., 
369(1), pp. 43–53. doi: 10.1016/j.yexcr.2018.04.029. 
Liaw, L., Birk, D. E., Ballas, C. B., Whitsitt, J. S., Davidson, J. M. and Hogan, B. L. (1998) ‘Altered 
wound healing in mice lacking a functional osteopontin gene (spp1).’, Journal of Clinical Investigation, 
101(7), pp. 1468–1478. doi: 10.1172/jci2131. 
Liguori, M., Solinas, G., Germano, G., Mantovani, A. and Allavena, P. (2011) ‘Tumor-associated 
macrophages as incessant builders and destroyers of the cancer stroma’, Cancers, 3(4), pp. 3740–
3761. doi: 10.3390/cancers3043740. 
Lim, K. P., Cirillo, N., Hassona, Y., Wei, W., Thurlow, Johanna K., Cheong, S. C., Pitiyage, G., 
Parkinson, E. K. and Prime, S. S. (2011) ‘Fibroblast gene expression profile reflects the stage of tumour 
progression in oral squamous cell carcinoma’, Journal of Pathology, 223(4), pp. 459–469. doi: 
10.1002/path.2841. 
Lim, K. P., Cirillo, N., Hassona, Y., Wei, W., Thurlow, Johanna K, Cheong, S. C., Pitiyage, G., 
Parkinson, E. K. and Prime, S. S. (2011) ‘Fibroblast gene expression profile reflects the stage of tumour 




Lin, J. and Ding, D. (2017) ‘The prognostic role of the cancer stem cell marker CD44 in ovarian cancer: 
A meta-analysis’, Cancer Cell International. BioMed Central, 17(1), pp. 1–11. doi: 10.1186/s12935-
016-0376-4. 
Lindquist, D., Romanitan, M., Hammarstedt, L., Näsman, A., Dahlstrand, H., Lindholm, J., Onelöv, L., 
Ramqvist, T., Ye, W., Munck-Wikland, E. and Dalianis, T. (2007) ‘Human papillomavirus is a favourable 
prognostic factor in tonsillar cancer and its oncogenic role is supported by the expression of E6 and 
E7’, Molecular Oncology, 1(3), pp. 350–355. doi: 10.1016/j.molonc.2007.08.005. 
Liu, F., Lagares, D., Choi, K. M., Stopfer, L., Marinković, A., Vrbanac, V., Probst, C. K., Hiemer, S. E., 
Sisson, T. H., Horowitz, J. C., Rosas, I. O., Fredenburgh, L. E., Feghali-Bostwick, C., Varelas, X., 
Tager, A. M. and Tschumperlin, D. J. (2015) ‘Mechanosignaling through YAP and TAZ drives fibroblast 
activation and fibrosis’, American Journal of Physiology - Lung Cellular and Molecular Physiology, 
308(4), pp. L344–L357. doi: 10.1152/ajplung.00300.2014. 
Liu, K., Hu, H., Jiang, H., Liu, C., Zhang, H., Gong, S., Wei, D. and Yu, Z. (2020) ‘Upregulation of 
secreted phosphoprotein 1 affects malignant progression, prognosis, and resistance to cetuximab via 
the KRAS/MEK pathway in head and neck cancer’, Molecular Carcinogenesis, 59(10), pp. 1147–1158. 
doi: 10.1002/mc.23245. 
Liu, T., Han, C., Wang, S., Fang, P., Ma, Z., Xu, L. and Yin, R. (2019) ‘Cancer-associated fibroblasts: 
An emerging target of anti-cancer immunotherapy’, Journal of Hematology and Oncology. Journal of 
Hematology & Oncology, 12(1), pp. 1–15. doi: 10.1186/s13045-019-0770-1. 
Liu, W. L., Zhang, H., Zheng, Y., Wang, H. T., Chen, F. H., Xu, L., Wei, Y., Sun, Y. Q., Shi, J. B. and 
Li, H. B. (2015) ‘Expression and regulation of osteopontin in chronic rhinosinusitis with nasal polyps’, 
Clinical and Experimental Allergy, 45(2), pp. 414–422. doi: 10.1111/cea.12320. 
Liu, Y., Hu, T., Shen, J., Li, S. F., Lin, J. W., Zheng, X. H., Gao, Q. H. and Zhou, H. M. (2006) 
‘Separation, cultivation and biological characteristics of oral carcinoma-associated fibroblasts’, Oral 
Diseases, 12(4), pp. 375–380. doi: 10.1111/j.1601-0825.2005.01207.x. 
Lloyd, A. C. (2013) ‘XThe regulation of cell size’, Cell. Elsevier Inc., 154(6), p. 1194. doi: 
10.1016/j.cell.2013.08.053. 
Loffredo, F. S., Steinhauser, M. L., Jay, S. M., Gannon, J., Pancoast, J. R., Yalamanchi, P., Sinha, M., 
Dall’Osso, C., Khong, D., Shadrach, J. L., Miller, C. M., Singer, B. S., Stewart, A., Psychogios, N., 
Gerszten, R. E., Hartigan, A. J., Kim, M. J., Serwold, T., Wagers, A. J. and Lee, R. T. (2013) ‘Growth 
differentiation factor 11 is a circulating factor that reverses age-related cardiac hypertrophy’, Cell, 
153(4), pp. 828–839. doi: 10.1016/j.cell.2013.04.015. 
Logan, B., 2016. McMinn's color atlas of head and neck anatomy. 5th ed. Elsevier Limited, 
p.397. 
Löhr, M., Schmidt, C., Ringel, J., Kluth, M., Müller, P., Nizze, H. and Jesnowski, R. (2001) 
‘Transforming growth factor-β1 induces desmoplasia in an experimental model of human pancreatic 
carcinoma’, Cancer Research, 61(2), pp. 550–555. 
Longworth, M. S. and Laimins, L. a (2004) ‘Pathogenesis of Human Papillomaviruses in Differentiating 
Epithelia Pathogenesis of Human Papillomaviruses in Differentiating Epithelia’, Microbiology and 
molecular biology reviews, 68(2), pp. 362–372. doi: 10.1128/MMBR.68.2.362. 
Lotfi, N., Thome, R., Rezaei, N., Zhang, G. X., Rezaei, A., Rostami, A. and Esmaeil, N. (2019) ‘Roles 
345 
 
of GM-CSF in the pathogenesis of autoimmune diseases: An update’, Frontiers in Immunology, 10(6), 
pp. 1–14. doi: 10.3389/fimmu.2019.01265. 
Loughran, O., Clark, L. J., Bond, J., Baker, A., Berry, I. J., Edington, K. G., Ly, I. S., Simmons, R., Haw, 
R., Black, D. M., Newbold, R. F. and Parkinson, E. K. (1997) ‘Evidence for the inactivation of multiple 
replicative lifespan genes in immortal human squamous cell carcinoma keratinocytes’, Oncogene, 
14(16), pp. 1955–1964. doi: 10.1038/sj.onc.1201028. 
Louie, K. S., Mehanna, H. and Sasieni, P. (2015) ‘Trends in head and neck cancers in England from 
1995 to 2011 and projections up to 2025’, Oral Oncology. Elsevier Ltd, 51(4), pp. 341–348. doi: 
10.1016/j.oraloncology.2015.01.002. 
Lu, P., Weaver, V. M. and Werb, Z. (2012) ‘The extracellular matrix: a dynamic niche in cancer 
progression.’, The Journal of cell biology. The Rockefeller University Press, 196(4), pp. 395–406. doi: 
10.1083/jcb.201102147. 
Ludwig, N., Szczepanski, M. J., Gluszko, A., Szafarowski, T., Azambuja, J. H., Dolg, L., Gellrich, N. 
C., Kampmann, A., Whiteside, T. L. and Zimmerer, R. M. (2019) ‘CD44(+) tumor cells promote early 
angiogenesis in head and neck squamous cell carcinoma’, Cancer Letters. Elsevier, 467(9), pp. 85–
95. doi: 10.1016/j.canlet.2019.10.010. 
Luo, S. D., Chen, Y. J., Liu, C. T., Rau, K. M., Chen, Y. C., Tsai, H. T., Chen, C. H. and Chiu, T. J. 
(2015) ‘Osteopontin Involves Cisplatin Resistance and Poor Prognosis in Oral Squamous Cell 
Carcinoma’, BioMed Research International. Hindawi Publishing Corporation, 2015. doi: 
10.1155/2015/508587. 
Ma, C. and Lewis, J. (2012) ‘Small Biopsy Specimens Reliably Indicate p16 Expression Status of 
Oropharyngeal Squamous Cell Carcinoma’, Head and Neck Pathology, 6(2), pp. 208–215. doi: 
10.1007/s12105-011-0322-7. 
Mac, M. and Moody, C. A. (2020) ‘Epigenetic regulation of the human papillomavirus life cycle’, 
Pathogens. Seminars in Immunopathology, 9(6), pp. 1–18. doi: 10.3390/pathogens9060483. 
Madar, S., Goldstein, I. and Rotter, V. (2013) ‘“Cancer associated fibroblasts” – more than meets the 
eye’, Trends in Molecular Medicine, 19(8), pp. 447–453. doi: 10.1016/j.molmed.2013.05.004. 
Madsen, C. D., Pedersen, J. T., Venning, F. A., Singh, L. B., Moeendarbary, E., Charras, G., Cox, T. 
R., Sahai, E. and Erler, J. T. (2015) ‘ Hypoxia and loss of PHD 2 inactivate stromal fibroblasts to 
decrease tumour stiffness and metastasis ’, EMBO reports, 16(10), pp. 1394–1408. doi: 
10.15252/embr.201540107. 
Maleš, J., Mihalj, H., Šestak, A., Kralik, K. and Smolić, M., 2021. Osteopontin Levels in Patients 
with Squamous Metastatic Head and Neck Cancer. Medicina, 57(2), p.185. 
Malyankar, U. M., Almeida, M., Johnson, R. J., Pichler, R. H. and Giachelli, C. M. (1997) ‘Osteopontin 
regulation in cultured rat renal epithelial cells’, Kidney International. Elsevier Masson SAS, 51(6), pp. 
1766–1773. doi: 10.1038/ki.1997.243. 
Manukian, G., Bar-Ad, V., Lu, B., Argiris, A. and Johnson, J. M. (2019) ‘Combining radiation and 
immune checkpoint blockade in the treatment of head and neck squamous cell carcinoma’, Frontiers 
in Oncology, 9(3), pp. 1–14. doi: 10.3389/fonc.2019.00122. 
Maris, P., Blomme, A., Palacios, A. P., Costanza, B., Bellahcène, A., Bianchi, E., Gofflot, S., Drion, P., 
Trombino, G. E., Di Valentin, E., Cusumano, P. G., Maweja, S., Jerusalem, G., Delvenne, P., Lifrange, 
346 
 
E., Castronovo, V. and Turtoi, A. (2015) ‘Asporin Is a Fibroblast-Derived TGF-β1 Inhibitor and a Tumor 
Suppressor Associated with Good Prognosis in Breast Cancer’, PLoS Medicine, 12(9), pp. 1–29. doi: 
10.1371/journal.pmed.1001871. 
Marques, C., Priscila, S., Abreu, M. De, Ventorin, S., Laís, V. Z. and Jesus, M. De (2021) ‘Human 
Papillomavirus DNA Detection by Droplet Digital PCR in Formalin ‐ Fixed Paraffin ‐ Embedded Tumor 
Tissue from Oropharyngeal Squamous Cell Carcinoma Patients’, Molecular Diagnosis & Therapy. 
Springer International Publishing, 25(1), pp. 59–70. doi: 10.1007/s40291-020-00502-6. 
Marsh, D., Suchak, K., Moutasim, Karwan A, Vallath, S., Hopper, C., Jerjes, W., Upile, T., Kalavrezos, 
N., Violette, S. M., Weinreb, P. H., Chester, K. A., Chana, J. S., Marshall, J. F., Hart, I. R., Hackshaw, 
A. K., Piper, K. and Thomas, G. J. (2011) ‘Stromal features are predictive of disease mortality in oral 
cancer patients’, The Journal of Pathology, 223(4), pp. 470–481. doi: 10.1002/path.2830. 
Martel, C. De, Georges, D., Bray, F., Ferlay, J. and Clifford, G. M. (2020) ‘Global burden of cancer 
attributable to infections in 2018 : a worldwide incidence analysis’, The Lancet Global Health. 
International Agency for Research on Cancer, 8(2), pp. e180–e190. doi: 10.1016/S2214-
109X(19)30488-7. 
Martel, C., Plummer, M., Vignat, J. and Franceschi, S. (2017) ‘Worldwide burden of cancer attributable 
to HPV by site, country and HPV type’, International Journal of Cancer, 141(4), pp. 664–670. doi: 
10.1002/ijc.30716. 
Massagué, J. (2012) ‘TGFβ signalling in context’, Nature Reviews Molecular Cell Biology. Nature 
Publishing Group, 13(10), pp. 616–630. doi: 10.1038/nrm3434. 
Maxwell, J., Kumar, B., Feng, F., Worden, F., Lee, J., Eisbruch, A., Wolf, G., Prince, M., Moyer, J., 
Teknos, T., Chepeha, D., McHugh, J., Urba, S., Stoerker, J., Walline, H., Kurnit, D., Cordell, K., Davis, 
S., Ward, P., Bradford, C. and Carey, T., 2010. Tobacco Use in Human Papillomavirus-Positive 
Advanced Oropharynx Cancer Patients Related to Increased Risk of Distant Metastases and Tumor 
Recurrence. Clinical Cancer Research, 16(4), pp.1226-1235. 
Mazul, A., Rodriguez-Ormaza, Nidia. Taylor, J., Dipan D Desai2, F. and Paul Brennan, C. (2016) 
‘Prognostic significance of non-HPV16 genotypes in oropharyngeal squamous cell carcinoma’, 
Physiology & behavior, 176(10), pp. 139–148. doi: 10.1016/j.oraloncology.2016.08.019.Prognostic. 
McAllister, S. S., Gifford, A. M., Greiner, A. L., Kelleher, S. P., Saelzler, M. P., Ince, T. A., Reinhardt, 
F., Harris, L. N., Hylander, B. L., Repasky, E. A. and Weinberg, R. A. (2008) ‘Systemic Endocrine 
Instigation of Indolent Tumor Growth Requires Osteopontin’, Cell, 133(6), pp. 994–1005. doi: 
10.1016/j.cell.2008.04.045. 
McAnulty, R. J. (2007) ‘Fibroblasts and myofibroblasts: Their source, function and role in disease’, The 
International Journal of Biochemistry & Cell Biology. Pergamon, 39(4), pp. 666–671. doi: 
10.1016/J.BIOCEL.2006.11.005. 
McLaughlin-Drubin, M. E., Crum, C. P. and Münger, K. (2011) ‘Human papillomavirus E7 oncoprotein 
induces KDM6A and KDM6B histone demethylase expression and causes epigenetic reprogramming’, 
Proceedings of the National Academy of Sciences of the United States of America, 108(5), pp. 2130–
2135. doi: 10.1073/pnas.1009933108. 
Mehanna, H., Robinson, M., Hartley, A., Kong, A., Foran, Bernadette, Fulton-Lieuw, T., Dalby, 
M., Mistry, P., Sen, M., O’Toole, L., Al Booz, H., Dyker, K., Moleron, R., Whitaker, S., Brennan, 
Sinead, Cook, A., Griffin, M., Aynsley, E., Rolles, M., De Winton, E., Chan, A., Srinivasan, D., 
Nixon, I., Grumett, J., Leemans, C. R., Buter, J., Henderson, J., Harrington, K., McConkey, C., 
347 
 
Gray, A., Dunn, J., McArdle, O., Husband, D., Loo, V., Soe, W., Sridhar, T., Jankowska, P., 
Joseph, M., Geropantas, K., Vaidya, D., Vijayan, R., Hwang, D., Pettit, L., Brennan, Sinéad, 
Mendes, R., Forster, M., Evans, M., Foran, Bernie, Nankivell, P., Bryant, J., Sharma, N., Spruce, 
R., Brooks, J., Batis, N., Roques, T., Bidmead, M., Yang, H., Nutting, C., Tyler, J., Baines, H., 
Gasnier, A., Miles, E. and Clark, C. (2019) ‘Radiotherapy plus cisplatin or cetuximab in low-risk 
human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label 
randomised controlled phase 3 trial’, The Lancet, 393(10166), pp. 51–60. doi: 10.1016/S0140-
6736(18)32752-1. 
Melling, G. E. (2015) The Role of microRNA-145 in the Tumour Microenvironment . Ph.D, University 
of Sheffield. 
Melling, G. E., Flannery, S. E., Abidin, S. A., Clemmens, H., Prajapati, P., Hinsley, E. E., Hunt, S., 
Catto, J. W. F., Coletta, R. Della, Mellone, M., Thomas, G. J., Parkinson, E. K., Prime, S. S., Paterson, 
I. C., Buttle, D. J. and Lambert, D. W. (2018) ‘A miRNA-145/TGF-β1 negative feedback loop regulates 
the cancer-associated fibroblast phenotype’, Carcinogenesis. doi: 10.1093/carcin/bgy032. 
Mellone, M., Hanley, C. J., Thirdborough, S., Mellows, T., Garcia, E., Woo, J., Tod, J., Frampton, S., 
Jenei, V., Moutasim, K. A., Kabir, T. D., Brennan, P. A., Venturi, G., Ford, K., Herranz, N., Lim, K. P., 
Clarke, J., Lambert, D. W., Prime, S. S., Underwood, T. J., Vijayanand, P., Eliceiri, K. W., Woelk, C., 
King, E. V., Gil, J., Ottensmeier, C. H. and Thomas, G. J. (2016) ‘Induction of fibroblast senescence 
generates a non-fibrogenic myofibroblast phenotype that differentially impacts on cancer prognosis’, 
Aging, 9(1), pp. 114–132. doi: 10.18632/aging.101127. 
Mena, M., Taberna, M., Tous, S., Marquez, S., Clavero, O., Quiros, B., Lloveras, B., Alejo, M., Leon, 
X., Quer, M., Bagué, S., Mesia, R., Nogués, J., Gomà, M., Aguila, A., Bonfill, T., Blazquez, C., Guix, 
M., Hijano, R., Torres, M., Holzinger, D., Pawlita, M., Pavon, M. A., Bravo, I. G., de Sanjosé, S., Bosch, 
F. X. and Alemany, L. (2018) ‘Double positivity for HPV-DNA/p16ink4a is the biomarker with strongest 
diagnostic accuracy and prognostic value for human papillomavirus related oropharyngeal cancer 
patients’, Oral Oncology, 78(2), pp. 137–144. doi: 10.1016/j.oraloncology.2018.01.010. 
Mendez-Pena, J. E., Sadow, P. M., Nose, V. and Hoang, M. P. (2017) ‘RNA chromogenic in situ 
hybridization assay with clinical automated platform is a sensitive method in detecting high-risk human 
papillomavirus in squamous cell carcinoma’, Human Pathology. Elsevier Inc., 63, pp. 184–189. doi: 
10.1016/j.humpath.2017.02.021. 
Meng, W., Xia, Q., Wu, L., Chen, S., He, X., Zhang, L., Gao, Q. and Zhou, H. (2011) ‘Downregulation 
of TGF-beta receptor types II and III in oral squamous cell carcinoma and oral carcinoma-associated 
fibroblasts’, BMC Cancer. BioMed Central Ltd, 11(1), p. 88. doi: 10.1186/1471-2407-11-88. 
Meng, X. M., Nikolic-Paterson, D. J. and Lan, H. Y. (2016) ‘TGF-β: The master regulator of fibrosis’, 
Nature Reviews Nephrology. Nature Publishing Group, 12(6), pp. 325–338. doi: 
10.1038/nrneph.2016.48. 
Mirghani, H., Amen, F., Blanchard, P., Moreau, F., Guigay, J., Hartl, D. M. and Lacau St Guily, J. (2015) 
‘Treatment de-escalation in HPV-positive oropharyngeal carcinoma: Ongoing trials, critical issues and 
perspectives’, International Journal of Cancer, 136(7), pp. 1494–1503. doi: 10.1002/ijc.28847. 
Mirghani, H., Amen, F., Moreau, F., Guigay, J., Ferchiou, M., Melkane, A. E., Hartl, D. M. and Lacau 
St Guily, J. (2014) ‘Human papilloma virus testing in oropharyngeal squamous cell carcinoma: What 
the clinician should know’, Oral Oncology, 50(1), pp. 1–9. doi: 10.1016/j.oraloncology.2013.10.008. 
Mirghani, H., Casiraghi, O., Guerlain, J., Amen, F., He, M., Ma, X., Luo, Y., Mourareau, C., Drusch, F., 
Ben, A., Melkane, A., St, L., Badoual, C., Yves, J., Borget, I., Aupérin, A., Dalstein, V. and Vielh, P. 
348 
 
(2016) ‘Diagnosis of HPV driven oropharyngeal cancers : Comparing p16 based algorithms with the 
RNAscope HPV-test’, 62, pp. 101–108. doi: 10.1016/j.oraloncology.2016.10.009. 
Mirza, M., Shaughnessy, E., Hurley, J. K., Vanpatten, K. A., Pestano, G. A., He, B. and Weber, G. F. 
(2008) ‘Osteopontin-c is a selective marker of breast cancer’, International Journal of Cancer, 122(4), 
pp. 889–897. doi: 10.1002/ijc.23204. 
Moorman, H. R., Poschel, D., Klement, J. D., Lu, C., Redd, P. S. and Liu, K. (2020) ‘Osteopontin: A 
key regulator of tumor progression and immunomodulation’, Cancers, 12(11), pp. 1–31. doi: 
10.3390/cancers12113379. 
Morgan, I. M., DiNardo, L. J., & Windle, B. (2017). Integration of Human Papillomavirus Genomes in 
Head and Neck Cancer: Is It Time to Consider a Paradigm Shift?. Viruses, 9(8), 208. 
https://doi.org/10.3390/v9080208 
Mori, R., Shaw, T. J. and Martin, P. (2008) ‘Molecular mechanisms linking wound inflammation and 
fibrosis: Knockdown of osteopontin leads to rapid repair and reduced scarring’, Journal of Experimental 
Medicine, 205(1), pp. 43–51. doi: 10.1084/jem.20071412. 
Mourik, J. A., Leeksma, O. C., Reinders, J. H., de Groot, P. G. and Zandbergen-Spaargaren, J. (1985) 
‘Vascular endothelial cells synthesize a plasma membrane protein indistinguishable from the platelet 
membrane glycoprotein IIa’, Journal of Biological Chemistry, 260(20), pp. 11300–11306. doi: 
10.1016/S0021-9258(17)39180-9. 
Moutasim, K. A., Robinson, M. and Thavaraj, S. (2015) ‘Human papillomavirus testing in diagnostic 
head and neck histopathology’, Diagnostic Histopathology. Elsevier BV, 21(2), pp. 77–84. doi: 
10.1016/j.mpdhp.2015.02.002. 
Müller, S., Khuri, F. R., Kono, S. A., Beitler, J. J., Shin, D. M., & Saba, N. F. (2012). HPV positive 
squamous cell carcinoma of the oropharynx. Are we observing an unusual pattern of 
metastases?. Head and neck pathology, 6(3), pp. 336–344. https://doi.org/10.1007/s12105-012-0355-
6. 
Mughees, M., Sengupta, A., Khowal, S. and Wajid, S. (2021) ‘Mechanism of tumour microenvironment 
in the progression and development of oral cancer’, Molecular Biology Reports. Springer Netherlands, 
48(2), pp. 1773–1786. doi: 10.1007/s11033-020-06054-6. 
Mukaratirwa, S., Koninkx, J. F., Gruys, E. and Nederbragt, H. (2005) ‘Mutual paracrine effects of 
colorectal tumour cells and stromal cells: Modulation of tumour and stromal cell differentiation and 
extracellular matrix component production in culture’, International Journal of Experimental Pathology, 
86(4), pp. 219–229. doi: 10.1111/j.0959-9673.2005.00425.x. 
Näsman, A., Nordfors, C., Grün, N., Munck-Wikland, E., Ramqvist, T., Marklund, L., Lindquist, D. and 
Dalianis, T. (2013) ‘Absent/weak CD44 intensity and positive human papillomavirus (HPV) status in 
oropharyngeal squamous cell carcinoma indicates a very high survival’, Cancer Medicine, 2(4), pp. 
507–518. doi: 10.1002/cam4.90. 
Naugler, W. E. and Karin, M. (2008) ‘The wolf in sheep’s clothing: the role of interleukin-6 in immunity, 
inflammation and cancer’, Trends in Molecular Medicine, 14(3), pp. 109–119. doi: 
10.1016/j.molmed.2007.12.007. 
Neal, J. T., Li, X., Zhu, J., Giangarra, V., Caitlin, L., Ju, J., Liu, I. H., Chiou, S., Salahudeen, A. A., 
Smith, R., Deutsch, B. C., Liao, L., Zemek, A. J., Zhao, F., Schultz, L. M., Metzner, T. J., Nadauld, L. 
D., Tseng, Y., Alkhairy, S., Oh, C., Keskula, P., Mendoza-villanueva, D. and De, F. M. (2019) ‘Organoid 
349 
 
modeling of the tumor immune microenvironment James’, 175(7), pp. 1972–1988. doi: 
10.1016/j.cell.2018.11.021.Organoid. 
New, L. and Han, J. (1998) ‘The p38 MAP kinase pathway and its biological function’, Trends in 
Cardiovascular Medicine, 8(5), pp. 220–228. doi: 10.1016/S1050-1738(98)00012-7. 
Nice.org.uk. 2021. Overview | Cancer of the upper aerodigestive tract: assessment and 
management in people aged 16 and over | Guidance | NICE. [online] Available at: 
<https://www.nice.org.uk/guidance/ng36> [Accessed 14 March 2021]. 
Ninck, S., Reisser, C., Dyckhoff, G., Helmke, B., Bauer, H. and Herold-Mende, C. (2003) ‘Expression 
profiles of angiogenic growth factors in squamous cell carcinomas of the head and neck’, International 
Journal of Cancer, 106(1), pp. 34–44. doi: 10.1002/ijc.11188. 
O’Brien, E. R., Garvin, M. R., Stewart, D. K., Hinohara, T., Simpson, J. B., Schwartz, S. M. and 
Giachelli, C. M. (1994) ‘Osteopontin is synthesized by macrophage, smooth muscle, and endothelial 
cells in primary and restenotic human coronary atherosclerotic plaques’, Arteriosclerosis and 
Thrombosis, 14(10), pp. 1648–1656. doi: 10.1161/01.atv.14.10.1648. 
O’Sullivan, B., Huang, S. H., Perez-Ordonez, B., Massey, C., Siu, L. L., Weinreb, I., Hope, A., Kim, J., 
Bayley, A. J., Cummings, B., Ringash, J., Dawson, L. A., Cho, B. C. J., Chen, E., Irish, J., Gilbert, R. 
W., Hui, A., Liu, F.-F., Zhao, H., Waldron, J. N. and Xu, W. (2012) ‘Outcomes of HPV-related 
oropharyngeal cancer patients treated by radiotherapy alone using altered fractionation’, Radiotherapy 
and Oncology, 103(1), pp. 49–56. doi: 10.1016/j.radonc.2012.02.009. 
O’Sullivan, B., Huang, S. H., Siu, L. L., Waldron, J., Zhao, H., Perez-Ordonez, B., Weinreb, I., Kim, J., 
Ringash, J., Bayley, A., Dawson, L. A., Hope, A., Cho, J., Irish, J., Gilbert, R., Gullane, P., Hui, A., Liu, 
F.-F., Chen, E. and Xu, W. (2013) ‘Deintensification Candidate Subgroups in Human Papillomavirus–
Related Oropharyngeal Cancer According to Minimal Risk of Distant Metastasis’, Journal of Clinical 
Oncology, 31(5), pp. 543–550. doi: 10.1200/JCO.2012.44.0164. 
Ogbureke, K. U., Nikitakis, N. G., Warburton, G., Ord, R. A., Sauk, J. J., Waller, J. L. and Fisher, L. W. 
(2007) ‘Up-regulation of SIBLING proteins and correlation with cognate MMP expression in oral 
cancer’, Oral Oncology, 43(9), pp. 920–932. doi: 10.1016/j.oraloncology.2006.11.011. 
Ogbureke, K. U., Weinberger, P. M., Looney, S. W., Li, L. and Fisher, L. W. (2012) ‘Expressions of 
matrix metalloproteinase-9 (MMP-9), dentin sialophosphoprotein (DSPP), and osteopontin (OPN) at 
histologically negative surgical margins may predict recurrence of oral squamous cell carcinoma’, 
Oncotarget, 3(3), pp. 286–298. doi: 10.18632/oncotarget.373. 
Oguejiofor, k., 2016. Prognostic markers in oropharyngeal cancers. Ph.D. University of 
Manchester. 
Oh, J., Lee, Y. D. and Wagers, A. J. (2014) ‘Stem cell aging: Mechanisms, regulators and therapeutic 
opportunities’, Nature Medicine. Nature Publishing Group, 20(8), pp. 870–880. doi: 10.1038/nm.3651. 
Oh, K., Seo, M. W., Kim, Y. W. and Lee, D.-S. (2015) ‘Osteopontin Potentiates Pulmonary Inflammation 
and Fibrosis by Modulating IL-17/IFN-γ-secreting T-cell Ratios in Bleomycin-treated Mice’, Immune 
Network, 15(3), p. 142. doi: 10.4110/in.2015.15.3.142. 
Öhlund, D., Elyada, E. and Tuveson, D. (2014) ‘Fibroblast heterogeneity in the cancer wound’, Journal 
of Experimental Medicine, 211(8), pp. 1503–1523. doi: 10.1084/jem.20140692. 
350 
 
Öhlund, D., Handly-Santana, A., Biffi, G., Elyada, E., Almeida, A. S., Ponz-Sarvise, M., Corbo, V., Oni, 
T. E., Hearn, S. A., Lee, E. J., Chio, I. I. C., Hwang, C. Il, Tiriac, H., Baker, L. A., Engle, D. D., Feig, 
C., Kultti, A., Egeblad, M., Fearon, D. T., Crawford, J. M., Clevers, H., Park, Y. and Tuveson, D. A. 
(2017) ‘Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer’, The 
Journal of experimental medicine, 214(3), pp. 579–596. doi: 10.1084/jem.20162024. 
Olsen, C. L., Gardie, B., Yaswen, P. and Stampfer, M. R. (2002) ‘Raf-1-induced growth arrest in human 
mammary epithelial cells is p16-independent and is overcome in immortal cells during conversion’, 
Oncogene, 21(41), pp. 6328–6339. doi: 10.1038/sj.onc.1205780. 
Olthof, N. C., Speel, E. M., Kolligs, J., Haesevoets, A., Henfling, M., Ramaekers, F. C. S., Preuss, S. 
F., Drebber, U., Wieland, U., Silling, S., Lam, W. L., Vucic, E. A., Kremer, B., Klussmann, J. and 
Huebbers, C. U. (2014) ‘Comprehensive Analysis of HPV16 Integration in OSCC Reveals No 
Significant Impact of Physical Status on Viral Oncogene and Virally Disrupted Human Gene 
Expression’, 9(2), pp. 1–8. doi: 10.1371/journal.pone.0088718. 
Orimo, A. and Weinberg, R. A. (2006) ‘Stromal fibroblasts in cancer: A novel tumor-promoting cell 
type’, Cell Cycle, 5(15), pp. 1597–1601. doi: 10.4161/cc.5.15.3112. 
Orimo, A. and Weinberg, R. A. (2007) ‘Heterogeneity of stromal fibroblasts in tumors’, Cancer Biology 
and Therapy, 6(4), pp. 618–619. doi: 10.4161/cbt.6.4.4255. 
Oropharynx: Introduction. Radiology Key. 2021.  [online] Available at: 
<https://radiologykey.com/oropharynx-introduction/> [Accessed 9 March 2021]. 
Osei-Sarfo, K., Tang, X.-H., Urvalek, A. M., Scognamiglio, T. and Gudas, L. J. (2013) ‘The molecular 
features of tongue epithelium treated with the carcinogen 4-nitroquinoline-1-oxide and alcohol as a 
model for HNSCC’, Carcinogenesis, 34(11), pp. 2673–2681. doi: 10.1093/carcin/bgt223. 
Österreicher, C. H., Penz-Österreicher, M., Grivennikov, S. I., Guma, M., Koltsova, E. K., Datz, C., 
Sasik, R., Hardiman, G., Karin, M. and Brenner, D. A. (2011) ‘Fibroblast-specific protein 1 identifies an 
inflammatory subpopulation of macrophages in the liver’, Proceedings of the National Academy of 
Sciences of the United States of America, 108(1), pp. 308–313. doi: 10.1073/pnas.1017547108. 
Östman, A. and Augsten, M. (2009) ‘Cancer-associated fibroblasts and tumor growth - bystanders 
turning into key players’, Current Opinion in Genetics and Development, 19(1), pp. 67–73. doi: 
10.1016/j.gde.2009.01.003. 
Overgaard, J., Eriksen, J. G., Nordsmark, M., Alsner, J. and Horsman, M. R. (2005) ‘Plasma 
osteopontin, hypoxia, and response to the hypoxia sensitiser nimorazole in radiotherapy of head and 
neck cancer: Results from the DAHANCA 5 randomised double-blind placebo-controlled trial’, Lancet 
Oncology. Elsevier Ltd, 6(10), pp. 757–764. doi: 10.1016/S1470-2045(05)70292-8. 
Özdemir, B. C., Pentcheva-Hoang, T., Carstens, J. L., Zheng, X., Wu, C. C., Simpson, T. R., Laklai, 
H., Sugimoto, H., Kahlert, C., Novitskiy, S. V., DeJesus-Acosta, A., Sharma, P., Heidari, P., Mahmood, 
U., Chin, L., Moses, H. L., Weaver, V. M., Maitra, A., Allison, J. P., LeBleu, V. S. and Kalluri, R. (2014) 
‘Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and 
accelerates pancreas cancer with reduced survival’, Cancer Cell, 25(6), pp. 719–734. doi: 
10.1016/j.ccr.2014.04.005. 
Park, C. K., Jung, W. H. and Koo, J. S. (2016) ‘Expression of cancer-associated fibroblast-related 
proteins differs between invasive lobular carcinoma and invasive ductal carcinoma’, Breast Cancer 
Research and Treatment. Springer US, 159(1), pp. 55–69. doi: 10.1007/s10549-016-3929-2. 
351 
 
Park, J. E., Lenter, M. C., Zimmermann, R. N., Garin-Chesa, P., Old, L. J. and Rettig, W. J. (1999) 
‘Fibroblast activation protein, a dual specificity serine protease expressed in reactive human tumor 
stromal fibroblasts’, Journal of Biological Chemistry, 274(51), pp. 36505–36512. doi: 
10.1074/jbc.274.51.36505. 
Parkinson, E. K., James, E. L. and Prime, S. S. (2016) ‘Senescence-Derived Extracellular Molecules 
as Modulators of Oral Cancer Development: A Mini-Review’, Gerontology, 62(4), pp. 417–424. doi: 
10.1159/000440954. 
Parrinello, S., Coppe, J. P., Krtolica, A. and Campisi, J. (2005) ‘Stromal-epithelial interactions in aging 
and cancer: Senescent fibroblasts alter epithelial cell differentiation’, Journal of Cell Science, 118(3), 
pp. 485–496. doi: 10.1242/jcs.01635. 
Parsons, M. and Grabsch, H. (2009) ‘How to make tissue microarrays’, Diagnostic Histopathology. 
Elsevier Ltd., 15(3), pp. 142–150. doi: 10.1016/j.mpdhp.2009.01.010. 
Parts of the throat (pharynx). Mayo Clinic. 2021.  [online] Available at: 
<https://www.mayoclinic.org/parts-of-the-throat-pharynx/img-20005644> [Accessed 9 March 
2021]. 
Patel, A. K., Vipparthi, K., Thatikonda, V., Arun, I., Bhattacharjee, S., Sharan, R., Arun, P. and Singh, 
S. (2018) ‘A subtype of cancer-associated fibroblasts with lower expression of alpha-smooth muscle 
actin suppresses stemness through BMP4 in oral carcinoma’, Oncogenesis. Springer US, 7(10). doi: 
10.1038/s41389-018-0087-x. 
Pazolli, E., Luo, X., Brehm, S., Carbery, K., Chung, J. J., Prior, J. L., Doherty, J., Demehri, S., 
Salavaggione, L., Piwnica-Worms, D. and Stewart, S. A. (2009) ‘Senescent stromal-derived 
osteopontin promotes preneoplastic cell growth’, Cancer Research, 69(3), pp. 1230–1239. doi: 
10.1158/0008-5472.CAN-08-2970. 
Peacock, B. (2018) Characterisation of extracellular vesicles released by HPV+ and HPV- 
oropharyngeal carcinoma cells in vitro. Ph.D. University of Sheffield. 
Peacock, B., Rigby, A., Bradford, J., Pink, R., Hunter, K., Lambert, D. and Hunt, S. (2018) ‘Extracellular 
vesicle microRNA cargo is correlated with HPV status in oropharyngeal carcinoma’, Journal of Oral 
Pathology and Medicine, 47(10), pp. 954–963. doi: 10.1111/jop.12781. 
Petraki, C. D., Gregorakis, A. K., Vaslamatzis, M. M., Papanastasiou, P. A., Yousef, G. M., Levesque, 
M. A. and Diamandis, E. P. (2005) ‘Prognostic implications of the immunohistochemical expression of 
human kallikreins 5, 6, 10 and 11 in renal cell carcinoma’, Tumor Biology, 27(1), pp. 1–7. doi: 
10.1159/000090150. 
Pett, M. R., Alazawi, W. O. F., Roberts, I., Dowen, S., Smith, D. I., Stanley, M. A. and Coleman, N. 
(2004) ‘Acquisition of High-Level Chromosomal Instability Is Associated with Integration of Human 
Papillomavirus Type 16 in Cervical Keratinocytes’, 9, pp. 1359–1368. 
Pickard, R. K. L., Xiao, W., Broutian, T. R., He, X. and Gillison, M. L. (2012) ‘The Prevalence and 
Incidence of Oral Human Papillomavirus Infection Among Young Men and Women, Aged 18–30 
Years’, Sexually Transmitted Diseases, 39(7), pp. 559–566. doi: 10.1097/OLQ.0b013e31824f1c65. 
Pickering, C. R., Zhang, J., Yoo, S. Y., Bengtsson, L., Cortez, E., Xie, T., Zhang, D., Chung, W., 
Zweidler-mckay, P. A., Wu, X., El-naggar, A. K., Weinstein, J. N. and Frederick, M. J. (2014) 
‘Integrative genomic characterization of oral squamous cell carcinoma identifies frequent somatic 
drivers’, 3(7), pp. 1–21. doi: 10.1158/2159-8290.CD-12-0537.Integrative. 
352 
 
Pietras, A., Katz, A. M., Ekström, E. J., Wee, B., Halliday, J. J., Pitter, K. L., Werbeck, J. L., Amankulor, 
N. M., Huse, J. T. and Holland, E. C. (2014) ‘Osteopontin-CD44 signaling in the glioma perivascular 
niche enhances cancer stem cell phenotypes and promotes aggressive tumor growth’, Cell Stem Cell, 
14(3), pp. 357–369. doi: 10.1016/j.stem.2014.01.005. 
Plebani, M., Al, S., Verderio, P., Locati, L., Perrone, F., Quattrone, P., Carbone, A., Pilotti, S. and 
Gloghini, A. (2018) ‘In situ hybridization detection methods for HPV16 E6 / E7 mRNA in identifying 
transcriptionally active HPV infection of oropharyngeal carcinoma ’:, pp. 32–42. doi: 
10.1016/j.humpath.2017.09.011. 
Postlethwaite, A. E., Keski-Oja, J., Moses, H. L. and Kang, A. H. (1987) ‘Stimulation of the chemotactic 
migration of human fibroblasts by transforming growth factor β’, Journal of Experimental Medicine, 
165(1), pp. 251–256. doi: 10.1084/jem.165.1.251. 
Potdar, P. D. and Chaudhary, S. (2017) ‘Molecular characterization of cancer-associated fibroblasts 
isolated from human colorectal cancer as a major stromal cell component promoting metastasis’, 
Journal of Unexplored Medical Data, 2(1), pp. 1–8. doi: 10.20517/2572-8180.2016.10. 
Pourgholami, M. and Morris, D. (2008) ‘Inhibitors of Vascular Endothelial Growth Factor in Cancer’, 
Cardiovascular & Hematological Agents in Medicinal Chemistry, 6(4), pp. 343–347. doi: 
10.2174/187152508785909528. 
Powell, D. W., Adegboyega, P. A., Mari, J. F. Di and Mifflin, R. C. (2005) ‘Epithelial Cells and Their 
Neighbors I . Role of intestinal myofibroblasts in development , repair , and cancer’, pp. 2–7. doi: 
10.1152/ajpgi.00075.2005. 
Powell, D. W., Mifflin, R. C., Valentich, J. D., Crowe, S. E., Saada, J. I., & West, A. B. (1999). 
Myofibroblasts. I. Paracrine cells important in health and disease. The American journal of 
physiology, 277(1), pp.1–9. https://doi.org/10.1152/ajpcell.1999.277.1.C1 
Prasanna, V., Deepti, G., Dhiraj, T., Mane, A., Gill, S. S., Patil, T., Weber, G. F. and Kundu, G. C. 
(2021) ‘Tumor-derived osteopontin drives the resident fi broblast to myo fi broblast differentiation 
through Twist1 to promote breast cancer progression’, Oncogene. Springer US. doi: 10.1038/s41388-
021-01663-2. 
Prieto, L. I., Graves, S. I. and Baker, D. J. (2020) ‘Insights from In Vivo Studies of Cellular Senescence’, 
Cells, 9(4), pp. 1–13. 
Prime, S. S., Cirillo, N., Hassona, Y., Lambert, D. W., Paterson, I. C., Mellone, M., Thomas, G. J., 
James, E. N. L. and Parkinson, E. K. (2017) ‘Fibroblast activation and senescence in oral cancer’, 
Journal of Oral Pathology and Medicine, 46(2), pp. 82–88. doi: 10.1111/jop.12456. 
Proteinatlas.org. 2021. Tissue expression of SPP1 - Summary - The Human Protein Atlas. 
[online] Available at: <https://www.proteinatlas.org/ENSG00000118785-SPP1/tissue> [Accessed 
7 February 2021]. 
Punt, S., Dronkers, E. A. C., Welters, M. J. P., Goedemans, R., Koljenović, S., Bloemena, E., Snijders, 
P. J. F., Gorter, A., van der Burg, S. H., de Jong, R. J. B. and Jordanova, E. S. (2016) ‘A beneficial 
tumor microenvironment in oropharyngeal squamous cell carcinoma is characterized by a high T cell 
and low IL-17+ cell frequency’, Cancer Immunology, Immunotherapy, 65(4), pp. 393–403. doi: 
10.1007/s00262-016-1805-x. 
Puram, S. V, Bober, S. L., Daly, M. B., Program, C., Chase, F., Sciences, B., Care, P., Chase, F., 
Behavior, S. and Neoplasms, B. (2018) ‘Single-cell transcriptomic analysis of primary and metastatic 
353 
 
tumor ecosystems in head and neck cancer’, Cell, 123(24), pp. 4757–4763. doi: 
10.1016/j.cell.2017.10.044.Single-cell. 
Qian, B. Z. and Pollard, J. W. (2010) ‘Macrophage Diversity Enhances Tumor Progression and 
Metastasis’, Cell, 141(1), pp. 39–51. doi: 10.1016/j.cell.2010.03.014. 
Qin, C., Baba, O. and Butler, W., 2004. Post-translational Modifications of SIBLING Proteins and Their 
Roles in Osteogenesis and Dentinogenesis. Critical Reviews in Oral Biology & Medicine, 15(3), 
pp.126-136. 
Qin, X., Yan, M., Wang, Xu, Xu, Q., Wang, Xiaoning, Zhu, X., Shi, J., Li, Z., Zhang, J. and Chen, W. 
(2018) ‘Cancer-associated Fibroblast-derived IL-6 promotes head and neck cancer progression via the 
osteopontin-NF-kappa B signaling pathway’, Theranostics, 8(4), pp. 921–940. doi: 
10.7150/thno.22182. 
Qiu, Y., Hu, Y., Zhang, Z. Y., Ye, L., Xu, F. H., Schneider, M. E., Ma, X. L., Du, Y. X., Zuo, X. B., Zhou, 
F. S., Chen, G., Xie, X. S., Zhang, Y., Xia, H. Z., Wu, J. F. and Du, W. D. (2014) ‘Genetic association 
of osteopontin (OPN) and its receptor CD44 genes with susceptibility to Chinese gastric cancer 
patients’, Journal of Cancer Research and Clinical Oncology, 140(12), pp. 2143–2156. doi: 
10.1007/s00432-014-1761-9. 
Quail, D. F. and Joyce, J. A. (2013) ‘Microenvironmental regulation of tumor progression and 
metastasis’, Nature Medicine, 19(11), pp. 1423–1437. doi: 10.1038/nm.3394. 
Ragin, C. C., & Taioli, E. (2007). Survival of squamous cell carcinoma of the head and neck in relation 
to human papillomavirus infection: review and meta-analysis. International journal of cancer, 121(8), 
pp. 1813–1820. https://doi.org/10.1002/ijc.22851. 
Ragin C. C, Reshmi SC, Gollin SM. (2004) Mapping and analysis of HPV16 integration sites in a head 
and neck cancer cell line. Int J Cancer.  10;110(5): pp. 701-9. doi: 10.1002/ijc.20193. PMID: 15146560. 
Rahrotaban, S., Mahdavi, N., Abdollahi, A., Yazdani, F., Kaghazloo, A. and Derakhshan, S. (2019) 
‘Carcinoma-associated Fibroblasts are a Common Finding in the Microenvironment of HPV-positive 
Oropharyngeal Squamous Cell Carcinoma’, Applied Immunohistochemistry and Molecular 
Morphology, 27(9), pp. 683–688. doi: 10.1097/PAI.0000000000000687. 
Rail, C. J. N. and Rustgi, A. K. (1995) ‘CD44 Isoform Expression in Primary and Metastatic Pancreatic 
Adenocarcinoma’, Cancer Research, 55(9), pp. 1831–1835. 
Randén-Brady, R., Carpén, T., Jouhi, L., Syrjänen, S., Haglund, C., Tarkkanen, J., Remes, S., Mäkitie, 
A., Mattila, P. S., Silén, S. and Hagström, J. (2019) ‘In situ hybridization for high-risk HPV E6/E7 mRNA 
is a superior method for detecting transcriptionally active HPV in oropharyngeal cancer’, Human 
Pathology, 90, pp. 97–105. doi: 10.1016/j.humpath.2019.05.006. 
Rangaswami, H., Bulbule, A. and Kundu, G. C. (2006) ‘Osteopontin: Role in cell signaling and cancer 
progression’, Trends in Cell Biology, 16(2), pp. 79–87. doi: 10.1016/j.tcb.2005.12.005. 
Rettig, E., Kiess, A. P. and Fakhry, C. (2014) ‘The role of sexual behavior in head and neck cancer: 
Implications for prevention and therapy’, Expert Review of Anticancer Therapy, 15(1), pp. 35–49. doi: 
10.1586/14737140.2015.957189. 
Rettig, E. M., Fakhry, C., Khararjian, A. and Westra, W. H. (2018a) ‘Age profile of patients with 
oropharyngeal squamous cell carcinoma’, JAMA Otolaryngology - Head and Neck Surgery, 144(6), 
pp. 538–539. doi: 10.1001/jamaoto.2018.0310. 
354 
 
Rettig, E. M., Zaidi, M., Faraji, F., Eisele, D. W., El Asmar, M., Fung, N., D’Souza, G. and Fakhry, C. 
(2018b) ‘Oropharyngeal cancer is no longer a disease of younger patients and the prognostic 
advantage of Human Papillomavirus is attenuated among older patients: Analysis of the National 
Cancer Database’, Oral Oncology. Elsevier, 83(June), pp. 147–153. doi: 
10.1016/j.oraloncology.2018.06.013. 
Rhim, A. D., Oberstein, P. E., Thomas, D. H., Mirek, E. T., Palermo, C. F., Sastra, S. A., Dekleva, E. 
N., Saunders, T., Becerra, C. P., Tattersall, I. W., Westphalen, C. B., Kitajewski, J., Fernandez-
Barrena, M. G., Fernandez-Zapico, M. E., Iacobuzio-Donahue, C., Olive, K. P. and Stanger, B. Z. 
(2014) ‘Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma’, 
Cancer Cell. Elsevier Inc., 25(6), pp. 735–747. doi: 10.1016/j.ccr.2014.04.021. 
Riechelmann, H., Sauter, A., Golze, W., Hanft, G., Schroen, C., Hoermann, K., Erhardt, T. and Gronau, 
S. (2008) ‘Phase I trial with the CD44v6-targeting immunoconjugate bivatuzumab mertansine in head 
and neck squamous cell carcinoma’, Oral Oncology, 44(9), pp. 823–829. doi: 
10.1016/j.oraloncology.2007.10.009. 
Rinn, J. L., Bondre, C., Gladstone, H. B., Brown, P. O. and Chang, H. Y. (2006) ‘Anatomic demarcation 
by positional variation in fibroblast gene expression programs’, PLoS Genetics, 2(7), pp. 1084–1096. 
doi: 10.1371/journal.pgen.0020119. 
Robinson, M., Schache, A., Sloan, P. and Thavaraj, S. (2012) ‘HPV Specific Testing: A Requirement 
for Oropharyngeal Squamous Cell Carcinoma Patients’, Head and Neck Pathology, 6(SUPPL. 1), pp. 
83–90. doi: 10.1007/s12105-012-0370-7. 
Roden, D. F., Hobelmann, K., Vimawala, S., Richa, T., Fundakowski, C. E., Goldman, R., Luginbuhl, 
A., Curry, J. M. and Cognetti, D. M. (2020) ‘Evaluating the impact of smoking on disease-specific 
survival outcomes in patients with human papillomavirus–associated oropharyngeal cancer treated 
with transoral robotic surgery’, Cancer, 126(9), pp. 1873–1887. doi: 10.1002/cncr.32739. 
Rooper, L. M., Gandhi, M., Bishop, J. A. and Westra, W. H. (2016) ‘RNA in-situ hybridization is a 
practical and effective method for determining HPV status of oropharyngeal squamous cell carcinoma 
including discordant cases that are p16 positive by immunohistochemistry but HPV negative by DNA 
in-situ hybridization’, Oral Oncology. Elsevier Ltd, 55, pp. 11–16. doi: 
10.1016/j.oraloncology.2016.02.008. 
Routray, S., Kheur, S. M. and Kheur, M. (2013) ‘Osteopontin: A marker for invasive oral squamous cell 
carcinoma but not for potentially malignant epithelial dysplasias’, Annals of Diagnostic Pathology. 
Elsevier Inc., 17(5), pp. 421–424. doi: 10.1016/j.anndiagpath.2013.03.005. 
Safran, J. B., Butler, W. T., & Farach-Carson, M. C. (1998). Modulation of osteopontin post-
translational state by 1, 25-(OH)2-vitamin D3. Dependence on Ca2+ influx. The Journal of biological 
chemistry, 273(45), pp. 29935–29941. https://doi.org/10.1074/jbc.273.45.29935. 
Sahai, E., Astsaturov, I., Cukierman, E., DeNardo, D. G., Egeblad, M., Evans, R. M., Fearon, D., 
Greten, F. R., Hingorani, S. R., Hunter, T., Hynes, R. O., Jain, R. K., Janowitz, T., Jorgensen, C., 
Kimmelman, A. C., Kolonin, M. G., Maki, R. G., Powers, R. S., Puré, E., Ramirez, D. C., Scherz-
Shouval, R., Sherman, M. H., Stewart, S., Tlsty, T. D., Tuveson, D. A., Watt, F. M., Weaver, V., 
Weeraratna, A. T. and Werb, Z. (2020) ‘A framework for advancing our understanding of cancer-
associated fibroblasts’, Nature Reviews Cancer. Springer US, 20(3), pp. 174–186. doi: 
10.1038/s41568-019-0238-1. 
Salem, A. F., Sotgia, F. and Lisanti, M. P. (2013) ‘Smoke Cancer’, Cell Cycle, 12(5), pp. 818–825. 
355 
 
Salgueiredo-Giudice, F., Fornias-Sperandio, F., Martins-Pereira, É., da Costa dal Vechio, A. M., de 
Sousa, S. C. O. M. and dos Santos-Pinto-Junior, D. (2011) ‘The immunohistochemical profile of oral 
inflammatory myofibroblastic tumors’, Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, 
and Endodontology, 111(6), pp. 749–756. doi: 10.1016/j.tripleo.2010.12.023. 
Sanjose, S. De, Quint, W. G. V, Alemany, L., Geraets, D. T., Klaustermeier, J. E., Lloveras, B., Tous, 
S., Felix, A., Garland, S. M., Sasagawa, T., Ferrera, A., Hammouda, D., Mariani, L., Pelayo, A., Steiner, 
I., Oliva, E. and Valle, U. (2010) ‘Human papillomavirus genotype attribution in invasive cervical 
cancer : a retrospective cross-sectional worldwide study’, 11(11), pp. 7–11. doi: 10.1016/S1470-
2045(10)70230-8. 
Schache, A. G., Liloglou, T., Risk, J. M., Filia, A., Jones, T. M., Sheard, J., Woolgar, J. A., Helliwell, T. 
R., Triantafyllou, A., Robinson, M., Sloan, P., Harvey-Woodworth, C., Sisson, D. and Shaw, R. J. 
(2011) ‘Evaluation of human papilloma virus diagnostic testing in oropharyngeal squamous cell 
carcinoma: Sensitivity, specificity, and prognostic discrimination’, Clinical Cancer Research, 17(19), 
pp. 6262–6271. doi: 10.1158/1078-0432.CCR-11-0388. 
Schache, A. G., Liloglou, T., Risk, J. M., Jones, T. M., Ma, X.-J., Wang, H., Bui, S., Luo, Y., Sloan, P., 
Shaw, R. J. and Robinson, M. (2013) ‘Validation of a novel diagnostic standard in HPV-positive 
oropharyngeal squamous cell carcinoma.’, British journal of cancer. Nature Publishing Group, 108(6), 
pp. 1332–9. doi: 10.1038/bjc.2013.63. 
Schache, A. G., Powell, N. G., Cuschieri, K. S., Robinson, M., Leary, S., Mehanna, H., Rapozo, D., 
Long, A., Cubie, H., Junor, E., Monaghan, H., Harrington, K. J., Nutting, C. M., Schick, U., Lau, A. S., 
Upile, N., Sheard, J., Brougham, K., West, C. M. L., Oguejiofor, K., Thomas, S., Ness, A. R., Pring, M., 
Thomas, G. J., King, E. V., McCance, D. J., James, J. A., Moran, M., Sloan, P., Shaw, R. J., Evans, 
M. and Jones, T. M. (2016) ‘HPV-related oropharynx cancer in the United Kingdom: An evolution in 
the understanding of disease etiology’, Cancer Research, 76(22), pp. 6598–6606. doi: 10.1158/0008-
5472.CAN-16-0633. 
Schiffman, M., Clifford, G., & Buonaguro, F. M. (2009). Classification of weakly carcinogenic human 
papillomavirus types: addressing the limits of epidemiology at the borderline. Infectious agents and 
cancer, 4, p. 8. https://doi.org/10.1186/1750-9378-4-8. 
Schimizu, Y., Van Seventer, G. A., Siraganian, R., Wahl, L. and Shaw, S. (1989) ‘Dual role of the CD44 
molecule in T cell adhesion and activation’, The Journal of Immunology, 143(8), pp. 2457–2463. 
Schlotzhauer, W. S. and Chortyk, O. T. (1987) ‘Recent advances in studies on the pyrosynthesis of 
cigarette smoke constituents’, Journal of Analytical and Applied Pyrolysis, 12(3–4), pp. 193–222. doi: 
10.1016/0165-2370(87)85002-7. 
Schrank, T. P., Han, Y., Weiss, H., & Resto, V. A. (2011). Case-matching analysis of head and neck 
squamous cell carcinoma in racial and ethnic minorities in the United States--possible role for human 
papillomavirus in survival disparities. Head & neck, 33(1), 45–53. https://doi.org/10.1002/hed.21398. 
Schultz, J., Lorenz, P., Ibrahim, S. M., Kundt, G., Gross, G. and Kunz, M. (2009) ‘The functional -
443T/C osteopontin promoter polymorphism influences osteopontin gene expression in melanoma 
cells via binding of c-Myb transcription factor’, Molecular Carcinogenesis, 48(1), pp. 14–23. doi: 
10.1002/mc.20452. 
Screaton, G. R., Bell, M. V., Jackson, D. G., Cornelis, F. B., Gerth, U. and Bell, J. I. (1992) ‘Genomic 
structure of DNA encoding the lymphocyte homing receptor CD44 reveals at least 12 alternatively 
spliced exons’, Proceedings of the National Academy of Sciences of the United States of America, 
89(24), pp. 12160–12164. doi: 10.1073/pnas.89.24.12160. 
356 
 
Sedghizadeh, P. P., Billington, W. D., Paxton, D., Ebeed, R., Mahabady, S., Clark, G. T. and Enciso, 
R. (2016) ‘Is p16-positive oropharyngeal squamous cell carcinoma associated with favorable 
prognosis? A systematic review and meta-analysis’, Oral Oncology. Pergamon, 54, pp. 15–27. doi: 
10.1016/J.ORALONCOLOGY.2016.01.002. 
Selcuk, O., 2016. Human papillomavirus positive oropharyngeal cancer: The general 
information. Egyptian Journal of Ear, Nose, Throat and Allied Sciences, 17(3), pp.127-132. 
Semenza, G., 2000. Hypoxia, Clonal Selection, and the Role of HIF-1 in Tumor 
Progression. Critical Reviews in Biochemistry and Molecular Biology, 35(2), pp.71-103. 
Senbanjo, L. T. and Chellaiah, M. A. (2017) ‘CD44: A multifunctional cell surface adhesion receptor is 
a regulator of progression and metastasis of cancer cells’, Frontiers in Cell and Developmental Biology, 
5(3). doi: 10.3389/fcell.2017.00018. 
Senger, D. R., Wirth, D. F., & Hynes, R. O. (1979). Transformed mammalian cells secrete specific 
proteins and phosphoproteins. Cell, 16(4), pp. 885–893. https://doi.org/10.1016/0092-8674(79)90103-
x. 
Serini, G. and Gabbiani, G. (1999) ‘Mechanisms of myofibroblast activity and phenotypic modulation’, 
Experimental Cell Research, 250(2), pp. 273–283. doi: 10.1006/excr.1999.4543. 
Servais, C. and Erez, N. (2013) ‘From sentinel cells to inflammatory culprits: Cancer-associated 
fibroblasts in tumour-related inflammation’, Journal of Pathology, 229(2), pp. 198–207. doi: 
10.1002/path.4103. 
Shan, S. J. C., Scorilas, A., Katsaros, D. and Diamandis, E. P. (2007) ‘Transcriptional upregulation of 
human tissue kallikrein 6 in ovarian cancer: Clinical and mechanistic aspects’, British Journal of 
Cancer, 96(2), pp. 362–372. doi: 10.1038/sj.bjc.6603556. 
Sharon, Y., Raz, Y., Cohen, N., Ben-Shmuel, A., Schwartz, H., Geiger, T. and Erez, N. (2015) ‘Tumor-
derived osteopontin reprograms normal mammary fibroblasts to promote inflammation and tumor 
growth in breast cancer’, Cancer Research, 75(6), pp. 963–973. doi: 10.1158/0008-5472.CAN-14-
1990. 
Chin, L., Pomerantz, J., & DePinho, R. A. (1998). The INK4a/ARF tumor suppressor: one gene--two 
products--two pathways. Trends in biochemical sciences, 23(8), pp. 291–296. 
https://doi.org/10.1016/s0968-0004(98)01236-5. 
Sharpless, N. E. and Sherr, C. J. (2015) ‘Forging a signature of in vivo senescence’, Nature Reviews 
Cancer, 15(7), pp. 397–408. doi: 10.1038/nrc3960. 
Shelton, D. N., Chang, E., Whittier, P. S., Choi, D., & Funk, W. D. (1999). Microarray analysis of 
replicative senescence. Current biology : CB, 9(17), pp. 939–945. https://doi.org/10.1016/s0960-
9822(99)80420-5. 
Shelton, J., Purgina, B. M., Cipriani, N. A., Dupont, W. D., Plummer, D. and Lewis, J. S. (2017) ‘p16 
immunohistochemistry in oropharyngeal squamous cell carcinoma: a comparison of antibody clones 
using patient outcomes and high-risk human papillomavirus RNA status’, Nature Publishing Group, 30, 
pp. 1194–1203. doi: 10.1038/modpathol.2017.31. 
Shen, Z., Qin, X., Yan, M., Li, R., Chen, G., Zhang, J. and Chen, W. (2017) ‘Cancer-associated 
fibroblasts promote cancer cell growth through a miR-7-RASSF2-PAR-4 axis in the tumor 
microenvironment’, Oncotarget, 8(1), pp. 1290–1303. doi: 10.18632/oncotarget.13609. 
357 
 
Sheth, S., Farquhar, D. R., Lenze, N. R., Mazul, A., Brennan, P., Anantharaman, D., Abedi-Ardekani, 
B., Zevallos, J. P., Hayes, D. N. and Olshan, F. (2021) ‘Decreased overall survival in black patients 
with HPV-associated oropharyngeal cancer’, American Journal of Otolaryngology - Head and Neck 
Medicine and Surgery. Elsevier Inc., 42(1), p. 102780. doi: 10.1016/j.amjoto.2020.102780. 
Shiga, K., Hara, M., Nagasaki, T., Sato, T., Takahashi, H. and Takeyama, H., 2015. Cancer-
Associated Fibroblasts: Their Characteristics and Their Roles in Tumor Growth. Cancers, 7(4), 
pp.2443-2458.. 
Salmaninejad, A., Valilou, S. F., Soltani, A., Ahmadi, S., Abarghan, Y. J., Rosengren, R. J., & 
Sahebkar, A. (2019). Tumor-associated macrophages: role in cancer development and therapeutic 
implications. Cellular oncology (Dordrecht), 42(5), pp. 591–608. https://doi.org/10.1007/s13402-019-
00453-z. 
Shinohara, M. L., Jansson, M., Hwang, E. S., Werneck, M. B. F., Glimcher, L. H. and Cantor, H. (2005) 
‘T-bet-dependent expression of osteopontin contributes to T cell polarization’, Proceedings of the 
National Academy of Sciences of the United States of America, 102(47), pp. 17101–17106. doi: 
10.1073/pnas.0508666102. 
Shinohara, M. L., Kim, H. J., Kim, J. H., Garcia, V. A. and Cantor, H. (2008) ‘Alternative translation of 
osteopontin generates intracellular and secreted isoforms that mediate distinct biological activities in 
dendritic cells’, Proceedings of the National Academy of Sciences of the United States of America, 
105(20), pp. 7235–7239. doi: 10.1073/pnas.0802301105. 
Shinohara, M. L., Linrong Lu, J. B., Werneck,  iriam B. F., Kobayashi, K. S., Glimcher, L. H. and Cantor, 
H. (2012) ‘Osteopontin expression is essential for interferon-α production by plasmacytoid dendritic 
cells’, Bone, 23(1), pp. 1–7. doi: 10.1038/ni1327.Osteopontin. 
Singhi, A. D., & Westra, W. H. (2010). Comparison of human papillomavirus in situ hybridization and 
p16 immunohistochemistry in the detection of human papillomavirus-associated head and neck cancer 
based on a prospective clinical experience. Cancer, 116(9), pp. 2166–2173. 
https://doi.org/10.1002/cncr.25033. 
Smeets, S. J., Hesselink, A. T., Speel, E.-J. M., Haesevoets, A., Snijders, P. J. F., Pawlita, M., Meijer, 
C. J. L. M., Braakhuis, B. J. M., Leemans, C. R. and Brakenhoff, R. H. (2007) ‘A novel algorithm for 
reliable detection of human papillomavirus in paraffin embedded head and neck cancer specimen’, 
International Journal of Cancer. Wiley Subscription Services, Inc., A Wiley Company, 121(11), pp. 
2465–2472. doi: 10.1002/ijc.22980. 
Son, H. K., Park, I., Kim, J. Y., Kim, D. K., Illeperuma, R. P., Bae, J. Y., Lee, D. Y., Oh, E. S., Jung, D. 
W., Williams, D. R. and Kim, J. (2015) ‘A Distinct Role for Interleukin-6 as a Major Mediator of Cellular 
Adjustment to an Altered Culture Condition’, Journal of Cellular Biochemistry, 116(11), pp. 2552–2562. 
doi: 10.1002/jcb.25200. 
Stein, A. P., Saha, S., Kraninger, J. L., Swick, A. D., Yu, M., Lambert, P. F., & Kimple, R. J. (2015). 
Prevalence of Human Papillomavirus in Oropharyngeal Cancer: A Systematic Review. Cancer journal 
(Sudbury, Mass.), 21(3), pp. 138–146. https://doi.org/10.1097/PPO.0000000000000115. 
Stjernstrøm, K. D., Jensen, J. S., Kronberg, K., Grønhøj, C. and Buchwald, C. Von (2019) ‘Current 
status of human papillomavirus positivity in oropharyn geal squamous cell carcinoma in Europe : a 
systematic review’, Acta Oto-Laryngologica. Taylor & Francis, 139(12), pp. 1112–1116. doi: 
10.1080/00016489.2019.1669820. 
Stransky, N., Egloff, A. M., Tward, A. D., Kostic, A. D., Cibulskis, K., Sivachenko, A., Kryukov, G. V., 
358 
 
Lawrence, M. S., Sougnez, C., McKenna, A., Shefler, E., Ramos, A. H., Stojanov, P., Carter, S. L., 
Voet, D., Cortés, M. L., Auclair, D., Berger, M. F., Saksena, G., Guiducci, C., Onofrio, R. C., Parkin, 
M., Romkes, M., Weissfeld, J. L., Seethala, R. R., Wang, L., Rangel-Escareño, C., Fernandez-Lopez, 
J. C., Hidalgo-Miranda, A., Melendez-Zajgla, J., Winckler, W., Ardlie, K., Gabriel, S. B., Meyerson, M., 
Lander, E. S., Getz, G., Golub, T. R., Garraway, L. A. and Grandis, J. R. (2011) ‘The mutational 
landscape of head and neck squamous cell carcinoma’, Science, 333(6046), pp. 1157–1160. doi: 
10.1126/science.1208130. 
Strutz, F., Okada, H., Lo, C. W., Danoff, T., Carone, R. L., Tomaszewski, J. E. and Neilson, E. G. 
(1995) ‘Identification and characterization of a fibroblast marker: FSP1’, Journal of Cell Biology, 130(2), 
pp. 393–405. doi: 10.1083/jcb.130.2.393. 
Sturgis, E. M., & Ang, K. K. (2011). The epidemic of HPV-associated oropharyngeal cancer is here: is 
it time to change our treatment paradigms?. Journal of the National Comprehensive Cancer Network : 
JNCCN, 9(6), pp. 665–673. https://doi.org/10.6004/jnccn.2011.0055. 
Subramani, V. N., Narashman, M., Thiyagarajan, M., Davidmunuswamy, B. and Jayamani, L. (2015) 
‘Expression of osteopontin in oral squamous cell carcinoma and its surgical margins-an 
immunohistochemical study’, Journal of Clinical and Diagnostic Research, 9(11), pp. ZC66–ZC69. doi: 
10.7860/JCDR/2015/12777.6836. 
Sugimoto, H., Mundel, T. M., Kieran, M. W., & Kalluri, R. (2006). Identification of fibroblast 
heterogeneity in the tumor microenvironment. Cancer biology & therapy, 5(12), pp. 1640–1646. 
https://doi.org/10.4161/cbt.5.12.3354. 
Sun, B. S., Li, Y., Zhang, Z. F., You, J. and Wang, C. L. (2013) ‘Osteopontin combined with CD44v6, 
a novel prognostic biomarker in non-small cell lung cancer undergoing curative resection’, Annals of 
Thoracic Surgery. Elsevier Inc, 96(6), pp. 1943–1951. doi: 10.1016/j.athoracsur.2013.07.089. 
Sun, W., Liu, D. B., Li, W. W., Zhang, L. L., Long, G. X., Wang, J. F., Mei, Q. and Hu, G. Q. (2014) 
‘Interleukin-6 promotes the migration and invasion of nasopharyngeal carcinoma cell lines and 
upregulates the expression of MMP-2 and MMP-9’, International Journal of Oncology, 44(5), pp. 1551–
1560. doi: 10.3892/ijo.2014.2323. 
Suresh, K., Shah, P. V., Coates, S., Alexiev, B. A. and Samant, S. (2021) ‘In situ hybridization for high 
risk HPV E6/E7 mRNA in oropharyngeal squamous cell carcinoma’, American Journal of 
Otolaryngology - Head and Neck Medicine and Surgery. Elsevier Inc., 42(1), p. 102782. doi: 
10.1016/j.amjoto.2020.102782. 
Tang et al., 2005 (2008) ‘Sp1 Regulates Osteopontin Expression in SW480 Human Colon 
Adenocarcinoma Cells’, Bone, 23(1), pp. 1–7. 
Tchou, J., Zhang, P. J., Bi, Y., Satija, C., Marjumdar, R., Stephen, T. L., Lo, A., Chen, H., Mies, C., 
June, C. H., Conejo-Garcia, J. and Puré, E. (2013) ‘Fibroblast activation protein expression by stromal 
cells and tumor-associated macrophages in human breast cancer’, Human Pathology. Elsevier Inc., 
44(11), pp. 2549–2557. doi: 10.1016/j.humpath.2013.06.016. 
Terabe, M., & Berzofsky, J. A. (2007). NKT cells in immunoregulation of tumor immunity: a new 
immunoregulatory axis. Trends in immunology, 28(11), pp. 491–496. 
https://doi.org/10.1016/j.it.2007.05.008. 
Thavasu, P. W., Longhurst, S., Joel, S. P., Slevin, M. L. and Balkwill, F. R. (1992) ‘Measuring cytokine 
levels in blood. Importance of anticoagulants, processing, and storage conditions’, Journal of 
Immunological Methods, 153(1–2), pp. 115–124. doi: 10.1016/0022-1759(92)90313-I. 
359 
 
Thibaudeau, E., Fortin, B., Coutlée, F., Nguyen-Tan, P., Weng, X., Audet, M.-L., Abboud, O., Guertin, 
L., Christopoulos, A., Tabet, J. and Soulières, D. (2013) ‘HPV Prevalence and Prognostic Value in a 
Prospective Cohort of 255 Patients with Locally Advanced HNSCC: A Single-Centre Experience.’, 
International journal of otolaryngology. Hindawi, 2013, p. 437815. doi: 10.1155/2013/437815. 
Thiery J. P. (2002). Epithelial-mesenchymal transitions in tumour progression. Nature reviews. 
Cancer, 2(6), 442–454. https://doi.org/10.1038/nrc822. 
Thiery, J. P., Acloque, H., Huang, R. Y. J. and Nieto, M. A. (2009) ‘Epithelial-Mesenchymal Transitions 
in Development and Disease’, pp. 871–890. doi: 10.1016/j.cell.2009.11.007. 
Tilli, T. M., Thuler, L. C., Matos, A. R., Coutinho-Camillo, C. M., Soares, F. A., da Silva, E. A., Neves, 
A. F., Goulart, L. R. and Gimba, E. R. (2012) ‘Expression analysis of osteopontin mRNA splice variants 
in prostate cancer and benign prostatic hyperplasia’, Experimental and Molecular Pathology. Elsevier 
Inc., 92(1), pp. 13–19. doi: 10.1016/j.yexmp.2011.09.014. 
Tlsty, T. D. (2001) ‘Stromal cells can contribute oncogenic signals’, Seminars in Cancer Biology, 11(2), 
pp. 97–104. doi: 10.1006/scbi.2000.0361. 
Todorović, M. M. and Zvrko, E. Z. (2013) ‘Immunoregulatory cytokines and chronic tonsillitis’, Bosnian 
Journal of Basic Medical Sciences, 13(4), pp. 230–236. doi: 10.17305/bjbms.2013.2330. 
Tomasek, J. J., Gabbiani, G., Hinz, B., Chaponnier, C. and Brown, R. A. (2002) ‘Myofibroblasts and 
mechano-regulation of connective tissue remodelling’, Nature Reviews Molecular Cell Biology, 3(5), 
pp. 349–363. doi: 10.1038/nrm809. 
Tschumperlin, D. J. (2013) ‘Fibroblasts and the ground they walk on’, Physiology, 28(6), pp. 380–390. 
doi: 10.1152/physiol.00024.2013. 
Tzelgov, J. and Henik, A., 1991. Suppression situations in psychological research: Definitions, 
implications, and applications. Psychological Bulletin, 109(3), pp.524-536.  
Uchibori, T., Matsuda, K., Shimodaira, T., Sugano, M., Uehara, T. and Honda, T. (2017) ‘IL-6 trans-
signaling is another pathway to upregulate Osteopontin’, Cytokine. Elsevier Ltd, 90, pp. 88–95. doi: 
10.1016/j.cyto.2016.11.006. 
Ukpo, O. C., Flanagan, J. J., Ma, X. J., Luo, Y., Thorstad, W. L. and Lewis, J. S. (2011) ‘High-risk 
human papillomavirus E6/E7 mRNA detection by a novel in situ hybridization assay strongly correlates 
with p16 expression and patient outcomes in oropharyngeal squamous cell carcinoma’, American 
Journal of Surgical Pathology, 35(9), pp. 1343–1350. doi: 10.1097/PAS.0b013e318220e59d. 
Valach, J., Fík, Z., Strnad, H., Chovanec, M., Plzák, J., Cada, Z., Szabo, P., Sáchová, J., Hroudová, 
M., Urbanová, M., Steffl, M., Pačes, J., Mazánek, J., Vlček, C., Betka, J., Kaltner, H., André, S., Gabius, 
H. J., Kodet, R., Smetana, K., Jr, … Kolář, M. (2012). Smooth muscle actin-expressing stromal 
fibroblasts in head and neck squamous cell carcinoma: increased expression of galectin-1 and 
induction of poor prognosis factors. International journal of cancer, 131(11), pp. 2499–2508. 
https://doi.org/10.1002/ijc.27550. 
.Vaughan, M. B., Howard, E. W. and Tomasek, J. J. (2000) ‘Transforming growth factor-β1 promotes 
the morphological and functional differentiation of the myofibroblast’, Experimental Cell Research, 
257(1), pp. 180–189. doi: 10.1006/excr.2000.4869. 
Vaupel, P., Mayer, A., Briest, S. and Höckel, M. (2003) ‘Oxygenation Gain Factor: A Novel Parameter 
360 
 
Characterizing the Association between Hemoglobin Level and the Oxygenation Status of Breast 
Cancers’, Cancer Research, 63(22), pp. 7634–7637. 
Vered, M., Allon, I., Buchner, A. and Dayan, D. (2007) ‘Stromal myofibroblasts and malignant 
transformation in a 4NQO rat tongue carcinogenesis model’, Oral Oncology, 43(10), pp. 999–1006. 
doi: 10.1016/j.oraloncology.2006.11.007. 
Viallard, J. F., Bloch-Michel, C., Neau-Cransac, M., Taupin, J. L., Garrigue, S., Miossec, V., Mercie, 
P., Pellegrin, J. L. and Moreau, J. F. (2001) ‘HLA-DR expression on lymphocyte subsets as a marker 
of disease activity in patients with systemic lupus erythematosus’, Clinical and Experimental 
Immunology, 125(3), pp. 485–491. doi: 10.1046/j.1365-2249.2001.01623.x. 
Virgilio, L., Shuster, M., Gollin, S. M., Veronese, M. L., Ohta, M., Huebner, K., & Croce, C. M. (1996). 
FHIT gene alterations in head and neck squamous cell carcinomas. Proceedings of the National 
Academy of Sciences of the United States of America, 93(18), pp. 9770–9775. 
https://doi.org/10.1073/pnas.93.18.9770. 
Wai, P. Y., & Kuo, P. C. (2004). The role of Osteopontin in tumor metastasis. The Journal of surgical 
research, 121(2), 228–241. https://doi.org/10.1016/j.jss.2004.03.028. 
Wain, S. L., Kier, R., Vollmer, R. T., & Bossen, E. H. (1986). Basaloid-squamous carcinoma of the 
tongue, hypopharynx, and larynx: report of 10 cases. Human pathology, 17(11), pp. 1158–1166. 
https://doi.org/10.1016/s0046-8177(86)80422-1. 
Wald, A. I., Hoskins, E. E., Wells, S. I., Ferris, R. L. and Khan, S. A. (2011) ‘Alteration of microRNA 
profiles in squamous cell carcinoma of the head and neck cell lines by human papillomavirus’, Head & 
Neck, 33(4), pp. 504–512. doi: 10.1002/hed.21475. 
Wang, M., Su, Z. and Amoah, P. (2020) ‘Crosstalk among colon cancer-derived exosomes , fi broblast-
derived exosomes , and macrophage phenotypes in colon cancer metastasis’, International 
Immunopharmacology. Elsevier, 81(11), p. 106298. doi: 10.1016/j.intimp.2020.106298. 
Wang, S. J. and Bourguignon, L. Y. W. (2011) ‘Role of hyaluronan-mediated CD44 signaling in head 
and neck squamous cell carcinoma progression and chemoresistance’, American Journal of 
Pathology. Elsevier Inc., 178(3), pp. 956–963. doi: 10.1016/j.ajpath.2010.11.077. 
Wang, Z., Tang, Y., Xie, L., Huang, A., Xue, C., Gu, Z., Wang, K. and Zong, S. (2019) ‘The prognostic 
and clinical value of CD44 in colorectal cancer: A meta-analysis’, Frontiers in Oncology, 9(4), pp. 1–
11. doi: 10.3389/fonc.2019.00309. 
Weber, C. E., Kothari, A. N., Wai, P. Y., Li, N. Y., Driver, J., Zapf, M. A. C., Franzen, C. A., Gupta, G. 
N., Osipo, C., Zlobin, A., Syn, W. K., Zhang, J., Kuo, P. C. and Mi, Z. (2015) ‘Osteopontin mediates an 
MZF1-TGF-β1-dependent transformation of mesenchymal stem cells into cancer-associated 
fibroblasts in breast cancer’, Oncogene, 34(37), pp. 4821–4833. doi: 10.1038/onc.2014.410. 
Weber, G. F., Ashkar, S., Glimcher, M. J., & Cantor, H. (1996). Receptor-ligand interaction between 
CD44 and osteopontin (Eta-1). Science (New York, N.Y.), 271(5248), pp. 509–512. 
https://doi.org/10.1126/science.271.5248.509. 
Weber, G., Lett, G. and Haubein, N., 2010. Osteopontin is a marker for cancer aggressiveness and 
patient survival. British Journal of Cancer, 103(6), pp.861-869. doi: 10.1038/sj.bjc.6605834. 
Weber, R. G., Scheer, M., Born, I. A., Joos, S., Cobbers, J. M. J. L., Hofele, C., Reifenberger, G., 
Zöller, J. E. and Lichter, P. (1998) ‘Recurrent chromosomal imbalances detected in biopsy material 
361 
 
from oral premalignant and malignant lesions by combined tissue microdissection, universal DNA 
amplification, and comparative genomic hybridization’, American Journal of Pathology, 153(1), pp. 
295–303. doi: 10.1016/S0002-9440(10)65571-X. 
Wei, L. Y., Lee, J. J., Yeh, C. Y., Yang, C. J., Kok, S. H., Ko, J. Y., Tsai, F. C., & Chia, J. S. (2019). 
Reciprocal activation of cancer-associated fibroblasts and oral squamous carcinoma cells through 
CXCL1. Oral oncology, 88, pp.115–123. https://doi.org/10.1016/j.oraloncology.2018.11.002. 
Weinberger, P. M., Yu, Z., Haffty, B. G., Kowalski, D., Harigopal, M., Brandsma, J., Sasaki, C., Joe, J., 
Camp, R. L., Rimm, D. L. and Psyrri, A. (2006) ‘Molecular classification identifies a subset of human 
papillomavirus- associated oropharyngeal cancers with favorable prognosis’, Journal of Clinical 
Oncology, 24(5), pp. 736–747. doi: 10.1200/JCO.2004.00.3335. 
Welters, M. J., Ma, W., Santegoets, S. J., Goedemans, R., Ehsan, I., Jordanova, E. S., Van Ham, V. 
J., Van Unen, V., Koning, F., Van Egmond, S. I., Charoentong, P., Trajanoski, Z., Van Der Velden, L. 
A. and Van Der Burg, S. H. (2018) ‘Intratumoral HPV16-specific T cells constitute a type I–oriented 
tumor microenvironment to improve survival in HPV16-driven oropharyngeal cancer’, Clinical Cancer 
Research, 24(3), pp. 634–647. doi: 10.1158/1078-0432.CCR-17-2140. 
Westra, W. H. (2012) ‘The morphologic profile of HPV-related head and neck squamous carcinoma: 
implications for diagnosis, prognosis, and clinical management.’, Head and neck pathology. Springer, 
6 Suppl 1(Suppl 1), pp. S48-54. doi: 10.1007/s12105-012-0371-6. 
Westra, W. H. (2014) ‘Detection of human papillomavirus (HPV) in clinical samples: Evolving methods 
and strategies for the accurate determination of HPV status of head and neck carcinomas’, Oral 
Oncology. Elsevier Ltd, 50(9), pp. 771–779. doi: 10.1016/j.oraloncology.2014.05.004. 
White, J. S., Weissfeld, J. L., Ragin, C. C. R., Rossie, K. M., Martin, C. L., Shuster, M., Ishwad, C. S., 
Law, J. C., Myers, E. N., Johnson, J. T. and Gollin, S. M. (2007) ‘The influence of clinical and 
demographic risk factors on the establishment of head and neck squamous cell carcinoma cell lines’, 
Oral Oncology, 43(7), pp. 701–712. doi: 10.1016/j.oraloncology.2006.09.001. 
Wiest, T., Schwarz, E., Enders, C., Flechtenmacher, C. and Bosch, F. X. (2002) ‘Involvement of intact 
HPV16 E6/E7 gene expression in head and neck cancers with unaltered p53 status and perturbed 
pRB cell cycle control’, Oncogene, 21(10), pp. 1510–1517. doi: 10.1038/sj.onc.1205214. 
Windon, M. J., D’Souza, G., Rettig, E. M., Westra, W. H., van Zante, A., Wang, S. J., Ryan, W. R., 
Mydlarz, W. K., Ha, P. K., Miles, B. A., Koch, W., Gourin, C., Eisele, D. W. and Fakhry, C. (2018) 
‘Increasing prevalence of human papillomavirus–positive oropharyngeal cancers among older adults’, 
Cancer, 124(14), pp. 2993–2999. doi: 10.1002/cncr.31385. 
Wipff, P.-J., Rifkin, D. B., Meister, J.-J. and Hinz, B. (2007) ‘Myofibroblast contraction activates latent 
TGF-β1 from the extracellular matrix’, The Journal of Cell Biology, 179(6), pp. 1311–1323. doi: 
10.1083/jcb.200704042. 
Witkiewicz, A. K., Knudsen, K. E., Dicker, A. P. and Knudsen, E. S. (2011) ‘The meaning of p16ink4a 
expression in tumors: Functional significance, clinical associations and future developments’, Cell 
Cycle, 10(15), pp. 2497–2503. doi: 10.4161/cc.10.15.16776. 
Wong, T. S., Kwong, D. L. W., Sham, J., Wei, W. I., Kwong, Y. L. and Yuen, A. P. W. (2005) ‘Elevation 
of plasma osteopontin level in patients with undifferentiated nasopharyngeal carcinoma’, European 
Journal of Surgical Oncology, 31(5), pp. 555–558. doi: 10.1016/j.ejso.2005.01.005. 
Wu, T., Hong, Y., Jia, L., Wu, J., Xia, J., Wang, J., Hu, Q. and Cheng, B. (2016) ‘Modulation of IL-1β 
362 
 
reprogrammes the tumor microenvironment to interrupt oral carcinogenesis’, Scientific Reports. Nature 
Publishing Group, 6(February), pp. 1–10. doi: 10.1038/srep20208. 
Würdemann, N., Wagner, S., Sharma, S. J., Prigge, E. S., Reuschenbach, M., Gattenlöhner, S., 
Klussmann, J. P., & Wittekindt, C. (2017). Prognostic Impact of AJCC/UICC 8th Edition New Staging 
Rules in Oropharyngeal Squamous Cell Carcinoma. Frontiers in oncology, 7, p.129. 
https://doi.org/10.3389/fonc.2017.00129. 
Xi, L. F., Schiffman, M., Koutsky, L. A., Hughes, J. P., Winer, R. L., Mao, C., Hulbert, A., Lee, S. K., 
Shen, Z., & Kiviat, N. B. (2014). Lineages of oncogenic human papillomavirus types other than type 
16 and 18 and risk for cervical intraepithelial neoplasia. Journal of the National Cancer 
Institute, 106(10), dju270. https://doi.org/10.1093/jnci/dju270. 
Xing, F., Saidou, J., & Watabe, K. (2010). Cancer associated fibroblasts (CAFs) in tumor 
microenvironment. Frontiers in bioscience (Landmark edition), 15, pp.166–179. 
https://doi.org/10.2741/3613. 
Yamashita, M., Ogawa, T., Zhang, X., Hanamura, N., Kashikura, Y., Takamura, M., Yoneda, M. and 
Shiraishi, T. (2012) ‘Role of stromal myofibroblasts in invasive breast cancer: Stromal expression of 
alpha-smooth muscle actin correlates with worse clinical outcome’, Breast Cancer, 19(2), pp. 170–
176. doi: 10.1007/s12282-010-0234-5. 
Yim, E.K. and Park, J.S. (2005) ‘The Role of HPV E6 and E7 Oncoproteins in HPV-associated Cervical 
Carcinogenesis’, Cancer Research and Treatment, 37(6), p. 319. doi: 10.4143/crt.2005.37.6.319. 
Yin, L. X., D’Souza, G., Westra, W. H., Wang, S. J., van Zante, A., Zhang, Y., Rettig, E. M., Ryan, W. 
R., Ha, P. K., Wentz, A., Koch, W., Eisele, D. W. and Fakhry, C. (2018) ‘Prognostic factors for human 
papillomavirus–positive and negative oropharyngeal carcinomas’, Laryngoscope, 128(8), pp. E287–
E295. doi: 10.1002/lary.27130. 
Young, M. F., Kerr, J. M., Termine, J. D., Wewer, U. M., Wang, M. G., McBride, O. W. and Fisher, L. 
W. (1990) ‘cDNA cloning, mRNA distribution and heterogeneity, chromosomal location, and RFLP 
analysis of human osteopontin (OPN)’, Genomics, 7(4), pp. 491–502. doi: 10.1016/0888-
7543(90)90191-V. 
Yu, S.-H., Zheng, Q., Esopi, D., Macgregor-Das, A., Luo, J., Antonarakis, E. S., Drake, C. G., Vessella, 
R., Morrissey, C., De Marzo, A. M. and Sfanos, K. S. (2015) ‘A Paracrine Role for IL6 in Prostate 
Cancer Patients: Lack of Production by Primary or Metastatic Tumor Cells’, Cancer Immunology 
Research, 3(10), pp. 1175–1184. doi: 10.1158/2326-6066.CIR-15-0013. 
Yuan, G. C., Cai, L., Elowitz, M., Enver, T., Fan, G., Guo, G., Irizarry, R., Kharchenko, P., Kim, J., 
Orkin, S., Quackenbush, J., Saadatpour, A., Schroeder, T., Shivdasani, R. and Tirosh, I. (2017) 
‘Challenges and emerging directions in single-cell analysis’, Genome Biology. Genome Biology, 18(1), 
pp. 1–8. doi: 10.1186/s13059-017-1218-y. 
Zamani, M., Grønhøj, C., Jensen, D. H., Carlander, A. F., Agander, T., Kiss, K., Olsen, C., Baandrup, 
L., Nielsen, F. C., Andersen, E., Friborg, J. and von Buchwald, C. (2020) ‘The current epidemic of 
HPV-associated oropharyngeal cancer: An 18-year Danish population-based study with 2,169 
patients’, European Journal of Cancer. Elsevier Ltd, 134, pp. 52–59. doi: 10.1016/j.ejca.2020.04.027. 
Zaravinos, A. (2014) ‘An updated overview of HPV-associated head and neck carcinomas’, 
Oncotarget, 5(12), pp. 3956–69. doi: 10.18632/oncotarget.1934. 
Zhan, S., Liu, Z., Zhang, M., Guo, T., Quan, Q., Huang, L., Guo, L., Cao, L. and Zhang, X. (2020) 
363 
 
‘Overexpression of B7-H3 in α-SMA-Positive Fibroblasts Is Associated With Cancer Progression and 
Survival in Gastric Adenocarcinomas’, Frontiers in Oncology, 9(1), pp. 1–13. doi: 
10.3389/fonc.2019.01466. 
Zhang, H., Guo, M., Chen, J. H., Wang, Z., Du, X. F., Liu, P. X. and Li, W. H. (2014) ‘Osteopontin 
knockdown inhibits α v ,β 3 integrin-induced cell migration and invasion and promotes apoptosis of 
breast cancer cells by inducing autophagy and inactivating the PI3K/Akt/mTOR Pathway’, Cellular 
Physiology and Biochemistry, 33(4), pp. 991–1002. doi: 10.1159/000358670. 
Zhang, H., Liu, F. Y., Liu, Y. H., Peng, Y. M., Liao, Q., & Zhang, K. (2005). Effect of TGF-β1 Stimulation 
on the Smad Signal Transduction Pathway of Human Peritoneal Mesothelial Cells. International journal 
of biomedical science : IJBS, 1(1), pp.8–15. 
Zhang, L., Sharma, S., Zhu, L. X., Kogai, T., Hershman, J. M., Brent, G. A., Dubinett, S. M. and Huang, 
M. (2003) ‘Nonradioactive iodide effectively induces apoptosis in genetically modified lung cancer 
cells’, Cancer Research, 63(16), pp. 5065–5072. 
Zhao, F., Zhang, Yi, Wang, H., Jin, M., He, S., Shi, Y., Guo, Y. and Zhang, Yanyun (2011) ‘Blockade 
of osteopontin reduces alloreactive CD8+ T cell-mediated graft-versus-host disease’, Blood, 117(5), 
pp. 1723–1733. doi: 10.1182/blood-2010-04-281659. 
Zhao, H., Chen, Q., Alam, A., Cui, J., Suen, K. C., Soo, A. P., Eguchi, S., Gu, J., & Ma, D. (2018). The 
role of osteopontin in the progression of solid organ tumour. Cell death & disease, 9(3), 356. 
https://doi.org/10.1038/s41419-018-0391-6. 
Zheng, Z. M., & Baker, C. C. (2006). Papillomavirus genome structure, expression, and post-
transcriptional regulation. Frontiers in bioscience : a journal and virtual library, 11, pp. 2286–2302. 
https://doi.org/10.2741/1971. 
Zhu, B., Suzuki, K., Goldberg, H. A., Rittling, S. R., Denhardt, D. T., McCulloch, C. A. G. and Sodek, 
J. (2004) ‘Osteopontin Modulates CD44-Dependent Chemotaxis of Peritoneal Macrophages Through 
G-Protein-Coupled Receptors: Evidence of a Role for an Intracellular Form of Osteopontin’, Journal of 
Cellular Physiology, 198(1), pp. 155–167. doi: 10.1002/jcp.10394. 
Zhu, Q., Zhang, X., Zhang, L., Li, W., Wu, H., Yuan, X., Mao, F., Wang, M., Zhu, W., Qian, H. and Xu, 
W. (2014) ‘The IL-6-STAT3 axis mediates a reciprocal crosstalk between cancer-derived mesenchymal 
stem cells and neutrophils to synergistically prompt gastric cancer progression’, Cell Death and 
Disease, 5(6), pp. 1–11. doi: 10.1038/cddis.2014.263. 
Zohar, R., Lee, W., Arora, P., Cheifetz, S., McCulloch, C. and Sodek, J. (1997) ‘Single cell analysis of 
intracellular osteopontin in osteogenic cultures of fetal rat calvarial cells’, Journal of Cellular 
Physiology, 170(1), pp. 88–100. doi: 10.1002/(SICI)1097-4652(199701)170:1<88::AID-
JCP10>3.0.CO;2-K. 
Zohar, R., Suzuki, N., Suzuki, K., Arora, P., Glogauer, M., McCulloch, C. A., & Sodek, J. (2000). 
Intracellular osteopontin is an integral component of the CD44-ERM complex involved in cell 
migration. Journal of cellular physiology, 184(1), 118–130. https://doi.org/10.1002/(SICI)1097-
4652(200007)184:1<118::AID-JCP13>3.0.CO;2-Y. 
Zou, C., Luo, Q., Qin, J., Shi, Y., Yang, L., Ju, B. and Song, G. (2013) ‘Osteopontin Promotes 
Mesenchymal Stem Cell Migration and Lessens Cell Stiffness via Integrin β1, FAK, and ERK 
Pathways’, Cell Biochemistry and Biophysics, 65(3), pp. 455–462. doi: 10.1007/s12013-012-9449-8. 
Zumsteg, Z. S., Cook-Wiens, G., Yoshida, E., Shiao, S. L., Lee, N. Y., Mita, A., Jeon, C., Goodman, 
364 
 
M. T. and Ho, A. S. (2016) ‘Incidence of oropharyngeal cancer among elderly patients in the United 
States’, JAMA Oncology, 2(12), pp. 1617–1623. doi: 10.1001/jamaoncol.2016.1804. 
 
 
